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Abstract 
 
Engineering novel lantibiotics to target gut pathogens 
 
Infections with multi-drug resistant bacteria are an urgent health security threat and 
bacteriocins such as the subclass of lantibiotics represent a promising alternative source 
to traditional antibiotics. The gut intestinal tract ecosystem has a complex set of bacteria 
with a huge bacteriogenic potential and it can be explored as a source for new lantibiotic 
peptides. Using a genome mining approach, a clos gene cluster that has the potential to 
encode for novel lantibiotics was previously discovered in a strain of Blautia isolated 
from the human gut. This clos operon may encode two nisin-like peptides. 
 
Several nisin derived clos-like sequences were generated, however they did not have 
improved properties when tested under GI tract conditions. Since we lack the molecular 
tools to manipulate the original Blautia obeum A2-162 gut bacterium that harbours the 
clos operon, the entire clos cluster was cloned in Lactococcus lactis where it was possible 
to obtain heterologous expression of the Clos peptides under the control of the nisin 
inducible NisRK regulatory system. The production of preClosA was demonstrated using 
an antibody raised against the Clos leader. The biological activity of the Clos peptide was 
confirmed after treatment with trypsin where the Clos leader was presumably cleaved, 
releasing the biologically active and mature Clos peptide that was highly active against 
two clinically important pathogens, Clostridium perfringens and Clostridium difficile as 
well as against L. lactis MG1614 sensitive indicator strains. Using immunoprecipitation, 
we obtained pure Clos peptides in solution and after trypsin treatment and alkylation of 
the cysteine residues, the post-translational modifications and the structure of the 
preClosA peptides were confirmed. Some of the anticipated dehydrations and ring 
formations (Rings D and E) were also identified using LC-MS.  
 
The approach taken in this PhD project confirms that genome mining can be used to 
identify more gut bacteria with potential to produce novel lantibiotics.  
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1.1 Antibiotic resistance crisis  
Antibiotic resistance is a global health threat and a crisis which has become a major 
challenge of the 21st century. It is responsible for the rise in the frequency of antibiotic 
resistance from several classified bacteria which represent a considerable and urgent issue 
in the health care system. Among the bacteria that are no longer responding to routinely 
used antibiotics (as listed by the Centers for Disease Control and Prevention), are 
pathogens like methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus 
faecalis, Mycobacterium tuberculosis and Clostridium difficile [1]. Bacterial infections 
with these so called superbugs or multi-drug resistant bacteria (MDR) are becoming a 
serious threat. Treating infections from MDR is a significant burden in the clinical 
environment and on the finance of the patients, families and the healthcare professionals 
[1]. The antibiotic crisis has also emerged from the rapid spread of antibiotic resistance, 
the misuse and the frequency of overused medications which puts into danger the efficacy 
of currently available antibiotics [2]. In order to control the MDR bacteria at a global 
level, novel approaches to the treatment of infections from pathogens are needed as well 
as better diagnosis, a thorough monitoring of prescriptions and prevention of transmitting 
infections. A greater collaboration between different involved parties to develop and 
invest into new agents that fight against the antibiotic resistance crisis is highly desirable. 
The crisis has been more alarming since there has been a decline and even a lack of 
development of new drugs by the pharmaceutical industries. This is because the process 
costs of development and production are high and not economically profitable, it is 
financially risky and the associated requirements for getting a drug in the clinic are very 
challenging [3, 4]. 
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1.2 Pitfalls and solutions for the crisis of antibiotic resistance   
 The problem with the rise in MDR bacteria      
While infections with MDR bacteria represent a serious threat on the life expectancy of  
humans, the general trend among clinicians and pharmaceutical industries is to routinely 
administer and develop broad spectrum antibiotics. As a consequence, a number of 
antibiotic-associated changes in the commensal population of the gut microbiota have 
been reported. Cotter et al. [5] investigated these changes by high throughput DNA 
sequencing and pointed asthma, allergies, atopic dermatitis, cholera, candidiasis fungus, 
and colitis induced by pathogens, eczema, autoimmune encephalitis as emerging 
antibiotic-associated diseases. Therefore, not only is the development of bacterial 
resistance a worrying problem associated with antibiotic overuse, but there is also an 
undefined collateral damage inflicted onto the beneficial microbial populations in the gut 
which are necessary as they contribute to the human health.  
For instance, vancomycin, also known as the antibiotic of last resort, and metronidazole, 
are the principal antibiotics used for the treatment against infections with the clinically 
important gut pathogen C. difficile, which affects particularly the elderly, as the infections 
spread in hospitals and in care homes with an alarming increasing carriage rate [1]. It is 
generally understood that broad-spectrum usage of antibiotics induces diseases and these 
routinely used therapies result in perturbation of the microbiota, reductions of the 
functional barrier of the mucus layer, disruption in the intestinal homeostasis and in the 
integrity of the intestinal defence mechanism. Under normal conditions, the host is being 
protected against the invasion of pathogens or inflammation, however antibiotics cause 
additional dysbiosis in the distal colon and disturb the normal function of microbiota [1]. 
Similarly, antimicrobial resistance is also being triggered by the extensive use of the 
antibiotics by the farmers to keep the animals alive.  
Consequently, a therapeutic agent, a therapy or new available strategies are expected to 
emerge and to be implemented in order to diminish the negative impact of antibiotics used 
to tackle the MDR bacterial infections [5].  
 
 
 
Chapter 1 
   
4 
 
 Solution for the antibiotic resistance crisis  
Several therapeutic alternatives for treatment of infections with gut intestina (GI) tract 
pathogens were reviewed by Mathur et al. [6]. One therapeutic strategy that could address 
the rapid emergence of antibiotic resistance of infectious pathogens is quorum quenching 
[7], which could be used to manipulate the virulence of gene expression and inhibit the 
process of quorum-sensing. This was successfully demonstrated in in vivo infection 
models with different pathogens such as S. aureus [7, 8]. Another possible strategy would 
be the use of faecal transplantation therapy for the treatment of GI tract diseases 
particularly from MDR C. difficile infections, phage therapy, and the use of prebiotics or 
probiotics [9, 10]. 
The discovery of new antibiotics to treat serious infections has been slowed down by a 
lack of tools used for the possible exploitation of the enormous amount of bacteria from 
natural environments, which can not be generally cultivated in the laboratory [11]. 
The best potent alternative to the negative impact and to the damage caused by the 
extensive overuse of broad spectrum antibiotics is the usage of the group of novel 
antibiotics, such as the so called class of bacteriocins, a highly diverse family of bacterial 
toxins. Bacteriocins are small antimicrobial peptides, ribosomally synthesised, which 
undergo extensive post-translational modification (PTM) and that can be tailored to 
control various pathogens. Bacteriocins are an attractive therapeutic alternative due to 
their relatively low toxicity, a narrow spectrum of antimicrobial activity and their efficient 
mode of action against MDR pathogens. Numerous bacteriocins are very active at 
nanomolar concentrations and they target a very narrow range of molecules [12, 13].  
As an example, the beneficial effect of using of thuricin CD bacteriocin, from the 
sactibiotics family, was highlighted in a human distal colon model and it was compared 
to the use of the conventional antibiotics (vancomycin, metronidazole), and lacticin 3147 
bacteriocin against infections with C. difficile [1, 14]. These infections usually cause fatal 
diseases and antibiotic induced diarrhoea which often result from the development of 
spores which are antibiotic-resistant. Interestingly, it was demonstrated that thuricin CD 
can eliminate C. difficile bacteria specifically from trillions of bacteria in a model gut 
system. Therefore, it should be universally accepted that the narrow spectrum 
antimicrobials represent the main source for the treatment strategies of the future.  
Bioengineering of bacteriocins can create new bacteriocins with increased stability, 
potency and with potentially superior properties of clinical interest [15].  
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A number of reviews highlight the advances in the research on bacteriocins such as the 
increasing interest for them to be used as a viable alternative to conventional antibiotics, 
their use as a novel way to address spore-related problems or the advances in the 
molecular and bioinformatics tools necessary for the discovery and development of novel 
bacteriocins as potent therapeutic agents [3, 12, 13, 16, 17].  
1.3 Alternative agents to antibiotics - definition of current bacteriocins   
The bacteriocin family comprises a diversity of proteins that vary in terms of size, 
microbial target, mode of action, release and immunity mechanism [18]. Bacteriocins are 
classified into two main groups: the toxins produced by Gram-negative bacteria and those 
produced by Gram-positive bacteria. It can be presumed that most bacterial genera 
produce one or more bacteriocins; the ones produced by Gram-positive bacteria, such as 
lantibiotics, have been the focus of much attention as a result of their potential commercial 
applications, including staphylococci and enterococci [19].  
Two main features distinguish the majority of bacteriocins from classical antibiotics: they 
are protein based ribosomally synthesised molecules and they have a relatively narrow 
spectrum for cell killing [18]. Bacteriocins have unusual amino acids incorporated as a 
result of extensive post-translational modifications that they undergo. Bacteriocins are 
ubiquitous in nature and in recent years, they have been targeted for use in human health, 
veterinary medicine, and food preservation since they can be bioengineered to create 
pathogen-specific designer drugs [20-22] as it is further described in section 1.6.  
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1.4 Promising research in the field of bacteriocins  
 Unexplored resources and novel biotechnologies for the discovery of 
bacteriocins 
Some bacteriocins are produced by bacteria with Generally Regarded As Safe (GRAS) 
status or food-grade bacteria. In contrast, it was reported that several Gram-positive 
pathogens are also producing lantibiotics including bacterial strains such as S. aureus, 
Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, 
Streptococcus mutans, Streptococcus uberis and E. faecalis [16]. The advantages of using 
these compounds for the enhancement of virulence of the infectious pathogenic strains 
was reviewed by Daly et al. [19].  
The discovery of new lantibiotics is facilitated by exploring unknown environments and 
by screening of microbes isolated from previously under scrutinized ecological niches. 
This is not only to tackle an urgent need to address the threat of antibiotic resistance but 
also because there has been a clear decline in the discovery of novel antimicrobials from 
the traditional sources. In general, fungi and actinomycetes have been so far the main 
source of antibiotics which are now clinically used.  
Bibb et al. [23] have reviewed the work done on manipulating the production of 
antibiotics in actinomycetes. Actinomycetes are Gram-positive bacteria that are original 
from the soil or marine sources and they possess huge potential for the production of 
clinically important antimicrobial peptides. Almost half of all classes of antibiotics that 
are used clinically, around 50 different compounds, are derived from actinomycetes [23]. 
The development of genome sequencing facilitated the discovery of an increasing 
numbers of biosynthetic gene clusters that encode for natural products with useful and 
interesting structures and functionalities. For instance, microbisporicin is a potent 
bactericidal lantibiotic variant which is active against a wide range of Gram-positive 
bacterial pathogens, such as S. aureus and Bacillus megaterium as it inhibits the 
peptidoglycan synthesis by binding to lipid II. Microbisporicin is also active against 
methicillin-resistant and vancomycin-intermediate resistant strains of S. aureus and also 
against some Gram-negative species, which is unusual for a lantibiotic. Foulston et al. 
[24] reported the discovery of the novel biosynthetic gene cluster for microbisporicin 
produced by the actinomycete Microbispora coralline where the genes were identified 
using a genome scanning approach. The biosynthetic gene cluster was isolated from a M. 
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corallina cosmid library, cloned and characterised in order to elucidate the functions of 
individual genes and to understand the process of biosynthesis of this lantibiotic. Even if 
microbisporicin is already commercialised and it has been demonstrated to have superior 
efficacy in animal models of MDR infections compared with the drugs of last resort 
(linezolid and vancomycin), the knowledge gained from this study may ultimately enable 
the development of variants with improved clinical activity [24]. 
Several candidates of the lantibiotic class of peptides have been successful as novel 
treatments against infections with MDR: mutacin 1140 (MU1140) and microbisporicin 
(NAI-107) are in the late pre-clinical trials against Gram-positive bacteria; NVB302 is 
tested in a Phase I clinical trial for the treatment of infections with C. difficile, whereas 
duramycin has completed Phase II clinical trials to be used for the treatment of cystic 
fibrosis [25]. Nevertheless, novel methods to identify lantibiotics are needed, as specified 
below, since the more traditional methods for the discovery of lantibiotics (e.g.: by 
induction, production and identification) are time-consuming; the traditional methods are 
also inefficient since they also create a barrier for the rapid detection of novel 
antimicrobial peptides.  
Next generation sequencing is an emerging and revolutionising method of making 
hundreds of new genome sequences publically available. Genome mining approaches can 
also facilitate the identification of new natural products and the subsequent elucidation of 
their biosynthetic pathways [26]. 
Novel bacteriocin gene clusters from the GI tract microbes have been identified in silico 
as part of the Human Microbiome Project, which reinforces the idea that the human gut 
microbiota is yet an unexplored but resourceful source for new antimicrobial peptides that 
could be active against infections from gut pathogens [27]. The human gut microbiota 
consists of approx. 100 trillion microbial cells and by taking advantage of the 
bioinformatics approaches and next generation sequencing technologies, bacteriocins 
could be used as therapeutic tools that would have a meaningful and beneficial influence 
on various aspects of human physiology such as the immune system, metabolism, 
absorption of nutrients etc. [27].  
Reviews on the use of synthetic biology for bacteriocin discovery and bioengineering of 
lantibiotic-derived sequences have suggested to combine the genome mining procedures 
with heterologous expression systems and high-throughput screening which offers a 
promising strategy to elicit novel bacteriocins [28]. 
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 Applications of bacteriocins  
Apart from their antimicrobial activity and their use to fight against infections with MDR 
bacteria, bacteriocins have been reported to be used in a number of other applications 
since they have a positive and beneficial influence on the health of the host organism. 
Several studies have suggested that bacteriocin producing strains can be used for their 
potential probiotic traits [29, 30] since they can modulate the gut microbiota [5, 31] and 
can be explored as promising candidates for future applications as clinical therapeutics 
[32, 33]. The role of the gut bacteria in the gut tract brain axis and the beneficial effects 
of bacteriocins have also been considered [34-37]. The use of the antibiotics in 
agriculture, food preservation and food safety applications has been reviewed [38].  
 Bioengineering of bacteriocins  
Many bacterial species have developed antimicrobial defence systems as an ecological 
advantage to survive against competitors, leading to the production of ribosomally 
synthesised antimicrobial peptides known as bacteriocins as potential chemotherapeutic 
agents [39]. The widespread distribution of gene-encoded peptides reflects their 
importance as a line of defence against microbial attack since they are amenable to being 
genetically modified [40]. The class II bacteriocins are known to be used as enzyme 
inhibitors, anti-HIV agents [11, 41-43].  
The unique nature of the bacterial cell wall means that it continues to represent an 
important target when screening for and developing new antimicrobial peptides. As a 
consequence, significant advances have been made in our understanding of the genetic 
determinants encoding bacteriocin production, their organisation and molecular 
mechanisms by which they mediate antibiosis. 
In 1925, Gratia identified the first original antimicrobial protein produced by Escherichia 
coli (a Gram-negative bacterium) [44] termed ‘colicin’. Since then, bacteriocins have 
been one of the most extensively studied microbial defence system [40]. Bacteriocin 
genes are either chromosomally or plasmid encoded which makes them accessible for 
genetic manipulation. The resulting toxin protein employs a variety of killing 
mechanisms: cytoplasmic membrane pore formation, interference with cell wall 
synthesis, and nuclease activity [45, 46].  
It should be noted that unlike antibiotics, bacteriocins are not used for medical purposes, 
therefore they are more commonly referred to as biological food preservatives. Table 1 
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summarises the main differences between antibiotics and bacteriocins in an attempt to 
emphasise that the latter are clearly distinguishable from clinical antibiotics [40].  
Characteristic Bacteriocins Antibiotics 
Application Food Clinical 
Synthesis Ribosomal Secondary metabolite 
Activity Narrow spectrum Varying spectrum 
Host cell immunity Yes No 
Mechanism of target cell 
resistance or tolerance 
Usually adaptation affecting cell 
membrane composition 
Usually a genetically transferable 
determinant affecting different 
sites depending the mode of action 
Interaction requirements Sometimes docking molecules Specific target 
Mode of action Mostly pore formation, but in a few 
cases possibly cell wall biosynthesis 
Cell membrane or intracellular 
targets 
Toxicity/side effects None known Yes 
Table 1 - Bacteriocins vs. antibiotics as taken from Cleveland et al. [40]. 
Bacteriocins are natural compounds; some are found in the fermented food available on 
the market. They are inactivated by enzymes, such as trypsin and pepsin, found in the GI 
tract and therefore, they do not alter the microbiota of the digestive tract. As a 
consequence, bacteriocins are not considered antibiotics; otherwise, they may not be used 
in human food, since the use of antibiotics in food is illegal [12]. The only bacteriocin 
considered by the Food and Agriculture Organization (FAO) as GRAS is nisin and it is 
used as a food additive. Nisin is often added to foods such as cheese to prevent the growth 
of pathogens like Clostridium and Listeria. Nisin inhibits the outgrowth of Clostridium 
botulinum spores in cheese spreads [40] and it is approved as a food additive in the United 
States for this purpose and it is also used as a food preservative worldwide including in 
the United Kingdom.   
The search for alternative drugs that inhibit cell wall synthesis has led to the discovery of 
various lantibiotic peptides which can inhibit bacterial cell wall biosynthesis by binding 
to the essential precursor of peptidoglycan, lipid II. Interestingly, it has been shown that 
unlike the docking motif of vancomycin, the lantibiotic nisin can bind to the 
pyrophosphate group of lipid II, a highly conserved chemical group [15]. As a result of 
this observation, a number of assumptions have been made: firstly, since lipid II is an 
essential and invariable region, the development of bacterial resistance is massively 
decreased; secondly, because it is gene encoded and may be more amenable to 
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derivatisation, nisin could act as a template for the design of novel drugs with structural 
features that promote high-affinity binding to lipid II  or to other antimicrobial targets [3].  
Therefore, by taking advantage of the available tools and knowledge, it is now possible 
to perform genetic engineering of bacteriocins which have been precisely tailored to 
target either a wide range or specific number of pathogens that are involved in causing 
infectious diseases [18]. 
The defining structural elements of bacteriocins offer not only structural and biological 
function to these peptides but also they make bacteriocins increasingly resistant to 
proteolysis from internal proteases as well as they offer tolerance to oxidation [12]. 
Therefore, the enzyme-mediated post-translationally modifications (PTM) introduced in 
bacteriocins, allow bacteriocins to particularly exhibit various mechanisms of action 
compared to currently used chemotherapeutics [15].  
Several desirable features in bacteriocins which are introduced by PTM, such as the 
unusual rings and amino acids, gives them the potential to be used in various applications 
such as pharmaceutical, biochemical, agricultural, food industries as well as both in 
human and veterinary medicine. Nevertheless, the subclass of bacteriocins described 
above, the lantibiotic peptides possess limitations for routine and widespread use. Some 
examples are the instability and insolubility at physiological pH and the predisposition to 
being degraded by intestinal proteases which prompted the need to bioengineer 
lantibiotics with higher potency and stability [47]. 
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1.5 GI tract solution to fix a GI tract problem  
Infections with the GI tract pathogen C. difficile have increased dramatically in the past 
years and the efficacy of standard therapies is decreasing. Rea et al. [1, 14] have 
considered the potential of bacteriocins produced by the GI tract bacteria, probiotics as 
well as phages to function as antimicrobial agents for the treatment of C. difficile 
infections in the human GI tract. O’Conner et al. [48] have reported the discovery of a 
novel nisin H variant produced by a GI tract strain of Streptococcus hyointestinalis 
DPC6484 which inhibits a range of Gram-positive bacteria such as listeria, enterococci, 
bacilli, streptococci and staphylococci. Marcille et al. [49] described the discovery and 
the analysis of two new lantibiotics, trypsin-dependent, ruminococcin A and 
ruminococcin C, derived from the commensal bacterium from the human intestinal 
microbiota, Ruminococcus gnavus E1 and which have anti-Clostridium perfringens 
activity [50, 51]. O’Shea et al. [52] have also reported the discovery of a novel bacteriocin 
from a porcine intestinal isolate, Lactobacillus salivarius DPC6502, and investigated its 
biological activity against S. aureus and Listeria monocytogenes pathogenic species. A 
similar study on bactoferin A [53] has indicated that it is a broad spectrum bacteriocin 
and that it could be used to manipulate the gut microbiota to benefit the human health 
especially as it may have a positive impact on bacterial anaerobic population of 
Bacteroides, Clostridium and Bifidibacterium spp. Interestingly, Lactobacillus salivarius 
strains isolated both from porcine and human GI tract were shown to produce multiple 
bacteriocins from a single locus using the same biosynthetic machinery which explains 
its ability to compete and dominate within the complex ecosystem of the microbiota [54].  
The above mentioned studies highlight the diversity and the dynamic environment of the 
microbiota. The GI tract represents a huge and yet unexplored environment for bioactive 
antimicrobial peptides. These bacteriocins do not only represent a probiotic trait for the 
producer intestinal strains, as they fight against infections and signal the immunity 
system, but they also have the potential to control gut bacterial populations in order to 
exert a beneficial effect on the human health [53].  
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1.6 Lantibiotics - gene cluster, structure and biosynthesis 
 Definition of lantibiotics  
Classification of bacteriocins is still under review; their definite classification has proved 
difficult due to their diversity [55, 56]. While some schemes agree on the two main 
classes, class I (lantibiotics) and class II (unmodified peptides), other schemes have 
proposed four classes [57, 58]. Table 2 illustrates the considerable diversity among 
bacteriocins and in particular among lantibiotics [59]. 
Category Characteristics and subcategories Bacteriocins    
(group representatives) 
Class I. Lantibiotics Heat stable peptides, encoded by a structural 
gene (generically named lanA).  Ribosomally 
synthesized peptides that undergo PTM. 
Molecular weight <10 kDa. Contain 
lanthionine (Lan) and β-methyl lanthionine 
(MeLan) bridges that give lantibiotics their 
characteristic conformations and stability. 
 
Type A: Flexible, elongated molecules. nisin, subtilin, gallidermin, 
epidermin, microbisporicin 
Type B: Globular molecules with no net 
charge or net negative charge. 
Mersacidin, actagardine, 
cinnamycin, duramycin 
Class II. Small heat  
stable bacteriocins 
Single or two-peptide bacteriocins. Pediocin PA-1, sakacins A, P, 
leucocin A, carnobacteriocins, 
lactococcins G and F, lactacin F,  
plantaricin EF and JK 
Class III.   
Large heat-labile 
bacteriocins 
Heat-labile proteins. Molecular weight >30 
kDa. 
Helveticins J and V-1829, 
acidophilucin A, lactacins A and 
B 
Class IV 
 
Complex bacteriocins carrying lipid or 
carbohydrate moieties. 
Venezuelin 
Table 2 - Classification of bacteriocins [56, 59-62]. 
The alignment of the sequences reveals a number of conserved amino acids stretches that 
are present both within and across subclasses that may represent functional domains. The 
name of these subclasses reflects the prototypical lantibiotic in each case and a few 
examples of lantibiotics are illustrated in Figure 1 [38].  
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Figure 1 - Structures of representative members of the seven subgroups of lantibiotics taken from Xie et al. 
[63].  
Abu, 2-aminobutyric acid; Ala-S-Ala: lanthionine - Lan (red); Abu-S-Ala: 3-methyllanthionine MeLan 
(blue); Dha, dehydroalanine and Dhb, dehydrobutyrine (green). All other post-translational modifications 
including Asp-OH, β-hydroxy aspartate, are shown in purple.  
According to the classification of bacteriocins, lantibiotics are type A bacteriocins 
characterised by lanthionine (Lan) and methyl lanthionine ((Me)Lan) bridges that give 
lantibiotics their characteristic conformations and stability [60]. Lantibiotics are produced 
by a range of Gram-positive bacteria including lactic acid bacteria (LAB), Streptomycetes 
and Clostridia. Lactobacillus, Lactococcus, Leuconostoc, Streptococcus, and 
Carnobacterium are among several LAB genera, which are capable of producing small 
antimicrobial peptides that inhibit a broad range of Gram-positive bacteria [40, 57].  
Many different types of lantibiotics have been identified and characterised especially the 
ones produced by LAB [58, 64] (Figure 1). The industrial importance of the LAB is 
evidenced by their GRAS status, due to their ubiquitous appearance in food and their 
contribution to the healthy microbiota of human mucosal surfaces. LAB are rod-shaped 
bacilli or cocci characterised by an increased tolerance to a lower pH range. This aspect 
partially enables LAB to outcompete other bacteria in a natural fermentation process, as 
they can withstand the increased acidity from organic acid production (e.g. lactic acid). 
Chapter 1 
   
14 
 
Even if lantibiotics have been extensively studied for their application in foods, only a 
few of them have been used in livestock or considered as viable to treat human infectious 
diseases [16]. 
The biosynthesis of lantibiotics from Gram-positive bacteria is self-regulated with 
dedicated transport mechanisms that facilitate their release [65]. Their most common 
mode of action involves pore formation in the cell membrane and dissipation of the proton 
motive force.  Lantibiotics can inhibit the growth of Gram-positive bacteria, whereas the 
Gram-negative bacteria are protected from their lethal effect by the presence of an outer 
membrane [17, 31]. Gram-negative infectious bacteria responsible for human, animal or 
plant diseases, such as Aeromonas, Escherichia, Xanthomonas, Erqinis, and 
Pseudomonas, can be sensitive to lantibiotics if they are coupled with chelating agents. 
Consequently, the potential use of lantibiotics and their derivatives is now being 
extensively investigated in order to inhibit these pathogens.    
 Structural features of lantibiotics 
Lantibiotics have a much higher specific activity compared to the vast class of 
bacteriocins. Their antimicrobial activity against sensitive strains can be detected at 
picomolar to nanomolar concentrations, although the action spectra are often narrow at 
these concentrations [59]. In the context of fermentation, important targets include 
spoilage organisms such as species of Clostridium, Lactobacilli and foodborne pathogens 
including L. monocytogenes, Staphylococcus spp., Enterococcus spp. and Bacillus spp. 
[66]. Some lantibiotics are characterised by a high content of uncommon amino acids 
which form ring structures also known as  thio-ether cross-links (Figure 2) [63]. Enzyme-
mediated PTM are responsible for converting the ribosomally synthesized, inactive and 
immature prepeptides into peptides that contain the characteristic features of lantibiotics. 
The maturation of lantibiotics takes place via two main reactions to form thio-ether cross-
links: serine and threonine amino acids in the core region are dehydrated and sulphur 
from the cysteine residues are added onto the resulting double bonds of the dehydrated 
residues [15, 67]. Since the gene clusters involved in the biosynthesis of lantibiotics have 
been sequenced, the PTM have been the focus of extensive research [63, 68].  
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Figure 2 - Post-translational modifications in lantibiotics.  
(a) General scheme of the biosynthesis of ribosomally synthesised peptides; Xn* indicates a modified 
residue, RNP means ribosomally synthesized natural products.  
(b) Mechanism of thio-ether cross-links formation.  
(c) Examples of structural motifs characteristic to lantibiotics. Abu, 2-aminobutyric acid; Dha, 2,3-
didehydroalanine; Dhb, (Z)-2,3-didehydrobutyrine; Lab, labionin. As taken from Xie et al. [63], Knerr et 
al. [62]. 
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 Lantibiotic gene clusters, biosynthesis and mode of action 
All the necessary genes for the biosynthesis of a lantibiotic peptide are located on a gene 
cluster (operon).  A number of genes have been identified, including genes encoding the 
precursor peptide, enzymes responsible for specific amino acid modifications, proteases 
able to remove the leader peptide, ABC-superfamily transport proteins involved in 
lantibiotic translocation, regulatory proteins controlling lantibiotic biosynthesis and 
immunity proteins that protect the producing strain from the action of its own lantibiotic 
[63]. Some examples of the gene clusters for lantibiotics are illustrated in Figure 3.  
 
Figure 3 - Biosynthetic gene clusters of the lantibiotics as taken from Xie et al. [63].  
The genetic markers for lantibiotics have been discussed in great detail in various reviews [56, 58, 60, 69, 
70]. The genes for the production of active lantibiotics are usually found on operon clusters and have been 
well studied. Most characterised lantibiotic operons belong to type A and many lantibiotic homologous 
genes are found among the sequenced lantibiotic gene clusters [13, 25]. The colours indicate the functions 
of lan. 
The biosynthetic gene clusters for these highly modified lantibiotic peptides are localised 
either on the bacterial chromosome or are encoded on mobile elements such as plasmids 
or transposons [71-73]. The biosynthetic genes have been given the generic locus symbol 
lan and their products are designated by their functions such as structural (LanA), 
modification (LanB and LanC or LanM), processing (LanP, LanT), transport (LanT), 
immunity (LanI, LanH, LanFEG), and regulation (LanR and LanK) systems; the 
functions are indicated by colours in Figure 3.  Some lantibiotics may have extra genes 
(lanQ, lanX) that are involved in regulation (Figure 3, Figure 4) [60, 69, 74-76].  
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Figure 4 - Lantibiotic biosynthesis taken from Field et al. [13, 15]. 
The precursor peptide (LanA) is ribosomally produced from the structural gene, lanA. 
Serine, threonine and cysteine are three amino acid residues found in the core region that 
are subject to the modification reactions to form the characteristic structures of 
lantibiotics: lanthionine (Lan) or methyl lanthionine (MeLan). In the case of nisin, a type 
A lantibiotic, these modifications are carried out by NisB and NisC enzymes via a two-
step route [13, 77] (Figure 5). For type B lantibiotics (e.g. lacticin 481), a bifunctional 
enzyme, LanM, performs both reactions. Further modifications lead to the formation of 
other modified amino acids which are present in different lantibiotics. For example, D-
alanines (LanJ) or S-aminovinyl-cysteine (LanD) [21]. Type A peptides are then exported 
out of the cell via a dedicated transporter (LanT), followed by proteolytic removal of the 
leader sequence by LanP which can be located inside or outside of the cell. The NisP 
extracellular protease, found in the nisin cluster, removes the leader peptide and activates 
the lantibiotic followed by the export of the core peptide performed by the ABC-type 
transporter NisT [13]. In the case of class II lantibiotics, a multifunctional LanT performs 
both roles even if the cleavage of the leader before or after the export is not fully 
understood. In both cases the result is the production of the active peptide. 
Lantibiotics are synthesised as biologically inactive precursor prepeptides consisting of 
an N-terminal leader peptide attached to the core region [74]. The leader peptide may 
function to maintain the peptide in a biologically inactive form during the maturation 
process until export. It also serves as a recognition sequence for the modifications and 
transport enzymes by facilitating and promoting the interaction with these precursor 
proteins [63, 78]. 
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Figure 5 - Illustration of the biosynthesis of nisin as taken from Knerr et al. [62].  
The inactive precursor peptide contains a leader peptide that guides both the modification and transport 
machinery. The steps for PTM are highlighted: Ser and Thr dehydration (green) by NisB to give 
dehydroalanines (Dha) and dehydrobutyrines (Dhb) (orange). The NisC catalysed cyclization of Dha and 
Dhb with Cys residues in the C-terminus which results in the formation of lanthionine rings (Lan is Ala-S-
Ala, MeLan is Abu-S-Ala). Post-translationally modified and mature nisin is exported by NisT outside the 
cell and the prenisin precursor peptide is activated by NisP, to give leaderless and active nisin. Rings A to 
E are annotated from the N-terminus and Abu is the aminobutyric acid. 
The structural organisation of nisin (Figure 5) allows it to have dual activity by using lipid 
II as a docking molecule for subsequent pore formation [21]. Transglycosylation, 
necessary for the formation of peptidoglycan, is inhibited because of the ability of nisin 
to bind lipid II. Following the binding of lipid II, the second function of nisin is to 
facilitate pore formation, which results in cell death by the rapid efflux of small 
cytoplasmic compounds and the dissipation of vital ion gradients [79-81]. It should be 
noted that lipid II is also the target of the type B lantibiotic mersacidin and actagardine as 
well as the glycopeptide antibiotics vancomycin, teicoplanin, ramoplanin, and the 
mannopeptimycins [16, 80]. Early studies indicated that the cationic nature of nisin allows 
binding to anion phospholipid bilayer through electrostatic interactions [82].  
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 Immunity and regulation  
In order to maintain a balance between nisin biosynthesis and immunity, the process of 
nisin production is regulated by a two-component system comprised of nisRK genes 
which encode for a sensor receptor histidine kinase, NisK, and a transcriptional response 
regulator, NisR.  
The mature nisin acts as other peptide pheromone involved in activation of its own 
biosynthesis via a two-component signal transduction machinery composed of NisK and 
NisR. Extracellular changes detected by NisK initiate a signal cascade that triggers the 
response regulator to activate the transcription of the regulated genes. These regulated 
genes may include the structural gene, the export genes, the immunity genes, and 
occasionally, the regulatory genes themselves [74]. Some lantibiotic producers 
autoregulate their own synthesis and operate as quorum sensing molecules allowing cells 
to sense other organisms in the environment in a cell density-dependent manner [83]. 
In order for the producing strain to synthesise the antimicrobial peptides, it has to be 
immune to the action of its own product. An efficient self-protection system is vital for 
the survival of the lantibiotic-producing bacterial strain against nisin, therefore, immunity 
is maintained by two systems: a lipoprotein NisI and an ABC transporter, NisFEG which 
expels nisin from the membrane of the producing strain [76]. As aforementioned, nisin 
producers also encode transport systems as a second mechanism of immunity; in some 
cases, the bacteriocin is transported out of the cell, lowering the concentration of the 
antimicrobial peptide below an inhibitory threshold (Figure 6) [59].   
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Figure 6 - Schematic representation of nisin biosynthesis and regulation in L. lactis taken from Cheigh et 
al. [84].  
 Resistance to nisin  
The main target of nisin in sensitive strains is the cytoplasmic membrane where it binds 
to the lipid II and gets incorporated to form ion channels or pores through which efflux 
of ions, ATP and amino acids results in destruction of the membrane potential. It has been 
shown that nisin-resistant strains are likely to arise. Many Gram-positive bacteria were 
shown to be resistant to nisin due their ability to synthesise nisin-specific proteases, 
termed nisinases, which could inactivate nisin [81]. 
The ability of some pathogens to develop resistance to nisin is clearly an obstacle to the 
development of new food or therapeutic applications. Nisinases are specific to nisin-
resistant strains and are produced by several species, including Bacillus cereus, B. 
megaterium, B. polymyxa, S. aureus, Streptococcus agalacticae, Strep. thermophilus, 
Lactobacillus plantarum and E. faecalis.  Although the presence of these enzymes was 
reported in several bacterial strains, a conclusive study indicating the presence of 
nisinases in L. lactis is still missing [85].  Nisin resistance of these aforementioned strains 
was reported to be conferred by a specific nisin resistance gene (nsr), which is located on 
a 60-kb lactococcal plasmid, pNP40, and encodes a 35-kDa nisin resistance protein 
(NSR). These genes have already been cloned and sequenced but their mode of action has 
not been elucidated yet. An additional mechanism of immunity or resistance of these 
strains, not genetically linked to production of nisin, was also reported in which a nisin 
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immunity gene was linked to lactoccocal plasmid DNA and it was associated with phage 
resistance [85].  
It has been shown that resistance to nisin is not dependent on the level of lipid II content 
in the cell membrane; a number of protoplasts containing different amounts of lipid II in 
their membrane were used to show that their membranes were equally sensitive to nisin 
[86]. Therefore, it was assumed that the development of nisin resistance among Gram-
positive bacteria was connected to changes in the cell wall structure architecture which is 
the most plausible explanations for acquired nisin resistance [85].  
1.7 Natural nisin variants  
Mature nisin is an antimicrobial peptide consisting of 34 amino acids residues of which 
13 are post-translationally modified resulting in pentacyclic peptide and it is typically 
produced by Lactoccocus lactis strains [87]. Although many lantibiotics have been shown 
to be effective against pathogens and spoilage bacteria, nisin is probably the best 
characterised lantibiotic and is the only antimicrobial peptide approved for use in food in 
its partially purified form [80].  Nine natural derivatives of nisin (nisin A, nisin Z, nisin 
Q, nisin F, nisin U and U2, nisin H, nisin P, and a distantly related nisin-like lantibiotic 
salivaricin D) have so far been identified (Figure 7) [48]. Nisin displays four different 
activities: 1. it autoinduces its own synthesis, 2. it inhibits the growth of target bacteria 
by membrane pore formation, 3. it inhibits bacterial growth by interfering with cell wall 
synthesis, 4. it inhibits the outgrowth of spores [88]. 
Nisin is amphiphilic in nature: the N-terminal region includes many hydrophilic residues 
which interact with phospholipid head-groups, whereas the C-terminal region has more 
hydrophilic residues as shown by NMR studies [89]. The hydrophilic and hydrophobic 
residues are located on opposite sides of the molecule as a consequence of the 
conformational restrictions imposed by the lanthionine rings [87].  
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Figure 7 - Structures of natural variants nisin A and nisin Z and putative structures of variant nisins Q, U 
and U2 as taken from Field et al. [87].  
In black, amino acid differences between the natural nisin variants. In grey, post-translational 
modifications.  Dha, dehydroalanine; Dhb, dehydrobutyrine; Abu, 2-aminobutyric acid; Ala-S-Ala, 
lanthionine; Abu-S-Ala, 3-methyllanthionine. 
Nisin derivatives are mainly composed of two structural domains:  the N-terminal domain 
(Rings A, B, C) is linked to the C-terminal domain (Rings D, E) by a flexible hinge region 
(positions 20, 21, 22). The unique mode of action as described by Field et al. [87] makes 
nisin highly potent at nanomolar concentrations against many Gram-positive bacteria. 
NMR analysis of the nisin-lipid II complex reveals that Rings A and B of nisin bind to 
the pyrophosphate moiety of lipid II with a hydrogen bond. On the basis of these findings, 
the residues in the hinge region or the residues in Rings A and B have been mainly 
targeted for mutagenesis [13].  
1.8  Bioengineering of nisin  
The biosynthesis of lantibiotics of type A seems to be a complex process. This makes it 
difficult to make changes in the sequence of the prepeptide (inactive form of the 
lantibiotic) and to predict the effect on the biosynthetic pathway. Even if some studies 
have given hints for the function of individual amino acids, there is a lack of knowledge 
in terms of the effect of individual or multiple mutations in the nisin structure. So far, 
little is known about the residues important for the interaction with the modification, 
export and processing systems and in the regulation of expression. In vitro bioengineering 
of novel compounds, in combination with a defined set of guidelines predicting where 
permissive modifications can be applied, may allow to incorporate thio-ether bridges in 
addition to or to substitute for more labile cysteine disulphide bridges [16]. These 
developments could ultimately permit the rational design and assembly of more 
constrained peptide configurations with enhanced stability in natural or synthetic 
peptides. In summary, current knowledge of in vitro and in vivo based technologies may 
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enable researchers to not only appropriately modify lantibiotics but also introduce amino 
acids and modifications not typically encountered in nature as part of the efforts to 
generate peptides with enhanced structural features.  
In vivo engineering of lantibiotics readily generates peptides and enables the rapid use of 
manipulated genes and (host) organisms. In the case of nisin, a mutated nisA gene can be 
expressed in the original producer strain by replacement of the original structural gene. 
An alternative strategy is the heterologous expression of a biosynthetic gene cluster; this 
provides a simple approach for constructing and producing the large number of structural 
analogues required for further studies in the structure-activity relationship of lantibiotics 
[90]. With the gene replacement systems described for nisin [91-93] and subtilin [83], the 
only alterations to the genome are the specific mutations introduced in the structural gene. 
Random mutagenesis also seems a powerful approach for generating lantibiotics with 
desired properties, provided that an adequate and sensitive phenotypic screening method 
is available [87]. 
Dodd et al. [94] performed gene replacement experiments for the construction and testing 
of a parent strain (FI7990 expression host) followed by transformation of a nisin cluster 
in L. lactis strain; this was done to substitute a chromosomal sequence for an equivalent 
region which resulted in very low levels of expression/ frequency of mutants exhibiting 
specific nisin antimicrobial activities when mutations were done on a chromosome. In a 
later study, Dodd et al. [95, 96] reported the use of a developed expression-system that 
allows the exclusive production of novel nisin variants which are encoded by mutated 
prenisin obtained by the site directed mutagenesis of the nisA genes.   
The original study indicated the presence of a reduced level of immunity which was 
explained by the fact that the strains which acquired a nisA gene by gene replacement 
may not have recovered full immunity before the nisin molecule exerted the antimicrobial 
activity, hence their growth was impeded. To improve this protocol and to recover the 
nisin immunity, Dodd et al. [95] included an addition of nisin (10 pg/ml) to the GM17 
agar plates to select for those colonies which were immune to this level of nisin. A similar 
approach to the one described above was being taken in this PhD project.  
Large numbers of nisin mutants have already been generated and characterised [12]. 
Single or multiple mutations have resulted in different effects on antimicrobial activity, 
physical properties such as solubility or (thermo)stability when the mutants were tested 
against a selected and a limited number of target strains [38]. All these studies have 
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provided a wealth of information on fundamental aspects of nisin biosynthesis, secretion 
and processing and have started to bring light on the immunity and the effect of in vivo 
and in vitro modifications of nisin. In early studies, several nisin mutants were generated 
by site-directed mutagenesis [13]; the active peptides were present in the supernatant of 
the cultures where processes such as unusual amino acid formation, transport and 
processing of the leader peptide were part of the normal biosynthetic pathway. Among 
the numerous bioengineered nisin variants generated to date, only a few of them have 
exhibited improved functionality such as higher antimicrobial activity against some 
indicator strains. Notable examples are: Asn27Lys and His31Lys mutants of nisin Z 
which have increased solubility at a neutral pH without changing their antimicrobial 
activity; the Thr2Ser mutant of nisin Z displayed increased activity; Asn20Lys and 
Met21Lys mutants of nisin Z showed slightly decreased activity against Gram-positive 
bacteria, but have improved activity against several Gram-negative bacteria [93]. 
In a more systematic approach, Field et al. [13, 16] have taken advantage of in vivo 
engineering to construct and screen for highly potent nisin variants. By using random (site 
saturation) mutagenesis in the hinge region of nisin A, a number of variants were 
successfully engineered with enhanced antimicrobial activity: Ans20Pro, Met21Val and 
Lys22Thr mutants of nisin A which displayed enhanced antimicrobial activity against 
pathogenic bacteria such as L. monocytogenes and S. aureus compared to the wild type 
nisin peptide [16, 88]. Further random-based mutations of these amino acids generated 
nisin variants with increased antimicrobial activity. In contrast, in vitro engineering is not 
suitable for the generation of libraries containing huge numbers of variants; instead, it can 
be used for more drastic engineering by combining biological and chemical approaches 
[90]. 
Several studies have reported the bioengineering of novel nisin mutants with improved 
physico-chemical properties and biological activity compared to nisin [15]. Even if nisin 
has been approved by FDA and it is used as a food preservative worldwide for a number 
of years (GRAS status), nisin is not stable under physiological conditions [47]. 
Bioengineering of nisin could help to create a nisin mutant that can be used as a 
therapeutic agent in a clinical setting in the future. If such a nisin mutant is developed 
which is effective at physiological pH such as for lacticin 3147 lantibiotic [32], the novel 
compound could have considerable potential for biomedical applications including the 
fight against GI tract infections from MDR pathogens.  
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1.9 Background to previous work on the project 
Earlier work in the group involved screening of the gut microbiota to identify and 
characterise novel gene clusters that may encode bacteriocins with antimicrobial activity. 
A PCR based genome mining approach to identify a novel gene cluster encoding 
lantibiotics in a strain of Blautia obeum A2-162 isolated from the human GI tract was 
used previously by Hatziioanou [97]. The predicted ClosA1 peptides were nisin-like 
lantibiotics with more than one lanA gene (type A lantibiotics). All the four closA genes 
have GG type leader peptides typical of type B lantibiotics. Nisin has a PR type leader 
peptide sequence. However, this is an example of a type A lantibiotic containing type B 
(GG) leader peptide sequences. So far, the structures of these potential types A lantibiotics 
and their antimicrobial activity have not been fully characterised (Figure 8).   
The clos gene cluster encoding putative lantibiotics of the Blautia obeum A2-162 strain 
was sequenced and lantibiotic clos gene functions were investigated by heterologous 
expression in L.  lactis. Attempts to clone different designed constructs into the nisin 
inducible pUK200 vector using initially E. coli followed by L. lactis indicated that the 
genes may be lethal for E. coli. It was also found that members of the Blautia obeum A2-
162 gene cluster showed some cross-reactivity with the nisin machinery (Hatziioanou et 
al., in preparation). Attempts to induce antimicrobial production in liquid culture, purify 
and characterise the active peptides were not successful. Also, attempts to induce 
antimicrobial production using nisin A in strain Blautia obeum A2-162 were unsuccessful 
after growth in the presence of 100 ng/ml of nisin A. 
In her work, Hatziioanou [97] did show that the novel gene cluster can be subcloned and 
expressed in L. lactis; despite complementation with the closA gene on an inducible 
plasmid, the expression of mature biologically active ClosA peptides was not possible. 
Hatziioanou also tried to express the clos gene cluster in L. lactis MG1614 and to use the 
nisin A biosynthetic machinery to modify and to produce active ClosA peptides. Even if 
cloning of the novel clos operon in the nisin system of L. lactis was successful, the nisin 
machinery may have not expressed, modified and released active Clos antimicrobial 
peptide since none of these steps were demonstrated in Hatziioanou’s work [97]. A 
possible explanation was that the unique ClosA peptides may have not been modified due 
to the lack of a protease capable of cleaving the leader peptides from the modified and 
mature core peptides. A protein the size of the calculated ClosA prepeptide which 
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hybridised to the antiClos leader antibody was however detected but it was not confirmed 
by MS. This could further explain the absence of a fully active Clos peptide.  
 
Figure 8 - Nisin and clos gene clusters and protein sequences.  
The nisin machinery and the original structure of nisin, used as a template, will allow the generation of 
clos-like nisin mutants illustrated in (b); (c) arrangement of the sequenced clos lantibiotic cluster 
highlighting the genes identified from Blautia obeum A2-162 strain. The predicted structures of one of the 
two mature ClosA peptides (ClosA1, A2, A3 are identical) will be used to identify and substitute amino 
acids in the original nisin sequence (c).  
The genes in the clos cluster were colour coded: structural genes in black (closA1-4), modification genes 
in orange (closBC), transport gene in blue (closT), immunity genes in purple (closFEG, closI), regulatory 
genes in green (closR1K1, closR2K2). Abu, Dha and Dhb are unusual amino acids introduced by PTM. 
Adapted from Hatziioanou  [97]. 
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Alignment of nisin (Figure 8, A) and the predicted structure of the ClosA1 peptide (Figure 
8, C) indicated the presence of a highly conserved number of amino acids [97]. Using the 
nisin sequence as a template, amino acid substitutions were introduced to give 12 nisin 
variants with features of the ClosA1-3 peptide as illustrated in Figure 8, B. The ClosA 
peptides are identical with one amino acid difference in the leader peptide. The predicted 
structure of the second putative ClosA4 peptide was illustrated in Figure 20, chapter 4.  
The genetic manipulation of the entire clos gene cluster from Blautia obeum A2-162 
producing strain will allow knowledge-based improvements in Clos antimicrobial 
production and Clos bioactivity as well as the application of genetic engineering to 
develop novel, potentially improved clos-like nisin derivatives. Understanding if and how 
active lantibiotics from this clos novel gene clusters are made could enable the 
development of clos-like nisin variants with improved clinical activity. 
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1.10 Scope of the PhD thesis  
The principle aims of this PhD project were to establish if the novel clos cluster identified 
earlier in a gut bacterium by genome mining was able to produce active Clos 
antimicrobial peptide as well as to identify nisin mutants with improved bioactivity under 
GI tract conditions. This is due to the need for new therapies effective against bacterial 
infections due to antimicrobial resistance. Lantibiotics such as nisin can be used as food 
preservatives, however they are unstable in the human gut and the clos cluster was 
identified in commensal gut bacteria. 
To demonstrate the aims, a number of approaches were taken. 
 Generation and characterisation of Clos-like nisin mutants 
To genetically engineer Clos-like nisin mutants and to determine the stability of purified 
peptides under gastrointestinal tract conditions (temperature, physiological pH).  
 Identification and functional characterisation of promoters in the clos operon 
To genetically engineer a reporter gene promoter system for the identification and 
assessment of functional promoters in the clos cluster, to measure the specific pepI 
activity and to determine which regulatory system switches on which clos promoters.  
 Heterologous expression of Clos peptides  
To perform the heterologous expression of the preClosA peptides using the nisin induced 
clos cluster, to cleave the leader with external proteases such as trypsin and to investigate 
the biological activity against indicator strains including gut pathogens using the overlay 
assays.  
 Structure confirmation of the preclosA peptide 
To perform scaled up isolation of immunoprecipitated preClosA peptides, to detect and 
to investigate PTM introduced by the clos cluster machinery and to finally validate the 
structure of the Clos peptides by comparison with nisin using MS.  
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2.1 Microbiology Work  
The following material and methods were used throughout the PhD project. Details about 
bacterial strains and plasmids are in Table 4 to Table 7, buffers and their protocols in 
Table 3. Consumables were purchased from Sigma Aldrich (Dorset, UK) unless stated 
otherwise. 
 Culture media  
Trypsin bovine pancreas mix (Sigma-Aldrich) or pure Trypsin (Promega, Mass Spec 
Grade) were prepared in fresh Trypsin Resuspension Buffer (Promega) or in 50 mM 
acetic acid. Trypsin was used for digestion of Clos peptides and for the cleavage of the 
Clos leader to give active antimicrobial peptide.  
1) Nisin A (Aplin & Barrett Ltd, Beaminster, UK) was used to induce antimicrobial 
production and it was prepared in 0.2 μm filter in 50% diluted HCl pH adjusted 
to 3.0. Aliquots of the stock were stored at -20°C at concentrations of 10 mg/ml 
and 10 μg/ml. 
2) For the induction of nisin mutants and purification in large fermenters, nisin 
powder (Sigma, 2.5 % sodium chloride and denatured milk solids) was used and 
prepared as above  
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Table 3 - List of liquid and solid media used in this thesis. 
The solid media was prepared by adding 1.5 % (w/v) agar to the appropriate medium before autoclaving.  
*For the overlay assay, the solid agar medium was prepared by adding 0.7 % agar (Oxoid) to M17. For 
antimicrobial screening of producer strains, 20 mg/l NaHCO3 was added to the solid media before seeding 
unless stated otherwise. For antimicrobial screening of purified nisin mutants, the pH of medium was 
adjusted to pH 3.0, 5.0, 5.5, 6.0, 6.5, 7.0 prior to addition of agar and autoclaving.  
**The SPY-S special media was used for the scale up production of nisin mutants in 300 ml or 11 l 
fermenters.  
 
 
 Details State 
L medium 10 g/l bacto tryptone, 5 g/l bacto yeast 
extract, 5 g/l NaCl, 1 g/l glucose. 
Liquid, solid*  
MRS medium  
(de Man-Rogosa-Sharpe, 
modified with glucose 
addition) 
8 g/l lab lemco (Oxoid), 10 g/l peptone 
(Oxoid), 5 g/l yeast extract (Difco), 5 g/l 
sodium acetate.3H2O, 2 g/l K2HPO4, 2 
g/l triammonium citrate, 5.75 mg/l 
MgSO4.7H2O, 1.4 mg/l MgSO4.4H2O, 1 
ml Tween 80 and 20 g/l glucose). 
Liquid, solid* 
BHI + c media 
 
Brain heart infusion, Oxoid + 
complements: 50 mg/l vitamin K, 5 mg/l 
hemin, 1 mg/l resazurin, 0.5g/l 
cysteine). 
Liquid, solid* 
M17 (Oxoid) Prepared from ready prepared 
commercial powder. 
Liquid, solid* 
Robertson’s cooked meat 
medium 
Purchased from Southern Group 
Laboratories Ltd, UK. 
Liquid 
GM17 5 g/l glucose to M17 media after 
autoclaving. 
Liquid, solid* 
SPY-S* 
 
9 g yeast extract, 9 g peptone, 9 g  
K2HPO4, 1.8 g NaCl, 0.018 g  
MgSO4.7 H2O, 810 ml UPH2O. Adjust 
to pH 6.0 with 10N NaOH. Add 90 ml 
of 30 % sucrose post autoclaving.   
Media used in fermenters  
SM17 & 3 % glycine 11.175 g M17 broth powder, 51.35 g 
sucrose, 9 g glycine in 300 ml UPH2O.  
Used for preparation of  
L. lactis 
(ultra) electrocompetent 
cells (3 day protocol) 
SOC broth  2 % Tryptone, 0.5 % yeast extract  
8.56 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM glucose, 
all diluted in  UPH2O, adjust to pH 7.0 
Used for preparation of  
E. coli electrocompetent 
cells  
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 List of bacterial strains and their growth conditions  
The (non) genetically modified bacterial organisms and all the plasmids used or generated 
in this PhD thesis are listed in Table 4 to Table 7. Lists of antibiotic concentrations are in 
Table 8. 
The L. lactis strains, listed in Table 6 and Table 7 were obtained from in-house culture 
collections (IFR, Norwich, UK) and some of the strains were generated in this study. All 
strains were stored at -80°C in multiple use 1 ml aliquots in 40 % glycerol and grown in 
media under conditions as in Table 3. 
All bacterial strains were grown in aerobic conditions. If anaerobic conditions were 
necessary, media was pre-reduced in an anaerobic chamber (Don Whitley, UK) overnight 
in an atmosphere of 5 % CO2, 10 % H2 in N2.  
Stocks of Clostridium species were stored in Robertson’s cooked meat medium (Southern 
Group Laboratory, Corby). One hundred μl of the stock was used to inoculate pre-reduced 
BHI (with complements) which was then transferred immediately to the anaerobic cabinet 
and incubated at 37°C overnight. C. difficile and C. perfringens were further subcultured 
before they were used in the experiments.  
Cell density was measured with a CECIL CE2041 S/W version R0044 spectrophotometer 
using bandwidth 4 nm wavelength 600 nm [98]. 
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Table 4 - List of plasmids used in this work. 
Plasmid Details (reference) Antibiotic 
Selection* 
pIL253 Simon and Chopin [97, 99] Ery 
pUK200 Cloning shuttle vector under the 
control of the nisin promoter PnisA 
[100]  
Cm 
pTG262 Shearman et al. [98] Cm 
pNisI pTG262_PnisA with nisI Cm 
pUK200_NisL_ClosA1(IE) 
pFI2734  
Hatziioanou [97] 
 
Cm 
pUK200_NisL_ClosA1(YK)                         
pFI2735 
Hatziioanou [97] 
 
Cm 
pUK200_NisL_ClosA4   
pFI2736 
Hatziioanou [97] 
 
Cm 
pNisL-NisA  pUK200_PnisA with the nisin A 
leader sequence followed 
by the nisA structural sequence 
pUK200_PnisA_nisA 
Cm 
pClosCluster pILClosCluster Ery 
pClosL_closA34 (pFI2728) 
pTG262_PnisA_Clos 
Leader+closA34 
 
pFI2728 with Blautia obeum A2-162 
lanA copy 3 and 4 genes  
 
pTG262_PnisA with closA3 followed 
by strain Blautia obeum A2-162 
RBS and closA4 [97] 
Cm 
pFI2724 pIL252_ClosCluster (17 kp clos 
cluster isolated from  
Blautia obeum A2-162); 6B [97] 
Ery 
pFI2725 pFI2725 (pIL253 Clos Cluster) with 
Clos A1A2A3A4 deleted 
FI7847 
pIL253_ClosCluster(ΔclosA) 
Ery 
pFI2734  pUK200 with nisA leader- Blautia 
obeum A2-162 closA (triplicate 
sequence) structural gene with IE 
start site. 
Cm 
pFI2735 pUK200 with nisA leader- Blautia 
obeum A2-162 closA (triplicate 
sequence) structural gene with YK 
start site.  
Cm 
*Ery is Erythromycin, Cm is chloramphenicol. 
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Table 5 - List of plasmids constructed in this work. 
Plasmid Description Antibiotic 
resistance 
pFI2724 pIL253 with Clos Cluster 6B Ery 
ppTG262_nisA 
or 
pNisL-NisA  b 
pTG262_PnisA with nisin leader sequence followed 
by nisA structural gene  
Cm 
ppIL_NisI pIL253 with nisin promoter (PnisA) and nisI 
immunity genes 
Ery 
ppUK200_I4K pUK200_nisA_I4K mutant with nisin leader 
sequence followed by nisA structural gene with the 
I4K mutation (lysine(K) substituted isoleucine(I) 
on position 4) 
Cm 
ppTG262_I4K pTG262_nisA_I4K with nisin leader sequence 
followed by nisA structural gene with the I4K 
mutation (lysine(K) substituted isoleucine(I) on 
position 4) 
Cm 
ppUK200_ L6A pUK200_nisA_L6A mutant Cm 
ppTG262_L6A pTG262_nisA_L6A mutant Cm 
ppTG262_ I4K_L6A pTG262_nisA_ I4K_L6A mutant  Cm 
ppTG262_ A15I pTG262_nisA_A15I mutant  Cm 
ppUK200_ A15I pUK200_nisA_ A15I mutant  Cm 
ppTG262_ G18T pTG262_nisA_G18T mutant  Cm 
ppTG262_ A15I_G18T pTG262_nisA_A15I_G18T mutant  Cm 
ppTG262_ N20P pTG262_nisA_N20P mutant  Cm 
ppTG262_ M21L pTG262_nisA_ M21L mutant  Cm 
ppTG262_ N20P_M21L pTG262_nisA_N20P_M21L mutant  Cm 
ppTG262_ H27G pTG262_nisA_H27G mutant  Cm 
ppTG262_  
H27G_S29H_ H31T_V32G_ 
S33K   
pTG262_nisA_H27G_S29H_ H31T_V32G_ 
S33K mutant  
Cm 
ppTG262_H31T_V32G_ 
S33K   
pTG262_nisA_ H31T_V32G_ S33K mutant    Cm 
pPClosA1A4_pepI 
 
pPClosA_pepI 
MG1614 or UKLc10 with pIL253_PClosA1A4_pepI 
 
pIL253 with ClosA1A4 promoter sequence 
(PClosA1A4) followed by pepI reporter gene.  
Ery 
pPClosBTC_pepI 
 
pPClosBTC_I 
MG1614 or UKLc10 with pIL253_PClosBTC_pepI  
 
pIL253 with BTC promoter sequence (PClosBTC) 
followed by pepI reporter gene.   
Ery 
pPClosFEG _pepI 
 
pPClosFEG _I 
MG1614 or UKLc10 with pIL253_ PClosFEG _pepI 
 
pIL253 with FEG promoter sequence (PClosFEG) 
followed by pepI reporter gene . 
Ery 
pPClosR2K2_pepI 
 
pPClosR2K2_I 
MG1614 or UKLc10 with pIL253_ PClosR2K2_pepI 
 
pIL253 with R2K2 promoter sequence (PClosR2K2) 
followed by pepI reporter gene. 
Ery 
pPnisA _closR1K1 
 
pUK200_PnisA with ClosR1K1 two-component 
regulatory system sequence/gene(s) from the clos 
cluster of Blautia obeum A2-162 
Cm 
pPnisA _closR2K2 
 
pUK200_PnisA with ClosR2K2 two-component 
regulatory system sequence/gene(s) from the clos 
cluster of Blautia obeum A2-162 
Cm 
pPnisA _closΔR1K1 
Frameshift 
MG1614 or UKLC10 with pUK200_PnisA with 
closR1K1 with mutation/ frameshift in ClosR1. 
Cm 
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pFI2735 MG1614 with pUK200 with nisA leader- Blautia 
obeum A2-162 (triplicate sequence) closA 
structural gene with YK start site.  
Cm 
pNisL_ClosA1(IE_IT) pTG262 with nisA leader- Blautia obeum A2-162 
(single sequence, A1≡A2≡A3) closA structural 
gene with the start site IT instead of IE. 
Cm 
pNisL_ClosA1(YK_IT) pTG262_NisL_closA with the start site IT instead 
of YK. 
Cm 
pNisL_ClosA1(IE) pTG262_NisL_closA with the start site IE. Cm 
pNisL_ClosA1(YK) pTG262_NisL_closA with the start site YK.  Cm 
pNisL_ClosA4 pTG262_NisL_closA4  Cm 
pLC6B pIL253 containing the strain Blautia obeum A2-
162 lantibiotic cluster from clone 6B  
Ery 
pLC6BΔA pLC6B ΔclosA  Ery 
 
Table 6 - List of organisms and their growth conditions used in this thesis.  
Organism strain name/ 
number 
Media Details on growth 
conditions and 
description  
Antibiotic 
resistance 
Lactococcus lactis MG1614 GM17 L. lactis MG712 cured 
of plasmids and 
prophage, Smr Rifr 
Gasson  [101]  
37°C, static 
Smr, 
streptomycin 
resistance; 
Rifr, 
rifampicin 
resistance. 
Lactococcus lactis FI5876 GM17 MG1614::Tn5301, 
transconjugant, 
nisin producer [102] 
37°C, static 
 
Escherichia coli  MC1022 L broth  37°C, 250 rpm 
Plasmid free [103] 
 
Bacillus cereus 
0880 
ATCC 9139 BHI 37°C, 220 rpm N/A 
Bacillus subtilis ATCC 9139 BHI 37°C, 220 rpm N/A 
Clostridium 
difficile** 
NCTC11204 BHI+C* 37°C, anaerobic N/A 
Clostridium 
perfringens** 
NCTC3110 BHI+C* 37°C, anaerobic  N/A 
Enterococcus 
faecalis 
ATCC376 MRS(HM)+ 
glucose 
37°C, static  N/A 
Enterococcus 
faecium 
ATCC6057 BHI 37°C, static  N/A 
L. lactis MG1614 GM17 30°C, static N/A 
Leuconostoc 
mesenteroides sub 
mes. 2205 
ATCC8293 MRS(HM)+ 
glucose 
30°C, static N/A 
Listeria innocua ATCC33090 BHI 37°C, shaken N/A 
Listeria ivanovii NCTC11007 BHI 37°C, shaken N/A 
Listeria 
monocytogenes 
FI10270 BHI 37°C, shaken N/A 
Micrococcus 
luteus 
FI10640 MRS(HM)+ 
glucose 
37°C, static N/A 
Staphylococcus 
aureus 
FI10139 BHI 37°C, static N/A 
L. lactis FI5876  
 
MG1614 with nisin 
biosynthetic operon 
N/A 
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L. lactis FI7847  
 
 
GM17 
FI5876 ΔnisA N/A 
L. lactis FI8438 FI5876 ΔnisP N/A 
L. lactis  pClosCluster +  
pPnisA_closLeader_clo
sA34 
pIL253 with 
ClosCluster and 
pTG262_PnisA and 
closLeader and 
closA34 structural 
genes       
Cm, Ery 
L. lactis FI10899 FI8438 with pFI2734 
= pUK200 with nisA 
leader- Blautia obeum 
A2-162 lanA (3 
sequence) structural 
gene with IE start site 
Cm 
L. lactis FI10900 FI8438 with pFI2735 
= pUK200 with nisA 
leader- Blautia obeum 
A2-162 lanA (3 
sequences) structural 
gene with YK start site 
Cm 
L. lactis NisL_ClosA1(IE)  
 
 
 
 
GM17* 
FI7847 with pNisL-
ClosA1 with IE start 
site (in pUK200 or 
pTG262) 
Cm 
L. lactis NisL_ClosA1 
(YK) 
FI7847 with pNisL-
ClosA1 with YK start 
site (in pUK200 or 
pTG262) 
Cm 
L. lactis NisL_ClosA4 FI7847 with pNisL-
ClosA4 (in pUK200 or 
pTG262) 
Cm 
L. lactis NisL_ClosA1 
(IE_IT) 
FI7847 with pNisL-
ClosA1 (in pTG262) 
Cm 
L. lactis NisL_ClosA1 
(YK_IT) 
FI7847 with pNisL-
ClosA1 (in pTG262) 
[97] 
Cm 
L. lactis UKLc10  
 
 
 
 
 
GM17 
 
nisRK regulatory 
genes inserted into 
chromosome at pepN 
locus  
N/A 
L. lactis  GH204 pUK200I = pUK200_ 
PnisA with pepI reporter 
gene from Lb. 
delbrueckii  
Cm 
L. lactis FI10235 MG5267 with pIL253 
[97] 
Er 
L. lactis FI10881 MG1614 with pFI2724 
(pIL253 with Clos 
Cluster 6B) [97] 
Er 
L. lactis FI10882 MG1614_pFI2725 
(pIL253 Clos Cluster) 
ΔclosA1-4 [97] 
Er 
L. lactis FI10885 MG1614 with 
pTG262_PnisA 
_ClosL_closA34 
Cm 
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pPClosBTC_pepI 
pPClosBTC_I 
MG1614 with pIL253_PClosBTC_pepI  
pIL253 with BTC promoter sequence (PClosBTC) followed by 
pepI reporter gene.   
Ery 
pPClosFEG _pepI 
pPClosFEG _I 
UKLc10 with pIL253_ PClosFEG _pepI 
pIL253 with FEG promoter sequence (PClosFEG) followed by 
pepI reporter gene. 
Ery 
pPClosR2K2_pepI 
pPClosR2K2_I 
UKLc10 with pIL253_ PClosR2K2_pepI 
pIL253 with R2K2 promoter sequence (PClosR2K2) followed by 
pepI reporter gene. 
Ery 
pPClosR2K2_pepI 
pPClosR2K2_I 
MG1614 with pIL253_ PClosR2K2_pepI 
pIL253 with R2K2 promoter sequence (PClosR2K2) followed by 
pepI reporter gene. 
Ery 
 
*in pUK200 and in pTG262 plasmids.  
Table 7 - List of organisms made and their growth conditions used in this thesis. 
Organism Strain name/ 
number 
Details on growth conditions and 
description  
Antibiotic 
resistance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L. lactis 
UKLc10_CC UKLC10 with pClosCluster      Er 
UKLc10_CC_cA34 UKLC10 with pClosCluster and                  
pPnisA_closLeader_closA34 
Er, Cm
FI7369 FI7332+pFI378,pTG262_nisA [94]  Cm 
FI7847_CC      FI7847 with pClosCluster      
FI7847+pILClosCluster      
Er 
FI7847_CC_cA34 FI7847 with pClosCluster (ΔclosA) and 
pPnisA_ closLeader_closA34 
FI7847+pILClosCluster (ΔclosA)    + 
pTG262_ pPnisA_ClosLeader_ closA34     
Er, Cm 
CC(ΔClosA)  & 
NisL_ClosA1(IE) 
FI7847 with pTG262 clos cluster   
with closA structural genes deleted 
and pTG262_PnisA with nisin leader 
sequence and ClosA1 (IE start site) 
structural gene sequence  
FI7847+pIL253_CLosCluster(ΔclosA)+ 
NisL_ClosA1(IE) 
Er, Cm 
CC(ΔClosA) & 
NisL_ClosA1(YK) 
FI7847 with pTG262 clos cluster   
with closA structural genes deleted 
and pTG262_PnisA with nisin leader 
sequence and ClosA1 (YK start site) 
structural gene sequence  
FI7847+pIL253_ClosCluster(ΔclosA)+ 
NisL_ClosA1(YK) 
Er, Cm 
CC(ΔClosA)  & 
NisL_ClosA4 
FI7847 with pTG262 clos cluster   
with closA structural genes deleted 
and pTG262_PnisA with nisin leader 
sequence and closA4 structural gene 
sequence  
FI7847+pIL253_ClosCluster(ΔclosA)+Nis
L_ClosA4 
Er, Cm 
CC(ΔClosA) & 
NisL_ClosA1 
(IE_IT) 
FI7847 with pTG262 clos cluster   
with closA structural genes deleted 
and pTG262_PnisA with nisin leader 
sequence and ClosA1 (IT start site instead 
of IT) structural gene sequence  
FI7847+pIL253_ClosCluster(ΔclosA)+ 
NisL_ClosA1(IE_IT) 
Er, Cm 
CC(ΔClosA) & 
NisL_ClosA1 
(YK_IT) 
FI7847 with pTG262 clos cluster   
with closA structural genes deleted 
Er, Cm 
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and pTG262_PnisA with nisin leader 
sequence and ClosA1 (IT start site instead 
of YK) structural gene sequence  
FI7847+pIL253_ClosCluster(ΔclosA)+             
NisL_ClosA1(YK_IT) 
 
Table 8 - The antibiotics used for general genetic modifications and selection studies. 
Antibiotic Solvent used for 
preparation 
Final concentration 
for L. lactis 
Final concentration 
for E. coli 
Chloramphenicol 
(Cm) 
Ethanol  5 μg/ml 15 μg/ml 
Erythromycin 
(Er) 
Ethanol 5 μg/ml 100 μg/ml 
 Bioassays for antimicrobial activity 
 Bacterial overlay assay (deferred antagonism assay) with colonies 
For the overlay assay [16], the nisin derivative or Clos peptide producers were grown 
overnight in 10 ml liquid cultures. 1 to 5 µl of the overnight culture were spotted onto 
GM17 agar plates typically containing nisin (0, 10, 100 ng/ml) with appropriate 
antibiotics (if required), and incubated overnight at 30°C. The plates were irradiated under 
UV light on AlphaImager (Alpha Innotech) for 15 min prior to being overlaid with soft 
agar seeded with 1-2 % of the indicator culture and incubated overnight at the optimal 
temperature for the sensitive strains. Zones of clearing in the indicator lawn were 
compared against control: nisin producing wild type strain FI5876 [102] and empty vector 
negative control.  
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 Plate diffusion assay (well diffusion assay) with supernatant 
Nisin A (Aplin & Barrett Ltd, Beaminster, UK) was prepared as described in section 
2.1.1.  
For the large scale production and purification in large fermenters of the nisin mutants, 
the producing strains were induced with Sigma nisin powder (Sigma, 2.5 %, balance 
sodium chloride and denatured milk solids) which was used and prepared as above. 
Nisin standards. A stock nisin solution of 1 mg/ml was prepared by adding 1 mg of 
commercial nisin into 50 % diluted HCl at pH 3.0. Standard nisin solutions of 15, 12, 9, 
6, 3, 1.5, 0.9, 0.6, 0.3 µg/ml were prepared using nisin stock solution, either in 50 % 
diluted HCl pH 3.0 or 1 M phosphate buffer pH 6.0 and used to construct the standard 
curve (Figure 9).  
Nisin bioassay. Based on the method of Olasupo et al. [104], the bioassay agar plates 
were prepared for different indicator strains and optimal media were used for each 
organism. Typically 95 ml of melted M17 agar at 55°C was mixed with 5 ml of 10 % 
glucose and 2 ml of 1:1 (1/4) Ringers:Tween 20 and inoculated with 1 ml of a 24 h culture 
of the corresponding nisin-sensitive strain. 100 ml of aseptic agar was poured into sterile 
square Petri dishes and allowed to solidify for 2 h or overnight at 4°C. Wells were bored 
into the agar using a 7-mm outer diameter stainless steel borer. Samples were prepared 
from 1 ml of acidified overnight culture to pH 3.0, centrifuged at 4000 rpm for 10 min, 
then the supernatant was filter sterilised with a 0.2 µm filter. 200 µl of sample nisin 
standards were loaded onto the plates, incubated for 3-5 h at 4°C (to allow for diffusion) 
then incubated as appropriate for each sensitive strain. Digital callipers were used to 
measure the diameter of the inhibition zone around each well in triplicate; the diameters 
were averaged and the well diameter was subtracted from this measurement. Figure 9 has 
all the equations used to calculate nisin mutant peptide concentrations based on the nisin 
standard curve [16].  
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A. B.  
C.  
Figure 9 - Nisin standard curve from a plate diffusion bioassay using culture supernatants. 
 
For each equation, a number in blue was associated (1-5). The nisin standard curve (A) was plotted by using 
the measurements taken in the plate diffusion assay (B) and the equations in C. X and y of nisin (in blue, 
1-3) were determined from the standard curve, then the real concentrations of nisin or of the nisin mutants 
(I4K and H27G) were determined based on the same equations (in blue, 3-5). L. lactis MG1614 was used 
as an indicator strain in this assay.  
 Drop Test with supernatant 
Cultures of overnight indicator strains were diluted 1:10 or 1:100 in phosphate buffer 
saline (PBS), then lawns were made on solid agar using a sterile cotton swab and air dried. 
Overnight liquid cultures were centrifuged for 10 min at 4000 rpm, the supernatant was 
then filtered through a 0.22 µm filter to remove bacteria and stored at 4°C. Aliquots of 5 
to 10 μl samples were placed aerobically on the surface of the lawn, air dried and 
incubated at optimal temperature specific for the sensitive strain. For anaerobic indicator 
strains, lawns were made aerobically on pre-reduced BHI solid media and air dried 
anaerobically for at least 5 min. 
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 Bacterial growth analysis by Scanning and Transmission electron 
microscopy  
L. lactis strains were grown overnight from glycerol stocks. 1 ml of cell suspension from 
16 h cultures was centrifuged at 4000 g, 5 min at RT, and washed with PBS twice then 
resuspended in 1 ml PBS. Samples were taken over for SEM (Scanning Electron 
Microscopy) and TEM (Transmission Electron Microscopy) experiments as performed 
by Kathryn Cross (IFR) using methods described previously [105]. 
2.2 Molecular Biology Work  
Molecular biology protocols were performed by conventional methods according to 
Sambrook et al. [106] and by using kits according to the manufacturer’s instructions.  
 Oligonucleotides             
Oligonucleotides were synthesized by Sigma-Aldrich (Dorset, UK) and are listed in Table 
9. 
Table 9 - Oligonucleotides used or designed in this work. 
Primer name  Primer sequence (5’-3’)  Reference  
universal GTTTTCCCAGTCACGACGTTGT  
 
 
 
Oligonucleotides 
used in this work. 
reverse AGCGGATAACAATTTCACACAGGA  
p54 CGGCTCTGATTAAATTCTGAAG 
p55 AACGGTTGAGCTTTAAATGAAC 
p181 GCGAAGATAACAGTGACTCTA 
pTG262_B_R TACGAATTCTGCAGCCCG  
 
Oligonucleotides 
designed in this 
work. 
 
pTG262_S_F CGCTATGTACACCCGGTTG 
pTG262_S_R CGGGCTGCAGAATTCGTA 
SalI_F: TAAGTCGACGGCCAGTGC 
G18T_F ACAGGAATTCTGATGACTTGTAACA 
H27G_F [Phos]CTGATGGGTTGTAACATGAAAACAGCAACT
TGTGGTTGTAGTATTCACGTAAGCAAATAAG 
H27G_R [Phos]GATCCTTATTTGCTTACGTGAATACTACAAC
CACAAGTTGCTGTTTTCATGTTACAACCCATCAGA
GCT 
N20P_F [Phos]CTGATGGGTTGTCCCATGAAAACAGCAACTT
GTCATTGTAGTATTCACGTAAGCAAATAAG 
N20P_R [Phos]GATCCTTATTTGCTTACGTGAATACTACAAT
GACAAGTTGCTGTTTTCATGGGACAACCCATCAG
AGCT 
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M21L_F [Phos]CTGATGGGTTGTAACTTGAAAACAGCAACTT
GTCATTGTAGTATTCACGTAAGCAAATAAG 
M21L_R Phos]GATCCTTATTTGCTTACGTGAATACTACAATG
ACAAGTTGCTGTTTTCAAGTTACAACCCATCAGAG
CT 
N20P_M21L_F [Phos]CTGATGGGTTGTCCCTTGAAAACAGCAACTT
GTCATTGTAGTATTCACGTAAGCAAATAAG 
N20P_M21L_R [Phos]GATCCTTATTTGCTTACGTGAATACTACAAT
GACAAGTTGCTGTTTTCAAGGGACAACCCATCAG
AGCT 
H31Dhb_V32G_ 
Dha33K_F 
[Phos]CTGATGGGTTGTAACATGAAAACAGCAACT
TGTCATTGTAGTATTACCGGAAAAAAATAAG 
H31Dhb_V32G_ 
Dha33K_R 
[Phos]GATCCTTATTTTTTTCCGGTAATACTACAAT
GACAAGTTGCTGTTTTCATGTTACAACCCATCAGA
GCT 
H27G_S29H_ 
H31Dhb_V32G_D
ha33K_F 
[Phos]CTGATGGGTTGTAACATGAAAACAGCAACT
TGTGGTTGTCATATTACCGGAAAAAAATAAG 
H27G_S29H_ 
H31Dhb_V32G_D
ha33K_R 
[Phos]GATCCTTATTTTTTTCCGGTAATATGACAAC
CACAAGTTGCTGTTTTCATGTTACAACCCATCAGA
GCT 
I4K_L6A_F [Phos]CATGAGTACAAAAGATTTTAACTTGGATTTG
GTATCTGTTTCGAAGAAAGATTCAGGTGC 
ATCACCACGCATTACAAGTAAATCGGCATGTACA
CCCGGTTGTAAAACAGGAGCTCG 
I4K_L6A_R [Phos]ATCCGAGCTCCTGTTTTACAACCGGGTGTAC
ATGCCGATTTACTTGTAATGCGTGGTGAT 
GCACCTGAATCTTTCTTCGAAACAGATACCAAATC
CAAGTTAAAATCTTTTGTACT 
pIL253_For GGTGTGTGTGTCTTGTTGTTAGT 
pIL253_Rev AAAAAGCAGTTTAAAATTGTTGCT 
pIL253F: CGACAATGATTGTATTTGC 
pIL253R: TAGTTCTTGTGGTTACGTGG 
pIL253_F_Rev GCGACAATGATTGTATTTGCTTG 
pIL253_F_Rev1 CTGTTGCGACAATGATTGTATTTGC 
pIL_RevPC GTGACTCTAGAATTCTGCAGCCC 
pepForÂ CTCTGACATTTTCCAGCTCCTTG 
pepREVÂ Â CAAGGAGCTGGAAAATGTCAGAG 
closR1K1_F_splice GAAGCCAGTAATGGATGCGACTAC 
closR1K1_R_splice GTAGTCGCATCCATTACTGGCTTC 
closR2K2_F_splice TATGACATTACACTTAGTTGGCATC 
closR2K2_R_splice GATGCCAACTAAGTGTAATGTCATA 
ClosR1K1_F CAACCATGGTGGATGTTAGTAA 
ClosR2K2_F GCAGACCATGGAAAATATACTTG 
ClosR1K1_R_SalI GGTGTAGTCGACCAGAGCTAAC 
ClosR1K1_R_ 
BamHI 
GACACCCGGATCCTATAAAGTAA 
ClosR2K2_R_SalI TATATGTCGACTCATATACTCCCG 
ClosR2K2_R_ 
BamHI 
TTGGATCCGACAAGTTAGTGT 
PClosBTC-F TATAAGATCTTGGTGCTGTGGTAAGC 
PBTC-F TATAACAGATTAGGAGGTAGAAATGCAAATCACA
GAAAAA 
PBTC-R TTTTTCTGTGATTTGCATTTCTACCTCCTAATCTGT
TATA 
PClosR2K2-F GAAGAGATCTTATACCTGCGAGTATTACAAGTC 
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PCRK-F CATAAAGGAGCAGATAATGCAAATCACAGAAAA
ATATC 
PCRK-R GATATTTTTCTGTGATTTGCATTATCTGCTCCTTTA
TG 
PFEG-F AAAAGGAGATGTATAATAATATGCAAATCACAGA
AA 
PFEG-R TTTCTGTGATTTGCATATTATTATACATCTCCTTTT 
PClosFEG-F TGTAGATCTTTAGAAGGAACG 
pepI-R GTGACTCGAGAATTCTGCAGCCC 
PClosBTC_F AAAGATCTTGGTGCTGTGGTAAG 
pepI_R AGCCTCGAGAACAGTGACTCTAGAA 
PBTC_F AGGTAGAAATGCAAATCACAGAAA 
PBTC_R TGATTTGCATTTCTACCTCCTAAT 
PClosR2K2_F GAAGAGATCTTATACCTGCGAGTA 
PCRK_F GCAGATAATGCAAATCACAGAAA 
PCRK_R1 TGATTTGCATTATCTGCTCCTT 
PCRK_R2 TGATTTGCATTATCTGCTCCTTT 
PClosA_F TTACAAGATCTATTGTGACACAGCA 
PCA_F CACCAAATGCAAATCACAGAAA 
PCA_R TGATTTGCATTTGGTGCCTCC 
PClosFEG_F TGTAGATCTTTAGAAGGAACGACC 
PFEG_F GTATAATAATATGCAAATCACAGAAA 
PFEG_R TGATTTGCATATTATTATACATCTCCT 
PCfeg_Forward TGAAGGAGAGAAGAAGAGCGATAATTTATG 
pIL253R_Forward TGGATTAGTTCTTGTGGTTACGTGGTT 
pIL253_For CCGATGATAAGCTGTCAAACATGAG 
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 Agarose gel electrophoresis of nucleic acids  
DNA was typically loaded on a 1 % or 2 % (w/v, for shorter bands) agarose gel cast in  
0.5 x TBE buffer (Fisher Scientific). 5 μl of 1 kb Hyperladder I (Bioline, UK), 100 bp 
was used as a DNA size marker (NEB) (Figure 10). The amount of DNA in each lane was 
estimated according to Hyperladder. 1 μl of loading buffer was mixed with samples prior 
to loading into the gel. 5 to 10 μl of sample mixed with 1 x loading buffer were loaded 
into the appropriate wells. The gel electrophoresis was performed in 0.5 x TBE buffer 
until completion. The gels were stained in ethidium bromide for 30 min, rinsed in ultra-
pure water UPH2O and visualised with UV light using the AlphaImager machine.  
 
Figure 10 - Size marker: 5 µl of 1 kb Hyperladder I was loaded on a 1 % agarose gel and visualized using 
ethidium bromide.  
 Genomic DNA extraction  
Genomic DNA was extracted from mid exponential phase cells of L. lactis using the 
genomic DNA extraction kit with Genomic Tip 500/G columns (Qiagen) as described by 
the manufacturer with the following modification. For L. lactis, 50 U mutanolysin 
(Sigma) was added to improve lysis of the cell wall. For the DNA quantification, 1 to 5 
µl aliquots of genomic DNA were run on a 1 % agarose gel. Alternatively, a Nanodrop 
instrument machine software (Thermo Scientific) was used with the DNA peaks being at 
260 nm. The extracted DNA was confirmed to be of good quality when the absorbance 
ratio (260/280 nm is RNA/protein ratio) was 1.7 to 2. The ratio is a measure of protein 
contamination in the sample.  
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 Plasmid preparation, excision from agarose gel and DNA purification 
kits  
A number of kits were used according to the manufacturers’ protocols:  
For plasmid preparation: E.Z.N.A Plasmid Mini Kit I (Omega Bio-Tec), QIAprep spin 
miniprep kit (Qiagen).  
For DNA band excision from gel: QIAEXII Gel extraction kit (Qiagen, Sussex, UK). 
For the purification of PCR products: Sureclean (Bioline, London, UK). 
 Plasmid preparation  
For plasmid preparation, a 10 ml overnight culture of E. coli or L. lactis was centrifuged 
for 10 min at 4000 rpm, 4°C. For L. lactis, the pellet was resuspended in 300 μl P1 buffer 
from Qiagen plasmid kit and 5 mg/ml of lysozyme powder was added After the mix was 
removed to a new 1.5 ml Eppendorf tube, 50 U mutanolysin was added (for L. lactis) to 
ensure cell lysis. After 15 min incubation at 37°C, plasmid preparation was continued 
according to the manufacturers’ instructions. For the plasmid preparations from E. coli 
cells, the manufacturers’ protocols were followed. The quality of the plasmid DNA was 
checked on an agarose gel and DNA concentration was assessed by Nanodrop.  
 Extraction of DNA bands from an agarose gel 
Fragments of DNA were separated in agarose gels and the excised bands from the gel 
with a clean scalpel and further purified using the instructions from the QIAquick gel 
extraction kit. In short, the agarose gel slice that contains the DNA band of interest was 
dissolved in a neutral pH, high salt buffer from the kit, and then applied to a silica-gel 
membrane mounted in a microcentrifuge tube. The DNA was trapped on the membrane 
while the unwanted impurities were washed away. The DNA was finally eluted in 30 μl 
of elution buffer. Quantification of DNA was performed using a 1 % (w/v) agarose gel.  
 DNA purification using Sure Clean 
For purification of the PCR products, Sure-Clean (Bioline) was used to rapidly remove 
PCR reaction components like primers, dNTPs, buffer, short DNA fragments and the 
enzyme. The clean-up was done according to the manufacturer’s instructions: DNA was 
incubated with the dye, and an equal volume of Sure Clean buffer for 30 min at room 
temperature (RT). The mix was centrifuged for 10 min at 14, 000 g at RT and washed 
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twice with 70 % ethanol. The air-dried pellet was eluted in 5 to 20 µl of elution buffer 
and the concentration was read by Nanodrop.  
 DNA digestion with restriction enzymes (restriction digests)  
Restriction enzyme digestion of plasmid or genomic DNA was carried out using the 
enzyme manufacturer’s instructions as described by New England Biolabs (NEB, Herts, 
UK). For the double digestion of DNA, an optimal buffer was selected from the literature 
of Roche or NEB. The reaction volume was usually 10 µl per 1 µl of enzyme, and unless 
otherwise stated the digestion was carried out for 1 hour at 37°C per 1 µl of enzyme. After 
incubation, the enzymes were heat-inactivated at 80°C and the products were purified 
with Sure-Clean (Bioline).  
To calculate the amount of enzyme to add in the reaction mix, the following formula was 
used as adapted from NEB. This method of calculation proved sometimes to work better 
in cloning.  
Size of Vector DNA (kb) / size of plasmid to be cut (kb) x 
x no of cuts in plasmid / no of cuts in Vector DNA = N Unit/µg (1 fold).  
This means that for 1-fold restriction, N units will cut 1 µg of plasmid. 2 to 5-fold excess 
were typically used for restriction. The size of the vector DNA, where the enzyme is 
usually defined, and the number of cuts in the Vector DNA were taken from the 
manufacturer’s catalog.  
 General methods for PCR 
PCR Sprint (Thermo Scientific) and Professional Basic (Biometra) thermal cyclers were 
typically used to perform polymerase chain reaction (PCR). Primers were usually 
designed with an annealing temperature (TA) of 55 - 60°C, with TA for most applications 
of 56°C unless it was otherwise stated. 
Oligonucleotides and primers were designed and ordered from Sigma Genosys (UK). The 
melting temperatures were calculated as follows:  
- for GoTaq reactions used http://www.oligoevaluator.com/OligoCalcServlet;  
- for Phusion PCR used: http://www.thermoscientificbio.com/webtools/tmc/;  
- Reverse primers were obtained by swapping the sequence on  
http://www.basic.northwestern.edu/biotools/oligocalc.html  
(the only exception was with the splice primers).  
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reaction volumes of 50 µl were prepared in special PCR tubes and the conditions typically 
used for different applications are listed in Table 10 and Table 11.  
Table 10 - Composition of PCR reactions mix. GoTaq polymerase (Promega) (left) and Phusion polymerase 
(Finnzymes) (right). 
GoTaq polymerase Phusion polymerase 
Component  Quantity  Component  Quantity  
DNA template  1 μl  DNA template  1 μl (~5 or 50 ng)  
5 x GoTaq Reaction Buffer 
(Promega)  
10 μl  5 x Phusion Reaction Buffer 
(finnzymes)  
10 μl  
0.2 mM of each dNTP 
(Bioline)  
0.4 μl  0.2 mM of each dNTP 
(Bioline)  
0.4 μl  
Forward primer 20 μM 
(Sigma Genosys)  
1 μl  Forward primer 20 μM 
(Sigma Genosys)  
1.25 μl  
Reverse primer 20 μM 
(Sigma Genosys)  
1 μl  Reverse primer 20 μM 
(Sigma Genosys)  
1.25 μl  
UPH2O 36.35 μl  UPH2O  35.7 μl  
1.25 U/μl GoTaq DNA 
polymerase (Promega)  
0.25 μl  1 U/μl Phusion Polymerase 
(finnzymes)  
0.4 μl  
Total volume  50 μl 
 
Table 11 - PCR cycling conditions for GoTaq polymerase and Phusion polymerase.  
GoTaq polymerase Phusion polymerase 
Temperature & time Cycles  Temperature Cycles 
95 °C              2 min 
95 °C             30 s 
55-60 °C*       30 s 
72 °C           1 min/kb 
72 °C              5 min  
x 1 cycle  
x 25-30 cycles; 
x 25-30 cycles; 
x 25-30 cycles 
x 1 cycle  
98 °C             30 sec  
98 °C             10 s 
TA°C**         30 s 
72 °C       15-30s/kb 
72 °C             5 min 
x 1 cycle  
x 25-30 cycles; 
x 25-30 cycles; 
x 25-30 cycles 
x 1 cycle  
*Annealing temperature (TA) is adjusted depending on the primer melting temperature, TA is max Tm-3.  
**TA is Tm (or ≤20 bp primers or Tm+3°C for >20 bp primers. 
 
The Phusion kit was used for high-fidelity amplification of genes (genomic/plasmid 
DNA) for cloning applications such as the construction of a plasmid. The GoTaq PCR kit 
was used for general analytical PCR with colonies from plates or with ligation products. 
For colony PCR with GoTaq, individual colonies of E. coli or L. lactis were picked from 
the agar plates using a sterile toothpick and were smeared into 9 µl of UPH2O. 1 µl of this 
mix was then transferred in the PCR tube before adding the appropriate PCR mix and 
DNA was amplified using the appropriate conditions as indicated in Table 11.  
PCR was also used to screen colonies picked with a sterile toothpick and resuspended in 
10 µl of sterile UPH2O. 1 µl of mixture was added to a 50 µl PCR reaction volume as 
template DNA (Table 11, Table 12).   
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 Splice overlap extension PCR 
Splice overlap extension PCR was used as described previously [107] either for site-
directed mutagenesis [108] to introduce mutations in the original structure of nisin (to 
generate clos-like nisin mutants) or to create new plasmids (by joining PCR promoter 
sequences and the gene sequences of interest). The splice overlap reaction components 
are listed in Table 12 and the method for splice overlap PCR is illustrated in Figure 11. 
A.  
B.  
Figure 11 - Diagrams for splice overlap extension PCR. 
A. To join/ligate 2 PCR fragments to make a new product eg: SeqA + SeqB have a new promoter region 
and a gene site. P1, p4 are the outer primers and p3, p2 are the inner primers. P2 was designed to be 100 % 
match to the right hand end (3’ end) of SeqA with a tail complementary to the start of SeqB (5’ end). P3 
was designed to be 100 % match to the left hand end of SeqB (5’ end) with a tail that is complementary to 
the right of SeqA (3’ end). The sequences were fused during PCR, as the overlapping sequences hybridized 
and extended to make a full-length sequence.  
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B. To insert a mutation (M). The inner primers, p2 and p3, were designed in a similar fashion as in A 
however the mutation was added to the matching tail of p2 in the 5’ end of Seq B and for p3 in the 3’ end 
of Seq A.  
Table 12 - Details for splice overlap extension PCR. 
Phusion polymerase 
Component  Quantity  Temperature & time No. of cycles  
DNA template  *1 μl (~1 or 50 ng)  
**1 μl or 4 μl (1 or 4 
ng) 
98°C ……30 sec 
 x 1 cycle 
98°C ……10 sec 
x 5 cycles 5 x Phusion reaction buffer 
(Finnzymes)  
10 μl  TA1*……..30 sec 
dNTP (100 mM stock, Bioline)  0.4 μl  72°C 15-30 s/kbs 
Forward primer 20 μM (Sigma 
Genosys)  
1.25 μl  98°C ……10 sec 
x 20 cycles Reverse primer 20 μM (Sigma 
Genosys)  
1.25 μl  TA2** ……..30 sec 
UPH2O 35.7 μl  72°C 15-30 s/kb 
Phusion Polymerase 
(Finnzymes)  
0.4 μl  72°C            5 min 
x 1 cycle 
Total volume  50 μl   
*For the first PCR rounds the templates are Seq A or Seq B (- Diagrams for splice overlap extension PCR.). 
TA1 was calculated as NN of the overlap (approx. 37°C) or if multiple products were seen, TA was raised 
to TA of whole primer minus the miss match (approx. 50°C).  
**For the second round of PCR, the template is SeqA with matching tail and Seq B with matching tail. 
TA2 was calculated as the lower Tm for ≤20 bp primers or Tm+3°C for >20 bp primers. 
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Primers for splice overlap PCR for both cases (Figure 11, A and B) were designed using 
the following rules:  
- for p2 and p3 splice primers, the 100 % matching sequence should be approx. 15 
bp with a similar length of tail;  
- the nearest neighbour (NN) for the overlap is calculated with 
http://www.basic.northwestern.edu/biotools/ oligocalc.html); NN values should 
be above 37°C; 
- for p1 and p4 end primers with a maximum of 20 bp in length, the annealing 
temperature (TA) will be the lower Tm; Tm is calculated using 
http://www.thermoscientificbio.com/webtools/tmc/;  
- for p1 and p4 end primers:  
TA is or Tm+3°C for >20 bp primers. 
TA is the lower Tm for ≤20 bp primers.  
For method development the cycle parameters were:  
- 5 cycles of the NN of the splice primer 100 % matching sequence (overlap).  
- 5 x TA1 was approx. 37°C.   
20 cycles of TA the whole outer primer (or TA calculated for the end primer, whichever 
is lower). 
- TA2 = the lower Tm (≤20 bp primers) or  
- TA2 = Tm+3°C for >20 bp primers. 
If multiple products were seen, TA1 was raised to a max of TA calculated as TA of whole 
primer minus the miss match.  
5 x TA1 was approx. 50°C.  
After SeqA and SeqB with matching tails were purified with Sure Clean, 1 ng or 4 ng of 
each PCR product were used in the splice overlap extension PCR reaction with the end 
primers’ (p1 and p4).  
TA was either the NN of the ENTIRE overlap region between the two sequences (SeqA 
and SeqB) or TA was the lowest TA calculated for the end primers if this TA was lower). 
The details for cloning are specific for L. lactis.  
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 Vector DNA dephosphorylation  
In order to remove 5’ phosphate groups from restricted plasmid vectors and to prevent 
self-ligation of vectors, the Antarctic Phosphatase (NEB) was used according to the 
manufacturer’s instructions. Dephosphorylated vector was purified with SureClean to 
remove the reaction components including the restriction enzyme (Table 13). 
Table 13 - Details of dephosphorylation of plasmid vector. 
Antarctic Phosphatase 
Component  Quantity  Temperature & time 
DNA template  
restricted DNA in any buffer  
1 μg (usually in 50 μl 
PCR reaction mix) 15 min at 37°C for 5’ 
extensions or blunt ends 
Or 
60 min for 3’ extensions 
Heat inactivate at 80°C for 20 
min. 
10 x Antarctic Phosphatase 
buffer (NEB), 
2.5 μl  
UPH2O. 1 μl  
5 U/µl Antarctic Phosphatase 1.5 μl  
Total volume  25 μl 
 DNA ligation  
Ligation of DNA sequences was carried out using Fast-Link™ DNA Ligation Kit 
(Epicentre Biotechnologies) by following the manufacturer’s instructions. Typically, 10-
20 ng/µl of restriction-digested, dephosphorylated purified vector (150 - 300 ng/µl in final 
volume) was used in a 1:3 molar ratio with the restriction-digested, purified insert 
fragment. For blunt-end ligations, a 1:5 molar ratio was suggested by the manufacturer 
(Table 14).  
Table 14 - Details for ligation of insert and plasmid vector. 
 
Ligation was initially performed using the manufacturer’s protocol regarding the molar 
ratios (Figure 12). On several occasions, ligation worked better with 0.07 pmoles of 
vector and 3 or 5-fold molar excess of insert for sticky end and blunt end ligation 
respectively.  
1 μl of the ligation product was amplified with GoTaq polymerase and loaded on a 1 % 
agarose gel to check the amplified ligation products. The ligation products were then 
Fast-Link™ DNA Ligation 
Component  Quantity  Temperature & time 
10 × Fast-Link Ligation Buffer 1.5 μl 
Optimal incubation time 2 h to 
overnight at RT. 
Heat inactivated at 70°C for 
15 min. 
10 mM ATP 1.5 μl 
Vector 0.07 pmoles A μl  
Insert 0.35 pmoles B μl 
UPH2O Up to 15 μl 
Fast-Link DNA Ligase 1 μl 
Total volume  15 μl 
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purified using Sure-Clean to remove the enzyme, then the product was resuspended in 5 
µl of elution buffer. Typically, 2.5-5 μl of ligation (100 - 500 ng) or 750 - 1000 ng for 
bigger inserts (>1500 bp) were used to transform electrocompetent L. lactis cells.  
 
Figure 12 - Illustration of ligation PCR. 
A. forward (pF) and reverse primers (pR) are annealing on the new vector template; B. Possible products 
of the ligation reaction: a) self-ligated vector, b) vector with insert, c) vector with double insert. 
 Preparation and transformation of E. coli   
E. coli MC1022 [103] cells were prepared as electro-competent and transformed with 
DNA. Briefly, 40 ml pre-warmed L broth (with antibiotic) was inoculated with 800 µl of 
an overnight culture of E. coli and incubated at 37°C shaking (250 rpm) until the optical 
density at 600 nm (OD600) was 0.5-0.6. The cultures were chilled on ice and processed 
immediately. Ice-cold liquid cultures were harvested by centrifugation (3000 g, 10 min, 
4°C), washed twice in ice-cold 10 % glycerol with resuspension by gentle agitation then 
centrifuged (10 min, 3000 g, 4°C). Finally, the cell pellet was resuspend in 400 μl of ice-
cold 10 % glycerol and 40 μl aliquots were used immediately for transformation or flash 
frozen in liquid nitrogen or dry ice and stored at -80°C. 
Electroporation of the target DNA to the electrocompetent E. coli cells was performed 
with ice cold reagents and glassware. Purified ligation product (100-500 ng) was added 
to E. coli cells, mixed and incubated for 1 min on ice. The mix was pipetted into pre- 
chilled electroporation cuvettes (Cellprojects, UK) and electroporated at 2.5 kV, 200 Ω 
resistance and 25 μF using a Gene Pulse Xcell (BioRad) capacitance. 460 μl of SOC broth 
was added in the cuvette, transferred to a tube then incubated by shaking (225 rpm) for 2 
h at 37°C. Next, 100 μl of electroporated cells was plated onto L agar with antibiotic 
selection. Plates were incubated for 1-2 days at 37°C to allow colonies to grow.  
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The transformation efficiency for empty vector control was calculated as number of 
transformants per μg of DNA. 
 Preparation and transformation of L. lactis 
 Preparation of L. lactis electrocompetent cells  
To prepare L. lactis electrocompetent cells, pre-warmed 47.5 ml of M17 supplemented 
with 2.5 % glycine and 2.5 ml of 10 % glucose were inoculated with 3 ml overnight L. 
lactis culture and incubated at 30°C until OD600 was 0.5-0.6. The cultures were chilled on 
ice and harvested by centrifugation (3000 x g, 10 min, 4°C), washed twice in 1/5 volumes 
of ice cold electroporation buffer (0.5 M sucrose in 10 % glycerol) with gentle mixing. 
The pellet was resuspended in 1/100 volumes ice cold electroporation buffer, dispensed 
in 40 μl aliquots, transformed or flash frozen immediately in dry ice and acetone, then 
stored at -80°C until ready to use. 
 Preparation of L. lactis (ultra)electrocompetent cells (3-day 
protocol)  
To increase the competency of transformation, L. lactis (ultra)electrocompetent cells were 
prepared using a modified 3 day protocol described by Holo & Nes [109]. 300 ml SM17 
(51.35 g in 11.174 g M17 broth powder was topped up to 300 ml with UPH2O) media 
with 3 % (9 g) glycine was prepared fresh, aliquoted in 10 ml, 50 ml and 200 ml then 
autoclaved. Prior to inoculation, 0.5 % (w/v) glucose was added to pre-warmed SM17. 
10 ml SM17 with 3 % glycine was inoculated with 100 µl of L. lactis from a glycerol 
stock and incubated for 24 h at 30°C. 50 ml SGM17 with 3 % glycine was inoculated 
with 1 in 10 (v/v) overnight culture and incubated overnight at 30°C. 200 ml pre-warmed 
SGM17 with 3 % glycine was inoculated with 12.5 % (v/v) of overnight culture and 
grown at 30°C until the OD600 was 0.2-0.3 (to prevent lysis of the cells). The pre-chilled 
liquid culture was harvested by centrifugation (5000 x g, 10 min, 4°C), the cells were 
washed once with an equal volume of ice-cold 10 % glycerol/0.5 M sucrose, once with 
25 % of 10 % glycerol/0.5 M sucrose/50 mM EDTA, incubated on ice for 15 min then 
washed with an equal volume of ice-cold 10 % glycerol/0.5 M sucrose. All buffers were 
prepared fresh, filter sterilized and prechilled, and the cells were gently resuspended and 
centrifuged at 5000 x g, 10 min, 4°C between washes. 1/100 volume of ice cold 10 % 
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glycerol/0.5 M sucrose was used to resuspend the pellet, then 40 μl aliquots were used 
immediately to transform or they were flash frozen in liquid nitrogen and stored at -80°C. 
 Electroporation of electrocompetent L. lactis 
Electroporation of the target DNA to the (ultra)electrocompetent L. lactis cells was 
performed with ice cold reagents and glassware. Purified ligation product (100-500 ng) 
was added to a 40 μl cell aliquot which was mixed, incubated for 1 min on ice before the 
mix was electroporated at 2.5 kV, 200 Ω resistance and 25 μF in a electroporation cuvette 
using a Gene Pulse Xcell (BioRad). 460 μl or 960 μl transformation buffer (10 ml 
M17/0.5 M sucrose with 125 µl of 40 % glucose, filter sterilised 200 µl 1 M MgCl2 and 
200 µl 0.1 M CaCl2) was added in the cuvette then transferred in a pre-chilled 2 ml screw 
cap tube and incubated on ice for 10 min. Electroporated cells were further incubated at 
30°C for 2 h. 100 μl of electroporated cells (or dilutions) was plated onto GM17 agar with 
antibiotic selection. Colonies were allowed to grow for 2-3 days at 30°C before they were 
picked with a sterile toothpick.  
 DNA sequencing  
15 μl of purified DNA was sequenced using by Eurofins Genomics, UK. Reagents were 
added to the tube as follows:  
- template DNA: plasmid up to 15 kbp: 50 -100 ng/µl or  
- PCR products:150-300 bp: 1 ng/µl;  
- 300–1000 bp: 5 ng/µl;  
- >1000bp: 10 ng/µl.  
- 1 μl of primer with a concentration of 20 pmol/μl (20 μM) 
- UPH2O up to 17 μl total reaction volume.  
Analysis of the sequences was performed using Finch TV tool (version 1.4), EditSeq and 
Seqmatch II (DNAStar) tools. 
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2.3 Scaled-up production and purification of nisin mutants on Fractogel 
Supernatants from L. lactis wild type nisin and nisin mutant producing strains were 
purified on Fractogel TSK Butyl-Toyopearl 650M media (Anachem) as described 
previously [96, 110, 111] with the following modifications.  
Producers of the nisin mutant peptides were grown from glycerol overnight in GM17 at 
30°C. Next, 10-14 litres of SPY-S media were inoculated to a starting OD600 of 1, and 
cells were grown with antibiotic and 10 ng/ml nisin (to ensure peptide production and 
growth) for typically 16-20 h at 30°C with a constant pH 6.0 as monitored with a pH 
meter. pH was kept to 6.0 by addition of 10 M NaOH to counteract the lactic acid 
produced by the bacterial strain. Next, the supernatants were harvested by pH adjustment 
to 2.5 with 50 % HCl and by removing the cells by centrifugation (10, 000 x g, 10 min, 
4°C). The cell-free culture supernatant of the producing strains was pH adjusted to 5.0 
with 10 M NaOH. After addition of 0.5 M (NH4)2SO4 and filtering of the supernatant on 
0.45 µm filters (Millipore), the sample was loaded on a pre-treated Fractogel TSK Butyl-
Toyopearl 650 M column at 3 ml/min flow rate. As the volume was large, this step was 
optimally performed in several stages overnight with 10 ml fractions collected. To 
monitor the protein elution, the absorbance at 220 nm was measured. The column was 
washed with 10 bed volumes of 0.5 M (NH4)2SO4 and subsequently with deionized water 
until an A220 below 0.5 was achieved. The bound antimicrobial peptides were then eluted 
using 5 mM HCl and assayed in drop tests or plate diffusion assays against L. lactis 
MG1614 [101] as indicator strain.  
Active fractions showing indication of antimicrobial activity were pooled, the pH was 
adjusted to 6.5 with NaOH, re-adjusted to pH 3.5 using glacial acetic acid, lyophilized 
and the quantified powder was stored at 4°C.  
Final purification and analysis of the purified fractions were achieved by C18 reverse-
phase semi-preparative high-performance liquid chromatography column (RP-HPLC) 
(Luna C18 (2), 5 µm, 250 x 21.20 mm) (see section 2.6). Solvents A (0.1 % trifluoroacetic 
acid, TFA in water) and B (0.1 % TFA in 70 % ACN, HPLC grade acetonitrile (ACN) 
(Fisher Scientific) and methanol (Fisher Scientific) were used with a grade and purity of 
95 % or greater. Solvent 70 % ACN with 0.1 % TFA was prepared by adding 700 ml 
HPLC grade ACN to a volumetric flask, 300 ml UPH2O and adding 1 ml of TFA to a 
final volume of approx. 1 l. 
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Peptides were eluted with a linear gradient from 5 % to 100 % of B over 40 min at a flow 
rate of 3 ml/min. The elution was monitored at A220, A254, A280. Fractions from C18 were 
next tested by drop test (not pH adjusted) against L. lactis MG1614 and by Maldi-ToF. 
Confirmed active fractions were combined, concentrated and the acid was removed by 
pH adjustment as above using NaOH to get to pH 6.5, and glacial acetic acid to pH 3.5. 
This was to prevent degradation upon lyophilisation. The lyophilized powder was then 
stored at -20°C until ready to use. To test the antimicrobial activity of the peptide, the 
powder was initially dissolved in 50% diluted HCl at pH 3.0. Following an overnight 
incubation of the resuspended peptide at 4°C, the peptide was tested against different 
sensitive strains using plate diffusion assays.  
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2.4 Biochemistry and analysis of proteins 
 Solutions and buffers    
Table 15 - Solutions and buffers used in this study.  
 
 
 
 
 
 
Solution/buffer Composition and instructions for 
preparation 
Method used for  
1 M Tris HCl, pH 7.2, 
buffer (pH 7.0, 7.5, 8.0) 
121 g TRIZMA-Base (Sigma), made up 
to 1 l with UPH2O, pH adjusted with 1 
M HCl. 
Cell extraction 
1 M MgCl2 95.21 g MgCl2 (Sigma) made up to 1 
litre with UPH2O 
Electrophoresis  
0.1 M CaCl2 11.098 g CaCl2 (Sigma) made up to 1 
litre with UPH2O 
Electrophoresis 
Colony wash buffer  10 mM Tris pH 8.0, 1 mM EDTA pH 
8.0, 100 mM NaCl in UPH2O.  
To prepare PCR reaction from 
colonies  
1 M NaCl 58.44 g NaCl (Sigma), made to 1 litre 
with UPH2O.  
Plate diffusion of mutants at 
different pH (different buffers) 
TBS buffer 10 mM Tris pH 7.5,  
150 mM NaCl in UPH2O 
Western blot  
TBS-Tween/Triton 
buffer 
20 mM Tris pH 7.5, 500 mM NaCl,  
0.05 % (v/v) Tween 20 (Sigma), 0.2 % 
(v/v) Triton X-100 (Sigma) in UPH2O.  
Western blot  
20 × NUPAGE  
Transfer buffer 
Bicine 10.2 g, Bis-Tris 13.1 g,  
EDTA 0.75 g, made to 125 ml with  
UPH2O 
Western blot  
1 × NUPAGE  
Transfer buffer 
50 ml of 20 × NUPAGE buffer, 1 ml of  
NUPAGE antioxidant, 100 ml of 
methanol, 849 ml of UPH2O.  
 
Transformation buffer  
 
9.5 ml M17 broth + 0.5 % Sucrose + 125 
ul 40 % glycerol, 200 µl of 20 mM 
MgCl2 (2.03 g  MgCl2 in 10 ml  UPH2O, 
200 µl CaCl2 (2 mM) (0.13 g CaCl2 in 
10 ml of UPH2O 
Used for transformation of L. lactis 
electrocompentent cells 
Loading dye   0.015 % bromophenol blue (Sigma),  
10 % glycerol (Sigma), 0.5 x TBE 
buffer. 
DNA gels  
SDS gel loading buffer 
(2x) 
10 % (w/v) SDS, 40 % (v/v) glycerol, 
250 mM Tris HCl (pH 6.8) up to 10 ml 
total volume.  
Protein gel electrophoresis 
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 Bradford assay to measure protein concentration 
Proteins were quantified using the method of Bradford [112] and Bradford’s reagent kit 
(Biorad) in a colorimetric protein assay which is based on a shift in absorbance of the 
Coomassie Brilliant Blue G-250 dye; in acidic conditions, the dye’s red form is converted 
into a blue form after it binds to the protein [112]. The BSA assay standards were prepared 
using commercial bovine serum albumin (BSA) from NEB, prepared in the same buffer 
as the cell extract, usually 0.1 M Tris HCl, pH 7.4, at concentrations ranging from 0, 20, 
40 to 200 μg/ml. A dilution of 1:200 of the sample was applied. 10 µl of each standards 
and diluted samples were pipetted in duplicate into a sterile, flat-bottomed, 96-well 
microtitre plate (Sterilin). 190 µl of freshly prepared colorimetric indicator (4 ml 
Bradford’s reagent in 16 ml UPH2O) were dispensed into each well, then the samples 
were mixed on the SoftMax plate reader (Molecular Devices), any bubbles were removed 
and the plates were finally incubated at ambient temperature for 5 min before read at 
OD600. A mean concentration of the duplicate samples was calculated. The concentration 
of the proteins was determined by plotting the standard curve and by using the equation 
generated from that curve as in Figure 13.  
 
Figure 13 - Example of BSA calibration curve used to calculate protein concentration. 
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 SDS polyacrylamide gel electrophoresis 
All the sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
materials were purchased from Invitrogen (Paisley, UK). Typically 10 µg of protein was 
prepared as described in Table 16 where samples were heated, chilled in ice and 
electrophoresed in 2-(N-morpholino) ethane sulfonic acid (MES) with antioxidant; the 
gel was finally stained using Safestain. Once heated, the proteins were kept stable in their 
denatured state by the NuPAGE LDS sample buffer.  
Table 16 - Composition of protein samples mix before heating at 70°C for 10 min and loading on the 
NuPage Novex gels for protein gel or western blot analysis. 
 
 
 
 
 
 
 
 
 
 
 
* For band excision from protein gel, the maximum amount of protein was loaded, (approx. 30 µg). The 
aim was to cut out the bands (gel slice) for the protein of interest, perform alkylation and trypsin digestion 
and subsequent LC-MS and Maldi-ToF analysis.  
 
10 µl of the pre-stained marker SeeBlue Plus 2 (Figure 14) (Invitrogen) and the heated 
and chilled samples were loaded on to the protein gel. The protein gel was prepared and 
run according to the Invitrogen NuPAGE gel instructions. The gel was finally removed 
from the outer chamber and stained with Simply Blue Safestain or it was used for western 
blot analysis. 
Component  µl  µl* 
Total volume of sample + H2O  
(10 µg) or (30 µg)* 
 
6.5 9.75 13 14 
Reducing agent  
 
1 1.5 2  
LDS sample buffer  
 
2.5 3.75 5  
SDS gel loading buffer (2x)  6  
Total volume (µl)  10 15 20 20 
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Figure 14 - Protein markers. See Blue Plus prestained ladder (Invitrogen) in MES buffer highlighted by the 
arrow. 
 Western blot analysis 
For western blotting, the Clos containing samples were prepared as described above, run 
and detected on 12 % Bis-Tris NuPAGE gels in MES (Invitrogen) with polyclonal 
antiClos leader peptide antibody. For peptide detection, 6.5 μl (sample+UPH2O) was 
supplemented with 1 μl Reducing Agent, 2.5 μl LDS sample buffer. For gel extraction 
from gel slices for trypsin digestion, 6 μl of SDS gel loading buffer (2 x) was added to 14 
μl of sample. The samples mixes were heated to 70°C for 10 min, loaded on the gel and 
ran the gel at 30 V for about 1 h. The electrophoresed proteins were transferred onto a 
polyvinylidene difluoride membrane (PVDF) using the western transfer methodology and 
reagents from Invitrogen NuPAGE (Figure 15).  
 
 
Figure 15 - Western blot assembly. The same buffers as described in Table 15 were used.  
Chapter 2 
   
61 
 
The blot module was inserted into the lower buffer chamber of the electrophoresis tank 
(Invitrogen).  
The recipes for all the buffers are detailed in Table 15. After transfer, the PVDF 
membrane was washed with 2 x TBS buffer for 10 min. To avoid non-specific interactions 
of the antiClos leader antibody with the membrane, the membrane was then incubated in 
blocking buffer for 1 h shaking or overnight at 4°C.  
The membrane was washed with 2 x 50 ml TBS-Tween/Triton buffer for 10 min (Table 
15) and once with TBS buffer. It was then incubated with 1:200 (v/v) primary polyclonal 
antiClos leader peptide antibody raised against rabbit by Genscript Corp (NJ, USA). The 
antigen was a synthesized N-terminal acetylated ClosA1-3 leader peptide H2N-
AKFDDFDLDVTKTAAQGGC-CONH2 (without the first methionine [113]) in rabbits 
[97]. 50 μl of antibody in 10 ml 3 % BSA was added and incubated with the membrane 
for 1 h. 
The unbound primary antibody was removed by washing the membrane with 2 x TBS-
Tween/Triton buffer for 10 min, with 1 x TBS buffer, then the membrane was exposed to 
1:5000 (v/v) anti-Rabbit IgG-alkaline phosphatase secondary antibody (Sigma) for 1 h at 
RT. After 10 min washes with 4 x TBS-Tween/Triton buffer, colorimetric detection was 
performed with Sigma Fast BCIP/NBT (5-Bromo-4-chloro-3-indolyl phosphate/ Nitro 
blue tetrazolium) as a substrate. The tablet was resuspended in 10 ml, incubated with the 
protein side of membrane without moving for 1-15 min until enough colour development. 
To stop the colour development reaction, the membrane was washed with 2 x UPH2O and 
it was left to dry for visualisation of the bands [113]. 
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 Protein extraction  
L. lactis strains expressing hybrid plasmids were cultured from glycerol stocks in 10 ml 
GM17 media overnight then subcultured in 100 ml pre-warmed media to a starting OD600 
of 0.1 with antibiotic addition. At OD600 0.5-0.6 (mid exponential phase), cultures were 
induced with 10 ng/ml nisin and typically incubated for another 3 h at 30˚C unless 
otherwise stated. The culture was divided in 50 ml portions and transferred in 50 ml 
centrifuge tubes (corning) to harvest cells by cell centrifugation (4000 x g, 15 min, 4˚C). 
The pellet was further processed to prepare cell extracts while the supernatant was treated 
to obtain the trichloroacetic acid (TCA)/acetone precipitated proteins (Figure 16) [114].   
 
Figure 16 - Processing of liquid cultures: TCA/acetone precipitation of proteins from the supernatant and 
cell extraction from cell pellet of the original culture. 
 Bead beating extraction of crude proteins  
The collected pelleted cells were washed once with 0.025-0.2 M Tris HCl pH 7.4, 
transferred to 2 ml tubes and resuspended in 1 ml buffer, centrifuged to remove the buffer, 
flash frozen in dry ice and stored at 4°C. Soluble protein extracts were produced by bead 
beating with 500 µl buffer and 200 µl glass beads using a FastPrep FR120 cell disrupter, 
4 x 30 sec speed 6 with 5 to 10 min on ice between beatings [115]. The tubes were 
centrifuged for 5 min (10,000 x g, 4°C), the cell extract was removed to fresh 0.5 ml tube, 
spun again for 30 min to remove the glass beads. The supernatant containing concentrated 
crude protein/cell extracts was transferred to a new tube and stored at -20˚C until ready 
to use. Protein concentration was quantified by Bradford assay as 1:200 dilution in Tris 
HCl buffer, pH 7.4 buffer.   
 
 
 
Cells pellet for 
cell extract  
Proteins were 
precipitated with  
acetone from the 
supernatant  
western blotting 
Gel, cut gel 
bands out  
Alkylation with eg. IAA + 
Tryptic Digestion  
LC MS/MS 
Maldi-ToF  
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 TCA protein precipitation from culture supernatant 
Culture supernatants were collected by centrifugation and filtered with a 0.45 μm filter. 
Supernatant total proteins were precipitated and concentrated from the filtered 
supernatant by addition of 1 g/ml cold TCA (25 %, v/v) and incubation at 4˚C for 2 h or 
overnight. Concentrated and precipitated proteins were pelleted by centrifugation (4000 
x g, 30 minutes, 4˚C), washed with 25 % ice cold acetone, dried at RT or by incubating 
at 50˚C until acetone was completely evaporated. Pellet was stored at -20˚C and 
resuspended in 50 mM sodium acetate (pH 5.5) until fully dissolved and used in western 
blot. Proteins of expected mass were identified by SDS-PAGE electrophoresis and 
immunoblotting as described above [116]. 
 Colony Mass Spectrometry 
Colony Mass Spectrometry (CMS) using isopropanol for extraction of nisin mutants from 
inside the cells, is an adapted method from Field et al. [16]. Prior to the MS analysis, 
cultures grown overnight were plated on agar. The samples prepared with this method 
were: 1) 1 ml of liquid culture (fresh or stored at 4˚C) was spun and washed with 1 ml of 
UPH2O or 2) single colonies picked with a sterile loop from overnight incubated plates. 
The resulting cell pellet or the colony were resuspended thoroughly in 50 µl of 70 % 
isopropanol adjusted to pH 2.0 with 1.5 % formic acid, then sonicated for 10 to 15 min in 
a water bath. The suspension was vortexed and centrifuged for 2 min at 13000 x g, and 
the supernatant was removed for Maldi-ToF analysis. Extracts were diluted 1 in 2 with 
0.1 % TFA and spotted on pre-coated matrix.   
 Protein Immunoprecipitation  
Protein immunoprecipitation (IP) of Clos was carried out using an optimised method 
based on the Pierce Crosslink Immunoprecipitation Kits (26147, 20423, Thermo Fisher 
Scientific) with the following modifications. The IP procedure was used to affinity purify 
Clos on small or large scale IP reactions. More specific details on buffers and reagents 
volumes and concentrations were added in chapter 6. 
Figure 17 is a diagram of antibody binding to Protein A/G agarose resin, the basis for 
traditional immunoprecipitation and co-immunoprecipitation methods.  
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Figure 17 - Diagram to summarise purification of Clos from a mix of proteins using two 
immunoprecipitation (IP) methods. 
A) IP using crosslinker and B) co-IP as adapted from the manufacturer’s technical guide. 
1. Binding step: Clos-containing sample, antiClos leader antibody (Ab) and beaded agarose affinity beads 
(eg: Protein A/G) were allowed to bind. 2. Wash step: non-bound components of the sample were washed 
away; 3. Elution step: conditioning buffer disrupted the binding interactions to give A) pure Clos peptide 
or B) a complex of Clos co-IP with antiClos leader antibody. 
All washes were done by centrifugations at 1000 x g for 1 min in the small column 
provided by the Pierce Crosslink IP Kit. For the scale up IP, incubations were done in 50 
ml centrifuge tubes and the recovery of the supernatants/resin in the small column or 10 
ml column was done by centrifugation and gravity flow, respectively. The bulk of 
supernatant was run through the column a few times. Fresh buffer was used for the wash 
steps. All the flow through of the remaining samples and washes were recovered for 
further analysis by western blot. In order to remove contamination with detergent from 
the reagents, IP Lyis/Wash buffer was replaced with 0.025 mM Tris HCl buffer, pH 7.4.  
In one scaled up IP reaction, 0.025 mM TrisHCl buffer, pH 7.4 buffer was used to obtain 
cell extraction and for subsequent wash steps. All the reagents were left at RT prior to 
being used as in the manufacturer’s instructions.  
Samples used were typically 1. cell extracts in Tris buffer (0.025 mM) or in IP Lysis/Wash 
buffer, both in the presence/absence of a protease inhibitor cocktail or 2. cell-free culture 
supernatant. Based on the WB, the best option was to use cell extract in 0.025 mM Tris 
HCl buffer, pH 7.4.    
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Two methods were used for the assembly of the immobilized protein complex: 1) 
sequential or 2) in one step (Figure 18, Figure 19). In the sequential method (used for 
method development), 2 ml antibody (approx.70 µg) and Clos cell lysate (extract in Tris 
buffer) were incubated overnight. One ml of slurry (500 µl affinity beads) was then added 
to calculate optimal Ab:Ag ratio and to capture the antiClos leader antibody and Clos 
antigen complex by incubation for 6 h at 4°C on a vortex mixer. Aliquots were collected 
at every stage of the purification process and visualised by western blotting.  
 
Figure 18 - Diagram of the sequential method to immunoprecipitate the antigen - Clos peptide. 
Figure 18 is an illustration of the antiClos leader antibody that binds to Protein A/G 
agarose resin, as adapted from Thermo Scientific Pierce IP Kit. In short, the antiClos 
leader antibody was immobilized on a beaded support through the Protein A, IgG binding 
protein, which in turn was bound on the agarose resin. A non-crosslinked antibody was 
used. The Clos peptide was co-immunoprecipitated (IP) with the antibody as illustrated 
in Figure 17. 
 
Figure 19 - Diagram of the one step IP method. 
AntiClos leader antibody immobilization method to Protein A/G agarose resin was 
adapted from Thermo Scientific Pierce IP Kit. DSS crosslinker was used to covalently 
attach the antibody to Protein A/G beaded agarose resin. In comparison to the traditional 
sequential IP methods, the one step method allows the elution of Clos without 
contamination from antiClos leader antibody. 
In the one step method (scaled up IP/larger scale of IP), the antiClos leader antibody was 
first incubated with 1 ml of slurry (500 µl resin), 0.5 ml 20 x coupling buffer, 2 ml 
(approx. 70 µg) of antiClos leader antibody and 6.5 ml UPH2O. The 50 ml centrifuge tube 
containing the mix was incubated for 2 h at 4°C on a vortex mixer. Next, the mix was 
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transferred in a 10 ml column, the resin was washed with 2 x 3 ml elution buffer (to 
quench DSS) and with 2 x 3 ml Tris HCl, pH 7.4 buffer. The antibody was crosslinked 
with 1 ml of 2.5 mM DSS, 3.75 ml UPH2O, and 250 µl of 20 x coupling buffer by 
vortexing for 1 h at RT. After the bulk of supernatant was run through the column for a 
few times, it was then recovered by gravity flow and stored for later analysis. The resin 
was washed once with 3 ml elution buffer and twice with 3 ml Tris HCl, pH 7.4 buffer, 
then the crosslinked resin and Clos cell extracted in Tris HCl, pH 7.4 buffer were 
incubated overnight at 4°C on a vortex mixer (in 50 ml centrifuge tube). After the binding 
of Clos, antibody and support, the beads were recovered by centrifugation and washed 
extensively with 3 x 3 ml Tris HCl, pH 7.4 buffer and once with 1 ml of 1 x conditioning 
buffer.  
Elution of Clos from the beaded support was performed with 0.5 ml elution buffer by 
incubation for 5 minutes with vortexing at room temperature. After centrifugation, the 
eluate was collected in fresh tubes where 100 µl of 1 M Tris HCl, pH 9.5 was previously 
added to neutralize the buffer. The elution was repeated several times to give a series of 
fractions (F1-F4) that were frozen in dry ice immediately and stored at -20°C. The resins 
were regenerated and stored in 1 x coupling buffer at 4°C. Finally, to remove 
contamination with detergent that would interfere with Maldi-ToF and LC-MS, the 
eluates were further purified typically on a C8 cartridges/column (HyperSep). Clos was 
eluted with a linear gradient of 10 %, 15 % to 60 % acetonitrile in 0.1 % formic acid. (see 
section 2.5)  
In previous attempts to test the best purification method, a high spin column, C4 or C8 
ZipTip (HypersSep) protein purification methods were also used (see section 2.4.8). The 
new re-purified eluates in acetonitrile and formic acid had the concentrated buffer 
removed by drying under vacuum and the samples were resuspended in 5 % formic acid 
buffer for liquid chromatography–mass spectrometry (LC-MS) or matrix-assisted laser-
desorption ionisation time of flight (Maldi-ToF) mass spectrometry. For further structure 
characterisation, the re-purified eluates were also taken on Orbitrap and (IAA treated) 
and/or trypsin digested as in section 2.5.  
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 Preparation of gel slices for in–gel tryptic digestion  
Trypsin digestion of Clos containing gel slices was carried out using a method adapted 
from Saalbach et al. (JIC). Incubation time was 15 min unless otherwise noted and the 1 
ml washes were removed by 1 min centrifugation at 5, 000 g. The defrosted gel slices 
were each washed twice with 30 % ethanol at 65°C, twice in 50 % acetonitrile in 50 mM 
TEAB. After buffer was removed, either 10 mM dithiothreitol (DTT) or 10 mM (tris(2-
carboxyethyl) phosphine in 50 mM triethyl bicarbonate (TEAB) was added and the gel 
slices were incubated vortexing for 30 min at 55°C or at RT respectively. Alkylation was 
achieved by vortexing for 1 hour in the dark with one of the freshly prepared agents: 10 
mM iodoacetamide (IAA) [117-120]. The gel was then washed once in 50 mM TEAB, 
once in 50 % acetonitrile, once in 50 mM TEAB. After the buffer was removed from 
every step, single slices were placed into a petri dish, measured and cut into small pieces 
(1x1 mm) using scalpels. The small pieces were transferred with one drop of TEAB into 
fresh low protein collection binding tubes (Thermo Fisher). Finally, the pieces were 
washed once in 50 % acetonitrile in 50 mM TEAB, once in 50 % acetonitrile, once in 100 
% acetonitrile until gels shrunk and became hard and white. After acetonitrile was 
completely removed in a speed vac for 30 min, the samples were stored at -20°C ready 
for trypsin digestion, Maldi-ToF MS and LC-MS as performed by Gerhard Saalbach (see 
section 2.5). 
 Protein concentration-ZipTip and C4 column    
Removal of detergent contamination from antibody antigen purification (see section 
2.4.6) from the eluates was carried out on C4 and C8 ZipTip (Millipore) first, then on a 
C4 cartridge or C4 column (HyperSep). In an attempt to test which column was the best, 
C4 and C8 were compared and it was concluded that Clos did not bind C4 very strongly 
and had a good elution profile.  
For the ZipTip, the eluate was aspirated, dispensed through ZipTip to bind, wash, and 
elute pure Clos. The recovered repurified Clos was contaminant-free and eluted in 5 μl 
for direct transfer to MS. 
For a scaled purification, a C4 cartridge or C4 column was used. All washes and elutions 
were done by gravity flow and the flow through was collected at each step. The column 
was equilibrated in 3 ml of ACN, then it was washed twice in 3 ml of 0.1 % TFA. The 
eluates (E1-E4) from the antibody antigen purification (see section 2.4.6) were treated 
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with approx. 25 µl of 10 % TFA, until the pH was 3. Each eluate was loaded one after the 
other and ran by gravity. The column was washed with 1 ml of 0.1 % TFA, washed once 
with 3 ml 0.1 TFA, then twice with 3 ml 0.1 % formic acid and finally air dried. The 
peptide was eluted with a linear gradient: twice with 10 %, 1x with 15 %, 1x 20 %, 1x 25 
%, 1x 30 %. 1x 40 %, 1x 50 %, 1x 60 % of acetonitrile (v/v) in 0.1 % (v/v) formic acid. 
Eluent samples could also be concentrated by drying under vacuum and samples 
resuspended in 5 % formic acid for Maldi-ToF MS or LC-MS (see section 2.5).  
2.5 Mass Spectrometry 
Examples of typical samples used for MS are listed below:  
1. Liquid cultures prepared as isopropanol cell extracts from cell pellet, isopropanol 
resuspended pellets or cell free culture supernatants.  
2. Colony picked from agar plates extracted by isopropanol method;  
3. Liquid cultures prepared as cell extracts from bead beaten pellet, C4 column purified 
eluates originally collected from the antibody-antigen kit.  
 Matrix-Assisted Laser-Desorption Ionisation Time of Flight (Maldi-
ToF) 
The samples (1 µl) were spotted onto a PAC plate (Prespotted AnchorChipTM MALDI 
target plate, Bruker Daltonics, Coventry, UK), left for 3-5 min, and then the spots were 
washed shortly with 10 mM ammonium phosphate, 0.1 % TFA according to the 
manufacturer. Alternatively, samples were spotted onto polished steel plates (Bruker) and 
left until dry. After drying they were overlaid with 1 µl of a solution of α-cyano-4-
hydroxycinnamic acid (Sigma-Aldrich, Dorset, England) (5 mg/ml) in 50 % acetonitrile, 
0.1 % TFA. The samples were analysed by Maldi-ToF on a Bruker Autoflex Speed 
TOF/TOF. The instrument was calibrated using the pre-spotted standards of the PAC 
plate or SpheriCal® calibrants (Polymer Factory, Stockholm, Sweden). Samples were 
analysed using a method optimised for peptide analysis in the mass range 1000-7000 and 
spectra were summed from ca. 10 x 500 laser shots. Data were processed in FlexAnalysis 
(Bruker) to generate annotated spectra. 
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 Liquid chromatography-mass spectrometry (LC-MS)  
 LC-MS - Orbitrap Fusion Method 
Gel pieces were washed, treated with trypsin, and extracted according to standard 
procedures adapted from Shevchenko et al. [121]. Aliquots were analyzed by nanoLC-
MSMS on an Orbitrap Fusion™ Tribrid™ Mass Spectrometer coupled to an UltiMate® 
3000 RSLCnano LC system (Thermo Scientific, Hemel Hempstead, UK). The sample 
was separated on a PepMap™ 100 C18 LC Column (C18, 2 µm, 500 x 0.75 mm, Thermo) 
using a gradient of 0.75 % min-1 acetonitrile from 6 % to 40 % in water/0.1 % formic 
acid at a flow rate of 0.3 µl min-1 and infused directly into the mass spectrometer. The 
mass spectrometer was run in positive ion mode with quad isolation at 120K resolution 
over the mass range 400-1600 (m/z) for the precursor scans (orbitrap). One microscan of 
50 ms with an AGC target of 2e5 was used. MS2 threshold was set to 2e4 and precursors 
fragmented by both CID and HCD with CE=30 and an isolation window of 1.6 Da 
(quadrupole) using the automatic maximum speed option with ion injection for all 
available parallelizable time. Dynamic exclusion was set to 1 count and 40 s. Recalibrated 
peaklists were generated using MaxQuant 1.5.3.30 (www.MaxQuant.org) and the 
database search was performed with the merged HCD and CID peaklists using Mascot 
2.4 (Matrixscience, London, UK). The search was performed on a Lactobacillus lactis 
protein sequence database (uniprot) to which the clos peptide sequences had been added 
with a precursor tolerance of 6 ppm and a fragment tolerance of 0.6 Da. The enzyme was 
set to trypsin/P with a maximum of 2 allowed missed cleavages. All used modifications 
(Carbamidomethyl (C), oxidation (M), acetylation (Protein N-term), dehydro (T,S)) were 
set as variable modifications. The Mascot search results were imported into Scaffold 
4.4.1.1 (www.proteomsoftware.com) using identification probabilities of 99 % and 95 % 
for proteins and peptides [121, 122]. More specific details were also added in chapter 6. 
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 LC-MS - Synapt Method 
Typical samples were from:  
1) Liquid culture prepared as isopropanol cell extracts from cell pellet, isopropanol 
resuspended pellets or cell free culture supernatants.  
2) Colony picked from agar plates extracted by isopropanol method;  
3) Liquid cultures prepared as cell extracts from bead beaten pellet, C4 column purified 
eluates originally collected from the antibody-antigen kit.  
The samples were analysed by LCMS on a Synapt G2-Si mass spectrometer coupled to 
an Acquity UPLC system (Waters, Manchester, UK). Aliquots of the samples were 
injected onto an Aeris WIDEPORE 3.6µ C4 column (Phenomenex, Macclesfield, UK) 
and eluted with a gradient of 1-95 % (Acquity curve 7) in 14 min with a flow rate of 0.2 
ml min-1. The mass spectrometer was controlled by the Masslynx 4.1 software (Waters) 
and operated in positive Maldi-ToF and resolution mode with a capillary voltage of 2.5 
kV and a cone voltage of 40 V in the m/z range of 50-1600. Leu-enkephalin peptide (1 
ng per ml-1, Waters) was infused at 10 µl per min-1 as a lock mass and measured every 
30 s. More specific details were also added in chapter 6. 
2.6 Analytical High-Pressure Liquid Chromatography (HPLC)  
Lyophilised nisin mutants (collected from Fractogel, see section 2.3) were re-suspended 
in Buffer A and were further purified on a C18 RP-HPLC column. HPLC was carried out 
on a HP Agilent 1200 series semi-preparative system, consisting of two 1260 Infinity 
preparative pumps, a 1290 Infinity dual loop autosampler, a 1290 Infinity preparative 
fraction collector, and a 1260 Infinity diode array detector. Both auto sampler and fraction 
collector were equipped with thermostatic controllers. A Luna C18 (2) column with 
dimensions 5 µm, 250 x 10 mm was used. A 2 ml injection of sample was loaded onto 
the column and eluted at a 3 ml per min-1 flow rate, using a water/acetonitrile gradient 
containing 0.1 % TFA UV spectroscopy data were collected at 220 nm, 254 nm and 280 
nm. Fractions were collected as indicated by absorption at 220 nm. 
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3. Generation and characterisation of 
Clos-like nisin mutants 
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3.1 INTRODUCTION 
The development of new antimicrobial agents either as an alternative to antibiotics or as 
a food preservative is a matter of considerable importance; this is due to the rise in MDR 
pathogenic bacteria and the undesirable side-effects that many chemical preservatives 
may have. Consequently, there has been a great interest in developing bacteriocins into 
drugs for the treatment of pathogen-driven infections or into additives for the preservation 
of food and animal feed. The availability of molecular tools greatly facilitates the 
generation and characterisation of new bacteriocins and their derivatives.  
At present, nisin is the only bacteriocin that is widely used as a biopreservative and 
approved in over 40 countries for use as a food additive [40]. Genetic engineering of nisin 
as antimicrobial peptides with enhanced characteristics, which are more potent against a 
wider number of pathogenic strains, has been the focus of extensive research in the field 
of antimicrobial peptides [13, 87]. However, the use of nisin and its derivatives in a 
clinical setting is problematic as it is unstable and it has low solubility at physiological 
pH (pH 7.0) [47]. It was previously [47] shown that by using site-directed mutagenesis to 
introduce lysine into nisin Z, the solubility at pH 7.0 was enhanced and, more importantly, 
the novel bacteriocin had comparable antimicrobial activity to native nisin Z [123]. This 
indicated that an improved version of nisin may enable the use of the FDA-approved nisin 
as a therapeutic agent.  
Nisin is a ribosomally synthesised peptide with antimicrobial activity [124]. In a more 
systematic approach, Field et al. [87] took advantage of an in vivo engineering approach 
to construct and screen for highly potent nisin variants. By using random (site saturation) 
mutagenesis in the hinge region of nisin A, a number of variants were successfully 
engineered by amino acid substitutions: the Asn20Pro, Met21Val and Lys22Thr mutants 
of nisin A displayed enhanced antimicrobial activity against pathogenic bacteria such as 
Listeria monocytogenes and Staphylococcus aureus [13, 88, 90, 91].  
Nisin is a polycyclic lantibiotic peptide that contains unusual amino acids and it 
specifically binds and targets lipid II, a component of the bacterial cell wall, to form pores. 
Therefore, the action mode of nisin is bactericidal since it lyses the cell [125].  
Previous work on the screening of gut microbiota strains involved the use of a PCR based 
genome mining approach to identify a novel gene cluster (Figure 20) possibly encoding 
lantibiotics in a strain of Blautia obeum A2-162 isolated from the human GI tract [97]. 
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The predicted ClosA peptides are nisin-like peptides: three are exactly identical (ClosA1, 
ClosA2, ClosA3) and the fourth (ClosA4) has a different sequence (Figure 20). Compared 
to nisin, there are 12 amino acids different in ClosA1-3. The structures of these peptides 
and their antimicrobial activity have not been fully characterised. However, the Blautia 
strain showed variable and inconsistent antimicrobial activity against C. perfringens [97]. 
 
Figure 20 – Arrangement of the sequenced genes in the clos cluster identified from Blautia obeum A2-162 
strain.  
The predicted structure of mature ClosA1 and ClosA4 peptides with alternative start sites in red for ClosA1. 
The genes in the clos cluster are colour coded: structural genes in black (closA1-4), modification genes in 
orange (closB, closC), transport gene in blue (closT), immunity genes in purple (closFEG, closI), regulatory 
genes in green (closR1K1, closR2K2). Abu, Dha and Dhb are unusual amino acids introduced by ring 
formation and dehydration, respectively. The predicted Clos peptides differ from the structure of nisin by 
12 amino acids. Adapted from Hatziioanou [97]. 
Our hypothesis is that amino acid substitutions can be introduced in the nisin template to 
create functional clos-like nisin molecules that are expected to be active under GI tract 
conditions.   
The objective of this work was to use the nisin machinery and the genes identified in the 
novel clos cluster from Blautia obeum A2-162 to make a variety of engineered clos-like 
nisin variants. This will enable the investigation and the production of novel lantibiotics 
by expression in a lactococcal host strain. The ultimate aim was to tackle the great need 
for an improved treatment against GI tract diseases such as infections from GI tract 
pathogens. 
A nisin construct was made containing the nisA gene. This construct was subsequently 
used as a template to incorporate amino acid substitutions based on the ClosA1 peptide 
sequence. The nisA gene was subcloned into two expression vectors and transformed in 
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L. lactis MG1614 host strain. To test for nisin expression, these constructs were 
transformed into the L. lactis FI7847 (ΔnisA) strain. This host strain has the entire nisin 
gene cluster and a 20 bp deletion in nisA which created the ΔnisA phenotype and caused 
the structural peptide to be out of frame [95, 96]. After the expression of nisA, the highly 
active nisin construct was selected for further subcloning as it produced similar levels of 
nisin as the wild type L. lactis FI5876 nisin producing strain.  
A screening approach was then used to assess the antimicrobial production and nisin 
induction/self-induction of the mutant peptides using bioassays. The activity spectrum of 
these variants was also tested against different indicator strains aiming to detect mutants 
with similar or higher antimicrobial activities compared to the nisA construct. Colony 
Mass Spectrometry (CMS) allowed the successful detection of the mutant peptides and 
the intracellular processing of nisin such as effective proteolytic cleavage and full 
dehydration by NisB. Selected nisin mutants were purified and their specific activity and 
stability were tested under GI tract conditions. The results revealed that the purified I4K 
and H2G are novel bacteriocins, however their antimicrobial activity, stability and host 
range were not improved compared to the native nisin A.  
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3.2 MATERIALS AND METHODS   
 Generation of nisin derivatives 
Site-directed mutagenesis of nisA [94, 111, 126] was achieved by PCR and by designing 
oligomers for cloning (Tables 10-12). Splice overlap extension PCR is a straightforward 
and reliable method that facilitates the engineering of genes  [127]. PCR was performed 
as described in sections 2.2.6 and 2.2.7 [16]. 
 Selection of vectors for expression of modified nisin  
The insert containing the nisA structural gene was amplified from genomic or plasmid 
DNA from L. lactis strain FI5876 (nisin positive control) using the methods described in 
sections 2.2.3 and 2.2.4. Genomic DNA from L. lactis strain MG1614 (nisin negative 
control) was used as a negative control. The nisA wild type gene from bacterial genomic 
DNA was amplified with NisA_BspHF/NisA_BspHR primers to introduce the BspHI 
restriction site using the high fidelity Phusion DNA polymerase as described in section 
2.2.6.  
In order to optimise the cloning process, three different methods were used; the best 
cloning strategy was to use a NcoI, dephosphorylated pUK200 expression vector and an 
insert (PCR product with BspHI sites) cut with BspHI (section 3.3.1). The NcoI and BspHI 
restriction enzymes produce compatible cohesive ends (5’ TCATGA 3’) which allowed 
for cloning. The plasmid was initially cloned in L. lactis MG1614, then it was transformed 
in L. lactis FI7847 (ΔnisA) to allow for expression of the nisin peptide as described in 
section 2.2.  
The antimicrobial activity of the pUK200_nisA construct was low compared to the wild 
type positive control so a smaller pTG262 vector was further selected for cloning. The 
pUK200_nisA construct was double digested with SspI and EcoRI restriction enzymes to 
create one blunt end/one sticky end insert which was cloned into the HindIII cut, end 
filled and EcoRI digested pTG262 vector (section 3.3.1.1).   
The ligation product was used to transform electrocompetent L. lactis MG1614 strain. 
The transformants and controls were plated, and any positive controls were picked using 
toothpicks and grown in GM17 media with antibiotic selection. After sequence 
confirmation using primer NisA_BspHR (chapter 2), the plasmid was transformed in L. 
lactis FI7847 (ΔnisA) strain. 
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 Generation of novel clos-like nisin variants by site directed 
mutagenesis  
Splice overlap extension PCR was used to introduce I4K, L6A and A15I mutations to 
first make two PCR products using primer pairs which had matching tail with the amino 
acid substitution in. For I4K, the primer pair was nisA_I4K_F & pUK_R and pUK_F & 
nisA_I4K_R. The two PCR products were then overlapped and amplified using outer 
primers pUK_F & pUK_R as described in chapter 2. A similar splice overlap extension 
PCR cloning strategy was used to introduce I4K, L6A and A15I mutations in the nisA 
gene. The splice overlap extension PCR product was then digested with BglII and XhoI 
enzymes and cloned in pUK200 vector.  
The three nisin mutants and the nisA as a positive control were cloned in the lactoccocal 
vectors pUK200, then they were all transferred in pTG262. To introduce the other 
mutations in the nisin template, only the pTG262 vector was used for cloning. All the 
plasmids were initially made in L. lactis MG1614, then they were finally transformed in 
L. lactis FI7847 to allow for expression and further characterisation of the mutant 
peptides. All the subcloning steps (cloning and transformation in L. lactis) were 
performed as described in section 2.2.  
To introduce mutations in Ring C and in the C-terminus of nisin, a new cloning strategy 
that involved the use of a SacI restriction site (at amino acid position 15) was used. Table 
17 has details about the designed oligomer pairs used for cloning.   
Within the nisA gene there is a SacI restriction site and mutations were introduced by 
using oligonucleotides and cloning was organised in two ways: mutations between 
residues Ile1 to Ala15 were designed with the SacI site at the C-terminal of the 
oligonucleotide, whereas mutations between Leu16 to Lys34 were designed with SacI 
site at the N-terminus part of the oligonucleotide. 
Mutations in Ile1 to Ala15 of nisA (N-terminal to the SacI). This involved a two-step 
cloning strategy. A pUK200_I4K_L6A construct was first created using splice overlap 
extension PCR. The full region of nisin containing the mutation was then excised, and 
cloned in the pTG262 vector.  
Mutations in Leu16 to Lys34 of nisA (C-terminal to the SacI). The SacI restriction site 
at position 15 in nisin was also used to generate the following mutants: G18T, N20P, 
M21L, H27G, H27G_S29H_ H31T_V32G_ S33K, H31T_V32G_ S33K.  
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Table 17 - Details for splice overlap extension PCR fragments and oligomers to make nisin mutants.  
Mutation  Oligomer pair  Insert size * 
I4K_L6A I4K_L6A_F & I4K_L6A_R 123 bp cloned as 
BspHI/BamHI 
(1st part of nisin)  
G18T G18T_F & G18T_R 73 bp cloned as 
SacI/BamHI 
(2nd part of nisin) 
N20P N20P_F & N20P_R 73 bp cloned as 
SacI/BamHI 
(2nd part of nisin) 
M21L M21L_F & M21L_R 
N20P_M21L N20P_M21L_F &  N20P_M21L_R 
H27G  
H27G_S29H_ 
H31T_V32G_ S33K 
H27G_S29H_H31Dhb_V32G_Dha33K_F & 
H27G_S29H_H31Dhb_V32G_Dha33K_R 
H31T_V32G_ S33K H31Dhb_V32G_Dha33K_F & 
H31Dhb_V32G_Dha33K_R 
Mutation  Primer pair  Insert size** 
I4K nisA_I4K_F & pUK_R 
pUK_F & nisA_I4K_R 
575 bp cloned as 
BglII/XhoI 
 L6A nisA_L6A_F & pUK_R 
pUK_F & nisA_L6A_R 
A15I nisA_A15I_F & pUK_R 
pUK_F & nisA_ A15I _R 
A15I_G18T*** G18T_F & pUK_R 
pUK_F & A15I_R   
*The mutations were introduced by designing two oligonucleotide sequences (forward and reverse). 
Annealing was done with equimolar concentrations at 90-100°C for 5 minutes, with slow cooling to RT for 
60 minutes. A double stranded insert with restriction sites at each end was made and finally cloned in the 
pTG262 vector.   
**The mutations were introduced by splice overlap extension PCR in a pUK200 vector. The nisin fragment 
with the mutations in was then excised and cloned in pTG262 vector.  
*** The template was pUK200_nisA_A15I. 
 Production and characterisation of nisin mutants 
The nisin mutant and control strains were grown from glycerol in 10 ml of GM17 with 
10 µg/ml of chloramphenicol, subcultured in fresh media with antibiotic and induced with 
10 µg/ml of nisin (DuPond, UK). Liquid culture was either dropped on plates (overlay 
assay) or the cultures were acidified to pH 3.0 with HCl diluted to 50 %, centrifuged for 
10 min at 4000 x g then dropped on plate (drop test) or loaded in wells on a L. lactis strain  
seeded plated (plate diffusion assay) unless specified otherwise.  
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 Testing the antimicrobial activity of the engineered nisin variants   
To investigate the bioactivity, each nisin variant-producing strain was grown on GM17 
agar plates containing 10 µg/ml of chloramphenicol and a nisin concentration suitable for 
induction. The mixture was prepared by adding a final concentration of 10 ng/ml of native 
nisin to a pre-warmed 100 ml GM17 agar bottle prior to pouring into plates. 1 to 3 µl of 
an overnight liquid culture from each of the 12 nisin mutant producing strains were 
spotted onto the plates, which were then incubated at 30◦C for 12 h as described in section 
2.1. Colonies grown overnight (drop of liquid culture) were rendered non-viable as they 
were inactivated under UV and antimicrobial activity was detected by overlaying strains 
directly with soft agar seeded with a sensitive indicator strain and by identifying zones of 
growth inhibition. Plates were incubated overnight at the optimal temperature of the 
indicator strain (e.g. typically, plates were overlaid with L. lactis MG1614 and were 
incubated at 30◦C) as described in chapter 2, including the pTG262_nisA positive control 
and the pTG262 empty vector control. CMS was used to determine the relative molecular 
mass of the 12 nisin variants as described in section 2.5.  
 Screening of nisin mutant producer strains for their spectrum of 
activity  
The same methods were used as described in chapter 2 with the following modifications. 
Nisin A (DuPont, UK) was used to induce antimicrobial production and it was prepared 
in filter sterile 50 diluted HCl adjusted to pH 3.0. Aliquots of the stock were stored at -
20°C at concentrations of 10 mg/ml and 10 μg/ml. 
  Colony overlay assay 
The UV treated plates were each overlaid with soft agar on an appropriate plate seeded 
with one of the indicator strains: Micrococcus luteus, Bacillus cereus, Bacillus subtilis, 
Clostridium difficile, Clostridium perfringens, Enterococcus faecalis, Enterococcus 
faecium, Leuconostoc mesenteroides sub., Listeria innocua, Listeria ivanovii, and 
Staphylococcus aureus; then, they were incubated overnight at the optimal temperature 
for the growth of the indicator organism. 
 Drop test with culture supernatant 
Indicator strains grown overnight (listed in previous section) were diluted 1:10 or 1:100 
in PBS, then lawns of sensitive strains were made on solid agar suitable for each strain 
using cotton swabs. 12 overnight cultures of nisin mutant producing strains were acidified 
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to pH 3.0 with HCl diluted to 50 % and centrifuged for 10 min at 4000 x g. 5 to 10 μl 
aliquots of each cell free acidified supernatant were placed on the surface of each lawn, 
air dried and incubated overnight at the optimal temperature in aerobic conditions. A 
negative control with 50% diluted HCl alone was also included in the test.  
 Testing for self-induction capacity of nisin mutants 
Bioassay plates were seeded with L. lactis MG1614 nisin-sensitive indicator strain as 
described in 2.1 with modifications as described below. The bioassay was used for the 
detection of nisin mutant production in liquid cultures, which were previously induced 
with different concentrations of native nisin. 
L. lactis producer strains for 12 nisin variants were grown from glycerol in individual 10 
ml of GM17 with 10 µg/ml of chloramphenicol and subcultured (1:100) in fresh media 
with 10 ng/ml of nisin for induction in L. lactis FI7847 (ΔnisA) host strain. After 
overnight incubation with subinhibitory amount of nisin to allow for transcription 
initiation of mutated nisA sequence, the liquid cultures were subcultured with 0, 10, 100 
ng/ml of nisin. The induction capacity of each mutant was determined in relation to native 
nisin. The culture supernatants were assayed directly from an overnight culture, prepared 
by acidifying liquid cultures to pH 3.0, centrifuged to remove cells and filter sterilised. 
Plates were incubated at 4◦C for 3-5 h, prior to overnight incubation at 30◦C, to allow 
maximum diffusion of sample into the agar before the growth of the L. lactis MG1614 
indicator organism. Zones of inhibition for the induced mutants were compared to vector 
only negative control (pTG262 in FI7847). 
The zones of inhibition were measured for nisin standards over a suitable series of 
concentrations and were plotted against the logarithm of nisin standard concentrations. 
The nisin standard curve was then used to estimate the relative activity in the tested 
samples (see 2.1.3.2).  
 TEM of nisin mutant producer strains  
To investigate any change in phenotype of the cell morphology of nisin mutants 
H27G_S29H_ H31T_V32G_ S33K and L6A, nisin and the nisin mutant producer strains 
were cultured from glycerol in selective media, subcultured and induced with 10 ng/ml 
nisin. After strains were grown overnight, the cultured cells were analysed by 
transmission electron microscopy (TEM) by Kathryn Cross (IFR). 
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 Purification and assessment of bioactivity of nisin mutants  
 Optimising the amount of nisin used for induction  
Nisin induces its own production [74] however, I4K, L6A and H27G nisin mutants are 
not self-inducers based on section 3.2.2. In order to optimise the amount of nisin needed 
to induce nisin variants for the purpose of large scale peptide production, liquid cultures 
for I4K, L6A, H27G, pTG262_nisA (positive control) were grown with increasing 
concentrations of external nisin and bioactivity was assessed in plate diffusion assay. 
The four L. lactis bacterial strains were grown overnight from glycerol in 10 ml GM17, 
then they were subcultured with 10 ng/ml of nisin and grown overnight at 30◦C. Strains 
were subcultured with 0, 3, 30, 100 and 200 ng/ml of native nisin and incubated overnight. 
In this experiment, and for the scaled up production of nisin mutants in large fermenters, 
a nisin stock of 2.5 % pure nisin was purchased from Sigma. Nisin powder formulation 
contains 75 % NaCl and 22.5 % denatured milk solids. Nisin stock concentrations were 
prepared at 1 mg/ml in 50% diluted HCl to pH 3.0. In this study, the Sigma nisin 
concentrations were based on the pure nisin concentration not on weight of the 
formulation. 
 Purification of nisin mutants  
In order to maximize the scaled up peptide production in the 11-14 L fermenters, pH was 
maintained at 6.0. The nisin mutant-producer strains were grown from glycerol in 600 ml 
of GM17 with antibiotic then the overnight liquid cultures were subcultured in 1:100 in 
SPY-S media, or until initial OD600 reached 0.1. The liquid cultures were induced with 
100 ng/ml nisin powder (Sigma) (for H27G, nisin and L6A) or 200 ng/ml nisin (for I4K); 
10 µg/ml of chloramphenicol was also added for plasmid selection. The protocol 
described in chapter 2, section 2.3 was used.  
After the overnight liquid culture was harvested, the cell-free supernatant of the nisin 
mutants adjusted to pH 6.0 was purified using a two-step process. Culture supernatant 
was subjected to a first purification step involving hydrophobic interaction 
chromatography on Fractogel TSK Butyl 650-S. The second step involved purification of 
lyophilised and resuspended fractions on a C18 RP semi-preparative HPLC column. The 
purity of the Fractogel fractions was assessed on an analytical C18 HPLC column before 
it was further purified on semi-preparative RP-HPLC. The bioactivity of the peptide was 
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monitored via plate diffusion assays against L. lactis MG1614 as indicator strain and the 
extent and nature of the amino acid substitution was identified by Maldi-ToF. 
 Characterisation of purified nisin mutants 
 Determining the specific activity of I4K and H27G nisin mutants 
A range of concentrations for the purified I4K, H27G and wild type nisin A were tested 
for their ability to inhibit growth of L. lactis MG1614 by plate diffusion assays (chapter 
2, section 2.1.3).  
The aim was to select an equivalent concentration for I4K and H27G that would give 
similar antimicrobial activity as pure nisin. The antimicrobial activity was reported in 
nisin units: 1 unit of nisin was set as 100 % activity detected from 9 µg/ml of nisin.  
A stock solution of 1.5 mg/ml of nisin A, H27G and I4K was prepared by resuspending 
1.5 mg of pure nisin A (Du Pont, UK), pure H27G or pure I4K into diluted HCl to 50 % 
adjusted to pH 3.0. Standard solutions for each peptide were prepared in buffer as follows:  
For nisin: 15, 12, 9, 6, 3, 1.5, 0.9 and 0.6 µg/ml.  
For I4K: 50, 40, 30, 20, 10, 5, 2.5 µg/ml and 15, 12, 9, 5, 3 and 1.5 µg/ml.  
For H7G: 50, 40, 30, 20, 10, 5, 2.5, 0.9, 0.6 µg/ml and  
15, 12, 9, 5, 3, 1.5, 0.9, 0.6 and 0.3 µg/ml. 
9 µg of H27G, 40 µg of I4K and 9 µg of nisin were each resuspended in 1 ml of buffer as 
described in section 2.1.3.2. The three sets of samples and 1 set of buffer only were 
incubated at 37◦C for 7 days and triple aliquots were removed at set intervals and tested 
in plate diffusion assay against L. lactis MG1614 indicator strain.  
 Activity of purified nisin mutants under GI tract conditions  
The pH of the GI tract varies from 2.0 to 8.0 [128]. To test the bioactivity and the stability 
of purified nisin mutant peptides under GI tract conditions, peptides were incubated at pH 
values and temperature relevant to the GI tract.  
Initial stocks of purified H27G, I4K and pure nisin (Aplin & Barret) were redissolved in 
diluted HCl to 50 % adjusted to pH 3.0. 9 µg of H27G, 9 µg of nisin and 40 µg of I4K 
were dissolved in 1 ml of buffer at different pHs following the method described by 
Rollema et al. [47]. Solutions at pH 3.0, 4.0, 5.5, 6.0, 6.5 and 7.0 were prepared and 
incubated at 37◦C. For pH 3.0, no other buffer was used. For pH 4.0 to 5.5, and for pH 
range of 6.0, 6.5 and 7.0, 20 mM sodium acetate buffer and 20 mM sodium phosphate 
buffer were used, respectively. All peptide solutions contained 0.1 M NaCl and the 
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samples were incubated at 37◦C for 7 days. Aliquots were collected at regular time 
intervals and 200 µl (approx. 1.8 µg for H27G and nisin, 8 µg for I4K) of peptide was 
loaded in each well in duplicate plates. Aliquots were collected at time zero, and after 24 
h, 48 h, 68 h and 7 days of being incubated at 37◦C. Peptide stability and biological 
activity was determined by plated diffusion assay against L. lactis MG1614 incubated at 
30◦C.  
 Antimicrobial spectrum of activity of nisin mutants  
Solutions of 12, 9, 5, 3, 1.5, 0.9, 0.6 µg/ml of H27G and nisin A were prepared in 20 mM 
sodium phosphate at pH 6.0 and tested in plate diffusion assays. In order to mimic the GI 
tract conditions (colon for pH 6.0), both the peptide solutions as well as the seeded agar 
were prepared at pH 6.0 and plates were incubated at 37◦C overnight. The solutions were 
loaded on seeded plates with agar that was pH adjusted to 6 prior to loading the well. The 
selected indicator strains were grown in pH 6.0 adjusted medium: B. subtilis, C. difficile, 
C. perfringens, E. faecalis, E. faecium, L. ivanovii, S. aureus.   
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3.3 RESULTS 
 Generation of nisin derivatives 
 Cloning the original nisA gene in pUK200  
The aim was to create nisA mutants to incorporate features of the ClosA1 peptide. The 
original nisin structure was used as a template. The original nisA gene from L. lactis 
FI5876 was subcloned on a pUK200 expression vector in L. lactis FI7847 (∆nisA). 
The best cloning strategy is illustrated in Figure 21 and it involved the use of a two 
cohesive ends insert and a dephosphorylated vector.  
To confirm the formation of the desired mutation and the integrity of the wild type nisA 
gene, selected colonies were sequenced to confirm 100 % match to the original nisin gene 
sequence (data not shown). 
 
Figure 21 - Cloning nisA gene from genomic DNA of FI5876 to make A. pUK200_nisA and B. 
pTG262_nisA expression vectors. 
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 Design of clos-like nisin mutants  
The bioengineered nisin template pUK200_nisA was used to incorporate single and 
multiple mutations to generate a range of clos-like nisin mutant peptides (Figure 22). 
 
Figure 22 - Generation of clos-like nisin mutants.  
A range of nisin variants that have features of the ClosA1 peptide were generated by subsequent amino acid 
substitution in the original nisin structure as highlighted in red. 
The original nisA gene was subcloned in two expression vectors: pUK200 and pTG262 
to make pUK200_nisA and pTG262_nisA constructs, which were expressed in L. lactis 
containing the nisin gene cluster (ΔnisA). Induction of the nisin promoter (PnisA) by nisin 
and the expression of nisA by the nisin biosynthetic machinery in L. lactis strain were 
achieved with subinhibitory amounts of exogenous mature nisin and the antimicrobial 
activity was assessed (Figure 23).  
 
Figure 23 - Antimicrobial activity of nisA L. lactis producing strains overlaid with L. lactis MG1614 
indicator strain. This picture is a representative image of three independent agar plate diffusion assays.   
 
The pTG262_nisA construct was more effective compared to pUK200_nisA and it 
allowed the production of antimicrobial activity which proved to be nearly as high as the 
wild type nisin, FI5876; this plasmid was then used as a template to introduce subsequent 
mutations, followed by a short nisA structural gene.  
The difference in expression levels could be attributed to the plasmid copy number, as 
the halo size was different when nisA was expressed from either pUK200 or pTG262. 
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These results demonstrate that the nisA gene was successfully expressed by the nisin 
biosynthetic machinery of L. lactis strain. The pTG262_nisA construct was therefore 
selected for subsequent generation of the nisin mutants. 
 Construction of novel clos-like nisin variants by site directed 
mutagenesis 
One of the aims of the project was to make successive changes in the nisA gene of the 
nisin cluster using a nisin construct to alter the sequence and to generate a range of active 
clos-like nisin mutants. The aim of the work was to understand how flexible the nisin 
machinery is at tolerating amino acid substitution before it fails and can no longer modify 
and /or express any active peptide. Therefore, the effect of introducing single or multiple 
mutations in the rings was first assessed (Figure 22). The initial efforts to make nisin 
variants focussed on introducing modifications in the Rings A, C, E and the hinge region 
of nisin where they were previously found to have the largest effects on activity [40, 91]. 
Standard genetic engineering and manipulations were performed using established 
procedures. The splice overlap extension PCR strategy was employed to mutate the nisA 
gene which replaced the wild type nisA gene to make three nisin variants (I4K, L6A, 
A15I). Conventional PCR reactions with designed oligonucleotides allowed the 
successful construction of 9 additional nisin mutants. Forward and reverse single stranded 
oligomers were annealed to make a 73 bp insert (SacI/BamHI) or a 123 bp insert with a 
SacI site inside (BspHI/BamHI). The following mutants where made using the 73 bp 
insert: G18T, N20P, M21L, H27G, H27G_S29H_ H31T_V32G_ S33K, H31T_V32G_ 
S33K. Using the 123 bp insert the following mutant was made: I4K_L6A. The cloning 
process to make mutants A15I_G18T, N20P_M21L and H31T_V32G_ S33K will be 
described below. 
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Figure 24 - Splice overlap extension PCR products to introduce either I4K or L6A mutation in the 
pUK200_nisA construct. 
Two PCR products were made using one vector primer (pUK_R or pUK_F) and one primer that 
incorporated the changed nucleotides: nisA_I4K_F or nisA_I4K_R. The resulting 2 PCR products were 
then mixed and amplified with the vector primers (pUK_F/pUK_R) to give a splice overlap extension PCR 
product of 650 bp. Lane 1: reaction with 2 ng of the 2 PCR products; Lane 2: reaction with 8 ng of the 2 
PCR products, lane 3: control with one PCR product; lane 4: control with the second PCR product; lane 5: 
control with UPH2O, lane 6: marker, lane 7: reaction with used 2 ng of 2 PCR products, lane 8: reaction 
with used 8 ng of 2 PCR products, lane 9: control with one PCR product; lane 10: control with the second 
PCR product. 
The pUK200_nisA_I4K construct was made using splice overlap extension PCR and pairs 
of primers: nisA_I4K_F/pUK_R and pUK_F/nisA_I4K_R. The engineered splice overlap 
extension PCR fragment with the I4K mutation in was ligated in L. lactis MG1614 host 
strain (Figure 25). Sequencing of pUK200_nisA_I4K or L6A or A15I constructs 
confirmed the nisin mutant peptides had the correct mutation in. These pUK200 
constructs were then successfully electroporated into L. lactis FI7847 and confirmed by 
PCR from colonies obtained with antibiotic selection.   
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Figure 25 - Diagram to illustrate site directed mutagenesis of nisA gene to make I4K nisin single mutant.  
A. Splice overlap extension PCR to introduce Lysine mutation (K = AAA) at position 4 instead of 
Isoleucine (I = ATT) in nisin, B. cloning to make I4K mutant in pUK200 expression vector. Primer p3 is 
the nisA_I4K_F primer and p2 is the nisA_I4K_R primer.  
Since the cloning in the pTG262 plasmid improved expression of nisA, the three 
individual nisA mutated inserts (I4K, L6A and A15I) were excised and cloned as 
described in section 3.2.1.2. The pTG262_nisA plasmids with the incorporated mutations 
were finally cloned in L. lactis FI7847 (ΔnisA) host strain. 
To make the A15I_G18T double mutant in the pTG262_nisA expression vector, a two-
step cloning strategy was used: 1. pUK200_nisA_A15I construct was used as a template 
to introduce the G18T mutation by splice overlap extension PCR. 2. The A15I_G18T 
insert was excised and cloned to make pTG262_nisA_ A15I_G18T construct. 
Splice overlap extension PCR was performed as before using G18T_F/pUK_R and 
pUK_F/A15I_R sets of primers. The two PCR products were overlapped with the outer 
primers pUK_F and pUK_R, then the 650 bp insert was cut with BglII/XhoI. The 575 bp 
insert was cloned in pUK200_nisA_A15I vector previously digested with BglII and XhoI. 
Ligation, transformation and sequencing were performed as described in chapter 2. The 
new construct pUK200_nisA_A15I_G18T was digested with HindIII, end filled, and 
digested with XbaI and cloned into the pTG262_nisA vector digested with SspI and XbaI 
to make the pTG262_A15I_G18T. 
After numerous attempts to make mutants I4K_L6A, G18T, N20P using the same splice 
overlap extension PCR strategy, an alternative method was used for subsequent cloning 
which was routinely giving multiple bands. Initially, bands of interest were excised and 
purified from gel, however any subsequent attempts to create the correct constructs were 
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not successful according to DNA sequencing. Instead, pairs of single stranded DNA 
sequences, known as oligomers, were designed as detailed in Table 17. A SacI site 
identified at position 15 in the nisin sequence was used to plan a cloning strategy with the 
aim to introduce mutations in the nisA structural gene.  
Mutations in Ile1 to Ala15 of nisA (N-terminal to the SacI). This involved a two-step 
cloning strategy.  
1. A pUK200_I4K_L6A construct was made with splice overlap extension PCR.  
2. The entire nisin mutated region was excised and cloned in pTG262. 
Firstly, a 123 bp insert that comprises mutations before the SacI site (e.g. I4K_L6A nisin 
mutant) was made using a designed pair of forward and reverse oligonucleotides which 
were annealed to make a BspHI and a BamHI restriction site at each end (Figure 27, C). 
The 123 bp double stranded insert had a SacI site within the PCR overlap sequence, which 
was used for subsequent cloning. The insert was cloned in a pUK200 vector previously 
digested with NcoI and BamHI enzymes. Secondly, the resulting construct was digested 
with SacI and BamHI and ligated to a 73 bp PCR product (amplified with pTG262_S_F/ 
pTG262_B_R from pTG262_nisA), which was cut with SacI/BamHI. This step created 
the second part of nisin (Figure 26, Figure 27). 
The pTG262_nisA_I4K_L6A construct was made to allow for an enhanced expression of 
the mutant peptide. The pTG262 vector was digested with HindIII, end filled and digested 
with EcoRI. A 220 bp fragment was prepared as follows: the pUK200_nisA_I4K_L6A 
construct was digested with SspI/EcoRI and ligated to the prepared vector.  
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A. B.  
Figure 26 - Diagram to illustrate cloning in Ile1 to Ala15 of nisA (N-terminal to the SacI)  to create the 
I4K_L6A mutant (A) and cloning in Leu16 to Lys34 (C-terminal to the SacI) (B).  
I4K_L6A mutant was created using A. pUK200 NcoI/BamHI cut vector, 123 bp oligomer to introduce the 
I4K_L6A mutation and 73 bp oligomer to create the second half of nisin; B. pTG262 HindIII/EcoRI cut 
vector and SspI/EcoRI excised nisA_I4K_L6A fragment. M is I4K_L6A.  
Cloning after Leu16 to Lys34 (C-terminal to the SacI) was done in pTG262_nisA construct using a 73 bp 
oligomer. M is one of the mutants: G18T, N20P, M21L, H27G, H31T_V32G_S33K, H27G_S29H_ 
H31T_V32G_ S33K.  
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Mutations in Leu16 to Lys34 of nisA (C-terminal to the SacI). The SacI restriction site 
at position 15 in nisin was also used to generate the following mutants: G18T, N20P, 
M21L, H27G, H27G_S29H_ H31T_V32G_ S33K, H31T_V32G_ S33K.  
pTG262_nisA vector was restricted with SacI and BamHI. A 73 bp insert that comprised 
mutations after the SacI site was made using designed pairs of forward and reverse 
oligonucleotides which were annealed (Table 17). The 73 bp double stranded insert had 
a SacI/BamHI site already created by annealing as described above and in chapter 2.  
The new cloning strategy involved the use of the unique SacI restriction site that was 
located at position 15 in the Ring C of nisin (Figure 27). Pairs of forward and reverse 
single stranded oligonucleotides were annealed to make a 73 bp double stranded DNA 
insert bearing mutations and cloning was performed as in section 3.2.1.2. After the pair 
of oligonucleotides was annealed the resulting insert created the restriction sites for SacI 
and BamHI on each end. The SacI/BamHI fragments, incorporating mutations in nisA, 
were subsequently cloned into the multicloning site of the SacI/BamHI cut pTG262_nisA 
shuttle vector. The ligated construct was transformed into L. lactis MG1614.  
PCR and sequence analysis of L. lactis MG1614 transformants confirmed successful 
ligations and verified the position of amplified DNA within the nisA gene, creating an 
uninterrupted nisA structural coding region with the desired substitutions in the nisin 
template.  
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A.  
B.  
C.  D.  
Figure 27 - Illustration to introduce mutations in nisA sequence using oligomers.  
M = mutation  
A. nisA sequence with the SacI restriction site.  
Primer pair, universal and reverse, were used in PCR to confirm successful incorporation of mutations.  
B. Nisin structure in which SacI site is highlighted by a blue arrow.  
C. 73 bp (SacI/BamHI) fragment to make the second part of native nisin where 1. Single stranded DNA, 
forward oligomer (olg_F); 2. Single stranded DNA, forward oligomer (olg_R); 3. Double stranded DNA, 
with SacI restriction site at 5’ and BamHI site at 3’, there is no need to cut the insert as sites are already 
created by oligomer annealing.  
D. 123 bp (BspHI/ BamHI) fragment was used to make the first part of native nisin where 1. Single stranded 
DNA, forward oligomer (oligo_F); 2. Single stranded DNA, reverse oligomer (oligo_R); 3. 123 bp double 
stranded DNA, with BspHI restriction site at 5’, SacI restriction site and BamHI site at 3’ end.  
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An uninterrupted nisin sequence was created by using a combination of primers in PCR 
which included a 73 bp and a 123 bp sequence of amplified DNA fragments as illustrated 
in Figure 27. Splice overlap extension PCR and designed oligonucleotides were used to 
successfully introduce mutations in the nisin template. The successful generation of 
different cloning products during different steps of the cloning process were assessed by 
agarose gel electrophoresis (Figure 24).  
 Production and characterisation of nisin variants  
Several derivatives of nisin have so far been generated in which single or multiple amino 
acids were simultaneously changed (Figure 22). All nisin mutants were subject to 
bioassays such as the overlay assay, drop test or plate diffusion assay against indicator 
strains, most typically L. lactis MG1614, to identify the effect of amino acid substitutions.  
 Antimicrobial spectrum of nisin variants  
The overlay assay was used as a sensitive method for the initial screening of bioactivity 
of nisin mutant producing strains against nisin-sensitive indicator strains. The bioactivity 
of the mutants was compared to the nisin positive control strain: pTG262_nisA in FI7847 
(ΔnisA). The overlay assay was supported by other bioassays to determine if this 
enhanced bioactivity is attributable to enhanced specific activity [13, 16], production, 
solubility or to diffusion [17]. 
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A.  
B.  
Figure 28 - Antimicrobial activity of nisin-variant strains with induction by native nisin as monitored by 
(A) overlay assay and by (B) drop test against M. luteus.  
Antimicrobial activity shown as zones of clearing/bacterial inhibition against M. luteus. The pictures are a 
representative image of two independent agar plate diffusion assays (A) and drop tests (B).   
Colony overlay assay (A). Indicator strain: M. luteus. Positive controls: colonies of FI5876 wild type strain, 
nisin producing strain pTG262_nisA in L. lactis FI7847 (∆nisA) and the negative control strain: colonies of 
plasmid free L. lactis MG1614 and acidified GM17 media. Nisin mutants and Clos hybrids were expressed 
from pTG262 in L. lactis strain (∆nisA) (see section 3.2.5 and 3.3.5).  
Drop test (B). The level of bioactivity of acidified nisin mutant supernatant was determined from diffusion 
of sample spotted on a lawn of nisin sensitive M. luteus indicator strain.  
Similar bioactivity assays as in Figure 28 were performed using different indicator strains. 
The results were summarised in Table 18 and Table 19.  
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  Colony Supernatant 
Nisin mutant Location of 
mutation 
Activity in 
overlay 
assay 
Activity 
in drop 
test 
Activity in 
supernatant* (plate 
diffusion assay) 
I4K Ring A ++ + (v. low) ++ 
L6A +++  
+ (v. low) 
+++ 
I4K_L6A - - + 
A15I Ring C + ++ + 
G18T - - - 
A15I_G18T - +/++ +/- 
N20P Hinge region +++ (higher) +++ ++ 
M21L +++ +++ +++ 
N20P_M21L +++ ++ ++ 
H27G C-terminal 
end of nisin 
+++ +++ +++ 
H27G_S29H_ 
H31T_V32G_ S33K 
++ + + 
H31T_V32G_ S33K ++ ++ + 
 
Table 18 - The antimicrobial activity of Ring A, Ring C, Hinge region, Ring E and the C-terminal nisin 
mutants tested against M. luteus or L. lactis MG1614 indicator strains. 
The table highlights the bioactivity of each nisin mutant compared to nisin.   
Illustration of the nisin structure and the effect of the mutations on individual amino acids. The size of each 
amino acid corresponds to the antimicrobial activity of each nisin mutants as represented by the cytoscape 
software.  
*Bioactivity of nisin and nisin mutants’ from acidified culture supernatants tested against L. lactis MG1614; 
liquid cultures initially induced with 100 ng/ml of nisin as described in section 3.3.2.3 (Figure 30). 
FI7369 L. lactis strain is a nisin producer positive control with pTG262_nisA construct. 
Legend for overlay assay to assess bioactivity:  
‘+++’ = 80-100 %; ‘++’ = 50 - 80 %; ‘+’ = 20 - 50 %; ‘-’ = < 20 %.  
Legend for drop test to assess bioactivity/diffusion:  
‘+++’ = 50-100 %; ‘++’ = 50 %, ‘+’ = 20 %; ‘-’ = < 20 %. 
80 – 100 %, is wild-type nisin and it was used as a reference.   
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Table 18 summarises the relative antimicrobial activity of the nisin mutants compared to 
positive control: pTG262_nisA in FI7847 (ΔnisA) depicted from assays against M. luteus 
and L. lactis MG1614. It should be considered that for accurate comparison of bioactivity 
the peptides need to be purified, otherwise the amount of peptide on plate or exported in 
the supernatant remains unknown. The results confirm that the production, secretion and 
export of active peptides differ depending on the growth of mutants on liquid or solid 
media. 
 
Table 19 - Summary of antimicrobial activity of different nisin mutants from overlay assay using L. lactis 
MG1614 and nine other bacterial strains.  
All tested mutants and hybrids were expressed from pTG262 in the L. lactis FI7847 (ΔnisA) strain induced 
with 10 ng/ml of nisin. The pTG262_nisA in L. lactis FI7847 (ΔnisA) was used as a reference and it was 
active against all the tested indicators. The activity of this positive control was set as 100 %. Legend: +++ 
= 80-100 % activity; ++ = 50 - 80 % activity; + = 20 - 50 % activity; - = no activity. IC means inconclusive 
at it was difficult to distinguish the bioactivity from background. ‘+++/++’ means that the antimicrobial 
activity was very close to 80 %. ‘+/-’ means that the antimicrobial activity was very close or below 20 %. 
When L. ivanovii and L. innocua indicator strains were tested separately, the antimicrobial activity was 
very similar.  
Nisin was used as a reference and the antimicrobial activity of nisin mutants was 
compared to nisin. The results from the assays with 10 target indicator strains including 
pathogens are shown in Table 19. The best results were obtained from the producer of the 
H27G and N20P which exhibited very similar (80 – 100 % activity) of bioactivity 
compared to the nisin positive control. The nisin producer strain for the Ring A single 
mutant, I4K, generally showed as low levels of bioactivity compared to nisin when tested 
against L. mesenteroides. I4K was inactive against B. cereus whereas the double mutant 
was inactive against all tested strains. All three hinge mutants had high activity against 
all strains, with N20P having an equal level of activity against S. aureus, which is in line 
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with the results in literature [87] and very similar activity against M. luteus, C. perfringens 
and C. difficile. The Ring E and the C-terminal mutants were also active against different 
strains. H27G had very high activity against most of the strains; however, it was active 
against B. cereus in the same way as H27G_S29H_H31T_V32G_S33K and 
H31T_V32G_S33K peptides.  
Ring A mutants:  
In plate diffusion assays, the I4K mutant is less active than the positive control whereas 
the L6A mutant is more active both when induced with 10 or 100 ng/ml of nisin compared 
to nisin (Figure 30) as also summarised in Table 18. The I4K_L6A double mutant showed 
no activity in the bioassays against M. luteus. Interestingly, in the plate diffusion assay 
the I4K_L6A mutant (only the 100 ng/ml induced mutant was tested) there is an 
indication that antimicrobial production is present even if at low levels, when this is 
compared to the nisA construct or the vector only control (induced with 100 ng/ml). 
Overall I4K is more active than L6A in overlay assays, however L6A seems to give a 
bigger zone of inhibition than I4K when tested against C. perfringens. I4K, L6A and nisA 
have the same bioactivity when tested against C. difficile. However, L6A is not active 
against S. aureus and L. mesenteroides. Both nisin mutants lost their antimicrobial 
activity against B. cereus, but L6A was highly active against L. lactis MG1614 and M. 
luteus. Both single mutants were active against L. innocua, L. ivanovii, whereas the 
I4K_L6A double mutant was inactive.   
Ring C mutants:  
The A15I nisin mutant retained its bioactivity in the assays (Table 18, Table 19) even if 
it was at the lower limit of detection. The G18T single mutant had no bioactivity in either 
of the tests against M. luteus or L. lactis MG1614. In the plate diffusion assay, the zone 
of inhibition in the presence of 100 ng/ml is the same as the vector only control with nisin. 
Interestingly, A15I_G18T double mutant is active in the drop test, which is different from  
the lack of bioactivity seen with A15I_G18T and G18T in overlay bioassays. The most 
obvious bioactivity is indicated in the plate diffusion assay when A15I_G18T was grown 
with 10 ng/ml, which confirms antimicrobial production hence the zone of inhibition. 
With 100 ng/ml, the zone was similar to the vector control with added nisin.  
Screening of mutants in overlay assays indicated that mutations in Ring C had a drastic 
effect on the activity of the peptide. Mutation of both Ile4 and Leu6 residues in the 
I4K_L6A double mutant, or in Ala15, Gly18 residues in the A15I, G18T or A15I_G18T 
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double mutants may result in disruption of cyclization for other rings. This may explain 
the decreased/lack of antimicrobial activity from these mutant peptides (Figure 28, Figure 
30). The bioactivity of A15I was detected against L. mesenteroides, L. ivanovii,  
C. perfringens, M. luteus and L. lactis MG1614.  
Hinge mutants: 
For the pore formation step, the flexible hinge region between Rings A, B, C and Rings 
D, E is important as it allows for the translocation of the C-terminus of nisin across the 
membrane. The N20P nisin mutant had been previously synthesised and results with 
antimicrobial activity were reported [87], however for the purpose of having a direct 
comparison especially against the selected tested strains, N20P was also included in this 
study. Overall, mutations but not truncations in the hinge region seem to have a beneficial 
effect: mutants like N20P, M21V and K22S have been shown to have an improved 
antimicrobial activity against L. monocytogenes and/or S. aureus as well as other Gram-
positive pathogens [13, 15, 87] 
The N20P mutant produced a zone of inhibition comparable to the nisA construct tested 
against MG1614 as indicator organism (Figure 30). Compared to the nisin positive 
control, the bioactivity of N20P was enhanced in the overlay assay against M. luteus, 
whereas M12L was as good as the nisA construct in inhibiting the growth of the same 
organism. Interestingly, M21L proved to be self-inducing as it was active with no added 
nisin as illustrated in Figure 30. The zone of inhibition of M21L was comparable to the 
bioactivity of N20P. The N20P_M21L double hinge mutant was very active in all the 
tests. 
Ring E and C-terminal mutants:  
H27G seems to be the best of mutants in this region since H27G was highly active in all 
the tests (Table 18) and it produced zones of inhibition against M. luteus and L. lactis 
MG1614, which were comparable to nisin. In the plate diffusion assay, the two multiple 
mutants (H31T_V32G_ S33K and H27G_S29H_ H31T_V32G_ S33K) produced a good 
zone of inhibition with both 10 and 100 ng/ml of added nisin, which confirms that these 
mutants are active even if their bioactivity seems to be lowest compared to H27G or the 
nisA construct. H31T_V32G_ S33K was less active compared to the positive control but 
much more active than the multiple mutant H27G_S29H_ H31T_V32G_ S33K.  
Interestingly, H31T_V32G_ S33K seemed to be more active than H27G (Table 19) and 
as good as nisA when tested in overlay assay against C. perfringens. The activity of 
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H27G_S29H_ H31T_V32G_ S33K was similar to M21L and N20P_M21L but less 
against the positive control tested against C. perfringens. The multiple mutants totally 
lost their bioactivity when tested against S. aureus and B. cereus, activity was apparently 
present against L. mesenteroides, L. ivanovii, L. innocua and E. faecalis.  
 Confirmation of the engineered nisin variants by MS  
All the nisin mutants were grown and analysed to investigate the production of the 
corresponding peptides. Prior to the MS analysis, samples were prepared using a modified  
version as described in section 2.4.5.3 [87]. This was used to analyse the dehydration 
pattern of the nisin variants as described in chapter 2. 
Results obtained by using different bioassays are summarised in Figure 28, Table 18 and 
Table 19 and confirm the presence or the absence of an active antimicrobial nisin mutant 
peptide. The Maldi-ToF analysis described in here was used as a rapid test to confirm that 
the peptide was produced since some nisin variants may be stable, but they may lack 
antimicrobial activity.  
Figure 29 and Appendix 1 indicates that unique peptide masses, which could correspond 
to modified peptides were detected by MS. Peptides from the wild type FI5876 and the 
positive control, nisA construct, also gave matching observed masses. Figure 29 is an 
example of the Maldi-ToF spectrum, obtained after analysis of H27G nisin mutant 
peptide. 
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Figure 29 - Maldi-ToF analysis of the Ring E nisin mutant, H27G, a clos-like nisin mutant peptide.  
The observed masses correspond to the calculated masses of different monoisotopes. In red, observed and 
calculated masses are 100 % match; in black and bold, there is 1-unit difference between the observed and 
calculated mass of the peptide. H27G, is highlighted in red. A mixture of dehydrated forms of the nisin 
mutant ranging from 8- to 5- dehydrations was detected. The picture on the right is the overlay assay of 
H27G and nisin positive control also shown in Figure 28. 
([M+H]+ = 3272.580, [M+H]+ = 3326.610, [M+Na]+ = 3294.57, [M+Na]+ = 3330.610, [M+K]+ = 
3311.581). 
Results in Figure 29 and Appendix 1 suggested that the peptide masses corresponded to 
several dehydrated forms of the mutants; besides the expected fully dehydrated residues, 
additional products with partially dehydrated residues were also found. For instance, the 
observed mass of [M+H]+ = 3272.580 Da correlated to fully dehydrated peptide (8 
dehydrations). Since H27G was a nisin mutant and it is known that there is no mass 
change resulting from ring formation [129], it was assumed that the modification enzymes 
from FI7847 (nisin gene cluster, ΔnisA) would introduce both dehydrations and rings. As 
in the case of nisin, the most common forms range from 8- to 5- dehydrations. Fully 
modified nisin has 8 dehydrations. pTG262_nisA showed masses for nisin ranging from 
8- to 5- dehydrations and 2- to 1- dehydration (Appendix 1). Similarly, the single and 
multiple mutants in Ring E and the rest of the C-terminus part of nisin showed a number 
of different peptides, which included the predicted peaks of which the masses 
corresponded to 8- to 5- dehydrated residues. However, mutations in Ring A and in the 
hinge region showed a slightly different pattern: L6A had 8- to 4- dehydrations. 
Interestingly, the N20P_M21L double mutant in the hinge region is dehydrated almost 
fully (8- and 7 - dehydrations) and as a result it remained active in the overlay assay 
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(Table 18, Table 19, Figure 28). I4K, N20P and M21L single mutants have 8- to 6- 
dehydrations (for I4K), 8- to 6-, 4- to 2- (for N20P) and 8- to 4- dehydrations (for M21L).   
Mutations of the residues in Ring A and Ring C (I4K_L6A and G18T, respectively) 
resulted in an alternative dehydration pattern, which may explain the lack of antimicrobial 
activity. The I4K_L6A is the only mutant that had a spectrum with peaks, which 
corresponded to a mixture of dehydrations with either cleaved or uncleaved forms of the 
mutant peptide (Appendix 1); this may explain the lack of antimicrobial activity seen with 
this Ring A double mutant. Therefore, the newly installed amino acids at positions 4 and 
6, which are the closest to the protease restriction site, may have an effect on their 
structure which may prevent effective proteolytic cleavage and full dehydration by NisB. 
MS analysis of the G18T peptide clearly indicated the presence of mass peaks that 
correspond to unmodified peptide (0 dehydrations) as well as a range of dehydrated 
peptides that carry 8- to 5-, 3- and 1- dehydrations. Surprisingly, there was no indication 
of antimicrobial activity in G18T. Thus, despite the complete dehydration of the peptides, 
the rings may not have formed which could explain the lack of antimicrobial activity. 
In conclusion, the nisin mutants were characterised by Maldi-ToF to assess production, 
to identify and to confirm the modifications made by the nisin machinery especially 
looking at their dehydration pattern.   
 Self-induction capacity of nisin mutants 
In order to test the autoinduction capacity of the mutant peptides, the induced strains were 
subcultured in different inducible levels of native nisin during liquid growth. The 
activation of the nisin operon is positively regulated by nisin [74], therefore it was 
interesting to investigate if the nisin mutants could act as signal molecules that initiate the 
transcription of the structural gene using the nisin gene cluster [74]. 
Initial bioassays showed that there was a difference in the expression levels of the mutated 
nisA genes, as observed by assessment of antimicrobial activity (Figure 28). It was 
hypothesised that the variation may be due to the difference in induction capacity of the 
nisin mutants. 
Nisin mutants were grown with a subinhibitory amount of nisin (10 ng/ml of nisin) to 
allow for the nisin operon to be switched on. Then, the bioactivity present in the cell-free 
supernatants of the 12 engineered nisin mutant strains was determined using a plate 
diffusion assay (Figure 30).    
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All except for the M21L mutant peptide required continuous induction with native nisin 
in order to allow for antimicrobial production (Figure 30) which proved that M21L is a 
self-inducing mutant peptide. Baseline level of activity was set for the vector only control 
pTG262 in FI7847, induced with 100 ng/ml of native nisin, which produced a small hazy 
zone of growth inhibition. Although, there was a small zone of inhibition that was outside 
the range of the nisin standard curve, the inhibition zones were still taken into 
consideration. All of the nisin variants tested here were novel except for the M21L and 
the N20P hinge mutants which were constructed and described previously [16, 87, 123]. 
The 12 engineered nisin mutant strains, the pTG262_nisA positive control and the nisin 
wild type strain FI5876, gave an increased zone of inhibition when liquid cultures were 
subcultured in media that contained 100 ng/ml of nisin A (Figure 30). The G18T remained 
inactive when cultured with external nisin. Interestingly, A15I_G18T mutant was active. 
A zone of inhibition was only detected when the mutant was grown with 10 ng/ml of 
nisin. The inhibition zones of H27G, M21L, N21L and L6A supernatants were slightly 
lower than that of the positive control. The diffusion zones of I4K and N20P_M21L were 
at approximately 75 % of the size generated by the nisin positive control. Since there was 
no difference between the zone of inhibition of nisin variant I4K_L6A, H27G_S29H_ 
H31T_V32G_ S33K and H31T_V32G_ S33K compared to the pTG262 vector control 
induced with 100 ng/ml of nisin, it was concluded that the small halo was given by the 
external added nisin. The antimicrobial activity in the supernatant from the A15I_G18T 
and G18T nisin mutants was below the level of detection using this bioassay method. 
Therefore, no zone of inhibition from the mutant itself was observed for these two Ring 
C mutants.  
It was unclear if the diffusion zones from supernatants of nisin mutant strains were due 
to an improved or a deficient induction, or whether they were a reflection of the external 
nisin. The problem seems to be that the lowest end of the scale lacks sufficient resolution 
to measure small differences therefore, a different and perhaps more sensitive assay is 
required. Nevertheless, the biosynthesis of most of the nisin mutants was stimulated in 
here by using increased amounts of nisin. The levels of antimicrobial production were 
potentially detectable by plate diffusion bioassay as illustrated in Figure 30.  
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Figure 30 - Plate-diffusion assay to assess the bioactivity of the supernatant of 12 nisin-variant strains when 
non-induced (no nisin) and induced with exogenous native nisin (10 or 100 ng/ml) against L. lactis MG1614 
indicator strain. Control strains: pTG262 empty vector in FI7847, FI5876 wild type strain. The FI7369 
positive control is the L. lactis FI7847 with the pTG262_nisA plasmid. S is standard nisin (µg/ml). 
pTG262_nisA is positive control. This picture is a representative image of two independent agar plate 
diffusion assays. 
   
In summary, all the engineered strains were capable of peptide biosynthesis in the 
presence of exogenous nisin. The assays confirmed that these nisin mutant peptides, 
except for M21L, have lost their capacity to act as signalling molecules as a result of 
introducing single or multiple mutations, which is in line with other studies on the 
signalling capacity on nisin mutant peptides [8, 130]. In the plate assay, the absence of 
external nisin (no nisin) did not allow for the expression of mutated nisA (Figure 30).   
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 Phenotypic analysis of nisin variants 
During the growth of the FI7847 (ΔnisA) strain containing pTG262_nisA_L6A or 
pTG262_nisA_H27G_S29H_ H31T_V32G_ S33K, it was noted that these strains grew 
better in liquid media or broth than on solid media. Some nisin-variant strains displayed 
a highly flocculent phenotype when grown in broth at high OD value compared to other 
liquid cultures that aggregated on the bottom of the vial. There seemed to be a distinctive 
phenotype with the L6A mutant when grown on solid media for the overlay assays (Figure 
28), thus transmission electron microscopy (TEM) was employed to examine and 
compare cell morphology. TEM of the nisin variant producer strains, which offered 
valuable information on the complex phenotype that may be arising from changes in the 
bacterial cell wall and/or cell membrane. 
 
Figure 31 - TEM images of L. lactis FI7847 (ΔnisA) cells expressing different constructs.    
A. pTG262_nisA 
B. pTG262_nisA_H27G_S29H_ H31T_V32G_ S33K 
C. pTG262_nisA_L6A. 
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The TEM images for L6A mutant (Figure 31, C) showed a strong similarity in phenotype 
to the nisin positive control (Figure 31, A). Cells for the nisin positive control 
(pTG262_nisA) had a normal elongated shape, half of the cells were dividing and had 
characteristic scars on the surface for division. There was a mixed population of viable 
and very few nonviable cells. In contrast, the H27G_S29H_ H31T_V32G_ S33K nisin 
mutant cells were damaged since many cells appeared to have lysed suggesting a greater 
proportion of nonviable cells (Figure 31, B).  
The FI7847 strain contains the nisin A biosynthetic machinery. It may be that the nisin 
transport machinery could be clogged by the conformation of the peptides and pores may 
not be formed properly which would explain the observed phenotypes. The amino acid 
substitution in the nisin original strain to create different constructs in the FI7847 cells, is 
likely to have an impact on the antimicrobial activity of the nisin mutants. Another 
explanation for the phenotype could be the presence of a mixture of forms of the peptide: 
the precursor peptide with the leader peptide still attached (inactive form) or of the 
partially or fully modified mutant peptide.  
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 Purification of nisin variants 
I4K and L6A are Ring A nisin mutants, whereas H27G is a Ring E mutant. Previous 
results with these mutants demonstrated that they display an increased antimicrobial 
activity, therefore I4K, L6A and H27G were selected for further characterisation. The 
first aim was to induce the mutants with different amounts of nisin to maximise the 
production of the peptides, then these nisin variants were produced in large scale, purified 
and their specific activity was assessed against nisin. The specific activity of purified 
nisin mutants peptides would provide a more accurate comparison of the inhibitory effects 
of nisin variants. The variation in the observed bioactivity due to the induction capacity 
of the mutant peptides or variation in the level of peptide biosynthesis could therefore be 
eliminated. Liquid cultures were induced with a range of nisin concentrations to maximise 
the expression of the mutant peptide (Figure 32).  
 
Figure 32 - Supernatant antimicrobial activity in the engineered mutant producer strains (I4K, L6A, H27G) 
with induction by 0, 3, 30, 100 and 200 ng/ml nisin and monitored by plate-diffusion assay using L. lactis 
MG1614 as indicator strain. This picture is a representative image of three independent agar plate diffusion 
assays. 
   
The levels of supernatant activity were determined from the inhibition zones of L. lactis 
MG1614 using a standard curve of the positive control nisA which was also induced with 
nisin (data not shown).  
It was observed that induction of nisin mutants with 100 ng/ml of nisin resulted in 
maximal levels of antimicrobial activity, so this nisin concentration was selected for 
scaled up production and for future purification of L6A and H27G. For the I4K producing 
strain, 200 ng/ml of nisin was used. It is expected that the inducible amount of nisin used 
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in the large scale fermenters would elute at different elution time points compared to the 
elution peak of nisin. In order to maximize production, purify and further characterise the 
nisin mutants, the liquid cultures were grown in 11-15 L fermenters ensuring the pH was 
kept constant to pH 6.0 (Figure 33). 
 
Figure 33 - Scaled up production of nisin mutant peptides. 
Nisin mutant producing strains were incubated in a fermenter at 30◦C with stirring and the pH was 
maintained at 6.0 by a pH controller, using 5 M NaOH solution. 
Nisin is a low molecular weight peptide (active nisin is approx. 3.5 kDa) and it has a high 
number of hydrophobic residues which makes it amenable to be separated from other 
media components by the process of hydrophobic interaction chromatography.  
I4K and H27G were successfully purified using an optimised protocol and buffers as 
described in section 2.3. The yield obtained from the first step of purification on a 
Fractogel Toyopearl column was different depending on the nisin variant that was 
purified. 11 L of liquid cultures were grown in fermenters allowing for the production of 
150 mg and 50 mg for H27G and I4K, respectively. The large volume in the fermenters 
and an increase in cell density due to using optimal fermentation culture conditions and 
growth medium should have allowed for the protein yield to be improved. The yield of 
the I4K was 4.55 mg/l, and for H27G was 13.5 mg/l. Pure nisin was not purified in this 
work in order to have a direct comparison to the yield of the three peptides. However, 
even if the yield for I4K and H27G seemed to be low, the amount of peptide that was 
purified was sufficient for further characterisation.   
Active peptide was eluted with HCl, which was an essential step to ensure the release of 
mutant peptide from its hydrophobic attachment to the Fractogel Toyopearl column. It 
was previously shown that the presence of HCl in subsequent freeze-drying concentration 
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steps inactivates nisin [97]. To overcome that, the pH was changed to neutral with 5 M 
of NaOH. The pH was then decreased with glacial acetic acid, which allowed the 
formation of a salt that was removed in further purification steps. In this first step of 
purification, degradation products as well as media components were removed by the 
elution chromatogram and by SDS-PAGE gels (data not shown). 
The second step of purification involved to use the lyophilised powder from Fractogel 
and load onto a C18 RP-HPLC column to separate modified peptides. The H27G, L6A 
and I4K mutations introduced a change in the hydrophobicity of the mutants which means 
that the mutants had different retention time. 
 
Figure 34 - C18 RP-HPLC chromatogram of H27G (left), H27G supernatant antimicrobial activity of 
fractions collected from C18 semi-preparative column (right). 
Top chromatogram is the elution peak of the H27G from the C18 column during RP-HPLC purification 
step. Bottom chromatogram is a zoom in the main elution peaks.  
The first fractions, called F9 to F17, eluted from the C18 column after 5 min retention time. The second 
main peak and the set of fractions eluted after 20.8 min retention time correspond to fractions F49 to F60.  
The engineered mutant was purified from a liquid culture previously induced with 100 ng/ml of Sigma nisin 
and fractions were screened for their antimicrobial activity in plate diffusion assays. 
The levels of specific activity were determined from inhibition zones of L. lactis MG1614 using native 
nisin standard curve (in µg/ml) (stds).  
 
The Fractogel purification step resulted in the elimination of most of the contaminating 
material absorbing at 220 nm as illustrated for the H27G nisin mutant (Figure 34). A 
lyophilised pool of active fractions that eluted from the Fractogel column was taken on 
the C18 column for further purification. The main fraction was eluted from the C18 after 
a 27 min retention time. 
Initial screening of the nisin mutants against different indicator strains suggested that L6A 
would be an interesting candidate to purify (Table 18 and Table 19).  
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Despite exhaustive attempts to purify the L6A mutant peptide, it was not possible to 
produce any quantifiable amounts of this mutant peptide. The activity was not affected 
by low pH (HCl), since the pre-purified fractions of L6A from Fractogel were fully active 
for up to 48-hours at pH 3.5 (data not shown). The unsuccessful purification can be 
explained by a low level of expression even with optimal amount of inducer nisin peptide.  
Figure 35 shows that the L6A, I4K and H27G nisin variants binded to the C18 RP HPLC 
column. Since the interaction with the C18 column was moderate, it was therefore 
possible to elute the largest and most hydrophobic nisin mutant peptides using a gradient 
of a weak solvent such as acetonitrile. The more hydrophobic the mutation was, the 
stronger it bound to the column and the later it was eluted from the column (as seen in the 
elution gradient profiles, Figure 35). I4K and H27G mutants had different retention times 
of approx. 17 to 21 min and 21 to 22 min, respectively. The elution profile from RP-
HPLC C18 column was therefore monitored on a UV detector and the elution peaks for 
the purified peptide were collected at 220 nm (Figure 35). 
 
Figure 35 - RP-HPLC analysis of purified A. nisin, B. H27G, C. I4K, D. L6A. 
The concentration and the purity of nisin mutants was confirmed by analytical HPLC on an Agilent C18 
RP-HPLC column (data not shown). The area under the peak corresponds to the amount of injected peptide 
onto the C18 semi-preparative column used for purification. For accurate quantification of the peptides, the 
concentration of pure peptide was determined in plate diffusion assay against L. lactis MG1614 as indicator 
strain to test pure peptide solutions. 
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For the purification of H27G, the chromatogram indicated the presence of clear peaks at 
20 min retention time, which were collected without contamination; this was confirmed 
by further analytical RP-HPLC and Maldi-ToF (Figure 35). The elution profile of I4K 
nisin mutant revealed the presence of two very close main peaks on the separation 
gradient at 17 - 21 min retention time (red arrows). The fractions for I4K and H27G were 
assessed for their inhibitory effect in a plate diffusion assay against MG1614 (Figure 34, 
results for H27G) and the active fractions were pooled and lyophilised. 
In the case of I4K mutant, eluted peaks contained low levels of pure peptide. The activity 
was mainly lost during the C18 purification step. As in the case of L6A, the yield could 
perhaps be improved by loading more starting material to counteract the possibility that 
the L6A and I4K are poor producer strains. The relative molecular mass of I4K and H27G 
nisin variants was confirmed by Maldi-ToF. The observed masses are in agreement with 
the theoretical values as shown in Appendix 1.  
In conclusion, some of the nisin species were purified by chromatography on Fractogel 
TSK butyl 650-S followed by RP-HPLC. Analytical C18 HPLC was used to test the purity 
of the eluted fractions and the peptides were further purified on semi-preparative RP-
HPLC. The bioactivity of purified fractions was assessed using plate diffusion assay 
against the L. lactis MG1614 strain as before.  
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 Characterisation of pure nisin mutants  
 Determining the specific activity of I4K and H27G nisin variants 
The specific activities of nisin, I4K and H27G were determined in plate diffusion assays 
by loading different standard concentrations and are shown in Figure 36. The standard 
curves for nisin, I4K and H27G were compared.  
 
D.  
 
Figure 36 - The purified nisin mutants were loaded at different concentrations in plate diffusion assay to 
make standard curves. Plot and calculations (D) of standard curves for (A) nisin, (B) H27G and (C) I4K. 
Concentrations of pure peptides are written in white and expressed as µg/ml.  
These pictures are a representative image of three independent agar plate diffusion assays.   
The levels of activity of the pure peptide were determined from inhibition zones of L. lactis MG1614 strain. 
All standards are in µg/ml. The bioactivity given by 9 µg/ml of H27G and 40 µg/ml of I4K should fit on 
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the nisin standard curve to allow for quantification of peptide concentration relative to nisin (as expressed 
in nisin units). Figure 9 has details on how plot the standard curves to create the graph in D.  
 
The zone of inhibition produced by each peptide was measured and the level of 
antimicrobial activity was determined by comparison to their own standard curve (Figure 
36). Pure nisin was used as a positive control. The inhibition zone of pure H27G at 9 
µg/ml does fit to the nisin standard curve and it is a suitable concentration to be used for 
further testing. The activity of I4K at 9 µg/ml was too close to the lower level of detection 
to accurately determine its bioactivity at this concentration.  
Interestingly, the diffusion zone/halo for I4K did not have a sharp defined edge compared 
to H27G and nisin. The I4K mutant seemed to exhibit two zones of inhibition that were 
related to the activity of native nisin. For instance, at 40 µg/ml of I4K, the inner clear 
zone displayed an inhibition level equal to the 0.6 µg/ml native nisin standard, whereas 
the outer hazy zone gave a value that was between 0.6 and 0.9 µg/ml on the nisin standard 
curve. I4K had completely lost activity at 5 µg/ml (no halos were observed).  
We wanted to determine how much variant protein was needed in nisin units to achieve 
the same activity as nisin. For this purpose, high equimolar concentrations of I4K nisin 
mutant were required. In this study, there was an insufficient amount of I4K available to 
be fully tested. When H27G was used at a concentration of 50 µg/ml, it was observed that 
the indicator strain was still growing. Compared to H27G and nisin, I4K is far less active. 
Therefore, I4K peptide amounts beyond those available in these experiments would need 
to be added in order to obtain the same antimicrobial activity as for nisin at a level that is 
within the nisin standard curve.  
In order to test for the specific activity and stability of H27G, a concentration of 9 µg/ml 
was selected, since this concentration would give an equivalent level of activity compared 
to the nisin positive control standard curve. A starting concentration of 40 µg/ml was 
decided to be used for I4K. This is because any drop in the bioactivity of I4K due to 
degradation should still give a measurable zone of inhibition that would fit the nisin 
standard curve.  
In conclusion, the results from the plate diffusion assay shown in Figure 36 suggested 
that the H27G and nisin at 9 µg/ml, I4K at 40 µg/ml gave a good zone of inhibition that 
fitting on the nisin standard curve, therefore these concentrations were selected for further 
testing.  
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 Characterising the activity of nisin mutants under GI tract 
temperature and pH conditions 
In a previous study [47], the effect of pH from 2.0 to 8.0 and temperature (20◦C and 37◦C) 
on nisin activity was measured. At 37◦C there was a distinct pH dependence: bioactivity 
and stability of nisin A decreased as determined by RP-HPLC and in bioassay tests.  
Based on these observations, the pure nisin mutant peptides and nisin positive controls 
were prepared in different buffers and different pH and incubated at 37◦C over time.  
Aliquots of the I4K, H27G and nisin samples were collected at different time points and 
the effect of temperature and pH on the peptides was monitored by plate diffusion assays. 
Different concentration to create standard curves for each nisin mutant peptide were also 
loaded on the plates.  
The aim was to compare and assess the stability and specific activity of the mutants 
compared to the nisin positive control. Figure 36 shows that at T0, I4K was significantly 
less active than both nisin and H27G. Even if 40 µg/ml of I4K and 9 µg/ml of nisin and 
of H27G were used, the amount of peptides was normalised to 9 µg/ml of nisin 
equivalents in order to compare the bioactivity of equivalent amounts of peptide. There 
was a major decrease in the level of antimicrobial activity: I4K was approximately 1 % 
active compared to nisin whereas H27G had 30 to 40 % antimicrobial activity in 
comparison to nisin. The biological activity of the peptides against L. lactis was 
monitored over time in three independent agar plate diffusion assays (three biological 
replicates and three technical replicates).  
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Figure 37 - Comparison of the antimicrobial activity of equivalent amounts of peptides at different pH 
conditions after 20 min incubation at 37◦C. 
The amount of I4K, H27G was normalised to 9 µg/ml to compare the antimicrobial activity of equivalent 
amounts of peptides. The activity of nisin was set as 100 %. Shown are means ± standard error of the means 
(SEM) calculated as ± SD of mean, SD is standard deviation (3). The means and standard deviations plotted 
were based on three independent agar plate diffusion assays (three biological replicates and three technical 
replicates).  
‘*’ means 100% initial activity (T0) of nisin, H27G and I4K at pH 3.0, 5.5, 6.0, 6.5 and 7.0 respectively.  
‘**’ means that there is significant difference in the bioactivity of H27G compared to nisin at the tested 
pH.  
‘***’ means that there is significant difference in the bioactivity of I4K compared to nisin at the tested pH. 
 
The activity of I4K looked promising from plate diffusion assay with the supernatants 
from non-purified peptide (Figure 30), however it became clear that using the purified 
peptide the activity was a lot less (Figure 38, C). It was concluded that at any given time 
point and pH, the activity of I4K is 99 % less compared to nisin (Appendix 2). 
It was therefore concluded that due to the very low antimicrobial activity displayed by 
the two engineered purified nisin mutants compared to the wild type nisin, in the future, 
a higher amount of the pure peptides would be required to achieve a similar level of 
antimicrobial activity as the activity of the wild type nisin. The decreased activity of the 
pure peptides must be a consequence of the incorporation of mutations either at position 
4 or position 27. This means that these amino acid substitutions did not have a beneficial 
effect on activity, despite the fact that the stability seems to have improved slightly for 
the two mutant peptides.  
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 Stability of the nisin mutants 
We wanted to monitor the stability of the peptides under GI tract conditions. The same 
samples as in the previous section were used. The zones of inhibition from plate diffusion 
assays were compared to investigate the antimicrobial activity when the peptide was 
challenged at different pH, temperature and incubation time. In previous sections, it was 
established that the I4K and H27G nisin variants are less active compared, both in the 
supernatant as well as when testing their specific activity. In here, the inherent stability 
to low pH is considered. One of the controls was the buffer only control and the nisin 
variants are being compared against it; all the samples were treated the same to mimic the 
GI tract conditions. 
The specific activity at equivalent levels of protein was measured by normalising the 
values of the zones of inhibition (Figure 37). The bioactivity was reported for 9 µg/ml of 
nisin, 9 µg/ml of I4K and 9 µg/ml of H27G. The initial starting point (T0) was set as 
100% activity for each peptide. Note that 100 % activity of I4K is not the same as 100% 
activity as H27G and is different from 100 % activity of nisin. One needs to take into 
account how low the level of activity is for I4K and H27G at 9 µg/ml compared to the 
equivalent level of activity from 9 µg/ml of nisin (Figure 37).  
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C.  
Figure 38 - Testing the stability of nisin mutants under GI tract conditions.  
A. Testing the stability at pH 3.0 for nisin over time, H27G over time and I4K over time.  
B. Testing the stability at pH 7.0 for nisin over time, H27G over time and I4K over time.  
C. Plate diffusion assay to test bioactivity of solutions for I4K at 40 µg/ml, H27G and nisin at 9 µg/ml at 
pH 3.0, pH 5.5, pH 6.0, pH 6.5 and pH 7.0 after incubation at 37◦C for 24 h. L. lactis MG1614 was used as 
an indicator strain. This picture is a representative image of three independent agar plate diffusion assays. 
‘*’ means 100% initial activity (T0) of nisin, H27G and I4K at pH 3.0.  
‘**’ means that at T7 days, there is significant difference in the bioactivity of nisin, H27G and I4K 
compared to the bioactivity at T0 for the same peptide when tested for pH 3.0.  
‘x’ means 100% initial activity (T0) of nisin, H27G and I4K at pH 7.0. 
‘xx’ means that at T7 days, there is significant difference in the bioactivity of nisin, H27G and I4K 
compared to the bioactivity at T0 for the same peptide when tested for pH 7.0. The means and standard 
deviations plotted were based on three independent agar plate diffusion assays (three biological replicates 
and three technical replicates).  
 
The amount of I4K and H27G was normalised to 9 µg/ml to compare the antimicrobial 
activity of equivalent amounts of peptides (Figure 38). T0 value of each individual 
peptide was set as 100 % level of activity and the activity levels of each peptide 
determined over time are expressed as a percentage of these individual T0 values. 
The stability of I4K over 7 days was compared against its initial 100 % activity at a given 
pH. I4K has a longer term stability compared to H27G and nisin. The inhibitory activity 
of active I4K was reduced only to 40-50 %. At pH 6.0, the activity drop was to 30 % 
(Figure 39).  
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A similar pattern in the drop of activity was observed for I4K at pH range 3.0 to 7.0, 
particularly in the first 48 h. However, Figure 37 clearly shows that the initial starting 
activity of I4K is already low (1/900th of that of nisin), so this needs to be taken into 
consideration when comparing the level of stability of I4K to the level of stability of nisin. 
Apparently, the low level of activity that the I4K mutant has retained suggests I4K may 
be more stable than nisin at higher pH (see orange bar). However, the zone of inhibition 
of I4K is outside the range of nisin standards curves, therefore the error of measurement 
for these concentrations is higher as shown in Figure 38, C and these results cannot be 
conclusive.  
The effect of pH 3.0 to 6.5 on the stability of nisin A was moderate for 48 hours whereas 
at pH 7.0 the activity dropped rapidly to 50 % compared to a value of 15 % reduction for 
any of the other tested pH. After 68 h incubation at 37◦C, the activity of nisin at pH 3.0 to 
5.5 was of 70 %. At pH 6.0-7.0, there was a 50 % reduction in its bioactivity. After 7 
days, the level of nisin activity dropped dramatically to approx. 10 % in any tested pH. 
Therefore, nisin is indeed more stable at lower pH for the first 48 h, however it becomes 
very unstable and it degrades rapidly over time.  
In comparison to I4K and H27G, nisin retains a higher activity for 48 h at pH 3.0-6.5, 
however at pH 7.0 nisin is only 50 % active, whereas H27G is 65 % as active and I4K is 
95 % active. This would imply that at this pH, the 2 nisin mutants are more stable. 
However, the zones of inhibition measured with 9 µg/ml of nisin and H27G were more 
reliable to be measured as they all fit on the nisin standard curve; this is not the case with 
I4K. Also, one needs to consider that I4K was degrading when stored at – 20◦C and during 
handling, an effect that was enhanced during freeze thawing. To enable statistical 
comparison between the nisin variants with a fresh and hopefully non-degrading I4K 
peptides, using different treatments (pH, temperature), further replicates of these tests are 
necessary. 
H27G followed a similar trend in activity and stability as for nisin at pH 3.0-6.0. The 
mutant had a lower stability at both pH 6.5-7.0 of 60 % after 48 h and at pH 7.0 activity 
dropped down to 50 %. Unlike nisin, the activity of H27G decreased even further after 
68 h and it remained the same after 7 days. At pH 7.0, H27G seemed to be more stable 
(15 % to 30 %) compared to nisin (10 % on average) based on the 7-day time point. The 
activity of nisin drops by 90 % whereas for H27G the activity drops by 75 %. Based on 
Figure 37, the level of H27G is in theory 35 % of nisin units compared to 100 % of nisin 
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therefore one would need to add three times more pure H27G to get to 100 % activity of 
nisin. The 75 % drop in activity of H27G would be commercially significant/interesting 
if H27G had the same level of 100 % activity at equivalent amounts of peptide in nisin 
units.   
 
Figure 39 - Testing stability of nisin mutants under GI tract conditions: pH 5.5, 6.0 and 6.5 from T0 to T7 
days. The means and standard deviations plotted were based on three independent agar plate diffusion 
assays (three biological replicates and three technical replicates). 
 
 ‘*, x, ^’ means 100% initial activity (T0) of nisin, H27G and I4K at pH 5.5, 6.0 and 6.5 respectively.  
‘**’ means that at T7 days, there is significant difference in the bioactivity of nisin, H27G and I4K 
compared to the bioactivity at T0 for the same peptide when tested for pH 5.5.  
‘xx’ means that at T7 days, there is significant difference in the bioactivity of nisin, H27G and I4K 
compared to the bioactivity at T0 for the same peptide when tested for pH 6.0. 
‘^^’ means that at T7 days, there is significant difference in the bioactivity of nisin, H27G and I4K 
compared to the bioactivity at T0 for the same peptide when tested for pH 6.5.  
 
In all experiments, a reasonable correlation between the increase in pH (same peptide 
content/equivalent amount) and the decrease in biological activity against L. lactis strain 
was observed. A typical example is shown in Figure 39. There is a consistently higher 
biological activity relative to the amount of active nisin (at pH 3.0 to 6.0: 80-90 % active 
for 48 h for nisin, I4K and H27G). The peptides are most stable at pH 3.0 to 5.5 for the 
first 48 h of incubation at 37◦C.  
In the case of I4K nisin mutant, it is unclear if the observed stability is due to a significant 
improvement from protein engineering, or a reflection of the errors introduced by 
measuring the zone of inhibition in this pH range (3.0 to 7.0). Further repetition of 
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experiments using a higher amount of I4K would be required for clarification. Due to the 
time constrains, it was not possible to repeat the purification of I4K to produce higher 
yields to be used in further testing.  
Nisin, I4K and H27G were still stable and had antimicrobial activity until pH 7.0. The 
trend for their antimicrobial activities is shown in Figure 40. In conclusion, the results 
indicated that I4K and H27G did not have considerable enhanced activity, they 
maintained their stability compared to wild type nisin for the first 48 h when tested at 
37◦C (Figure 40).  
 
Figure 40 - Stability and activity of peptides at 9 µg/ml tested at 37◦C, pH 3.0, 5.5, 6.0, 6.5 and 7.0 at 
different time points: T0, T20, T48, T68 and T7days. 
 
The means and standard deviations plotted were based on three independent agar plate diffusion assays 
(three biological replicates and three technical replicates). 
Stability of nisin, H27G and I4K over time. Note that the Y scale was set at 10 µg/ml for the 3 mutants in 
one graph and in another graph, the y scale was modified to 0.5 µg/ml for the 3 mutants. There is also a 
graph on I4K where the Y scale was modified and zoomed to a maximum of 0.16 µg/ml.  
The table represents the decrease in percentage in antimicrobial activity calculated between T0 and T7 days 
for each pH. The data was collected from the same assays (3 independent agar plate diffusion assays) as 
described in section 3.3.4.2.  
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 Stability of I4K and H27G at storage conditions  
The observation that the I4K mutant is unstable under storage condition suggests that the 
mutation has no beneficial effect on stability (Figure 41). After purification, the yield of 
I4K was much lower compared to H27G (50 mg compared to 150 mg, respectively). In 
order to understand the drop in stability under storage conditions, standard curves of I4K 
were compared using: 1. freshly purified I4K, 2. I4K after incubation at -20◦C for approx. 
8 weeks (data not shown). The I4K was unstable at storage conditions of -20◦C. Although 
degradation was noticed during the handling of the I4K mutant, it was decided to continue 
with the characterisation of I4K since the peptide was still active. 
 
Figure 41 - Stability of I4K and H27G mutants at storage conditions.  
A. Freshly purified I4K mutant and after 6 weeks of incubation at -20◦C. The initial colour of I4K was never 
white, unlike for H27G, B. H27G powder after incubation for 6 weeks at -20◦C. During this time, both 
mutants were removed from – 20◦C for several times to prepare stocks and to perform plate diffusion assays 
as described above.  
 Spectrum of activity of pure clos-like nisin mutants   
Here, we aimed to verify the stability of nisin, I4K and H27G, and to evaluate their 
antimicrobial activity at pH 6.0 against GI tract pathogens: B. cereus, E. faecalis, E. 
faecium, L. ivanovii, C. perfringens, C. difficile and L. lactis MG1614 (for control). It was 
not possible to test the I4K nisin mutant as it proved to be unstable at storing conditions, 
it was degrading and the amount of the material was insufficient.  
Solutions of H27G and nisin prepared at pH 6.0 were loaded onto the agar plates seeded 
with indicator strains. The agar was adjusted to pH 6.0 and the plates were incubated at 
37◦C in order to mimic the conditions relevant to the GI tract.  
It was not possible to measure the antimicrobial activity against any of the other tested 
strains since the tested amounts of pure nisin mutants did not give any zone of inhibition 
at pH 6.0 and 37◦C. H27G did not show any activity compared to the nisin control because 
the tested concentration was too low or because it was unstable in these GI tract 
conditions. However, nisin did display bioactivity against all tested strains.    
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3.4 DISCUSSION  
In this chapter the genetic engineering of clos-like nisin mutants, induction and 
characterisation of their antimicrobial activity as well as optimisation of large-scale 
production and peptide purification were addressed.  
This work stemmed from the discovery of a novel clos gene cluster from a GI tract 
bacterium, Blautia obeum A2-162, and the identification of unique amino acids in the 
predicted structure of the three identical ClosA1 peptides. Compared to the well 
characterised lantibiotic prototype, nisin, ClosA1 has 12 different amino acids. It was 
noted before that nine natural nisin variants which differ by a few amino acids have been 
identified in L. lactis species, Streptococcus uberis [16], a Streptococcus hyointestinalis 
strain isolated from the humn gut, Streptococcus gallolyticus subsp. pasteurianus and 
Streptococcus sui [48]. Some of these natural nisin variants are known to have 
antimicrobial activity against a range of Gram-positive bacteria like staphylococci, 
streptococci, Listeria spp., bacilli, and enterococci.  
The hypothesis was therefore: the clos cluster was identified in a gut bacterium, any 
putative antimicrobial peptides should be stable and active under GI tract conditions and 
have antimicrobial activity against GI tract pathogens. It was speculated that Blautia 
obeum A2-162 could have bacteriocin like properties similar to nisin from L. lactis since 
their gene clusters and their peptides proved to have structure similarities. The well- 
prototype of lantibiotics, nisin, has antimicrobial activity against pathogenic  
Gram-positive bacteria such as C. difficile and C. perfringens. The creation of a library 
of clos-like nisin mutants and their successful characterisation using known methods [16, 
131] was therefore the focus of this chapter. The aim was to identify mutants that could 
be used as treatment for certain GI diseases potentially caused by GI pathogens [132].  
The construction of a range of clos-like nisin mutants was particularly interesting as they 
would incorporate one or more amino acid substitutions to make them look more like the 
putative ClosA1 peptide as illustrated in section 1.9, chapter 1 (Figure 8). These novel 
mutants would aid in the identification of novel bacteriocins that would have improved 
antimicrobial activity, enhanced stability at physiological pH and wider spectrum of 
activity particularly against gut pathogens.  
Site directed and random mutagenesis approaches have already been applied to create a 
vast library of nisin mutant peptides as reported in different studies [16]. Genetic 
engineering of the nisin A structural gene has recently been applied and nisin mutants 
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with improved antimicrobial activity have been identified [87]. The predicted putative 
antimicrobial peptides from the clos cluster bear structural similarities to nisin, which 
suggests that new peptides with improved properties that are active against GI tract 
pathogens may be generated.      
The pTG262_nisA construct had an antimicrobial activity that is similar to the wild type 
strain, FI5876. This plasmid was then used as a template to introduce subsequent 
mutations followed by a short nisA structural gene which includes a transcriptional 
terminator. The plasmid copy number influenced the expression levels of nisA when 
cloned in either pUK200 or pTG262. The zones of inhibition given by the pTG262_nisA 
construct were bigger. Both plasmids are known to be high copy number plasmids: 
pUK200 is a 3191 bp vector, pTG262 is a bigger size vector (5566 bp) and it is derived 
from the lactococcal plasmid pCK17 replicon [133]. One would expect that with low copy 
number the expression would be lower, however this is not the case in here. Results show 
that the expression of nisin in pTG262 was enhanced possibly due to the higher copy 
number vector. However, this is counter intuitive as it is expected that the bigger the 
plasmid the lower the copy number. The poor expression of nisin using pUK200 may be 
due to instability in this host strain and to the presence of a strong terminator. Therefore, 
low levels of expression for nisin or nisin mutant peptides were detected when pUK200 
was used.  
Examination of the literature revealed that previous experiments using site-directed 
mutagenesis and amino acid randomisation in the nisin template [16, 87] gave useful 
insight onto the importance of the conserved amino acids and the effects of altering and 
introducing alternative charges in the nisin molecule. The ability to produce nisin mutants 
by site-directed mutagenesis has proven an extremely powerful asset in the study of their 
modes of action. Studies which involved the deletion or the substitution of residues in the 
C-terminal part of nisin have shown that the C-terminal may not be important for 
biological activity [79, 130, 134]. On the other hand, other studies strongly suggested that 
the N-terminal of nisin is essential for binding to lipid II and hence it will have a greater 
effect on the overall activity of the mutant peptide [60].  
Previous studies using engineered nisin mutants and truncated nisin peptides (fragments) 
suggested that the N-terminal residues of a fully modified nisin peptide are also essential 
for the induction capacity of a mutant peptide [74, 95]. In a study with engineered 
truncated nisin, it was demonstrated that a nisin fragment that comprises intact Ring A to 
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Ring C is very important for the growth-inhibition activity and a truncated nisin 1-20 is 
sufficient in rendering an active peptide [134].  
Other studies suggested that in order for nisin to act as an antimicrobial peptide, the pore 
formation step is not essential, since a nisin fragment 1-28 that lacked any pore formation 
capacity was still active, while other C-terminally truncated mutants had only a slightly 
decreased activity. However, the ability of nisin to form pores is actually an advantage as 
nisin can indeed kill bacteria more efficiently and is more resistant to the development of 
resistance. Mutations in the hinge region are generally regarded as beneficial as attempts 
to engineer new nisin mutants with altered antimicrobial activity against a variety of 
organism and the enhancement of physicochemical properties by using site-directed 
mutagenesis have been successful. As a result, nisin mutants with enhanced antimicrobial 
activity against S. aureus and L. monocytogenes have been generated [87, 123, 135]. 
 Genetic engineering of clos-like nisin mutants. 
In this study, site-directed mutagenesis of nisin with controlled and targeted specific 
amino acids substitutions was based on the structure comparison between nisin and the 
predicted ClosA1 peptide. In this PhD project, the aim was to use the nisin machinery and 
the genes identified in the novel clos cluster to make a variety of engineered variants to 
investigate the production and activity of the novel lantibiotics by expression in L. lactis 
host strain. Genetic engineering of clos-like nisin mutants was achieved by subcloning 
the nisA gene routinely on pTG262. The plasmid was designed by fusing a single or 
multiple mutated nisA gene to the nisin promoter (PnisA) with the aim of substituting either 
individual or multiple amino acids in the nisin structure. The resulting constructs were 
confirmed by sequencing and the novel clos-like nisin mutants were subcloned in L. lactis 
strain (ΔnisA). Positive clones were characterised and tested for their antimicrobial 
activity. A survey of the literature indicated that most of the resulting 12 clos-like nisin 
variants were novel except for M21L and N20P hinge mutants, which had been 
synthesised previously and were highly active against pathogens as confirmed in this 
study [13, 16, 87].  
All the nisin mutant peptides described in this project were secreted both in the culture 
supernatant or on the agar plate as the nisin biosynthetic machinery worked well to 
introduce unusual amino acid and modifications, to transport and to process the leaderless 
peptides. However, limitations of the in vivo engineering may render the peptides 
inactive.  
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All the nisin variants biosynthesised and tested in this work maintained their antimicrobial 
activity except for one mutant in Ring C. Altering both the charge and the size of the new 
residues had an important effect on one or both mechanisms of action known for nisin: 
binding to lipid II and pore formation. In comparison to nisin, mutants with decreased 
activity were detected when they were screened against pathogens. Examination of 
literature revealed that the results obtained this work can be correlated with similar 
observations on amino acid substitution in nisin variants.  
All the mutants except for M21L lost their autoinduction capacity which was expected 
based on the observation that the first three lanthionine Rings A, B, C are essential for 
induction [74, 95, 96]. The importance and the integrity of Ring A and the modified amino 
acid Dha5 as a hydrophobic moiety for the biological activity had been previously shown 
[47]. Therefore, the I4K and L6A mutants may have disturbed the Dha5 rending them 
less active. The importance of Ring C for the biological activity of nisin was also 
demonstrated by replacing this Lan ring with a disulphide bond [130]. In this work, A15I 
and G18T, Ring C mutants, had very low antimicrobial activity and some were inactive 
such as the double nisin mutant, A15I_G18T.   
Another study, examined the interaction of lipid II with a number of nisin variant 
producers to identify structural elements of the nisin molecule. It was found that amino 
acid substitutions that affected the conformation of Rings A, B, C led to a reduction in 
binding of lipid II and the concentration of the peptide needed for formation of pores was 
increased [79]. 
The N-terminal rings in nisin play an important role in lipid II binding [80, 134] and 
genetic engineering resulting in minor variations within this region, greatly reduced the 
specific activity of the peptides. For instance, Ser3Thr (changing the first Lan residue to 
MetLan) led to a dramatic loss in activity [80]. Mutation in Ser3Thr sterically hinders the 
formation of the H-bond, thereby it decreased the affinity of the mutant for lipid II by 50-
fold [79]. Therefore, this may explain why cleavage or alteration of Ring A may 
ultimately lead to the complete elimination of bioactivity [134] which was the case with 
the Ring A double mutant: I4K_L6A. 
Mutation in the hinge region which reduced the flexibility of nisin had a negative effect 
on monolayer interactions and bioactivity, whereas mutations in the C-terminal part will 
impact the ionic interactions of nisin in a monomeric or oligomeric form with anionic 
lipids [82, 136, 137]. The hinge mutants generated in this work had similar or only slightly 
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decreased bioactivity compared to nisin which means that the introduction of Leu or Pro 
nonpolar residues had a neutral effect on bioactivity.  
It was previously shown that C-terminally truncated nisin A mutants that lack Rings D 
and E were capable of retaining significant bioactivity but they are unable to permeabilise 
the target membrane [88]. Most of the positive charges carried by nisin are held by C-
terminal residues: Lys-22, Lys-34, His-27, His-31 and it was shown that they are crucial 
for the initial interaction of nisin with the target membrane. Introduction of a negatively 
charged glutamate (Val32Glu) drastically reduced the interaction of nisin Z with the 
anionic lipids, whereas the addition of an extra positive charge (Val32Lys) led to 
improved binding ability [82]. In this work, H27G had an antimicrobial activity similar 
to nisin, whereas all the other C-terminal mutants retained their bioactivity but it 
decreased compared to nisin. Figure 42 illustrates the charges of the substituted residues.  
 
Figure 42 - Illustration of the structure and the charges of nisin and clos-like nisin mutants.  
The charges of residues in the original structure of nisin and in the new peptides are highlighted. N 
represents charge of the original nisin, plus (+) is positive charge, minus (-) is negative charge.  
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 Characterisation of clos-like nisin mutants  
Preliminary characterisation of non-purified peptides did allow for comparison of the 
relative antimicrobial activity. To account for the specific activity, purified peptides were 
compared to commercial purified nisin. Even if dehydration and cleavage of the peptides 
were confirmed by Maldi-ToF, in the case of the double mutants in Rings A and Ring C 
or for the G18T mutant, their lack of antimicrobial activity against indicator strains can 
be explained by different contributing factors. A possible explanation that could account 
for this is the improper modification by NisB and NisC; this may lead to degradation of 
the intermediate form of the peptides or to abolished production. Even though fully 
processed novel mutants can be isolated, it has been observed that degraded products or 
incompletely modified products are often present [60].  
Previous studies [138] have shown that an inactive nisin that was expressed in a strain 
where the nisin transport protein, NisT, had been mutated rendered a form of nisin that 
was incapable of inducing the nisin Z promoter, PnisZ, hence no nisin was secreted or 
exported outside the cell; instead it accumulated inside. This work has also shown that 
these bacteriocins will predominately accumulate as immature mutant peptides that are 
partially modified or that remain unmodified. Initial attempts to induce nisin mutant 
peptides using subinhibitory amounts of nisin indicated that there is a deficiency in the 
process of biosynthesis, either in their expression, processing, transport or secretion.  
Preliminary induction and characterisation of the peptides suggested that all nisin 
mutants, except for M21L, would need to be continuously induced with exogenous nisin. 
Since most of the mutants were active in the bioassays, it was speculated that the nisin 
leader must have been cleaved either by a dedicated nisin protease (NisP) or by 
intracellular proteolytic activity [138] to allow for the leaderless mutants to be exported. 
It was assumed that the lack of self-induction capacity was most likely due to a problem 
with the nisin modification machinery resulting from the mutations, which in turn it did 
not allow for secretion of predominantly fully modified mutant peptide. As a result, the 
high proportion of partially or unmodified peptide that accumulated in the cell was not 
capable of interacting with the signal recognition domain of the NisK for signal 
transduction, therefore none of the nisin mutants, except for M21L, could act as signal 
molecules.  
M21L was an interesting mutant as it regulated its own induction by accumulating in 
sufficient amount in the supernatant and by being successfully modified and processed 
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by the nisin machinery. These observations are in line with the Maldi-ToF results, which 
confirm that M21L was mainly 8- to 6- dehydrated, even though there were also 
indications that 5- to 4- dehydrations were also present. Since no measurements were 
made to investigate ring formation, it can only be assumed that the rings were indeed 
made since M21L has a very high activity similar to nisin. A fully modified form of nisin 
peptide is one of the pre-requisites for antimicrobial activity [139].   
Biological production by means of in vivo biosynthesis is very commercially attractive 
and it is targeted at fostering lanthipeptides manufacturing and their ultimate use in a 
clinical setting. Therefore, in vitro protein engineering permits the exploration of the 
structural and functional tolerance of the biosynthetic enzymes: the non-proteinogenic 
amino acids can be added to natural amino acids [60]. In the future, it is speculated that 
any problems with the inactive nisin mutants (i.e.: lack of modifications) could be 
overcome. Synthetic biology could be used to co-express ClosB and ClosC enzymes to 
make strain with new functions.  
Based on the example of Venter’s recent work [140], it would be possible to apply a 
whole-genome rational design and synthesis so as to create organisms that would 
synthesise the desired lantibiotics. Their aim is to create such a simple cell with essential 
‘core sets of conserved genetic functions’; the cell would allow to identify both the 
molecular and biological function of genes. This approach could be used in the future to 
explore the potential clos genes. However, the success of using the co-expression with 
ClosBC approach could depend for instance on whether the nisin leader is suitable for the 
substrate specificity of the clos modification machinery.  
The genetic engineering approach taken in here allowed for the production of some potent 
nisin-variant producing strains. However, none of the engineered strains produced a 
lantibiotic peptide with improved properties compared to nisin possibly because of 
degradation as well as their altered regulation. Therefore, the inability to induce in vivo 
synthesis will ultimately result in reduced or absence of antimicrobial production. This is 
the case with the inactive mutants generated in this work: Ring A and Ring C double 
mutants (I4K_L6A, A15I_G18T) and the Ring C single mutant (G18T) [130].  
In general, the replacement of hydrophobic amino acids, which are found naturally in 
nisin (nisin Q, U or U2) with another hydrophobic amino acid to give M21L is known to 
result in the retention of relatively high levels of bioactivity as seen in overlay assays 
against L. lactis, C. perfringens or M. luteus. However, it was reported that the bioactivity 
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of the producer of M21L is somewhat decreased to 58–76 % when expressed in a slightly 
different system [87]. In this project, asparagine substitution also had very interesting 
consequence in that the N20P strain had increased or similar relative bioactivity levels 
against all tested species. This effect was expected since it was previously established that 
the N20P mutant generally displays enhanced bioactivity against a number of S. 
aureus strains. With respect to the N20P_M21L double mutant, the bioactivity was only 
slightly decreased in the overlay assay against different indicator strains.   
Another interesting mutant created in this project is H27G located in Ring E. The 
consequence of incorporating the smaller glycine residue, to make H27G, resulted in a 
strain exhibiting similar relative bioactivity against L. lactis, C. perfringens and M. luteus. 
This is in good agreement with observations made in other studies where other small 
amino acids were used [141, 142]. The results from the bioassays confirmed these finding. 
Following site saturation mutagenesis of the C-terminal region of nisin, it was also now 
possible to assess the impact on bioactivity of two nisin mutant peptides that have three 
and five mutations, respectively. The two C-terminal nisin variants with multiple 
substitutions had slightly decreased levels of activity against C. perfringens and M. luteus. 
Their bioactivity had dramatically decreased when tested against L. lactis. This variation 
could be a consequence of the different sensitivity of the indicator strains or could be a 
consequence of measuring on the relative bioactivity rather than on specific activity.   
In contrast, the alanine- and lysine- containing Ring A mutants, I4K and L6A, had varying 
degrees of bioactivity (70-90 %) against all the tested strains, therefore establishing that 
at positions 4-6, replacement by small aminoacids is well tolerated. Interestingly, a 
peptide corresponding to I4K could not be detected by CMS, indicating a negative impact 
of the substitution on peptide production even though the mutant was indeed active in 
bioassays. With respect to the double mutant I4K_L6A, the effect of mutations was 
dramatic, as peptides were inactive against all indicator strains. This is perhaps because 
of the opening of Ring A or as a consequence of preventing the dehydration of the 
threonine residue in Ring A at position 5. In addition, the presence of masses 
corresponding to the uncleaved peptides suggested that the NisP proteolytic activity may 
be hampered in this mutant. Even if the introduction or the exchange of positively charged 
residues in nisin is generally tolerated, there are also structural considerations, with the 
bulkier lysine residue having the most negative influence, which seems to be the case 
with I4K_L6A.  
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Screening of nisin mutants against indicator strains indicated that some mutants have 
different levels of bioactivity. A possible increase in the bioactivity of nisin mutants 
compared to the positive control could be explained by a general increase in production 
or by an enhanced diffusion rate in the agar plate. The hinge mutants had an increased 
bioactivity which it could possibly be because of a greater specific activity against the 
target strain.  
The self-induction capacity of the nisin mutant peptides was also assessed. Their relative 
antimicrobial level of activity was compared against the vector control. The plate 
diffusion bioassay was not used for the purpose of quantifying the amount of bioactivity 
in nisin units as the amount of produced peptide in the supernatant was unknown. Despite 
generating a standard curve from positive control samples on the plate, the zones of 
inhibition produced by mutants were too low to accurately create their standard curves. 
The amount of peptide produced and then exported in the liquid culture could vary for 
every mutant peptide as a consequence of amino acid substitution. In future, for more 
accurate assessment of the amount of antimicrobial peptide, all the mutant peptides 
should be purified and their level of antimicrobial activity should be assessed relative to 
the amount of pure nisin mutant.  
To summarise, the work in this chapter involved the substitution of amino acids first in 
the rings of the nisin structure, then in the hinge region and in the C-terminal part of nisin.  
The number of clos-like nisin mutants was narrowed down in order to select and purify 
the ones that are potentially interesting candidates of bacteriocins with improved 
properties. It was hypothesized that the antimicrobial activity, stability, spectrum of 
activity and specific activity could be enhanced if mutations were first introduced in the 
rings. It was possible to assess the effect of mutations on the antimicrobial activity. 
Furthermore, preliminary results on the bioactivity of nisin mutants in culture supernatant 
and in assays with colonies from liquid cultures against ten indicator strains were also 
revealed. N20P and M21L hinge mutants had been previously synthesised, and as in other 
studies they had high antimicrobial activity. Therefore, they were not considered for 
purification. Assessment of the bioactivity of N20P had enhanced antimicrobial activity 
against S. aureus and L. monocytogenes which is in line with the finding from literature. 
Nisin mutants with amino acid substitutions in the hinge region that are not capable of 
pore formation but are still potent antibiotics also exist [125]. H27G is a Ring D nisin 
mutant that proved to be highly active. I4K and L6A are Ring A single mutant that 
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produced a zone of inhibition which was less than nisin. Therefore, I4K, L6A and H27G 
mutants were targeted for purification and subsequent bioactivity studies.  
 Purification and characterisation of pure I4K and H27G nisin mutants 
Fractogel TSK butyl 650-S (Merk) column chromatography, ultrafiltration, preparative 
RP-HPLC on C18 column, and lyophilisation allowed the successful removal of any non-
specific products from biosynthesis or any low molecular weight contaminants from the 
media. The purified I4K and H27G were successfully challenged to GI tract conditions 
and a more accurate and reproducible assessment of high specific biological activity was 
therefore possible.  
Initial attempts to produce and purify the I4K, L6A and H27G mutants from a 11 L 
fermenter using in-house optimised methods to purify nisin-like lantibiotic methods were 
only successful for I4K and H27G but not for the L6A nisin mutant; the unsuccessful 
purification of L6A could be explained by its poor production levels despite using an 
optimised scale-up purification method.  
Nisin shows a slow loss of activity during storage with respect to practical applications 
[123] and its solubility and stability is strongly dependent on pH. Nisin contains unusual 
unsaturated amino acids: dehydroalanine (Dha5, Dha33) and dehydrobutyrine (Dhb2). 
Due to these structural features and potential intermolecular nucleophilic addition 
reactions, the solubility and bioactivity of nisin drops in alkaline pH [47], therefore it was 
interesting to assess the effect of applying treatment to mimic the GI tract conditions: 
different pH and high temperature of 37◦C.  
Although full characterisation of the purified I4K was not completed to investigate the 
host range, the Ring A nisin mutant was successfully purified from culture supernatant 
by hydrophobic interaction chromatography using Fractogel Butyl-Toyopearl resins. The 
activity from I4K, L6A and H27G nisin mutants that were taken on Fractogel and on a 
C18 column (RP-HPLC purification step) was detected throughout the process using two 
steps of purification. Unique peaks for I4K and H27G were detected in Maldi-ToF, but 
not for L6A, and the successful purification of I4K and H27G was confirmed. Further 
Maldi-ToF analysis using fractions from the first purification step indicated that L6A was 
isolated and it was still active. However, no active antimicrobial peptide was detected 
from fractions collected from the C18 column even if they were further concentrated by 
freeze-drying. 
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Preliminary characterisation of the I4K antimicrobial showed that it was unstable over 
time. Using the plate diffusion assay however, it was possible to look for the specific 
activity of pure I4K and pure H27G in comparison to wild type nisin. All the mutants 
were incubated at pH relevant to the GI tract and incubated at 37◦C for 7 days during 
which time aliquots were removed and tested for their antimicrobial activity at different 
time points. Although, I4K was a promising good candidate to be purified and its specific 
activity was investigated, I4K is only 1 % as active as nisin in its pure form, and it 
degraded under storage conditions. To investigate this degradation phenomenon, I4K 
should be re-purified at a higher yield. On the other hand, pure H27G has a starting 
concentration of 35 to 40 % of nisin units compared to nisin when tested at any given pH. 
As with nisin, H27G was more stable at acidic pH over time and the biological activity 
dropped over time and as a result of increased in pH which is in line with previous 
observations from literature [47].  
In this study, preliminary bioassays with H27G, I4K and L6A against vegetative spores 
of C. perfringens and C. difficile indicated that these mutants had inhibitory activity. In 
previous studies [143], it was suggested that besides having two killing mechanism, the 
inhibition of the cell wall biosynthesis and pore formation, nisin can stop the outgrowth 
of spores by the release of two hydrolysing enzymes that promote autolysis of the cell 
wall in spores. A Dha residue at position 5 is essential for this activity [139]. It was 
speculated that since mutations in I4K and L6A are in the vicinity of the Dha5, the 
mutations may have interesting effects on bioactivity. Both I4K and L6A seemed to be 
active, however when I4K was finally successfully purified, it proved to be unstable. 
Also, a very high amount of the I4K nisin mutant peptide would need to be used to attain 
an equivalent level of activity as nisin. In general, I4K, H27G and nisin appeared to 
degrade in a similar fashion when exposed to GI tract conditions. 
Measurement of the specific activity of nisin variants indicated that the activity of nisin 
at any pH has exhibited a sharp decrease in the biological activity but particularly at 
higher pH, whereas for H27G and I4K the decrease was moderate. The activity declined 
to 10-15 % in the case of nisin, for H27G it was 30 % active on average (15-40 % active) 
whereas I4K maintained its activity to 40-67 % at any given pH. H27G was almost fully 
degraded after 68 h, with nearly complete loss of its antimicrobial activity particularly at 
pH 6.0 to 7.0. Nisin was still active at all pH values tested after 7 days which makes it the 
most stable peptide tested in this study.  
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The biggest challenges in this work involved identification of antimicrobial activity from 
C18 fractions with L6A due to low yield from culture supernatant or loss of antimicrobial 
activity during the purification steps, which is something that has been reported before 
for bacteriocin-like peptides [144].  
In this work, a limited number of clos-like nisin mutants was generated. Site-directed 
mutagenesis targeted the rings in the N-terminal part of nisin, the hinge region and the 
rings in the entire C-terminal part of nisin and the effect of the amino acids substitutions 
was tested. Their antimicrobial activity and spectrum of activity was assessed in order to 
confirm that certain mutations do not render the nisin variant inactive. Based on the 
results, it was concluded that a nisin variant that would comprise all the 12 possible 
mutations present in the ClosA1 peptide would not be a good candidate for the 
development of a lantibiotic peptide with enhanced activity and spectrum. In the future, 
the specific activity of the novel mutants made in this work could be assessed and the 
knowledge could inform on the rational design of potent lantibiotic peptides that would 
be clos-like nisin mutants.  
In conclusion, we have successfully produced and tested a range of nisin mutants with 
characteristics of the ClosA1 putative peptides and demonstrated the production of 
modified peptides by MS. Increased activity and variation in host range have been 
demonstrated as seen with results with N20P and M21L against C. difficile and  
C. perfringens (Table 18, data not shown in this work). Purification of H27G and I4K 
allowed for comparison of specific activity against nisin, none of the peptides had 
enhanced activity, stability of spectrum of activity against indicator strains. Future work 
would involve further attempts to purify and characterise L6A and I4K as well as 
introduce mutations in the nisin peptide to make the fully modified Clos peptide or nisin 
mutants with modifications in all the rings.   
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4.1 INTRODUCTION 
During the genome mining of the GI tract, a novel gene cluster, known as clos, was 
identified and sequenced [97]. This nisin-like clos gene cluster is considered to encode 
four peptides whose sequences have been predicted based on structure comparison to the 
nisin gene sequence (Figure 8, chapter 1). However, the real structures for the Clos 
peptides remain unknown and they have yet to be characterised. In order to understand if 
the clos cluster is active or if it is a silent operon, the functionality of the putative clos 
promoters was investigated. If the clos promoters are activated by induction with nisin, 
this will provide evidence that the associated genes are possibly expressed in the clos 
gene cluster. The L. lactis UKLc10 host strain chromosome contains the nisRK genes 
which regulate the activation of the PnisA promoter, one of the nisin-inducible promoters 
found in the nisin gene cluster [100, 145]. The L. lactis UKLc10 strain was therefore 
selected as a suitable host strain where the clos promoters were cloned to create a reporter 
gene expression (PClosA_pepI) system that could potentially be controlled by induction with 
nisin.  
The clos cluster of the Blautia obeum A2-162 strain is comprised of four copies of the 
closA genes: three are identical copies of closA (closA1, closA2, closA3) and they are 
predicted to encode for nisin-like lantibiotics, whereas the forth closA gene (closA4) may 
encode for a protein whose structure differs to any known lantibiotic [97] (chapter 3).  
Lactic acid bacteria often produce antimicrobial peptides (AMP) via quorum sensing and 
the autoregulation of nisin biosynthesis by the nisin lantibiotic peptide itself is a special 
example of this process [146]. The nisin response regulator, NisR, and the nisin sensor 
histidine kinase, NisK, proteins are part of a two-component regulatory system which is 
switched on by addition of subinhibitory amounts of extracellular nisin [74, 92]. 
Extracellular nisin acts as a signal which is transduced by the NisK auto-phosphorylation 
and this is followed by phosphate transfer to NisR. The transcription of any genes under 
control of the nisA promoter (PnisA and PnisF) is then activated (Figure 43). In nisin, 
transcripts that are comprised of nisA, nisABTCIP, nisABTCIPRK and nisFEG are 
formed as a result of transcriptional activation since both PnisA and PnisF are inducible 
promoters as they require nisin to be activated [147]. In contrast, the nisRK genes are 
expressed independent of induction, since the NisR promoter, (PnisR), is a constitutive 
non-inducible promoter [8].  
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Figure 43 - Model for nisin signal transduction pathway by the two-component regulatory system that 
consists of the nisin sensor histidine kinase, the NisK protein, and the nisin response regulator, NisR.  
NisR is phosphorylated, annotated as R-Pi. The nisRK genes are integrated on a chromosome. Adapted 
from Kuipers et al. [148]. T is terminator. ‘Rep origin’ is origin or replication.  
Figure 43 illustrates an UKLc10 L. lactis host strain with the nisRK genes chromosomally 
integrated where the target gene from the plasmid is expressed as a result of nisin 
induction and nisA promoter, PnisA, subsequent activation. UKLc10 was used as a host 
strain in which the nisin promoter is fused to a pepI reporter gene whose expression gives 
rise to a colour development and the pepI specific activity can be measured accurately 
[100]. The well-established concept behind the nisin signal transduction in the positive 
control strain, known as pUK200_ PnisA_pepI (pPnisA_I), has confirmed the need to 
develop similar expression systems in order to investigate the activation of the promoters 
in the clos cluster.  
A reporter gene, pepI, from Lactobacillus delbrueckii subsp. lactis [100] was used to 
investigate the activation of the four putative clos promoters identified in the clos cluster 
of the original gut bacterium, Blautia obeum A2-162. The reporter gene promoter systems 
were used to investigate the possible regulation of the clos promoters by either closRK or 
nisRK genes, the two-component regulatory systems as described in section 4.3.3.  
L. lactis UKLc10 is one of the few most suitable expression systems which relies on the 
use of nisin to induce fusions of clos or nisin promoters with a target pepI gene via the 
two-component nisin regulatory system, nisRK [100, 149]. The positive control has the 
advantage that expression of a target gene in L. lactis UKLc10 is inducible by 
subinhibitory amounts of nisin (10 ng/ml), in a series of up to several hundred fold 
(specific activity is approx. 35,000 nmol/mg/min) [147].  
We aimed to use this reporter system to investigate the activation of clos promoters. 
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4.2 MATERIALS AND METHODS  
 Designing of a pepI reporter gene promoter system  
 Bioinformatics analysis to identify the putative promoters  
The clos cluster was analysed using soft berry software to search for functional 
motifs/promoters. Putative regions which may be part of the RNA binding site in a 
promoter, which means it is the DNA sequences located at the -10 position, -35 position,  
and the transcription start site (TSS) as well as the ribosome binding site (RBS) were 
identified. The nisin and subtilin gene clusters were also used for comparison between 
the characteristic elements of a promoter sequence.  
http://www.softberry.com/berry.phtml?topic=bprom&group=programs&subgroup=gfin
db.  
 Cloning of the pepI reporter gene 
The PClosA, PClosR2K2, PClosBTC and PClosFEG promoters from the clos cluster were cloned 
individually using the primer pairs as listed in chapter 2 (section 2.2.1). For instance, 
PClosA_F/ PCA_R and PCA_F/ pepI-R or pepI_R primer pairs were used. The two PCR 
products where then spliced with PClosA_F/ pepI-R or pepI_R to generate approx. 510 
bp, 150 bp, 372 bp and 774 bp PCR products, for PClosA, PClosR2K2, PClosBTC and PClosFEG 
promoters, respectively.  
In each case, splice overlap extension PCR involved the use of two PCR products, one 
from each reaction (A and B) and the amplified fragments from each reaction were used 
as templates for the final splice reaction which involved the forward primer from reaction 
A and reverse primer from reaction B (see chapter 2). The splice products were then 
digested with BglII and XhoI, unique cloning sites to be used for translational fusions, 
and ligated into pIL253 plasmid cut with BamHI and SalI to create pPClosA_I, pPClosR2K2_I, 
pPClosBTC_I and pPClosFEG _I constructs. 
 Cloning of closRK in pUK200_ PnisA 
The sequence was aligned to the original expected sequences designed in Clonemanager 
and after sequence confirmation, the plasmid was transformed in ultra competent L. lactis 
UKLc10 cells for further testing as described in section 4.2.3.  
The forward primers, ClosR1K1_F and ClosR2K2_F, were designed to create NcoI 
restriction enzyme sites, whereas the reverse primers, ClosR1K1_R_BamHI and 
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ClosR2K2_R_BamHI or ClosR1K1_R_SalI and ClosR2K2_R_SalI, were designed to 
create either BamHI or SalI restriction enzyme sites, respectively. The closR1K1 and 
closR2K2 were fused to PnisA promoter individually using primer pair as listed in chapter 
2. For instance, primer pairs ClosR1K1_F/ClosR1K1_R_SalI were used to make a PCR 
product that was restricted with NcoI/SalI and cloned into pUK200_ PnisA restricted with 
NcoI and XhoI.  
 Generation of frameshift in closR1  
The pPnisA_cRK construct encodes for one of the two sets of clos two-component 
regulatory system. The UKLc10 L. lactis strain harbouring plasmid pPnisA_cR1K1 was 
grown overnight then harvested and the plasmid DNA was extracted using the Qiagen 
plasmid mini prep kit. The plasmid DNA was restricted for 2 h with AflII at 37°C, the 
enzymes were heat inactivated at 80°C for 20 min. The plasmid was blunt ended with T4 
DNA polymerase, purified by Sure Clean and the success of the digestion was assessed 
on an agarose DNA gel. For ligation, Fast link DNA ligase and the blunt end protocol 
were used. Restriction digests and all the cloning steps were performed using the optimal 
conditions described by the manufacturer (NEB, Herts, UK) (chapter 2). Each pPnisA_cRK 
plasmid was transformed into electrocompetent L. lactis MG1614. Clones were identified 
by colony PCR using primers p54/p181 and plasmid DNA from positive clones were 
sequenced with primer p54. The sequences were aligned to the original expected 
sequences designed in Clonemanager and the absence of one nucleotide introduced by 
AflII digestion was confirmed. The plasmid with the frameshift in the closR1 gene was 
transformed in ultra competent UKLc10 cells.  
 Transformation to make reporter gene and clos regulatory system 
A two plasmid system was created in L. lactis UKLc10: pPClos_I which encodes for the 
pepI reporter gene and pPnisA_cRK which encodes for one of the two sets of closRK two-
component regulatory system. One of the two plasmid systems incorporated pPClosA_I 
construct and pPnisA_cfsR1_cK1 that encodes for a mutated closR1 (frameshift). The 
positive control, pPnisA_I in L. lactis UKLc10, was kindly donated by Nikki Horn from 
the IFR collection. The pepI expression was achieved by induction with 10 ng/ml of nisin. 
Controls without nisin induction were also included. Strains that contain the pUK200 
and/or pTG262 expression vectors are chloramphenicol and/or erythromycin resistant, 
respectively.  
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 Measurement of pepI specific activity  
 Preparation of cell extracts 
Two 10 ml cultures of constructs in L. lactis UKLc10, MG1614 and FI7847 strains were 
grown from glycerol stock overnight, then two 100 ml fresh cultures were inoculated and 
grown to an optical density at 600 nm (OD600) of 0.5, then they were typically induced 
with nisin at 10 ng/ml for 2 h to activate the nisA and closA promoters, unless otherwise 
specified. Cell volumes equivalent to 37 OD600 units from the two separate cultures were 
harvested by centrifugation at 10,000 × g for 15 min at 4°C and the cell extracts were 
prepared following the method of Wegmann et al. [100, 149]. The resulting cell pellets 
were washed once in 0.2 M Tris HCl (pH 7.4) before freezing at -20°C. Individual thawed 
cell pellets was resuspended in 250 μl of 0.2 M Tris HCl (pH 7.4). Sonication to disrupt 
the cells was performed with four 10 s pulses, 6 µm amplitude, with 5 to 10 min pauses 
on ice between each pulse. The resulting supernatants containing the cell extracts were 
obtained after a 30 min centrifugation at 14,000 × g at 4°C.  
To maximize Clos peptide production, strains were grown for 12 h induced with 10 ng/ml 
of nisin and aliquots were collected at time zero, 2 h, 4 h, 6 h, 12 h and cell extracts were 
prepared and loaded on protein gels and analysed by western blotting.  
 PepI enzyme assays  
The specific activity of the peptidase I was assayed by using 50 μl of undiluted or diluted 
cell-free samples in 0.2 M Tris HCl (pH 7.4), with 0.7 mM L-proline p-nitroanilide 
trifluoroacetate salt (Sigma) as the substrate. The p-nitrophenol release was measured 
at A405 at 37°C for 15 minutes. Sample protein determination was performed at A600 using 
the Bio-Rad protein assay (Bio-Rad, United Kingdom) with standard BSA (New England 
BioLabs UK Ltd.) and typically 1/200 dilution of cell extracts, 1/1000 and 1/5000 
dilutions for the cell extract positive control. The specific peptidase activity was 
expressed as nanomoles of p-nitrophenol released from the chromogenic substrate per 
milligram of protein per minute (nmol/mg/min). The means and standard deviations 
plotted were based on two biological replicates each with two technical replicates.  
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4.3 RESULTS 
 Investigation of the clos promoters - bioinformatics analysis  
Computational analysis of the clos cluster with the soft berry software identified four 
putative clos promoter sites as illustrated in Figure 44. The characteristic elements of the 
clos promoters, -35 box, -10 box and RBS, are listed in Table 20, and they were compared 
to the promoters of nisin and subtilin.  
 
Figure 44 - Diagram of the clos cluster to highlight the four clos promoters detected by computational 
analysis in order to understand which one of the two sets of closRK genes regulates the biosynthesis of clos. 
Promoter 
(nucleotide 
start site) 
-10 box -35 box (lan –box)  
Promoter position score Promoter position score RBS* 
PClosA 
633 
632
0 
TTTTATATT 66 6304 TTGATA 
 
58 AGGAGG 6 bp  
to ATG 
PClosFEG 
717  
702 TTTTAATCT 55 684 TTTACA 47 AAGGAG
A 
11 bp 
to ATG 
PClosR2K2 
7236  
722
1 
TGTTATTAT 79 7202 GTGATT 20 AAGGAG
C 
5 bp  
to ATG 
PClosBTC 
9605  
959
0 
TTTGATAAT 50 9569 TTCAAA 40 AGGAGG 5 bp  
to ATG 
PnisA TACAAT 54 TCTGAN6TCTGA 81  
PnisF TATACT 39 TCTGAN6TCTGA 66 
PspaB TATAGT 122 TTGATN6TTGAT 148 
PspaS TACTAT 31 ATGATN6TTGAT 57 
PspaI TAGAAT 109 TTGATN6TTGAT 135 
Table 20 - Characteristic regions in the clos promoters and comparison to nisin and subtilin. 
*Represents the number of nucleotides (in base pairs) relative to the ATG start codon.  
-35 region is the lantibiotic box: subtilin box or nisin box. Details for nisin and subtilin promoter sites were 
adapted from Kleerebezem et al. [83, 146]. The scores for the search of clos promoters are given in the 
table and the positions of the predicted clos promoter sites where 1 is the first amino acid in the closF gene 
in the clos gene cluster [146].  TTGAT in -35 box represents half a SPA box. N6 represents 6 nucleotides 
in any combination.  
 
Previous transcription analysis of the PLanA promoter in nisin and subtilin suggested the 
presence of a nisin box [146], however further experiments need to be performed to 
identify an equivalent clos box.  
Target genes can be expressed in L. lactis host strains provided that the process is 
regulated by strong constitutive or inducible promoters via a two-component regulatory 
system. For nisin, it was demonstrated that constitutive expression of nisRK in an 
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uninduced state is possible since nisRK genes are expressed continuously to ensure a rapid 
build-up of immunity. In an induced state, the nisRK gene expression in the nisin gene 
cluster is enhanced [146].  
After the clos and nisin gene clusters were compared as they share a high level of 
structural similarity, it was predicted that their genes encode for highly similar proteins. 
Interestingly, the -35 box in PClosA has a half subtilin box. The spa-box is known to be 
involved in the subtilin-mediated regulation of spa gene expression as it represents the 
binding site of the SpaR regulator [146]. Therefore, it is believed that perhaps the half 
subtilin box may act as the binding site for ClosR since it was previously shown that the 
ClosR1K1 protein seems to be more similar to SpaR1K1 than its equivalent in nisin 
operon [97]. However, additional sigma factors may contribute to the transcription 
initiation of clos which is something that could be investigated in the future.  
 
 
 
Figure 45 - Comparison between the organisations of a) nisin, b) subtilin and c) clos biosynthetic gene 
clusters (predicted clos transcripts). 
The structural genes (in black), genes that encode proteins involved in maturation (in orange) and in 
transport (in blue), in leader processing (for nisin in yellow), in immunity of the producer (in purple), and 
in regulation (in green) are indicated. Adapted from Kleerebezem et al. [146]. The predicted transcripts 
would be formed due to activation of promoters.   
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Figure 45 illustrates the known location for both promoters and transcripts involved in 
the nisin and subtilin biosynthesis. Based on the in silico search, the clos promoters were 
also highlighted for the production of Clos.  
 Construction of plasmids to study PClos promoters  
A number of constructs were successfully made using the methods described before 
(section 4.2).  
Fusions of PClos promoters with pepI reporter genes were first created in L. lactis MG1614 
host strain, known as PClosA_pepI, PClosBTC_pepI, PClosFEG_pepI and PClosR2K2_pepI. Splice 
overlap extension PCR was used to amplify the sequence before the closA1-4, closBTC, 
closFEG and closR2K2 genes in the clos cluster sequence. These sequences include the 
essential elements present in any clos promoter.  
The primers for splice overlap extension PCR were designed to be complementary to the 
ATG start site of the pepI gene (reverse primer) and to the 3’ end of the promoter 
sequence. The outer primers were designed to create BglII and XhoI restriction enzyme 
sites at each end. After subsequent cloning steps and sequence confirmation these 
constructs were transformed into the L. lactis UKLc10 or FI7847 host strains. In order to 
determine if the PClos promoters are activated by nisin and regulated by nisRK genes, the 
specific activity of pepI was monitored in an enzyme assay.  
To identify if either of the two closRK systems can switch on any of the PClos promoters, 
the closRK genes were cloned under the control of the nisin promoter, PnisA, on a pTG262 
expression vector to make pTG262_PnisA_ClosRK constructs (Figure 46). The outer 
primers were designed to create NcoI and SalI or BamHI restriction enzyme sites at each 
end. 
 
Figure 46 - Expression of the closRK genes under the control of PnisA in a pTG262 expression vector.                  
L. lactis MG1614 host strain with no lanRK genes.  
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Similarly, to test if a non-functional ClosR1 would allow for activation of PClos promoters, 
a frameshift was introduced in ClosR1. A mutated closR1 (fscR1) and closK1 genes were 
expressed under the control of PnisA in a pTG262 expression vector to investigate the 
effect of a frameshift on the expression of a non-functional ClosR1K1 protein and results 
are presented in section 4.3.4.  
 Generation of reporter gene and clos promoter regulatory dual systems 
The first hypothesis was to assess if one of closRK systems is able to activate any of the 
four predicted promoters in the clos gene cluster. To test this idea, the first aim was to 
create a two plasmid system composed of one promoter reporter gene plasmid, known as 
pIL253_PClos_pepI or pPClos_I, and one nisin induced regulatory system, named pTG262_ 
PnisA_closRK or p PnisA_cRK. To further investigate if the regulatory genes from the nisin 
cluster alone would switch on clos promoters, the second aim was to create a set of strains 
to test if the nisRK system alone in the UKLc10 strain is able to regulate any of the PClos 
promoters (Figure 47). The expression of pepI reporter gene in UKLc10 host strain would 
give rise to a colour development and the pepI specific activity can be measured 
accurately. 
The second hypothesis was that the NisR and ClosR proteins in the dual system are 
competing for the same binding site in the PClos promoters. To investigate this, the aim 
was to mutate the closR gene to prevent binding of a non-functional ClosR protein to the 
PClos promoter (Table 21).  
Proline iminopeptidase I, pepI, reporter gene and expression vectors for L. lactis (pIL253 
and pTG262) were used to create a series of different constructs; using fusions to the pepI 
marker gene, high or low level protein expression vectors were created. The predicted 
four clos promoters were each fused to the pepI reporter gene, whereas each of the two 
closRK sets of two-component clos regulatory system (closR1K1 or closR2K2) were 
expressed under the control of the nisin induced PnisA via nisRK genes (in the chromosome 
of the L. lactis UKLc10 strain). To achieve optimal expression and to measure the full 
activity of the pepI reporter gene, alternative expression hosts were used. Different 
constructs were transformed in L. lactis MG1614 or UKLc10 host strains as listed in 
Table 21. 
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Full strain name  - Hypothesis 1 -  Aim 1 Shorter strain name  Regulatory system  
pUK200_ PnisA_pepI  
 
In UKLc10 
Positive 
control   
p PnisA_pepI   in UKLc10 nisRK genes on 
the chromosome 
pIL253_ PClosA_pepI + 
pTG262_ PnisA_closR1K1 
In UKLc10a 
 
Test strains  
p PClosA_I+ p PnisA_cR1K1  
nisRK genes on 
the chromosome 
 
 
pIL253_PClosBTC_pepI+  
pTG262_ PnisA_closR1K1 
pPClosBTC_I+  
pPnisA _cR1K1 
pIL253_ PClosFEG _pepI+ 
pTG262_ PnisA _closR1K1 
p PClosFEG _I+  
p PnisA _cR1K1 
pIL253_ PClosR2K2_pepI+ 
pTG262_ PnisA _closR1K1 
p PClosR2K2_I+  
p PnisA _cR1K1 
pIL253_ PClosA_pepI+  
pTG262_ PnisA _closR2K2 
p PClosA_I+ p PnisA _cR2K2 
pIL253_PClosBTC_pepI+  
pTG262_ PnisA _closR2K2 
pPClosBTC_I+  
p PnisA _cR2K2 
pIL253_ PClosFEG _pepI+  
pTG262_ PnisA _closR2K2 
p PClosFEG _I+  
p PnisA _cR2K2 
pIL253_PClosR2K2_pepI+ 
pTG262_ PnisA _closR2K2 
p PClosR2K2_I+  
p PnisA _cR2K2 
 pIL253_ PClosA_pepI + 
pTG262_ PnisA 
empty vector 
control 
p PClosA_I+ pPnisA nisRK genes on 
the chromosome 
pIL253_ PClosA_pepI + 
pTG262_ PnisA _closR1K1 
in MG1614b 
 
control strains 
p PClosA_I+ p PnisA_cR1K1  
 
no lanRK genes 
for MG1614 
 
control strains 
pIL253_ PClosR2K2_pepI+ 
pTG262_ PnisA _closR1K1 
p PClosR2K2_I+  
p PnisA_cR1K1 
pIL253_ PClosA_pepI+  
pTG262_ PnisA _closR2K2 
p PClosA_I+ p PnisA _cR2K2 
pIL253_PClosR2K2_pepI+ 
pTG262_ PnisA _closR2K2 
p PClosR2K2_I+  
p PnisA _cR2K2 
Full strain name –  Hypothesis 1 - Aim 2c Shorter strain name Regulatory system  
pIL253_PClosA_pepI 
pIL253_PClosBTC_pepI pIL253_ 
PClosFEG _pepI 
pIL253_ PClosR2K2_pepI 
In UKLc10 
 
Test strains  
p PClosA _I 
pPClosBTC_I 
p PClosFEG _I     in UKLc10 
p PClosR2K2_I 
nisRK genes on 
the chromosome 
 
 
pIL253_ PClosA _pepI  
pIL253_PClosBTC_pepI 
pIL253_ PClosFEG _pepI 
pIL253_ PClosR2K2_pepI 
In MG1614  
 
Control strains 
p PClosA _I 
pPClosBTC_I      in MG1614 
p PClosFEG _I 
p PClosR2K2_I    
no lanRK genes 
for MG1614 
 
 
Full strain name –  Hypothesis 2 - Aim 1d  Shorter strain name Regulatory system  
pIL253_ PClosA _pepI + 
pTG262_ PnisA _ 
_fsclosR1_closK1 
 
In UKLc10 
control strain 
p PClosA _I+  
p PnisA _fscR1_cK1 
 
 
frameshift in 
closR1 
nisRK genes on 
the chromosome 
Table 21 - List of constructs expressed in L. lactis UKLc10 (test strain) or MG1614 (control strain).  
To investigate if PClos promoters are active by measuring the pepI specific activity, two systems were 
created: a one plasmid system (hypothesis 1, aim 2) or two plasmid system (hypothesis 1, aim 1).  
The activation of individual PClos promoters fused to the pepI is mediated by one of the closRK systems. 
The closRK genes (closR1K1 or closR2K2) were each cloned and expressed under the control of PnisA and 
regulated by the nisRK genes. 
a pPnisA_I in UKLc10 strain is the positive control. The L. lactis UKLc10 strain has the nisin two-component 
regulatory system (nisRK genes) on the chromosome.   
b The L. lactis MG1614 strain is plasmid free.  
c The clos promoter reporter gene system (pPClos_I) was cloned in a pIL253 plasmid.  
d Control strains for hypothesis 2 contained a frameshift in the closR1 regulatory gene (closfsR1). 
In hypothesis 1, the pepI expression is expected to take place as a result of expression of closRK and the 
subsequent activation of PClos; in hypothesis 2, activation of PClos is controlled by nisRK. 
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Figure 47 - Diagram to illustrate hypothesis 1 (left): dual plasmid system, or hypothesis 2 (right): 1 plasmid 
system, to investigate the activation of clos promoters, PClos.  
In hypothesis 1, the pepI expression is expected to take place as a result of expression of closRK and the 
subsequent activation of PClos; in hypothesis 2, activation of PClos is controlled by nisRK. T is a terminator. 
Based on the diagrams in Figure 47, several constructs were made to investigate the 
putative activation of clos promoters via nisRK or closRK signal transduction event. The 
aim was to create a set of expression vectors that will allow the detection of different 
levels of protein expression: high, low or constitutive, using the pepI reporter system.  
 Studying the functionality of PClosA promoter 
 PepI expression under the control of ClosA promoter (PClosA)  
Wegmann et al. [149] have shown that the pPnisA_I in L. lactis UKLc10 positive control 
has a very high pepI activity of approx. 35,000 nmol/mg/min. This is based on the fact 
that nisin binds to PnisA promoter with high affinity and it induces the promoter through 
the signal transduction initiated by the nisRK genes. Therefore, the specific pepI activity 
of the constructs in Table 21 was measured to determine which set of closRK system 
activates which PClos promoter.  
The L. lactis UKLc10 strain has the nisRK genes on its chromosome, therefore it is 
expected that the PnisA promoter would be activated; this binding should allow for the 
subsequent expression of the target gene in constructs known as pPClos _I + pPnisA_cRK. 
The pPnisA_cRK construct encodes for one of the two closRK sets of regulatory genes: 
closR1K1 or closR2K2. Cell extracts were prepared and the pepI content was quantified 
by measuring the pepI specific activity by quantification of PepI. 
 The control strains known as pPClos_I in UKLc10 were designed to express the pepI 
reporter gene; this would take place if the activation of clos promoters is regulated by the 
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NisRK system alone. Therefore, cell extracts and the pepI activity assays were also 
performed with these constructs as illustrated in Figure 48. 
 
Figure 48 - Diagrams of different constructs to investigate the activation of PClosA via nisRK or closRK 
genes in L. lactis MG1614 negative control strain or in L. lactis UKLc10 test strains.  
Extracellular nisin (1) was added in order to activate the nisin or clos promoters (2). For details on the 
plasmids see Table 21. I is pepI, cRK is closR1K1 or closR2K2. The proposed steps for signal transductions 
were numbered and indicated by arrows.  
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The specific pepI enzyme activity of the cell extracts of constructs described in Table 21 
was measured to determine if any of the clos promoters is activated: PClosA, PClosR2K2, 
PClosFEG, PClosBTC. The results are plotted in Figure 49 to Figure 53.  
 
Figure 49 - Expression of pepI specific activity under the control of PClosA in L. lactis UKLc10 and MG1614 
host strains.  
Induction with nisin (+N), uninduced state (-N), N is nisin. Illustrations of signal transduction in a PClosA 
reporter gene construct, p PClosA_I, which is regulated only by nisRK system; in the dual plasmid systems, 
pPClosA_I + pPnisA_cRK, the activation may be regulated by nisRK and/or closRK. The control strain in 
MG1614, pPClosA_I + pPnisA_cRK, is devoid of the nisRK regulatory genes.  
The error bars represent standard deviations based on two biological replicates with two technical replicates 
each. Induction with 10 ng/ml of nisin was represented by (+N) and the uninduced form with (-N), where 
N stands for nisin. 
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The pepI specific activity in fusions to the PClosA promoter was determined using the 
constructs in Figure 49 and the non-normalised reported values were highlighted on the 
graph to account for differences in pepI expression levels. Hypothesis 1, aim 1 comprises 
the two-component plasmid system, whereas aim 2 is represented by the one plasmid 
system as detailed in Figure 50, Table 21.  
The results from Figure 49 indicated that the PClosA promoter in p PClosA_I did not display 
nisin-independent constitutive characteristics since without nisin no activity was detected. 
As it was shown previously [149], in an uninduced state. nisRK genes are constitutively 
expressed; this was also confirmed in here with the positive control, p PnisA_I, (-N), 
without nisin, where the pepI specific activity was approx. 250 nmol/mg/min (Figure 49). 
In contrast, no activity was detected for p PClosA_I without nisin which confirms that PClosA 
is a DNA binding site for the activated NisR only when nisin is present.   
In the positive control, pPClosA_I, where pepI expression is under the control of PnisA, NisR 
has a higher affinity for the nisin promoter (value of approx. 35 k nmol/mg/min, +N, 
section 4.3.4.4) and approx. 250 ng/mol/min without nisin (Figure 49, positive control, -
N). In contrast, NisR also binds to the PClosA promoter in pPClosA_I, (+N) construct, 
however the specific activity is lower (305 nmol/mg/min) when induced with nisin. The 
pepI activity seen with pPClosA_I (+N) is a very interesting result which means that the 
transcription of the pepI reporter gene is driven by the activated PClosA promoter which is 
triggered by nisin-mediated, NisRK-dependant signal transduction.      
To understand if the closRK system activates PnisA, several constructs known as pPClosA_I+ 
p PnisA_cRK were created and they were comprised of both PClosA and PnisA promoters 
(Figure 49). The first thing to note was the extremely low pepI activity. The pPClosA_I + 
pPnisA_cRK constructs induced with nisin (+N) gave 16 and 40 nmol/mg/min, for 
closR1K1 and closR2K2, respectively, whereas the empty vector control strain, pPClosA_I 
+ pPnisA, had 28 nmol/mg/min. Therefore, there was no significant pepI activity using 
both promoters. 
Results using all the strains in Figure 49, including the negative controls in MG1614, 
have indicated that there was no obvious difference between functional and non-
functional ClosR1 (fsclosR1) proteins using the frameshift constructs. The assumption is 
that the presence of two promoters, which are both competing for the same NisR, are 
responsible for the very poor pepI signal. Since NisR is binding with a higher affinity to 
the nisin box of PnisA, PnisA is favoured hence the lack of activation of PClosA and the lack 
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of pepI expression in the dual plasmid system. In contrast, the pPClosA_I control strain that 
contains only the PClosA promoter is clearly activated by nisin via the nisRK system present 
on the chromosome of UKLc10 strain. 
The clearly distinguishable pepI activity of 305 nmol/mg/min in pPClosA_I in UKLc10 
host strain with nisin (Figure 49), confirmed that since both nisR and nisK genes are 
integrated on the chromosome of UKLc10 strain, the expression of pepI was inducible by 
the wild type nisin. These results suggest that nisRK genes are necessary and perhaps 
sufficient for the activation of PClosA in this UKLc10 heterologous expression system 
which is not a perfect system. Therefore, in the one plasmid system, pPClosA_I, the closA 
promoter is definitely activated by nisin in this scenario (Figure 50).  
In contrast, in the dual plasmid system pPClosA_I + p PnisA_cRK, the pepI values were very 
close to the background, therefore activation of the PClosA promoter can not be confirmed 
in this system. Consequently, the aim 2 of hypothesis 1 was validated (Figure 50). It was 
interesting to observe that the presence of PnisA prevented notable activation of PClosA. 
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Figure 50 - Illustration of activation of PClosA promoter in different constructs mediated by the nisRK system 
in the UKLc10 strain.  
Based on the lack of specific activity seen from the dual plasmid system, a new hypothesis 
was considered by which the NisR and ClosR are competing against each other for the 
same binding site in the PClosA promoter. To test this, frameshift in the potential N-
terminal of ClosR was introduced in order to change the expressed protein and to disallow 
its binding to the PClosA. The frameshift removed 1 nucleotide to generate a new random 
sequence that has a stop codon created. The assumption was that the frameshift will 
favour the binding of NisR to the available target site in PClosA. Constructs known as 
pPClosA_I+p PnisA_fscR1_ cK1 were created that encode for non-functional ClosR 
proteins. Therefore, it was interesting to investigate the effect on the pepI activity in the 
new scenario (hypothesis 2, Figure 50, D). For proof of principle, it was decided that 
similar strains carrying a plasmid with a mutated closR2 was not necessary. Since 
pPClosA_I in UKLc10 was the only strain that gave a good pepI signal, no extra strains that 
had a frameshift in closR were tested.    
Figure 50 illustrates the proposed (A) and real mechanism (B) for hypothesis 1 including 
the real mechanism for hypothesis 2 (C, D). The proposed mechanism for hypothesis 1 
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(A) suggests that PClosA promoter would be activated by one set of the closRK genes; 
PClosA was fused to pepI and closRK were expressed under the control of PnisA. Based on 
the measurements for the pepI specific activity, the real mechanism for hypothesis 1 is 
that both clos and nisin promoters appear to be competing for the available NisR and that, 
based on the positive control, NisR has a higher affinity for PnisA, therefore the binding 
between the two is favoured. Since NisR is no longer available, NisR does not bind PClosA 
so it does not get activated. The assumption that NisR and ClosR are competing for the 
same DNA target site in PClosA is not valid if the empty vector control and the mechanism 
in hypothesis 2, are considered. The mechanism illustrated for hypothesis 2 (Figure 50, 
C, D) suggests that in the presence of two promoters, the NisR will still favour the PnisA 
binding site (Figure 50, D).  
 PepI expression under the control of ClosR2K2 promoter (PClosR2K2) 
Based on previous results (Figure 50), the PClosA is definitely an inducible promoter as it 
is activated by the nisRK regulatory system as seen with pPClosA_I in UKLc10 strain. 
However, the pepI specific activity observed with the p PClosR2K2_I control in Figure 51 is 
very low and there is not a significant difference between the specific activity in an 
induced (74 nmol/mg/min) compared to an uninduced state (51 nmol/mg/min). 
Interestingly, the L. lactis MG1614 control strain with p PClosR2K2_I + p PnisA_cRK, which 
lacks the essential nisRK genes for signal transduction, displayed a background level for 
the pepI specific activity of around 40 nmol/mg/min (for closR1K1) and 30 nmol/mg/min 
(for closR2K2) respectively in the presence and absence of an inducible amount of 
extracellular nisin. The background level with the PClosR2K2 constructs is very different 
from the equivalent control strain with PClosA constructs. The PClosA in L. lactis MG1614 
controls displayed a value of 4 nmol/mg/min (+N) and 0 nmol/mg/min (-N), respectively.  
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Figure 51 - Expression of the pepI under the control of PClosR2K2 in L. lactis UKLc10 and MG1614 host 
strains. 
N represents nisin, induction with nisin (+N), uninduced state (-N). Illustrations of signal transduction in a 
PClosR2K2 reporter gene construct, pPClosR2K2_I, which is regulated only by nisRK system; in the dual plasmid 
system, pPClosR2K2_I + pPnisA_cRK, the activation may be regulated by nisRK and/or closRK. An L. lactis 
MG1614, pPClosR2K2_I+ pPnisA_cRK, control strain was also included where no nisRK regulatory genes were 
present.  
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If the results for the PepI assay with the PClosR2K2_I and pPClosA_I in UKLc10 strains were 
compared, it would be difficult to conclude that PClosR2K2 is switched on by nisRK genes 
using this heterologous expression system due to the fact that the observed values are 
close to the background level seen with the MG1614 control strains (Figure 51).  
The pepI specific activity observed in the two plasmid system, indicate that perhaps the 
two promoters, PClosR2K2 and PnisA, are not competing for the activated NisR regulatory 
protein in this heterologous system.  
The lack of competition is confirmed by the PepI assay results. The PepI values for  
p PClosR2K2_I + p PnisA_cRK when induced with nisin was 48 and 72 nmol/mg/min whereas 
for p PClosR2K2_I, it was 74 nmol/mg/min.  
In conclusion, unlike the PepI assay with the PClosA constructs, the PnisA and PClosR2K2 do 
not appear to be competing for the same translational regulatory protein, NisR, in this 
expression system.  
 PepI specific activity assay under the control of ClosFEG and 
ClosBTC promoter (PClosFEG and PClosBTC) 
Figure 52 and Figure 53 illustrate the pepI specific activity obtained with p PClosFEG _I or 
pPClosBTC_I in UKLc10 strain. Results with the dual plasmid systems with p PClosFEG _I+ 
pPnisA_cRK and p PClosBTC_I+ p PnisA_cRK were also included. The first thing to note was 
the very low pepI activity particularly in the constructs with PClosFEG, demonstrating 
almost the complete absence of the pepI enzyme activity in the cell extracts. The 
constructs displayed a negligible amount of activity ranging from 1 to 4 nmol/mg/min for 
PClosFEG and values between 5 to 6 nmol/mg/min for PClosBTC, respectively.  
Chapter 4 
   
152 
 
 
Figure 52 - Expression of pepI specific activity under the control of  PClosFEG in L. lactis UKLc10 host strain.  
Induction with nisin (+N), uninduced state (-N), N is nisin. Illustrations of signal transduction in a PClosFEG 
reporter gene construct, pPClosFEG _I, which is regulated only by nisRK system; in the dual plasmid system, 
pPClosFEG _I + pPnisA_cRK, the activation may be regulated by nisRK and/or closRK.  
 
 
Figure 53 - Expression of pepI specific activity of cell extract under the control of PClosBTC in L. lactis 
UKLc10 host strain. 
Induction with nisin (+N), uninduced state (-N), N is nisin. Illustrations of signal transduction in a PClosBTC 
reporter gene construct, p PClosBTC_I, which is regulated only by nisRK system; in the dual plasmid, p PClosFEG 
_I + p PnisA_cRK, the activation may be regulated by nisRK and/or closRK.  
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Interestingly, in a nisin induced state (+N) the pepI activity of pPClosBTC_I strain is 18 
nmol/mg/min which is higher than all the other readings but still a low value. In 
conclusion, the closRK or the nisRK two-component regulatory systems are not capable 
of switching on the putative PClosBTC and PClosFEG clos promoters when they are expressed 
in the L. lactis UKLc10 heterologous system. 
 Comparison of the pepI specific activity assay under the control of 
different clos promoters  
To summarise, the sequences upstream of pepI in pPClosBTC_I, p PClosFEG _I and  
p PClosR2K2_I which were predicted to be clos promoters, did not act as DNA binding sites 
for NisR regulatory protein. This is confirmed by comparing the pepI activity against the 
positive control when induced with nisin (Figure 54). 
 
Figure 54 - Specific pepI enzyme activity of cell extract of the PnisA_pepI positive control  was compared 
to pPClos fused to pepI type of constructs in a nisin induced (+N) and an uninduced state (-N). The UKLc10 
with a nisRK genes on the chromosome was used as a host strain.  
The specific activity of pepI was measured from constructs (pPClosA_I) where pepI was expressed under the 
control of one of the four predicted clos promoters to determine if they are activated by the nisRK system 
in the UKLc10 host strain. N stands for nisin. 
The first striking observation in Figure 54 was the total lack of any pepI activity in 
pPClosFEG_I , as well as the very low activity close to the background levels for pPClosBTC_I. 
The same applies for pPClosR2K2_I compared to the L. lactis MG1614 background (Figure 
51 and Figure 54). Compared to the positive control, the observed activation of the closA 
promoter by the nisRK system is demonstrated by the pepI specific activity of 305 
nmol/mg/min with nisin induction.  
In conclusion, the pepI specific activity measured with the one plasmid reported gene 
constructs, pPClos_I, demostrated that none of the PClos promoters are constitutive 
promoters and that they are poor promoters in this L. lactis UKLc10 expression system. 
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PClosA is clearly switched on by induction with nisin when it is expressed and regulated 
by the nisRK genes in the L. lactis UKLc10 strain. The PClos_I fusion plasmids were 
similar except for the PClosA promoter which definitely has half a spa box. Therefore, the 
differences in the specific activity must probably be due to the fact that a promoter may 
not be active or activated by the nisRK system, or there may be a post-transcriptional 
effect like the stability of mRNA, the efficiency and the level of translation as well as 
protein stability that may explain the current results.  
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4.4 DISCUSSION 
In this chapter, the activation of putative clos promoters in the clos gene cluster was 
explored. The clos promoters were expressed in a pepI reporter gene expression system 
which is under the control of the nisRK genes. 
A survey of the literature suggests that a lantibiotic biosynthetic machinery is encoded by 
a gene cluster that is comprised of genes and promoters [150]. It was hypothesised that if 
clos promoters are activated by an inducer molecule, the clos cluster in the wild type 
strain could potentially express active lantibiotic peptides. In silico analysis of the 17 kb 
clos operon has led to the identification of four putative clos promoters, where the PClosA 
has half a spa box; this suggested that PClosA is a potential target recognition site for NisR 
or even for the ClosR regulatory proteins. The spa-box is the DNA target site for the 
regulatory gene in another class I lantibiotic gene cluster of subtilin [83, 126]. The 
sequences for the putative promoters were fused to the pepI reporter gene following the 
example of Wegmann et al. [100, 149].  
Based on previous published results [151] on the characterisation of the subtilin-regulated 
gene expression (SURE), a more robust pepI dual plasmid reporter gene promoter system 
was engineered. 
In this chapter, it was demonstrated that the PClosA putative clos promoter is activated by 
induction with nisin in a similar fashion as PnisA promoter.  Results from the pepI liquid 
assay (data not shown) indicated that PClosR2K2 and PClosBTC putative promoters may 
respond to the presence of nisin; this activation is dependent on the presence of the NisRK 
system, however these results were not validated by more accurate measurements in the 
pepI assay.  
Since the expression of the nisRK two-component regulatory system is constitutive, the 
hypothesis was that perhaps the closRK genes are also expressed nisin-independent, 
therefore closR1K1 and closR2K2 may follow a similar pattern as nisRK. The results from 
the pepI assay suggested that the clos promoters are not constitutive and that neither of 
the two closRK set of regulatory genes possess any role in the activation of clos promoters 
using this heterologous system. The presence of both nisin and clos promoters in the same 
system had a negative impact since they may have interfered with downstream reactions. 
Future work may involve to incorporate the closRK genes on a chromosome to create an 
alternative host strain with the pPnisA_I plasmid in by using the example of the UKLc10 
strain. 
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The same strong positive control, p PnisA_I in the UKLc10 strain, was used in this study 
as before [149]. The nisin promoter, PnisA, represents the DNA binding/target site for the 
phosphorylated NisR regulatory protein [152]. The PClos_pepI fusions were expressed on 
the high copy number pIL253 plasmid [153], whereas the positive control was under the 
control of PnisA and it was expressed in pUK200. Therefore, a direct comparison to the 
positive control is not strictly conclusive. The current results could only give a relative 
level of the promoter activity considering that the values could not be normalised and 
qPCR data was not available in here to account for the differences for individual transcript 
levels.  
A dual plasmid reporter gene system was used and results suggested that the NisR and 
ClosR may be competing for the same binding site in the PClosA promoter. It was shown 
that a frameshift in ClosR1 did not restore the signal. Apparently, competitive binding of 
NisR would favour PnisA rather than PClosA. Competition between PnisA and PClosA was 
confirmed by measurements of the pepI activity using strains pPClosA_I+p PnisA_cRK, 
pPClosA_I+p PnisA and pPClosA_I+p PnisA_fscR1_cK1; the values with the dual plasmid 
system were lower than the ones for pPClosA_I constructs, the one reporter gene plasmid 
strains, using nisin induction.  
Measurements of the specific pepI activity using the closRK or nisRK two-component 
regulatory systems demonstrated that the lanRK genes are not capable of switching on 
the putative PClosBTC and PClosFEG clos promoters when they are expressed in the L. lactis 
UKLc10 heterologous system. The clos promoters may be functional when they are 
present on the clos gene cluster, however UKLc10 may lack the correct transcriptional 
repressors and/or activators. Even if sigma factors in L. lactis host strain are present, the 
lactococcus sigma levels in this strain may not be suitable enough to bind to a Blautia 
obeum A2-162 type of promoters.  
The clos gene cluster has two sets of regulatory genes, one is under the direct control of 
the clos promoter, PClosR2K2. Previous work has shown that expression of PnisR promoter 
is constitutive [154]. Therefore, it was assumed that if the clos cluster was actively 
producing lantibiotic peptides, the ClosRK system should also be constitutive in order to 
allow for a fast accumulation of immunity. The results obtained in this study did not 
indicate that PClosR2K2 is either constitutive or that it can be activated by nisin induction, 
therefore the original hypothesis could not be validated.  
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In this chapter, the role of the closRK regulatory system has not been defined in this work. 
Even if it seems that the closRK genes may not interact with the clos promoters when 
nisin is present, preClosA production and activation/maturation of closA may be 
necessary for the ClosRK systems to become regulatory. Based on the knowledge about 
the location of the NisRK proteins in the nisin operon, it can be assumed that the ClosK 
sensor kinase of the two-component regulatory ClosRK system should also be exposed 
to the outside of the cell. This is because ClosK should respond to an extracellular inducer 
signal when the inducing peptide is added. The subsequent phosphorylation of the internal 
ClosR should stimulate the closA transcription provided that appropriate levels of the 
inducer peptide are added to the broth or to the agar media. It may be possible that the 
signal molecule such as the Clos peptide itself is synthesised in a higher concentration 
when cultured on agar plates rather than in liquid. In contrast, Clos may be too diluted 
when grown in liquid broth cultures thus any small amounts of Clos can not initiate 
transcription of the closA structural genes. 
In conclusion, the transcription of pepI genes is activated by nisin-mediated autoinduction 
and involves signal transduction by the nisin two-component regulatory system composed 
of NisR and NisK. The NisK sensor kinase will detect the nisin signal molecule, and after 
phosphotransfer to the NisR, the response regulator will be activated and it will bind to 
PClosA. This step will finally lead to increased pepI expression levels. Induction with 10 
ng/ml of nisin did not allow for a similar pepI specific activity to be detected when either 
PClosFEG, PClosBTC or PClosR2K2 promoters were present. In nisin, the activity levels of PnisA 
and PnisF promoters directly depend on the added nisin concentration; perhaps, there is 
also a linear dose response relationship between nisin and the resulting transcriptional 
level of pepI that could contribute to the activation of the three clos promoters. In the 
future, an increased amount of nisin should be added to test the possible activation of the 
clos promoters.  
Therefore, current results confirmed that PClosA is activated by NisRK proteins and 
perhaps additional activators or different sigma factors are required for the switching on 
of PClosFEG, PClosBTC and even of PClosR2K2. DNA fingerprinting could help to further 
understand the activation of the clos promoters [155]. This study is based on in silico 
predictions for the location of clos promoters. Similar to other studies that involved to 
test the regulation of lantibiotic gene clusters, RNA analysis may allow for a more 
accurate evaluation of the levels of clos gene transcription [119, 149]. 
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There is a great diversity in the regulation of the lantibiotic immunity and biosynthesis. 
The regulatory systems in lantibiotic gene clusters are responsible for both the 
biosynthesis of bacteriocins and their autoinduction, and it was shown that some lanRK 
regulatory genes target both pathogenic bacteria and the survival events inside the host 
organism [7]. Some examples of the diversity of the regulatory systems are given below.  
Several two-component lantibiotics are known to autoregulate their biosynthesis such as  
cytolysin, staphylococcin C55 and lacticin 3147 [7, 156]. A two-component regulatory 
systems (LanR, LanK) is responsible for controlling the regulation of lantibiotics except 
in the case of epidermin where regulation is done by a single protein (EpiQ) [157].  
Nisin and subtilin, two-component signal transduction systems regulate their biosynthesis 
and LanR acts on the promoter of the lanA, lantibiotic structural gene [7].  Nisin acts as 
a peptide pheromone in the process of quorum sensing in order to autoregulate its own 
biosynthesis through NisR and NisK proteins [74].  
The gene cluster for mersacidin encodes for three regulatory genes out of which 
MrsR2/K2 encode for a two-component regulatory system which controls the immunity 
gene transcription; the third gene encodes for a response regulator-like protein [158-160].  
The gene cluster for epidermin encodes for a response regulator type of protein, LanQ, 
which binds to the epiABCD promoter region to activate the lanA expression. However, 
it was proposed that the signal transduction process is completed by a histidine kinase 
from the host [157, 161].  
Similar to the pepI assay work performed in this chapter, a β-glucuronidase assay was 
used to investigate the activation of the four psp promoters cloned to gusA, the β-
glucuronidase reporter gene. The promoters were identified in the gene cluster of 
planosporicin. Three regulatory proteins were determined such as ‘an extracytoplasmic 
function σ factor (PspX), its cognate anti-σ factor (PspW), and a transcriptional activator 
(PspR) with a C-terminal helix-turn-helix DNA-binding domain’ [23].  
It is known that ruminococcin C (RumC) is a bacteriocin which is a trypsin-dependent 
peptide that was isolated from human feces [50, 162]. The impact of the environment on 
the regulation of lantibiotic biosynthesis had been previously reported [71, 163]. The 
transcription of the putative regulatory rumRK was shown to increase when trypsin was 
added and it was constitutive under non-inducing conditions [164].  
It was previously suggested that Blautia obeum A2-162 should respond to trypsin [97]. 
Since the clos cluster was isolated from the Blautia obeum A2-162 gut bacteria, it should 
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be noted that additional factors from the GI tract are necessary to investigate the activation 
of clos promoters which are yet to be identified.  
In order to understand if the clos gene cluster is actively producing, modifying and 
secreting an antimicrobial peptide, we needed to determine if the clos promoters are active 
to ensure that the required genes are expressed. Common difficulties with gene clusters 
are that the antimicrobial peptide remains inside the cell and it is not secreted which 
makes the lantibiotic peptide a less interesting candidate to explore further. Knowledge 
on the efficiency of the promoters to ensure that each lantibiotic biosynthesis step does 
takes place will ultimately allow us to develop an expression system to produce high yield 
(active) Clos peptide.  
Based on the nisin induced activation of the PClosA promoter using the NisRK regulatory 
system demonstrated in this chapter, the clos gene cluster will be expressed in the same 
UKLc10 heterologous expression system to investigate the production, detection and 
activation of the preClosA peptides as described in chapter 5.  
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5.1 INTRODUCTION 
In a previous study by Hatziioanou [97], the entire novel clos gene cluster was subcloned 
and expressed in L. lactis. Despite complementation with the closA gene on an inducible 
plasmid to try to improve expression of the Clos peptide, the expression of biologically 
active mature ClosA peptides was unsuccessful. However, a peptide of the size of the 
preClosA1 was detected at very low levels using an antibody designed to the ClosA1 leader. 
The closA structural sequences were also expressed fused to the nisin A leader in a nisin-
producing L. lactis strain of NisL_closA. The hybrid genes which included the N-terminal 
nisin leader sequence and the nisin promoter (PnisA) fused to the C-terminal of ClosA1(IE), 
ClosA1(YK) or ClosA4 protein were created in pUK200 expression vector and were 
expressed in ∆nisA and ∆nisP L. lactis host strains (Table 22).  
Since the exact end of the Clos leader and the start of the nisin-like closA structural sequence 
were uncertain, two constructs were previously designed with the N-terminal amino acids  
as IE or YK fused to the nisin leader [97]. Based on the comparison of known lantibiotic 
LanP cleavage sequences and with the sequences of other active lantibiotics, the cleavage 
site for ClosA leader peptide was proposed to be before either IE or YK start site. 
The first aim of this chapter was to investigate whether the nisin biosynthetic machinery 
would be able to recognise the nisin leader in a ‘nisin leader_closA’ hybrid, to modify, to 
secrete and to cleave the leader in order to produce active forms of the ClosA peptides.  
The role of a leader peptide in the precursor molecule is to maintain the peptide in an inactive 
form and to induce PTM such as the LanB and the LanC catalysed dehydration and ring 
formation of the prepeptide. For nisin, the leader peptide also plays a role in mediating the 
interaction with the NisT in the export of nisin [165].  
In the nisin leader_closA hybrids, it was expected that the NisP from the nisin biosynthetic 
system would remove the nisin leader peptide [150] even if the constructs do not have a 
typical recognition NisP site. If the NisP would not recognise the PR↓IE or PR↓YK cleavage 
site, a 6 kDa prepeptide is expected to be formed. To address this and based on the 
knowledge of the predicted amino acid content in the nisin leader peptide, a new cleavage 
site was designed as another aim of this chapter.  
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Previous work [97] indicated that attempts to express the Clos peptide in L. lactis FI7847 (L. 
lactis FI5876 ΔnisA) and FI8438 (L. lactis FI5876 ΔnisP) indicated that the strains may be 
capable of synthesizing a truncated nisin A homologue and possibly a full length 
unprocessed nisin precursor of 5961 Da, respectively. Previous results with the strain 
containing the nisin leader_closA1(YK) hybrid indicated that a prepeptide was visible in 
extracts from the culture supernatant and additional protein bands around 3.5 kDa in FI7847 
may have been detected in western blot. A consistent band appeared at 6 kDa in this strain 
which was absent in any of the controls. No antimicrobial activity or specific MS peaks that 
would confirm the presence of a Clos peptide was detected. However, unique proteins (Table 
22) that hybridised to the antinisin leader antibody in a closA1(YK) containing strain, 
confirms that the Clos peptide was made in the L. lactis MG1614 strain. Despite the western 
blot band was observed, the 6 kDa protein was not extracted due to poor yield, therefore 
processing of the peptide including PTM were not established.   
 Nisin leader _ClosA1(IE) nisin leader _ClosA1(YK) nisin leader_ClosA4 nisin  
Prepeptide 
with nisin 
leader 
6304 5836 6064 5961 
Leaderless 
peptide 
3840 3372 3599 3497 
Prepeptide 
with clos 
leader  
5837 5837 6417 NA 
Table 22 - Calculated masses of nisin leader_clos, clos leader_clos hybrids and leaderless precursor Clos 
peptides.  
The L. lactis FI7847 and FI8468 strains produce a 5962 Da nisin homologue; the mass of the Clos peptides 
should allow to distinguish between nisin and Clos. Based on Hatziioanou [97].  
Previous attempts to purify and characterise active Clos peptides were unsuccessful due to a 
number of possible reasons: poor yield, the absence of a protease and presence of 
unpredicted peptides or the use of the incorrect indicator strains. Understanding if and how 
active lantibiotics from the novel clos gene cluster are made could enable the development 
of variants with improved clinical activity since results from this thesis (chapter 3) showed 
that nisin expression was more effective from pTG262 expression vector.  
The first task was to excise the nisin leader_clos hybrids and to express them on a better 
pTG262 expression vector. In this chapter, the nisin leader_clos hybrids were also cloned 
with a more efficient designed putative recognition site for the nisin protease, NisP. The new 
nisin leader_closA hybrids that had the IT start site instead of IE or YK, were created and 
tested for the possible production and secretion of a leaderless ClosA peptide.  
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The nisin protease is a highly specific enzyme that removes the leader peptide from the fully 
modified and exported prenisin. Interestingly, it was shown that both L. lactis and B. subtilis 
lantibiotic producing strains, contain intracellular and cytoplasmic proteolytic activity. 
Secretion of leaderless lantibiotics was demonstrated in a deletion mutant strain or in the 
absence of lanP in subtilin and nisin [166-168]. It was hypothesised that the Clos leader 
peptide would play a similar role as the nisin leader peptide and that perhaps Blautia obeum 
A2-162 may have, still undetectable, internal proteolytic activity like other lantibiotics from 
the same family [83].   
The second task of this chapter was to express the entire clos cluster in the same nisin-
inducible controlled expression system, L. lactis UKLc10 strain which was used in chapter 
4. 
In a comparison between nisin and clos biosystems, nisA and closA1-4 encode the precursor 
Clos and nisin peptides (4 copies of closA and one copy of nisA, respectively). The clusters 
are also comprised of genes that encode for proteins involved in the maturation of the 
precursor preClosA or prenisin peptides: for PTM, ClosBC and NisBC, respectively, for 
export of the modified precursor peptide ClosT and NisT, respectively, and for immunity 
and for the protection of Blautia obeum A2-162 and L. lactis organisms: ClosFEGI and 
NisIFEG. Notably, a gene encoding an extracellular protease (NisP) responsible for cleavage 
of the nisin leader sequence is present in the nisin cluster to generate a mature nisin molecule. 
However, both subtilin and clos gene clusters do not contain a gene that encodes for a similar 
function, however unspecific serine proteases secreted by B. subtilis that are involved in the 
maturation of subtilin have been detected [146]. Finally, the nisin gene clusters contain genes 
that encode a nisRK two-component regulation systems, whereas two sets of closRK genes 
composed of a sensor kinase (ClosK1 or ClosK2) and a response regulator (ClosR1 or 
ClosR2) have been identified in the clos gene cluster.  
We aim to test the expression of the clos peptides from nisin leader_clos using the nisin 
biosynthetic machinery or clos leader_clos hybrids using the nisRK regulatory system of 
nisin. The aim is to also engineer an expression system to allow for improved Clos peptide 
production and to assess the biological activity of Clos. Another aim was to investigate if 
the pClosCluster in L. lactis in UKLc10 producing strain is able to synthesise clos when the 
producer is grown on plate and if trypsin is able to cleave the predicted Clos leader from the 
synthesised preClosA peptide to generate a series of Clos tryptic peptides. Finally, we 
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wanted to understand if the mature leaderless Clos peptide or the tryptic peptides display 
antimicrobial activity against a range of indicator strains.  
5.2 MATERIALS AND METHODS  
 Generation of nisin leader_clos hybrids and the design of NisP cleavage 
site  
Constructs in the pUK200 vector (Table 23) were used as templates to excise the nisin 
leader+closA insert using a set of primers as detailed in chapter 2. The inserts were cut with 
SspI and XbaI and cloned in a pTG262 vector digested with HindIII, endfilled and cut with 
XbaI to generate the constructs in Table 23.  
Plasmids in pUK200 Plasmids in pTG262 
pUK200_NisL_closA1(IE) pTG262_NisL_closA1(IE) 
pUK200_NisL_closA1(YK) pTG262_NisL_closA1(YK) 
pUK200_NisL_closA4 pTG262_NisL_closA4 
Table 23 - List of nisin leader_clos hybrids expressed in two expression vectors.  
The nisin leader_clos hybrids were cloned in pTG262 expression vector in L. lactis MG1614 
first to confirm the identity of the plasmid by sequencing, then they were transfered to 
FI7847 to allow for clos expression including cleavage of the nisin leader by NisP protease 
and export of leaderless Clos peptide across the membrane. Constructs were also 
transformed in FI8438 (ΔnisP).   
To create a new potential cleavage site for NisP, the IE and the YK predicted start sites were 
substituted by IT. Cloning was done with primer pairs as detailed in Table 24. 
Also, pTG262 vector was digested with SalI and SacI restriction enzymes and cloned with 
the 401 bp or 380 bp PCR product previously restricted with SalI and SacI restriction 
enzymes. After sequence confirmation, the new plasmids were transformed in L. lactis 
FI7847 (ΔnisA) and FI8438 (ΔnisP) strains. 
Mutation  Primer pair  Insert size 
ClosA1(IE)_IT ClosA1(IE)_IT_F & pUK200_Reverse 
SalI_F & ClosA1(IE)_IT_R  
401 bp 
ClosA1(YK)_IT ClosA1(YK)_IT_F & pUK200_Reverse 
SalI_F & ClosA1(YK)_IT_R 
380 bp 
Table 24 - Details to introduce mutations in the nisin leader to create the putative NisP cleavage site by 
designing two oligonucleotide sequences (forward and reverse).  
Annealing was done with equimolar concentrations at 90-100°C for 5 min, with slow cooling to room 
temperature for 60 min. A double stranded insert with restriction sites at each end was made and finally cloned 
in the pTG262 vector.  The mutations were introduced by splice overlap extension PCR in a pUK200 vector. 
The nisin fragment with the IT mutations in were excised and cloned in pTG262 vector.  
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 Biological activity and characterisation of Clos hybrids  
The nisin leader_clos hybrids obtained in the previous section were screened for their 
antimicrobial activity and for their self-induction capacity by inducing the strains with 0, 10 
or 100 ng/ml of nisin. Indicator strains used in drop tests, overlay assays and plate diffusion 
assays included B. subtilis, C. difficile, C. perfringens, E. faecalis, E. faecium, L. ivanovii 
and S. aureus using methods described in chapter 2. Maldi-ToF was performed as described 
in section 2.5.1.  
 Design of a model expression system for production of Clos 
 Cloning of the clos cluster in L. lactis UKLc10 to improve expression 
of clos 
The nisin biosynthetic machinery and/or the clos biosynthetic machinery were used to 
investigate if fully modified and biologically active Clos can be generated in L. lactis 
UKLc10 (nisRK) or FI7847 (ΔnisA) host strains. The plasmid pPnisA_ closLeader_closA34, 
which is comprised of one copy of the three identical copies (closA3) and the fourth unique 
closA structural gene, was used to investigate if expression of clos is enhanced with 
additional copies of the structural gene.  
Each pClosCluster plasmid and pClosCluster(ΔcA) plasmid was transformed into 
electrocompetent L. lactis UKLc10 strain. Clones were identified by colony PCR using 
primers pIL253F:/pIL253R: and plasmid DNA from positive clones was checked by 
restriction profiling with HindIII using methods as described in chapter 2.  
 Detection of preClosA peptide  
Cell extract and TCA precipitated supernatant of pClosCluster and pClosCluster+ 
pTG262_PnisA_ closLeader_closA34 in UKLc10 were loaded on 4-12 % Sodium Dodecyl 
sulphate PolyAcrylamide Gel Electrophoresis (SDS-PAGE), then the samples were blotted 
with 1/100 dilution of antiClos leader antibody on western blot following the same method 
as described in chapter 2.   
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 Testing biological activity of preClosA peptides  
The pClosCluster in UKLc10 strain was used as the test strain, positive control 
pTG262_nisA in FI7847, negative controls: pClosCluster (ΔcA) and pIL253 in UKLc10, 
UKLc10 strain alone. 
Strains were grown from glycerol in 10 ml of GM17, then subcultured for a number of days 
in fresh media and 10 ng/ml of nisin for induction. Colonies from 5 µl of liquid culture were 
grown on solid agar with NaHCO3, to prevent non-specific antimicrobial peptide activity, 
and induced on plate with 10 ng/ml nisin. The colonies were overlaid with agar medium 
containing the indicator strain and trypsin. Two different kinds of trypsin were used: 
Sequencing Grade Modified Trypsin (Promega, Southampton, UK), and Trypsin TPCK 
Treated from Bovine Pancreas (Sigma-Aldrich, Dorset, UK). The trypsin concentration was 
1 or 5 ng/µl (Promega) or 1, 5, 10 or 15 ng/µl (Sigma). A plate with no trypsin was also 
included as negative control. The same method was followed as described in section 2.1.3 
in chapter 2. For screening the antimicrobial activity several indicator strains were used as 
listed in chapter 2.  
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5.3 RESULTS 
 Generation of nisin leader_clos hybrids and the design of NisP cleavage 
site 
Previous results with expression of nisA (chapter 3) indicated that pTG262 is a better 
expression vector. Here, the nisin leader closA1(IE), closA1(YK) or closA4 hybrids were 
excised from pUK200 clones and subcloned into pTG262 as illustrated in Figure 55. Table 
25 has details of the sequences of the new constructs: pTG262_NisL_ClosA1(IE), 
pTG262_NisL_ClosA1(YK) and pTG262_NisL_ClosA4 (Figure 55, A).  
B.  
C.  
Figure 55 - Cloning to express nisin leader_ClosA1 and nisin leader_ClosA4 hybrids and to engineer a new 
NisP putative cleavage site by splice overlap extension PCR   
A. Expression of hybrids in pTG262 expression vector.  
B. Splice overlap extension PCR to introduce IT mutation in nisin leader_ClosA1(IE) or nisin leader_ 
ClosA1(YK) fusions.  
C. Cloning of mutated fusions into templates (pTG262_NisL_ClosA1(IE), pTG262_NisL_ClosA1(YK)).  
N is the nisin leader, IE and YK are the predicted start sites for ClosA1.  
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In order to create a more efficient recognition site for the nisin protease (NisP), the nisin 
leader peptide was fused to a peptide that has isoleucine and threonine (IT) as its start site. 
Splice overlap extension PCR was used to change the IE or the YK start sites in ClosA1 into 
IT to generate the following constructs: pTG262_NisL_ClosA1(IE)_IT, 
pTG262_NisL_ClosA1(YK)_IT constructs as described in Table 26 and Figure 55.  
Four PCR products were made by using pTG262_NisL_ClosA1(IE), 
pTG262_NisL_ClosA1(YK) constructs as templates and primer pairs: 1. ClosA1(IE)_IT_F 
& pUK_Reverse, SalI_F & ClosA1(IE)_IT_R and 2. ClosA1(YK)_IT_F & pUK_Reverse 
and SalI_F & ClosA1(YK)_IT_R, respectively. Each set of PCR products were then 
overlapped using outer primers SalI_F & pUK_Reverse primer pair. A similar splice overlap 
extension PCR cloning strategy was used as described in section 2.2.7 and in Figure 55. The 
spliced PCR products were then digested with SalI and SacI enzymes to give a 401 bp splice 
product (IE_IT) and a 380 bp product (YK_IT) and cloned in pTG262 vector restricted with 
SalI and SacI. Ligation, transformation and sequence confirmation were performed as 
described in chapter 2.  
The clos cluster lacks a protease that would cleave the leader peptide. Therefore, the 
constructs in Table 25 may express either a leaderless peptide or a peptide with the leader 
still attached.  
The nisin leader_clos peptide constructs do not have a typical recognisable NisP cleavage 
site. The new PR↓IT site should act as a cleavage site for NisP. Table 26 lists the mutations 
introduced in the YK or IE nisin leader_clos hybrids to introduce IT at the N-terminal of the 
core peptide.  
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Table 25 - Expression of nisin leader_clos hybrids in pTG262 expression vector.  
Nisin leader_ClosA hybrids were previously designed [97] to contain the full nisin leader peptide sequence 
‘MSTKDFNLDLVSVSKKDSGASPR’ followed by one of the predicted closA structural sequences to make: 
Nisin leader_closA1 (with IE possible start site to give a longer lantibiotic than nisin): 
IEPKYKSKSACTPGCPTGILMTCPLKTATCGCHITGK, or 
Nisin leader_ClosA1 (with YK possible start site to give a similar size peptide but with different start site than 
nisin): 
YKSKSACTPGCPTGILMTCPLKTATCGCHITGK  
Nisin leader_ClosA4 (unique structure, similar length to nisin when cut before IT): 
ITSQHSFCTPNCLTGFLCPPKTQLTCTCKLKGQ.  
 
The arrow (↓) in Table 25 highlights the predicted site for NisP protease cleavage. The 
sequence of the nisin leader peptide is before the arrow and it is expected to be removed by 
NisP in the L. lactis FI7847(ΔnisA) strain. 
ClosA 
hybrid  
mutants 
Strain & 
vector 
Prenisin with engineered NisP cleavage site* 
ClosA1 
(IE)_IT 
pTG262   
(ΔnisA) 
MSTKDFNLDLVSVSKKDSGASPR↓ITPKYKSKSACTPGCPTGILMTCPL
KTATCGCHITGK 
ClosA1 
(YK)_IT 
pTG262  
(ΔnisA) 
MSTKDFNLDLVSVSKKDSGASPR↓ITSKSACTPGCPTGILMTCPLKTAT
CGCHITGK 
Table 26 - The bioengineering of a putative NisP cleavage site by splice overlap extension PCR in two 
templates: ClosA1(IE) and ClosA1(YK) nisin leader_clos hybrids (see section 2.2.7). 
*Substituted amino acids are indicated in boldface type. The arrow in black represents the expected NisP 
cleavage site.  
 
In conclusion, three existing Clos hybrids, that include the nisin leader sequence fused to the 
closA structural sequences, were subcloned in the pTG262 expression vector. None of the 
hybrids were detected by colony MS in their cleaved or uncleaved form by Maldi-ToF. The 
nisin biosynthetic machinery in the L. lactis FI7847 host strain was not able to express any 
of the predicted 6 kDa peptide. The potential cleavage site for NisP was re-designed (Table 
26) as described above, however the 6 kDa peptides or their cleaved forms were not detected 
in MS.  
Clos 
hybrids 
Strain & 
vector  
Expected products     
ClosA1 
(IE) 
pTG262 
(ΔnisP)   
MSTKDFNLDLVSVSKKDSGASPRIEPKYKSKSACTPGCPTGILMTCPLKT
ATCGCHITGK             
ClosA1 
(IE) 
pTG262 
(ΔnisA)  
IEPKYKSKSACTPGCPTGILMTCPLKTATCGCHITGK 
MSTKDFNLDLVSVSKKDSGASPR↓IEPKYKSKSACTPGCPTGILMTCPLK
TATCGCHITGK 
ClosA1 
(YK) 
pTG262 
(ΔnisA)    
MSTKDFNLDLVSVSKKDSGASPRYKSKSACTPGCPTGILMTCPLKTATC
GCHITGK                                         
ClosA1 
(YK) 
pTG262 
(ΔnisA) 
YKSKSACTPGCPTGILMTCPLKTATCGCHITGK 
MSTKDFNLDLVSVSKKDSGASPR↓YKSKSACTPGCPTGILMTCPLKTAT
CGCHITGK 
ClosA4 pTG262 
(ΔnisA)  
MSTKDFNLDLVSVSKKDSGASPRITSQHSFCTPNCLTGFLCPPKTQLTCT
CKLKGQ                                          
ClosA4 pTG262 
(ΔnisA) 
ITSQHSFCTPNCLTGFLCPPKTQLTCTCKLKGQ 
MSTKDFNLDLVSVSKKDSGASPR↓ITSQHSFCTPNCLTGFLCPPKTQLTC
TCKLKGQ 
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The Clos hybrids were all screened in drop tests and antimicrobial activity assays against 
selected indicator strains: B. subtilis, C. difficile, C. perfringens, E. faecalis, E. faecium, L. 
ivanovii, S. aureus.  
The self-induction capacity of nisin leader_clos hybrids was tested by inducing the peptides 
with exogenous nisin. No antimicrobial activity was detected in the supernatants of any of 
the hybrids in Table 25 or Table 26. Results (Figure 56) indicated that closA1(YK) and 
closA1(IE)_IT displayed zones of inhibition which are similar to pTG262 empty vector 
control induced with 100 ng/ml of nisin. It was concluded that the observed bioactivity was 
due to the extracellularly added nisin and not from the modified active Clos peptide. Their 
small zone of inhibition made it difficult to realistically distinguish between any real 
antimicrobial activity and the control strain.  
 
Figure 56 - Plate diffusion assay of nisin leader_clos hybrids induced with 100 ng/ml of nisin.  
The activity of the peptide in the supernatant was determined from inhibition zones of L. lactis MG1614. The 
biosynthesis of the Clos hybrids and of the control strains was induced by adding 10 ng/ml of native nisin (Day 
2). The cultures were then subcultured and induced (Day 3) with 0, 10 or 100 ng/ml native nisin overnight (as 
marked in black, ‘+ 0, 10, 100’). 
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 Designing a model expression system for production of preClosA 
Previous work on the investigation of clos biosynthesis involved the cloning of the gene 
cluster on the pIL253 vector in L. lactis MG1614 host strain [97]. A 6 kDa band was detected 
in a western blot with the antiClos leader antibody when copies of the closA3, closA4 were 
overexpressed on a vector. However, the presence of the peptide was not demonstrated by 
Maldi-ToF. An explanation would be that the methods used at that time were not suitable 
enough for the detection of the nisin-like lantibiotic. The antiClos leader antibody was 
designed to bind to the Clos leader of ClosA1-3 peptides. It was expected that only a ClosA1 
precursor peptide would be detected by hybridisation in a western blot whereas the ClosA4 
precursor should not, since their leader peptides are different. The yield of this 6 kDa peptide 
was very low which prevented any further investigation into the structure, activity or 
function characterisation of this 6 kDa peptide.  
One hypothesis was that the Clos production may improve if the entire clos biosynthetic 
machinery would be switched on by the NisRK system. This could therefore facilitate the 
modification, secretion and processing of the Clos precursor peptides. To address this, the 
first aim was to switch on the PClos promoters via nisin induction, by expression of the clos 
gene cluster in the UKLc10 strain where the nisRK regulatory system is on the chromosome. 
In the proposed system, the two ClosRK regulatory systems are also present in the clos gene 
cluster and they could potentially be activated by induction with nisin. This assumption that 
nisin induces the activation of the PClosA promoter through the nisRK but not via the closRK 
regulatory system is based on the observations with the pepI assay (chapter 4). 
The second aim in this chapter was to express the clos cluster in the L. lactis FI7847 host 
strain which has the nisRK genes in the nisin biosynthetic cluster. As the clos cluster lacks a 
gene that encodes for a protease, we hypothesised that NisP may recognize and remove the 
Clos leader peptide from pClosCluster in L. lactis FI7847 host strain. Control strains with 
pClosCluster and with pClosCluster(ΔcA) expressed in L. lactis MG1614 and in FI7847 
were also included. The closA34 genes were overexpressed on a pTG262 vector in a strain 
where the clos cluster was already present.  
The third aim in this work was to test if once the cluster is switched on, the structural genes 
can be expressed and the Clos production can be amplified in the UKLc10 heterologous 
expression system. Therefore, the pClosCluster(ΔcA) in UKLc10 host strain was selected 
since the clos gene cluster was present with the structural genes knocked out to make the 
pClosCluster(ΔcA) + p PnisA _ cA34 in UKLc10 strain. This strain is based on a dual plasmid 
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system where the strong interaction between the activated NisR with the PnisA promoter 
should allow the expression, modification and secretion of the ClosA34 peptides in the 
presence of the clos biosynthetic machinery. The dual plasmid system was also cloned in 
FI7847 to facilitate the potential removal of the Clos leader peptide by NisP. 
The fourth aim in this work was addressed by expressing the entire clos cluster in the 
presence of additional copies of both closA3 and closA4 genes in either L. lactis UKLc10 or 
FI7847 host strains. It was assumed that if ClosA34 peptides are co-expressed, they may act 
as inducers for Clos peptide production and further processing in strains with two plasmids: 
pClosCluster+p PnisA_cA34.  
A number of strains were made (Table 27) in order to achieve the four aims.  
Full strain name   Shorter strain 
name  
Regulatory 
genes 
Reference 
pIL253_ClosCluster  
 
MG1614b pClosCluster in 
MG1614 
closR1K1 
closR2K2 
[97] 
pIL253_ClosCluster  
 
FI7847c pClosCluster in 
FI7847 
closR1K1 
closR2K2 
nisRK 
This work  
pIL253_ClosCluster  
 
UKLc10a pClosCluster in 
UKLc10 
closR1K1 
closR2K2 
nisRK 
This work  
pIL253_ClosCluster(ΔclosA) 
 
MG1614  PClosCluster 
(ΔcA) 
 in MG1614 
closR1K1 
closR2K2 
[97] 
pIL253_ClosCluster(ΔclosA) 
 
FI7847 pClosCluster 
(ΔcA) 
in FI7847 
closR1K1 
closR2K2 
nisRK 
This work  
pIL253_ClosCluster(ΔclosA) 
 
UKLc10 pClosCluster  
(ΔcA) 
in UKLc10 
closR1K1 
closR2K2 
nisRK 
This work  
pTG262_PnisA 
_closA3_closA4 
MG1614  p PnisA _cA34 
in MG1614 
none This work  
pTG262_PnisA 
_closA3_closA4 
FI7847 p PnisA _cA34 
in FI7847 
nisRK This work 
pTG262_PnisA 
_closA3_closA4 
UKLc10 p PnisA _cA34 
in UKLc10 
nisRK This work 
pIL253    
control strain  
UKLc10 pIL253 in 
UKLc10 
nisRK This work  
pIL253_ClosCluster (ΔclosA)  
+ pTG262_ PnisA 
control strain  
UKLc10 pClosCluster 
(ΔcA) 
 
closR1K1 
closR2K2 
nisRK 
This work  
pIL253_ClosCluster + 
pTG262_PnisA 
_closA3_closA4 
MG1614 pClosCluster +  
p PnisA _cA34 
 
closR1K1 
closR2K2 
 
[97] 
pIL253_ClosCluster + 
pTG262_PnisA 
_closA3_closA4 
UKLc10 pClosCluster +  
p PnisA _cA34 
 
closR1K1 
closR2K2 
nisRK 
This work  
pIL253_ClosCluster (ΔclosA) 
+pTG262_PnisA 
_closA3_closA4 
Test strain and control strain  
UKLc10 pClosCluster 
(ΔcA) + 
p PnisA _cA34 
closR1K1 
closR2K2 
nisRK 
This work  
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pIL253_ClosCluster + 
pTG262_PnisA 
_closA3_closA4 
FI7847 pClosCluster +  
p PnisA _cA34 
 
closR1K1 
closR2K2 
nisRK 
This work  
pIL253_ClosCluster (ΔclosA) 
+pTG262_PnisA 
_closA3_closA4 
Test strain and control strain  
FI7847 pClosCluster 
(ΔcA) + 
p PnisA _cA34 
closR1K1 
closR2K2 
nisRK 
This work  
pIL253_ClosCluster (ΔclosA) 
+ pTG262_ PnisA 
control strain 
FI7847 pClosCluster 
(ΔcA) + 
p PnisA 
closR1K1 
closR2K2 
nisRK 
This work  
pIL253+ pTG262_ PnisA 
empty vector control strain 
FI7847 pIL253+ pPnisA nisRK This work  
 
Table 27 - A number of expression systems were designed in order to improve the clos cluster production in 
L. lactis UKLc10 or FI7847 host strains. pClos_pepI constructs were cloned in pIL253.  
a Strain in UKLc10 has the nisin two-component regulatory system, nisRK, on the chromosome. 
b The L. lactis MG1614 strain is plasmid free.  
c The L. lactis FI7847 strain is the FI5876 with the nisin biosynthetic machinery (nisin gene cluster) with the 
structural genes knocked out (ΔnisA). It has one set of nisRK genes in the nisin cluster.  
d The pPnisA _ cA34 construct has two different copies of clos structural genes (closA3 and closA4).  
 
Besides examining if the nisRK genes switch on the PClosA promoter when the clos cluster is 
incorporated on a plasmid in UKLc10 host strain, we want to understand if the expected 6 
kDa Clos prepeptide is modified by the clos biosynthetic machinery and finally if the 
modified prepeptide is released or it becomes trapped in the clos transporter machinery. The 
time for Clos prepeptide maximum production, after incubation with 10 ng/ml of nisin, was 
optimised. In order to confirm that the 6 kDa band is the result of the closA1-4 expression, a 
pClosCluster (ΔcA) in UKLc10 control strain with the clos structural genes knocked out was 
included. 
To achieve optimal expression and purification of the Clos (pre)peptide from Clos 
leader_Clos peptide, alternative expression hosts were used.  
Table 27 also highlights the presence of any lanRK regulatory genes. 
In pPnisA_cA34 construct, there are two copies of the clos structural genes that encodes for 
two structurally different peptides. Both closA3 and closA4 structural genes are expressed 
under the control of the nisin promoter, PnisA. It is expected that either a preClosA precursor 
(Clos leader_Clos peptide) or a leaderless Clos peptide would be expressed from this  
pPnisA_cA34 construct. 
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Figure 57 - Confirmation of the plasmids present in different L. lactis host strains. 
Agarose gel with to confirm the correct constructs in L. lactis MG1614 and UKLc10 strains. The gel bands are 
fragments obtained from plasmid digestion with HindIII.  
Colonies for pClosCluster strains are notated as T15/5 and T1/1, T1/2, T1/3 (lanes 1-4). 
Colonies for control pClosCluster (ΔcA) in UKLc10 strains are notated as T2/1, T2/2, T2/3 (lanes 6-8). 
Colonies for control pIL253 in UKLc10 strains are notated as T3/3 (lane 11).  
Reference strains used in here (Table 27) to verify the integrity of the clos cluster are as follows: 
pIL253 empty vector in MG1614, pIL253_ClosCluster in MG1614, pIL253_ClosCluster (ΔcA) in MG1614. 
M is a DNA gel marker (Hyperladder I).  
Expected masses for pClosCluster: 419bp+1066 bp = 1500 bp, 1430 bp, 5209 bp, 9162 bp and for pIL253 is 
1066 bp, 3897 bp.  
Agarose gel with the digested plasmids revealed that some transformants, like T1/2 and T1/3, 
were expected to have the 17 kDA insert. However, when they were restricted with HindIII, 
a different restriction profile which is specific to an empty vector control was obtained 
(pIL253 in MG1614, lane 10 as reference, Figure 57). The results indicate that the clos 
cluster is unstable, therefore the strain with the correct pattern carring with the 
pIL253_ClosCluster plasmid, was selected for further investigation. 
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 Detection of 6 kDa peptide from heterologous systems  
To investigate if secretion or intracellular accumulation of Clos precursor peptides from 
these strains (Table 27) can be detected after expression in L. lactis UKLc10 or FI7847, a 
number of tests were used.  
Different methods were used for the detection of a 6 kDa or a 3.5 kDa peptide:  
1) CMS, LC-MS and Maldi-ToF with colonies from plates or liquid culture,  
2) western blotting with two sets of samples against antiClos (closA1) leader antibody (cell 
extracts and TCA precipitated supernatant),  
3) excised protein gel bands (two sets of samples) were analysed by LC-MS. The cysteines 
were labelled with S-alkylators. The samples were trypsin digested (chapter 6) and we 
purified 6 kDa Clos peptide (3). The results are described in chapter 6. 
Previous work involving the expression in FI7847 should have allowed for the detection of 
a 6 kDa preClosA peptide or of a leaderless Clos peptide of 3.5 kDa provided that NisP 
cleaved the Clos leader peptide.  
In this work, the expression in UKLc10 should allow for production of a 6 kDa prepeptide 
and possibly of a 3.5 kDa proved that if intracellular or cytoplasmic unspecific protease 
activity in L. lactis does take place to remove the Clos leader peptide. Unspecific protease 
activity is known to occur in other lantibiotics such as in nisin and in subtilin [166].  
Further work involving the labelling of cysteine residues, trypsin digestion to obtain tryptic 
fragments, fragmentation and analysis on LC-MS and Maldi-ToF described in chapter 6, 
would allow us to investigate the efficiency of the clos modification machinery to introduce 
PTM. Similar to other lantibiotic leader peptides such as nisin, the Clos leader peptide is 
expected to facilitate dehydration of amino acids by ClosB and to guide the cyclization 
reactions as performed by ClosC, that is formation of (Me)Lan rings.  
To optimise the maximum production of Clos, pClosCluster in MG1614 and pClosCluster 
in UKLc10 strains were induced with 10 ng/ml of nisin and incubated overnight. Aliquots 
of liquid cultures were collected at time zero, after 2 h, 4 h, 6 h, 12 h after nisin induction of 
UKLc10 strains. For L. lactis MG1614 and FI7847, the cultures were harvested at time zero, 
2 h and 12 h. In a previous study [97], a 6 kDa band was detected by western blot from the 
MG1614 strain induced for 12 h, however despite attempts to replicate the test, no Clos 
peptide was detected in this work. Also, the identity of the 6 kDa peptide in the MG1614 
strain was not revealed by MS analysis which would be required to validate and to confirm 
Chapter 5 
   
176 
 
the presence of preClosA in the western blot. Both cell extracts and TCA precipitated 
supernatant were prepared for several strains listed in  
Table 27. It was previously shown that induction with nisin is sufficient for 2 h in a UKLc10 
strain [149], therefore it was expected that if Clos was produced in any of the strains, it 
would have hybridised to the antiClos leader antibody in the aliquots collected at the 2 h 
time point.  
 
Figure 58 - Detection of Clos in a protein gel and in western blot.  
A. 10 µg of cell extracts were prepared from pClosCluster in L. lactis MG1614 and UKLc10 strain previously 
incubated with nisin for T0, 2 h, 12 h before loading on SDS-PAGE.  
B. Western blot with antiClos leader antibody of cell extracts bead beaten from L. lactis strains. Same samples 
were loaded (10 µg of cell extracts) as in A.  
C. Western blot with 30 µg of cell extracts from pClosCluster in UKLc10 harvested from nisin induced liquid 
cultures for T0, 2 h, 4 h, 6 h and 12 h.  
The antibody was used at 1/100 dilution. All the cloned constructs were expressed in UKLc10 host strain unless 
otherwise stated. N means nisin; T0 negative control means that the liquid culture was grown for 12 h without 
nisin induction. The protein standards were M: SeeBluePlus2, Pre-stained Protein Standard.  
The protein gel in Figure 58, A, shows that a band for a 6 kDa peptide could not be easily 
visualised and that the cell extract contains a mixture of proteins. The western blots in Figure 
58, B-C, clearly shows that there is no equivalent 6 kDa peptide produced from pClosCluster 
+ pPnisA_ cA34 in MG1614 strain negative control after induction with nisin for either 2 h or 
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12 h. In here, the 6 kDa peptide was not identified in a western blot from the same MG1614 
strain after 12 h incubation with nisin.  
The pClosCluster in L. lactis UKLc10 strain successfully produced a 6 kDa peptide as 
detected by hybridisation with the antiClos leader antibody (Figure 58, B-C) that should 
have hybridised to the Clos leader_ClosA1 peptide. This band was later confirmed by MS 
as being the precursor preClosA1 peptide (chapter 6). The bands in the western blot 
confirmed that the size of the secreted Clos peptide was approx. 6 kDa, which matches the 
size of the expected preClosA precursor peptide of 57 amino acids (excluding the N-terminal 
methionine residue). Detection was from cell extracts prepared from liquid cultures that were 
previously induced with nisin for 2 h, 4 h, 6 h but not for 12 h. The absence of a detectable 
preClosA peptide may suggest that the preClosA is only stable up to 6 h and maybe it is 
degraded after 6 h of being induced with nisin.  
Results in Figure 59 shows that a 6 kDa band of the expected size for preClosA can be 
detected from both samples pClosCluster and pClosCluster + pPnisA_ cA34 in UKLc10 
strains. This band was detected both inside the cell from the cell extracts as well as in the 
media in the TCA precipitated supernatant. This means that a proportion of the 6 kDa peptide 
is trapped within the cell as well as another proportion is secreted in the medium.   
The pClosCluster (ΔcA) + pPnisA_ cA34 in MG1614 strain has the closA structural genes 
knocked out; a 6 kDa peptide would be detected if ClosA34 proteins was biosynthesised. 
Since the NisRK proteins are absent, it was suggested that ClosR binds to PnisA to allow for 
expression of ClosA34 proteins. Consequently, only the mature ClosA34 proteins may act 
as an inducer which will activate the clos promoters to allow for the clos modification and 
transport machinery to become functional.  
These preliminary western blot results (Figure 58, Figure 59) confirmed that nisin-mediated 
activation of transcription of the clos genes involve signal transduction by the two-
component regulatory system (NisRK). A control with pClosCluster in UKLc10 without 
nisin was also included (Figure 58, sample at T0). Current results would indicate that there 
is no confirmation of the extent to which either or both ClosR1 and ClosK1 and/or ClosR2 
and ClosK2 proteins are involved in the activation of the closA transcription. Therefore, 
further testing would be necessary.   
The strain known as pClosCluster in FI7847 was designed to incorporate both the clos and 
the nis gene biosynthetic machinery. The aim was to have a system in which the nisRK genes 
and the nisP genes are present on the nisin cluster. This strain would facilitate the activation 
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of clos promoters and the possible cleavage of the Clos leader by the nisin protease. The clos 
cluster was expressed in the FI7847 host strain, however no form of a Clos peptide was 
detected after induction with 10 ng/ml of nisin; the cells were harvested after induction with 
nisin for 2 h and for 12 h. 
 
Figure 59 - TCA precipitated supernatant and cell extracts (CE) from clos cluster containing strains.  
The strains were induced with nisin for 3 h before harvesting unless specified otherwise. The legend of strains 
(all strain are in UKLc10 unless specified otherwise):  
pClosCluster (ΔcA) + pPnisA_ cA34 in MG1614,  
pClosCluster + pPnisA_ cA34 in UKLc10,                .  
pClosCluster in UKLc10, closR1K1 and closR2K2 genes in the clos gene cluster. The nisRK genes are on the 
chromosome of the UKLc10. 
M is SeeBluePlus2 marker in kDa. 30 µl of cell extract (CE) of total protein was loaded. 
To be noted that an inactive ClosA34 protein would not work an inducer in pClosCluster + pPnisA_ cA34 in 
UKLc10 strain.  
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Figure 60 - Proposed mechanisms for signal transduction in different strains where the clos cluster is expressed 
on a plasmid.  
The legend is:  
1. pClosCluster in MG1614, with no nisRK genes; mechanism based on western blot (Table 25). 
2. pClosCluster in MG1614, with no nisRK genes; mechanism is based on previous western blot results [97]. 
3. pClosCluster + pPnisA_ cA34 in MG1614, with no nisRK genes; mechanism is based on the assumption that 
closRK genes are working as suggested by previous work [97]. In this work, no band for a 6kDa peptide was 
detected in western blot [97]. 
4. pClosCluster in FI7847, with nisRK genes and two sets of the closRK genes.  
Bands detected for 6 kDa preClosA peptide (Figure 62).  
5. pClosCluster + pPnisA_ cA34 in FI7847, with nisRK genes, two sets of closRK genes.  
Proposed mechanism if all the regulatory genes mediate clos transcription.  
No band was detected in western blot in this work.  
6. pClosCluster + pPnisA_ cA34 in UKLc10, with nisRK genes, two sets of closRK genes. Proposed mechanism 
only if nisRK genes regulate transcription. 
Bands detected for 6 kDa preClosA peptide.  
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Figure 61 - Proposed mechanisms for signal transduction in different strains where the clos cluster is expressed 
on a plasmid.  
The legend is:  
7. pClosCluster + pPnisA_ cA34 in UKLc10, with nisRK genes and two sets of closRK genes. 
Proposed mechanism if all the regulatory genes mediate clos transcription. Bands detected for 6 kDa preClosA 
peptide. 
8. pClosCluster, in UKLc10, with nisRK genes, two sets of closRK genes.  
Proposed mechanism only if nisRK genes regulate transcription. Bands detected for 6 kDa preClosA peptide. 
9. pClosCluster, in UKLc10, with nisRK genes, two sets of closRK genes.  
Proposed mechanism if all the regulatory genes mediate clos transcription. Bands detected for 6 kDa preClosA 
peptide. 
 
Figure 60 and Figure 61 are illustrations of the proposed mechanisms for signal transduction 
which are based on the results from the western blot obtained in current and previous work 
(for MG1614 strains).  
The results from the western blot in Figure 62 indicated that a very faint band for a 6 kDa 
peptide expressed by pClosCluster in the FI7847 was detected when probed with the antiClos 
leader antibody. However, as for the other strains, the specificity of the antibody was 
unknown and further MS analysis would be required to confirm the identity of the preClosA 
peptide. A 6 kDa band was detected only in the TCA precipitated supernatant (Figure 62).  
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UKLc10 strains FI7847 strains 
pClosCluster (CE) in UKLc10 
pClosCluster  + pPnisA_ClosL_A34  (CE)  
pClosCluster (CE) in FI7847 
pClosCluster(ΔcA)  + pPnisA_ClosL_A34  (CE) 
pClosCluster (TCA) in UKLc10 
pClosCluster + pPnisA_ClosL_A34 (TCA)  
pClosCluster (TCA) in FI7847 
pClosCluster(ΔcA) + pPnisA_ClosL_A34  
Figure 62 - Western blot to test for the presence of the 6 kDa peptide, potentially the preClosA peptide, in cell 
extracts and TCA precipitated supernatant of constructs expressed in L. lactis UKLc10 or FI7847 host strain.  
Tested strains were listed in the table. The strains were grown and the samples were prepared as described in 
chapter 2; expression of the preClosA peptide was induced with 10 ng/ml of nisin for 3 h at 30◦C unless 
otherwise specified. CE is cell extract of total protein and 30 µg/ml were loaded. Western blotted with 1/100 
dilution with the antiClos leader antibody. M is SeeBluePlus2 marker in kDa. 
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Results in Figure 62 indicate the successful expression of a number of peptides in the 
UKLc10 strains. Based on the very high intensity of the bands, the peptide was produced in 
very good yield in both inside and outside the UKLc10 strains. However, from the current 
results it is not possible to suggest if this 6 kDa peptide is preferentially located either inside 
or outside the cell.  
In comparison to the samples in L. lactis UKLc10, FI7847 only showed a faint band and the 
western blot was prepared to compare the two strains. The potential expression of a 6 kDa 
peptide from pClosCluster in FI7847 strain is interesting. Only a 6 kDa protein band from 
the TCA precipitated supernatant could be detected from this strain which means that this 
peptide did not exclusively accumulate inside the cell or the peptide was secreted outside the 
cell. The pClosCluster construct in FI7847 would produce a preClosA peptide if the closA1-
4 structural genes were expressed. The observed poor yield may be due to the instability of 
the 17 kb clos cluster itself since it is expressed in a strain that already has the nisin gene 
cluster in. In contrast, no 6 kDa peptide was expressed by pClosCluster(ΔcA) + pPnisA_ 
closLeader_closA34 in UKLc10 strain. A 6 kDa peptide would be synthesised from this 
strain provided that the activated PnisA promoter would allow the expression of the closA34 
genes in the presence of the nisRK regulatory system.  
In conclusion, a 6 kDa peptide was identified in both TCA precipitated supernatant and CE 
from UKLc10 strains that hybridised to the antiClos leader antibody.  
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 Biological activity of trypsin cleaved preClosA peptides 
Earlier results in this chapter suggested that the preClosA peptide was expressed in broth 
culture and it was detected both in the cell extract and in the supernatant of a strain where 
the clos cluster functionality is under the control of nisRK regulatory system.  
The lack of proteases in the clos operon would suggest that a modified precursor peptide 
with the leader still attached could be produced in the UKLc10 heterologous system. The 
hypothesis is that external proteases are necessary for the cleavage of the leader peptide in 
order to obtain functional active Clos peptide.   
To investigate this hypothesis, the pClosCluster in L. lactis UKLc10 strain was grown on an 
agar plate and induced with nisin to allow for the biosynthesis of the preClosA peptide. The 
fact that colonies did grow on the solid media in the presence of inducible nisin did suggest 
that the clos immunity genes must also be expressed in agar cultures along with the other 
clos genes, therefore the Clos prepeptide was expected to be present on the plate.  
After colonies were grown on plates, they were treated with UV light, then they were 
overlaid with soft agar in which different indicator strains as well as various trypsin 
concentrations were added. Two different sources of trypsin were used: trypsin in a mix and 
pure trypsin from a kit at concentrations from 0 to 15 ng/µl. Consequently, a mixture of Clos 
tryptic peptides is predicted to be formed on the plates with trypsin. Colonies grown on plates 
overlaid with trypsin displayed antimicrobial activity against C. perfringens, C. difficile and 
L. lactis MG1614 indicator strains (Figure 63). Control plates overlaid with indicator strains 
but without trypsin were included and the results confirmed that antimicrobial activity was 
only possible if preClosA was digested with trypsin. This suggested that a 6 kDa preClosA 
does not display antimicrobial activity since the Clos leader is still attached. However, after 
trypsin digestion the resulting full length leaderless Clos or the tryptic peptides displayed 
antimicrobial activity against the tested sensitive strains.   
A number of other indicator strains were also tested, however the tryptic fragments were 
obtained by using a trypsin concentration between 1 to 15 ng/µl of trypsin. The nisin positive 
control strain was expected to produce a leaderless nisin peptide, therefore it displayed 
antimicrobial activity in plates with and without trypsin. Interestingly, even if nisin must 
have also been digested by trypsin, the resulting nisin tryptic peptides accumulated in high 
enough concentration to display biological activity against all the tested indicator strains. It 
may be that trypsin has been used at a concentration that has only allowed for the partial 
cleavage and the release of specific nisin fragments.  
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At higher trypsin concentrations, trypsin may have facilitated the accumulation of specific 
peptide that have biological activity. However, in the case of the indicator strains where 
antimicrobial activity from Clos fragments was not detected, a higher amount of Clos may 
facilitate the release of the active fragments if tested in the future.  
Interestingly, the closA gene expression was confirmed and the bioactivity that resulted after 
trypsin digestion of preClosA on the plate was significantly increased in a dose-dependent 
fashion which can be especially seen in the plates with L. lactis MG1614 (Figure 63). This 
observation was made by comparing the increase in the zone of inhibition given by raising 
amounts of trypsin. It was therefore concluded that increasing the trypsin concentration in 
the overlaying soft agar may facilitate the complete digestion of preClosA and the full 
accumulation of active Clos tryptic peptides. 
The biological activity obtained from trypsin treated preClosA follows the same trend when 
tested against L. lactis MG1614 as with the Clostridiales species. The biological activity 
increased until 10 ng/µl of trypsin, then it decreased at 15 ng/µl against C. perfringens. For 
C. difficile, the bioacitivity is high until 5 ng/µl of trypsin then it decreased with 15 ng/µl.  
The highest antimicrobial activity displayed by tryptic peptides was seen in plates tested 
against C. perfringes. Antimicrobial activity was compared between plates where the nisin 
positive control (nisin in FI7827) and the negative controls (no trypsin plates) were included. 
Results indicated that both Clos and nisin can be digested with trypsin to give a series of 
tryptic peptides that display biological activity when screened in overlay assay against C. 
perfringens and C. difficile as well as L. lactis MG1614.  
Trypsin was not killing the indicator strains since activity can only be observed around the 
growing cells and nisin and/or Clos production and not on the whole plate. Future work may 
involve to design of a good system to follow the time course cleavage of nisin and Clos 
peptides in solution or in on the plate.   
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Figure 63 - Overlay assay of L. lactis strains against A. C. perfringens, B. C. difficile, C. L. lactis MG1614  
indicator strains.  
These pictures are a representative image of three independent overlay assays. 
The samples were: pTG262_nisA in FI7847 (positive control), pClosCluster in UKLc10 strain.  
Negative control strains (C1, C2, C3): pClosCluster (ΔcA) and pIL253 in UKLc10, UKLc10 strain alone, 
respectively. Colonies were grown on solid agar with NaHCO3, and 10 ng/ml of nisin in order to induce clos 
and nis expression. The assay was overlaid with indicator strains and with different amounts of trypsin from 
two sources: 1 or 5 ng/µl of pure trypsin or 1, 5, 10 or 15 ng/µl of trypsin from a Promega, Mass Spec Grade 
kit. Negative control plates with no trypsin was also included. P means pure trypsin stock from kit. S means 
trypsin stock from Sigma. NaHCO3 was used to prevent non-specific antimicrobial peptide activity. 
Both the nisin and the clos tryptic peptides were active against the tested indicator strains.  
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5.4 DISCUSSION  
In this chapter, fusions of the closA structural genes to the nisin A leader peptide were 
expressed and a putative cleavage site for the NisP protease was created. All the constructs 
were cloned in L. lactis and they were tested to investigate the possible expression and 
modification of active Clos peptide by suing the the nisin biosynthetic machinery. 
Several studies reported the successful production and characterisation of novel lantibiotics 
using fusions of nisin leader and structural gene sequences and the biosynthetic machinery 
of nisin [93, 165]. Based on a recent example [169] and in order to overcome problems with 
the functional expression of NisP, the native nisin leader cleavage site was engineered in 
nisin leader_clos hybrids to resemble the one in nisin. Despite the introduction of the NisP 
cleavage site, the expression, modification, leader peptide cleavage and the transport of an 
active Clos peptide from nisin leader_clos fusions were not possible for a number of reasons.  
A survey of literature suggested that the nisin leader peptide is capable of guiding and of 
inducing PTM via NisB and NisC. Dehydrated amino acids and the ring formation 
(cyclization) reactions were therefore expected to take place in Clos provided that the 
expression of the nisin leader_clos hybrids was efficient in the first instance. Despite the fact 
that the engineered nisin leader is known to have mutational freedom [169] and induction of 
preClosA biosynthesis should be possible, accumulation or secretion of the Clos peptides 
was not detected by Maldi-ToF.  
The nisin leader plays a role in mediating the interaction with the NisT in the export of nisin. 
An intact nisin leader peptide is essential for NisB and NisC modification as it determines 
the substrate recognition and specificity of the two nisin modification enzymes [170]. The 
nisin leader is responsible for the functional binding of both enzymes; it also targets the 
substrate peptide to the NisT dedicated nisin transporter [165, 168]. NisT can transport 
different forms of nisin outside the cell such as fully modified, dehydrated as well as 
unmodified precursor nisin peptide or hybrids of nisin leader fused to lantibiotic or non-
lantibiotic peptides [78]. Either of the three enzymes bind to their substrate (various nisin 
forms) with different affinities which explain the variation in the extent of modifications 
[165]. Unfortunately, in this project the nisin machinery was not able to biosynthesise any 
detectable form of the Clos peptide.  
Van Heel et al. [165, 169, 171] have successfully produced modified active peptides by 
using a similar approach when testing the nisin leader hybrids. Therefore, the nisin 
expression and modification machinery have been shown to be functional when fusions of 
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the nisin leader peptide to the clos structural gene are expressed in a L. lactis host strain. The 
study suggested that when the original nisin leader cleavage site was used the expression of 
functional peptides was enhanced. In here, in order to overcome the challenge that the clos 
cluster may be a silent operon, the coding sequence of the lantibiotic core peptide was 
previously fused to the nisin leader peptide with two potential start sites: IE or YK [97]. 
Also, to address the issue with a non-compatible cleavage site, a novel NisP cleavage site 
was also created by introducing the IT mutation to substitute the IE and the YK start sites of 
the Clos core peptide.  
Aminoacid substitution in the N-terminus of lantibiotics can be detrimental for their 
antimicrobial activity. Therefore, it is of utmost importance to correctly predict the end of 
the candidate leader peptide as well as the start of the candidate core peptide. Alternatively, 
additional modifications that take place in the original structure of the core peptide might be 
essential for rendering an active Clos peptide and may explain the lack of detection of Clos 
in this work. In the case of Clos, it may be possible that modifications can only be facilitated 
and guided by the original Clos leader peptide and not by the nisin leader. 
The nisin modification machinery has a broad substrate tolerance [165, 172]. One 
explanation for the lack of preClosA could be explained by the partial incompatibility with 
the nisin modification system used in this work. Therefore, future work may involve to 
express both the nisin leader and closA1 (IE or YK) as well as closA4 hybrids into the same 
heterologous system. Structure comparison of the clos cluster with other lantibiotics would 
suggest that ClosA peptides are possibly part of a two-component system. Expression and 
antimicrobial activity would therefore require the presence of both ClosA1 and ClosA4 
peptides.  
In a study by Majchrzykiewicz et al. [173], a novel class II two-component lantibiotics 
which is not a homologue of nisin was biosynthesised using fusions to the nisin leader 
sequence. The peptides were produced by the nisin machinery, fully modified (dehydrate 
serine and threonine residues, lanthionine rings were introduced) and the biologically active 
peptides were secreted.  
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Another task of this chapter was to investigate if Clos production can be improved when the 
entire clos gene cluster is expressed in different host strains. Based on the pepI activity assays 
in chapter 4, the activation of PClosA is mediated by nisin induction and it involves the signal 
transduction by the nisin two-component regulatory system composed of NisR and NisK 
proteins.  
In chapter 4, an increased specific pepI activity under the control of PClosA promoter was 
confirmed when induced with nisin which means that an external signal peptide like nisin 
could initiate transcription particularly of the closA structural genes. Therefore, in this 
chapter, the assumption was that if the entire clos gene cluster was expressed in the presence 
of nisRK genes, the PClosA would be activated by the phosphorylated NisR. If correct 
transcription activators were present, the other promoters may be switched on in order to 
allow for the biosynthesis of the preClosA peptide. Based on the current results, the nisRK 
genes may be essential for the good production of the intermediate Clos peptide, when the 
strain is induced with nisin.  
In this chapter, in order to design an improved heterologous expression system that would 
allow for the production of Clos in higher yield and in order to achieve optimal expression 
and purification of preClosA, several host strains (L. lactis FI7847 and UKLc10) were used 
to clone the clos cluster. The L. lactis UKLc10 strain has the nisin two-component regulatory 
system, the nisRK genes, integrated on the chromosome. FI7847 is comprised of the nisin 
biosynthetic machinery (nisin gene cluster) with the structural gene knocked out (ΔnisA) and 
the nisRK genes present in the nisin gene cluster. 
A western blot with the antiClos leader antibody of the strain pClosCluster(ΔcA) + pPnisA_ 
ClosLeader_closA34 in FI7847 did not indicate presence of any specific bands, however the 
antibody did successfully hybridise to a 6 kDa peptide in the UKLc10 strain that contained 
the same construct. The precursor Clos peptide was not detected in a western blot or in MS 
when it was expressed in FI7847 strains. This means that even if the PnisA was switched on 
by nisin via the nisRK genes, the inducing signal was not strong enough to allow for the Clos 
leader_ closA34 prepeptide to be synthesised or the product was not stable. Nevertheless, the 
UKLc10 strain allowed for the successful biosynthesis of the preClosA peptide in high yield 
as well as for the export and its detection after induction with external nisin.  
The two pClosCluster and pClosCluster(ΔclosA)+ pPnisA_ ClosLeader_closA34 constructs 
in FI7847, were expressed under the control of both nisRK and closRK sets of two-
component regulatory system. However, the structural genes are located either on the clos 
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cluster or on a plasmid which could have an important impact on the expression efficiency. 
An extremely faint band for a 6 kDa band was detected in the western blot for the 
pClosCluster in FI7847 strain. This suggests that even though the background for the two 
constructs in FI7847 is the same (+/- closA34), the location and the copy number of the 
structural genes are important. Detection of the peptide was only possible in the TCA 
precipitated supernatant perhaps due to lower production or even degradation. It may be that 
the competition between the promoters prevented the accumulation of the preClosA peptide 
to reasonable detectable levels compared to other positive controls.   
The absence of a 6 kDa band in the pClosCluster(ΔcA)+pPnisA_ClosL_ cA34 may be due to 
either the location of the structural genes or the poor Clos production in this host strain. 
Another possibility would be that the Clos leader may have been cleaved by NisP and a 3.5 
kDa band for the leaderless Clos peptide could not hybrise to the antibody. To test this, gel 
slices were excised and they were subject to LC-MS, however no proteins were detected 
which confirmed that this scenario was not possible. The idea of expressing pClosCluster in 
the FI7847 host strain was based on the presence of the NisP protease on the nisin cluster. 
In contrast, the clos cluster in the UKLc10 host strain does not encode for a similar protease.  
It is known that the PnisR promoter displays nisin-independent and constitutive traits to allow 
for a fast accumulation of immunity to protect the producer against the effect of its own 
AMP [8, 146]. In FI7847, the nisRK genes are expressed continuously which should mediate 
the activation of the PClosA promoter in the clos cluster by induction with nisin. Therefore, 
the extracellular nisin should have enhanced the nisRK expression as part of the nisin operon 
to amplify the response triggered by nisin even further in any L. lactis FI7847 strain. 
However, the presence of two gene clusters, clos and nis, may not have been tolerated well 
by the hosts. One possibility is that the clos cluster may be unstable if cloned in strains with 
other plasmids or gene clusters already in.  
A survey of the literature suggests that the biosynthesis of some lantibiotic peptides is 
possible through a quorum sensing process [8, 83, 146]. Therefore, the clos cluster/Clos 
peptide may regulate similar phenotypic traits in the bacterial host strains and the Clos 
peptide may be a typical lantibiotic peptide that acts both as an inducing pheromone as well 
as an antimicrobial peptide. However, this is yet to be investigated in detail. The expression 
of a 6 kDa band was successfully confirmed in the UKLc10 strains from either the 
pClosCluster or pClosCluster+ pPnisA_ ClosLeader_closA34 constructs.   
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In this chapter, successful cleavage and detection of antimicrobial activity from active Clos 
tryptic peptides was demonstrated. The level of antimicrobial activity of the tryptic peptides 
against three tested indicator strains was similar when concentrations of 1 to 5 ng/µl of 
trypsin was used. Previous work on the Blautia obeum A2-162 indicated that antimicrobial 
activivity against C. perfringens was possible however it was not established if it was 
because of the Clos peptides [97].  
In here, the trysin treated preClos peptides were responsible for the observed antimicrobial 
activity against C. perfringens and for the first time good biological activity against C. 
difficile and L. lactis MG1614 was also confirmed.  
10 ng/µl of trypsin was a good concentration to give a big enough halo against C. perfringens 
whereas for C. difficile the biggest zone of inhibition was given by treatment with 5 ng/µl of 
trypsin. The antimicrobial activity from trypsin digested preClosA and nisin seemed greater 
and more reliable when tested against C. perfringens at 1-15 ng/µl of trypsin; at 1 ng/µl of 
trypsin there was a very big halo which means that at very low trypsin concentration, C. 
perfringens is more sensitive against the released Clos peptides compared to the other tested 
indicator strains. Further testing for antimicrobial activity should include the use of a pure 
stock of trypsin. These test would allow us to make more accurate comparison between 
plates with different indicator strains as well as test for the reproducibility of their biological 
activity. Compared to the nisin positive control, the antimicrobial activity from digested 
preClosA was slightly lower at any given trypsin concentration.  
However, an increasing amount of trypsin allowed for the accumulation of completely 
digested tryptic peptides, therefore the size of the halo increased proportionally. Since we 
do not have the molecular tools to manipulate bacterial strains isolated from the GI tract, the 
well described and developed L. lactis UKLc10 system used in this project can be 
manipulated to further investigate the functionality of the clos cluster [24, 174, 175].  
Similarly, heterologous expression, biosynthesis, and mutagenesis of type II lantibiotics 
from Bacillus licheniformis in E. coli was previously reported. A type II two-component 
lantibiotic, linchenicidin was heterologously expressed in a Gram-negative host, E. coli 
which also allowed for the further engineering and characterisation of the leaderless and 
active lantibiotic peptides [176]. 
The heterologous expression of a two-component, lanthionine-containing bacteriocins 
produced by L. lactis and E. faecalis, respectively, lacticin 3147 and cytolysin, was done in 
E. faecalis host strain. Only the lacticin 3147 biosynthetic machinery was successfully 
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heterologously expressed in the host strain to allow for the production of the lantibiotic with 
no haemolytic activity [175]. The use of a heterologous expression system allowed the 
mechanism of regulation for lacticin 3147 to be studied [177]. Similar to the work with 
lacticin 3147, in this study it was decided to investigate the expression system for clos by 
expressing the whole clos cluster in a L. lactis system which is more detectable and for which 
the molecular tools are known.   
Bibb et al. [23] have reported the identification, heterologous expression and 
characterisation of several gene clusters that encode for novel lantibiotics that are regulated 
differently. Some of the heterologous expression systems were excellent molecular tools for 
the functional analysis of the genes in the cluster.  In the absence of a dedicated LanP 
protease from the gene cluster that removes the leader peptide from microbisporicin, the 
Nonomuraea expression host strain allowed for the biosynthesis of a mature lantibiotic 
peptide since it also had the role for production of a general protease that successfully 
removed the leader peptide from the precursor [24]. The gene cluster for microbisporicin 
encodes for a number of putative regulatory proteins, such as ‘an extra cytoplasmic function 
(ECF) σ factor, σMibX, a likely cognate anti-σ factor, MibW, and a potential helix-turn-
helix DNA binding protein, MibR’. A model for the regulation of the biosynthesis of 
microbisporicin was proposed which was based on Maldi-ToF and qRT-PCR [23, 124].  
In conclusion, in this chapter, a Clos peptide was successfully expressed in a L. lactis 
heterologous system and novel antimicrobial activity against two important pathogens was 
demonstrated.  In the future, the aim would be to isolate the tryptic peptides obtained from 
cleaved of preClosA, characterise their biological activity and test the peptides for their 
potential use as inducers of the Blautia obeum A2-162 system. We have successfully showed 
the improved expression of biologically active Clos peptide and in the next chapter pure Clos 
peptide will be obtained and its structure will be confirmed.  
 
 
 
 
 
 
 
 
  
 
 
 
 
CHAPTER SIX 
 
6.  Structure confirmation of the 
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6.1 INTRODUCTION 
The clos cluster is comprised of four clos structural genes: three are identical except for 
their Clos leader peptide (ClosA1 leader + ClosA1 core peptide, ClosA23 leader + 
ClosA23 core peptide) and the fourth is a unique peptide (ClosA4 leader + ClosA4 core 
peptide) (Figure 64). In here, preClosA1-3 and ClosA1-3 were referred to as preClosA1 
(there is 1 amino acid difference in the leader peptide) and ClosA1 respectively, unless 
otherwise stated. The biosynthesis of the active clos cluster is illustrated in Figure 64 and 
it was predicted to involve the expression of a linear preClosA peptide and the 
introduction of modifications such as dehydration of serine and threonine residues and 
the subsequent ring formation between the dehydrated amino acids and the cysteine 
residues.  
Figure 64 illustrates the proposed steps for the biosynthesis of preClosA peptides which 
is based on comparison to other lantibiotic peptides [63, 69].  
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A.  
B.  
Figure 64 - Illustration of the predicted structure of preClosA and the steps for its biosynthesis: (A) 
preClosA1, (B) preClosA4.  
ClosA1 leaderless peptides have the same sequence. However, only the sequences of the leader peptides 
for ClosA2 and ClosA3 are identical. The ClosA1 leader peptide has a G instead of an A after the first 
methionine amino acid. 
Black arrows show two putative leader cleavage sites for ClosA1 and for ClosA4 as hypothesised by 
Hatziioanou [97].  
The legend for the steps involved in the biosynthesis and the PTM of preClosA peptides is as follows:  
1. Linear preClosA precursor peptide; the amino acids that will be dehydrated by ClosB are in red 
(serine) and in blue (threonine). Highlighted in red are also the threonine residues that are not 
being modified by ClosB as hypothesised by Hatziioanou  [97]. 
2. Linear peptide with dehydrations in to make dehydroalanine (Dha) and dehydrobutyrine (Dhb). 
3. The blue arrow highlights the amino acids that are involved in the (Me)Lan ring formation.  
4. PreClosA precursor peptide with dehydrations and rings formed.   
5. Leaderless and active Clos peptide with dehydrations and rings formed. 
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The predicted structure of the preClosA peptides is based on the comparison to the nisin 
lantibiotic peptide since clos has high sequence homology to nisin. The predicted start 
site for the ClosA1 peptide is either IE or YK (Figure 64, A), whereas the start site for 
ClosA4 could be IP or more likely IT (Figure 64, B) as highlighted by the black arrow. 
The sequence of ClosA1(IE), with IE as start site, would give a lantibiotic which is 3 - 4 
amino acids longer than nisin. The ClosA1(YK) peptide, with YK start site, would have 
the same size as nisin but with a leader peptide that has a different C-terminal sequence. 
The unique ClosA4 peptide with an IT start site would be of a similar length to nisin; the 
PRIT amino acid sequence in ClosA4 is common to other lantibiotics such as nisin, 
epidermin and staphylococcin T [97, 161, 169, 178]. 
The hypothesis was that the clos machinery introduces PTM in the preClosA peptides. 
Therefore, the aims of this chapter are to purify and to identify the preClosA peptides, to 
determine the structure of different forms of the preClosA peptide and to investigate their 
PTM. In order to investigate this, mass spectrometry analyses were performed on gel 
slices and pure concentrated Clos peptides produced by immunoprecipitation (IP) from 
an L. lactis strain encoding for the clos cluster using the heterologous system described 
in chapter 5. LC-MS provides highly accurate mass, and after trypsin digestion, there is 
also information about Clos peptide identity and its sequence.  
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6.2 MATERIALS AND METHODS  
 Small scale IP purification of preClosA peptide using antibody antigen 
method  
The pClosCluster in L. lactis UKLc10 strain was selected for the scaled up production 
and purification of Clos peptides. For the IP reaction, named WB2 (Table 28) the 
pClosCluster+pPnisA_ cA34 in UKLc10 strain was selected. The strain was grown to 
OD600 of 0.5, then it was induced with 10 ng/ml of nisin for 3 h at 30˚C before harvesting 
to prepare cell extracts. Cell extracts and cell-free medium samples were prepared and 
used as the starting material for preparation of the 6 kDa preClosA peptide. The Thermo 
Scientific Pierce IP Kit was used to obtain purified Clos peptide as described in sections 
2.4.6 and 2.5.   
At first, a few small scale immunoprecipitation (IP) reactions were performed to optimise 
the purification steps. The optimisation included the testing of different ratios of 
antigen/antibody (Ab/Ag) and the use of crosslinking (DSS) to immobilize the antiClos 
leader antibody to the Protein A/G agarose resin. Two types of samples were used as 
starting material for the IP reactions: 1. cell extracts in 0.025 M Tris HCl, pH 7.4 buffer 
or in IP Lysis/Wash buffer from the kit, both in the presence/absence of a protease 
inhibitor cocktail; 2. cell-free culture supernatant.  
Aliquots of all flow through and elution fractions were collected at every stage of the 
purification process and the presence of the Clos peptides was visualised by western 
blotting as described in section 2.4.5. In addition, Maldi-ToF MS and LC-MS were used 
to monitor the purification and the elution of Clos from the resins. 
After the ratio of antibody to antigen was adjusted (based on the rough estimation that 3 
mg of antibody can bind approx. 200 µg of Clos), a large amount of Clos was purified in 
one scaled up IP reaction performed with cell extract (0.025 M Tris HCl, pH 7.4 buffer). 
Again, aliquots of the fresh starting material and any collected fractions were analysed 
by western blotting and MS to detect the preClosA peptide.  
Some of the final eluted fractions still contained detergent from the buffers in the kit, and 
they were therefore re-purified on C8 cartridges (HyperSep). The preClosA peptide was 
eluted from the cartridge with steps of increasing concentrations of acetonitrile (in 
increments of 10 %) in 0.1 % formic acid (see section 2.5). 
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Name of 
experiment 
Details of buffers and protocol 
WB1 CE in 0.025 M Tris HCl pH 7.4 as cell 
extraction buffer  
pClosCluster in UKLc10 (50 ml 
culture) 
1 ml of CE (~15-20 mg) + 100 µl of Ab 
(¬3000 µg of total protein) incubated 
overnight at 4◦C while vortexing.  
50 µl of slurry (resins) incubated overnight 
in a falcon tube at 4◦C while vortexing.  
Expect: antibody antigen complex to elute.  
 
WB2 CE in 0.025 M Tris HCl pH 7.4 as cell 
extraction buffer  
pClosCluster+pPnisA_ cA34 
in UKLc10 (50 ml culture) 
WB3 CE in 0.025 M Tris HCl pH 7.4 as cell 
extraction buffer (650 ml culture) 
WB4 CE in 0.025 M Tris HCl pH 7.4 + 
protease inhibitors as cell extraction 
buffer (650 ml culture) 
WB5 CE in IP Lysis + protease inhibitors as 
cell extraction buffer (650 ml culture) 
WB8 1 ml cell free medium   1 ml cell free (no cell extract/no TCA) 
adjusted to pH 7.4 mixed with 0.2 % NP-40 
+ 100 µl Ab  
Incubated overnight at 4◦C, vortexing  
WB9 a CE in 0.025 M Tris HCl pH 7.4 as cell 
extraction buffer (650 ml culture) 
No crosslinker   
Same protocol as for WB1 to WB5   
Expect: pure Clos to elute.  
WB9 b   
Big reaction  
Scale up  
CE in 0.025 M Tris HCl pH 7.4 as cell 
extraction buffer (4 x 650 ml culture) 
With crosslinker   
1 ml of slurry (500 µl of resin) + 0.5 ml 20 
x coupling buffer + 2 ml antibody (¬64 mg 
total protein) + 6.5 ml UPH2O, incubating 
for 2 h vortexing; 
Put on column and wash a few times: 1 ml 
of 1 x coupling buffer and 2 x 3 ml of 1x 
coupling buffer;  
Use 1 ml of 2.5 mM DSS and add 3.75 ml 
water and 250 µl of 20 x coupling buffer to 
5 ml total volume (for crosslinking); 
Mix in the column and incubate;  
Spin and wash the column with elution 
buffer and IP Lysis/Wash buffer; 
Add 20 ml of Clos cell extract  
(approx. 300 mg total protein) in 0.025 M 
Tris HCl pH 7.4, incubate overnight in 
falcon tube, vortexing; 
Recover the mix and place back in the 
column, wash with IP Lysis and 1 x 0.025 
M Tris HCl pH 7.4 and conditioning buffer. 
Elute with 5 x 0.5 ml elution buffer. 
Expect: ~200 µg of Clos to elute. 
Table 28 - Details for small scale IP reactions with/without crosslinker, different extraction buffers were 
used; one large scale IP reaction with crosslinking. CE is cell extract. Ab is antibody, DSS crosslinker is 
from the IP kit.  
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For the small scale IP reactions, the same protocol as in the manufacturer’s instructions 
was used unless otherwise specified. For experiments WB1 to WB5 and WB8 no 
crosslinker was used so an Ab-Ag complex is expected to elute from the small scale IP 
reactions. WB9a is a small scale reaction with crosslinker and WB9b is a scaled up IP 
reaction; only purified preClosA, not in a complex, is expected to elute because of using 
the crosslinker. 
 Large scale IP purification of preClosA peptide  
Large scale IP purification of preClosA was performed in order to isolate the peptide in 
high yield, and to identify preClosA, for activity measurements of preClosA in solution 
and to understand PTM introduced by the clos machinery in the preClosA peptide. 
Based on previous estimations on the optimal antibody antigen ratios, a large scale IP 
reaction experiment was designed (Table 28). The cell extract was prepared in 0.025 M 
Tris HCl, pH 7.4 using the DSS crosslinker as follows: 1 ml of slurry (500 µl of resin) 
was first incubated with coupling buffer and 2 ml of antibody (¬64 mg total protein) and 
water for 2 h, vortexing in order to allow for the binding to occur. The mix was loaded 
on a column, washed and the crosslinking reaction was set up by incubating 1 ml of 2.5 
mM DSS crosslinker with coupling buffer and water up to 5 ml total volume. The mix 
was incubated for several hours on a column, then washed. Next, the crosslinked antibody 
coated resins were vortexed with 20 ml of Clos cell extract (¬ 300 mg total protein) in 
0.025 M Tris HCl pH 7.4 overnight. This step was performed to allow for the specific 
binding of preClosA to the antiClos leader antibody. The subsequent steps were 
performed as described in chapter 2 and the fractions were assessed in western blot to 
confirm the elution of preClosA. 
 Structure elucidation of the 6 kDa preClosA peptide  
The method was provided by JIC Proteomics Facility and performed by Dr. Gerhard 
Saalbach. 
Purified intact preClosA peptide was characterised by LC-MS on a Synapt G2-Si mass 
spectrometer coupled to an Acquity UPLC system (Waters, Manchester, UK). Aliquots 
of the samples were injected onto an Aeris WIDEPORE 3.6µ C4 column (Phenomenex, 
Macclesfield, UK) and eluted with a gradient of 1-95 % (Acquity curve 7) in 14 min with 
a flow rate of 0.2 ml min-1. The mass spectrometer was controlled by the Masslynx 4.1 
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software (Waters) and operated in positive MS-ToF and resolution mode with a capillary 
voltage of 2.5 kV and a cone voltage of 40 V in the m/z range of 50-1600. Leu-enkephalin 
peptide (1 ng ml-1, Waters) was infused at 10 µl min-1 as a lock mass and measured every 
30 s. Spectra were generated in Masslynx 4.1 by combining a number of scans, and the 
spectra were deconvoluted using the MaxEnt3 tool in Masslynx. 
Gel slices containing a 6 kDa band reacting with the antiClos leader antibody (chapter 2) 
were washed, treated with trypsin, and extracted according to standard procedures 
adapted from Shevchenko et al. [121]. Aliquots were analysed by nanoLC-MSMS on an 
Orbitrap Fusion™ Tribrid™ Mass Spectrometer coupled to an UltiMate® 3000 
RSLCnano LC system (Thermo Scientific, Hemel Hempstead, UK). The sample was 
separated on a PepMap™ 100 C18 LC Column (C18, 2 µm, 500x0.75 mm, Thermo) using 
a gradient of 0.75 % min-1 acetonitrile from 6 % to 40 % in water/0.1 % formic acid at a 
flow rate of 0.3 µl min-1 and infused directly into the mass spectrometer. The mass 
spectrometer was run in positive ion mode with quad isolation at 120K resolution over 
the mass range 400-1600 (m/z) for the precursor scans (orbitrap). One microscan of 50 
ms with an AGC target of 2e5 was used. MS2 threshold was set to 2e4 and precursors 
fragmented by both CID and HCD with CE=30 and an isolation window of 1.6 Da 
(quadrupole) using the automatic maximum speed option with ion injection for all 
available parallelizable time. Dynamic exclusion was set to 1 count and 40 s. Recalibrated 
peaklists were generated using MaxQuant 1.5.3.30 [122] and the database search was 
performed with the merged HCD and CID peaklists using Mascot 2.4.1 (Matrixscience, 
London, UK). The search was performed on a Lactobacillus lactis protein sequence 
database (uniprot) to which the clos peptide sequences had been added with a precursor 
tolerance of 6 ppm and a fragment tolerance of 0.6 Da. The enzyme was set to trypsin/P 
with a maximum of 2 allowed missed cleavages. All used modifications (C(-33) and C(-
1) of cysteine, dehydration (-18) of serine and threonine, S(-17) of serine, S(+15) of 
serine, oxidation of methionine and carbamidomethylation (CAM) of cysteine) were set 
as variable modifications. The Mascot search results were imported into Scaffold 4.4.1.1 
(www.proteomsoftware.com) using identification probabilities of 99 % and 95 % for 
proteins and peptides. 
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6.3 RESULTS AND DISCUSSION 
 Small scale IP purification and investigation of the 6 kDa peptide on 
western blot and MS  
In order to perform structure characterisation and to test the activity of pure peptide in 
solutions, a method was developed to specifically extract preClosA from cell cultures. 
Previous work (chapter 5) involved the loading of cell extracts or TCA precipitated 
proteins on a gel and to excise the 6 kDa gel bands with the aim to have MS confirmation 
that the peptide was indeed preClosA.  
MS analysis of 8 individual protein gel slices with constructs in UKLc10 confirmed the 
presence of several forms of preClosA peptides. MS results (Appendix 3) using preClosA 
from the excised protein bands, suggested that they still contained a large number of 
proteins, and other methods would be needed for the selective purification of preClosA 
from a mixture of proteins. 
After developing a pClosCluster construct in UKLc10 that allowed for an improved 
expression of the preClosA target protein, detection of the preClosA peptide was 
addressed. Western blot analysis only allowed for the detection of a 6 kDa peptide and 
further analysis is needed to confirm the protein identity.  
A small scale IP reaction was performed using the manufacturer’s instruction with 
optimised buffers and concentrations. The initial signal for the detection of preClosA was 
very weak in the western blot (elution 2, 3, Figure 65). A 6 kDa peptide was detected by 
the antiClos leader antibody in different fractions: in the starting material (cell extract in 
IP Lysis buffer), in elution 2 and elution 3, in different flow though wash steps. Eluate 2 
gave a positive signal in the western blot (Figure 65) and it was selected and analysed by 
LC-MS and by Maldi-ToF (section 6.3.2-6.3.3). The amount of purified preClosA was 
enough for its detection on Maldi-ToF which confirmed the presence of the preClosA 
peptide (Figure 66).  
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Figure 65 - Detection of a 6 kDa peptide on western blot with antiClos leader antibody.  
Samples were eluates (E) from antibody antigen purification reaction using crosslinking and IP lysis buffer. 
SM is cell extract total protein as the starting material. F1 is flow through after 4 h incubation, F2 is flow 
after the resin was washed, F3 is wash step after elution. The antiClos leader antibody was used at 1/100 
dilution. The black arrow highlights the 6 kDa peptide. M is the SeeBluePlus 2 marker in kDa.  
Results in Figure 66 indicated that one of the washing buffers used for the purification of 
preClosA contains a detergent; this was carried over and the eluted preClosA was 
contaminated with the detergent which interfered with the Maldi-ToF signal (Figure 66). 
The IP Lysis/wash buffer contains the 1 % NP-10 detergent so in order to remove 
contamination, a different extraction and wash buffer were considered. Alternatively, C8 
cartridges were used to re-purify some of the eluates.   
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Figure 66 - Maldi-ToF analysis of purified preClosA (elution 2) from an IP reaction using crosslinker.  
The values for the Maldi-ToF measurement are not perfectly accurate due to the heavy contamination with 
detergent. The peak at 5576 most likely corresponds to preClosA2 (expected m/z = 5574.7 Da). 
Detection of nisin from isopropanol extraction using Maldi-ToF is one of the most 
common methods for the characterisation of the peptide. In general, this method did not 
work for the detection of preClosA. Only in the presented attempt (Figure 66) peaks 
which would fit the expected mass of preClosA were detected. The masses of the main 
observed peaks most likely correspond to preClosA2 with 8 dehydrations (expected m/z 
= 5574.7 Da) and the same compound but with an addition of 17 Da was detected (peak 
at 5593 Da). The additional mass of 17 Da has also been observed in many spectra 
acquired for preClosA by LC-MS and seems to be a common pattern encountered in this 
work during the MS analysis of preClosA. The shift in mass is due to the fact that the 
instrument was not perfectly calibrated for this mass range however the most abundant 
peak is most likely preClosA2 at 5576 Da. LC-MS was also used for the detection of 
preClosA, however it will be discussed along with the other spectra in a later section. 
Several factors were varied: buffers for cell extraction and for the actual purification 
(incubation time with the beads, the use of a crosslinker, and the main source for the 
preClosA peptide). Some of the cell extractions and the subsequent steps were performed 
in IP Lysis buffer or in 0.025 M Tris HCl, pH 7.4 buffer. It was considered that the 
crosslinker could affect the binding of the antiClos leader peptide antibody, therefore two 
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different preClosA immobilization methods were tested: a one step IP method (with 
crosslinker) or a sequential IP method (no crosslinker) as described in chapter 2.  
It was assumed that the elution buffer from the kit could be too weak and preClosA might 
still be bound on the column which may explain the low yield in the eluates. To test if 
any amount of preClosA is still bound on the column after the final elution step, 10 to 20 
µl of the beads were boiled with SDS loading buffer (using the protocol in section 2.5), 
and analysed by western blotting  (Figure 67).     
Six small scale IP reactions were prepared using no crosslinker to investigate if preClosA 
(in complex with the antibody) was eluted in a much higher yield. The ratio between the 
antibody and the antigen that were needed were estimated and it was decided that 1 ml of 
CE (¬15-20 mg of total protein) and 100 µl of Ab (¬3 mg of total protein) would allow 
for the purification of the preClosA peptide as detailed in Table 28.  
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Figure 67 - Western blots to compare different extraction buffers in order to maximise the yields of 
extracted preClosA peptide. Efficient extraction of 6 kDa using different buffers.  
Several small scale IP reactions were performed and analysed here using the no crosslinking method. The 
same amount of sample and eluates was loaded in each well to compare the amount of extracted preClosA. 
The antiClos leader antibody was used to visualise the bands at 1/100 dilution. The IP reactions and their 
western blots were called WB1 to WB5, WB8, WB9 a.  
Samples: eluates 1-4 (E), E5 is a complex mix of resin, antibody and the uneluted preClosA peptide. F1 is 
flow after overnight incubation with the sample, F2 is the flow through after wash step, M is SeeBluePlus2 
marker in kDa, SM is the starting material, CE is cell extract total protein as the starting material. The black 
arrow highlights the presence of the 6 kDa peptide.  
The IP lysis buffer contains 1 % of NP-10 detergent and if used it is expected that more 
total protein will be extracted compared to using Tris HCl only buffer; it is unclear if 
increased total protein mix would mean an increased amount of the preClosA peptide. 
Therefore, in the WB8 experiment, the detergent containing buffer as well as the cell free 
supernatant/medium were used to facilitate the binding of the preClosA peptide to the 
antibody coated resins. 
Here, the pClosCluster in L. lactis UKLc10 strain has the clos cluster coding sequence 
expressed on a plasmid, therefore the preClosA peptide is expected to be accumulated 
and/or secreted outside the cell. Results in Figure 67 indicated that a 6 kDa peptide 
reacting with the preClosA antibody in western blots was efficiently extracted from the 
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complex total protein using different buffers. A 6 kDa band was mainly detected in elution 
2 and 3 (Figure 67) and MS analysis of these eluates confirmed that the 6 kDa preClosA 
was purified both from the total protein in the cell extracts as well as from the cell free 
medium. Very high intensity bands were detected in elutions 1 to 3 but also in elutions 4 
and 5 in some IP reactions (Figure 67).  
Therefore, successful purification of preClosA peptide was possible using two different 
samples (cell extract and TCA precipitated supernatant) and three buffers: 1) 0.025 M 
Tris HCl, pH 7.4, 2) 0.025 M Tris HCl, pH 7.4 plus protease inhibitors or 3) IP Lysis/wash 
buffer plus protease inhibitors buffer. Elution 5 contains unbound preClosA protein 
recovered from the resins after elution 4. Elution 5 in the western blots (Figure 67) 
confirmed that a small amount of the preClosA was still bound on the column.  
Some western blots for samples where the crosslinker IP method was used are illustrated 
in Figure 67, WB4 and results confirmed that the eluates contained an antibody-preClosA 
complex because high intensity bands were detected for the antibody in the upper area of 
the blot. The LC-MS analysis of the eluates confirmed that preClosA can be isolated in 
the absence of a detergent containing buffer (section 6.3.3).  
Based on the results in WB9a, where the 6 kDa peptide was purified in 0.025 M Tris HCl, 
pH 7.4 buffer, it was decided that this buffer system as well as the crosslinking method 
should be used for the large scale purification and high yield elution of the preClosA 
peptide described in section 6.3.3.   
The advantage of using the one step IP method is that it allows the elution of preClosA 
without contamination from antiClos leader peptide antibody, whereas in the traditional 
sequential IP method preClosA is eluted in a complex with the antibody (Figure 67). TCA 
precipitated supernatant was not used as a source for the starting material since TCA can 
denature proteins/peptides irreversibly which would affect the binding of preClosA 
peptide to the antibody.  
Even though a large amount of preClosA peptide was successfully isolated, the activity 
of the pure peptide in solution was not tested in this work. Future work should involve to 
take the preClosA peptide and place it on the agar plate which will then be overlaid with 
trypsin to allow for the release of active peptides tested against different indicator strains. 
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 Protein extraction and analysis of preClosA peptide from the excised 
gel slices  
 Mascot database search for identity of (pre)ClosA tryptic peptides  
In order to identify the tryptic peptides according to their specific masses and sequences, 
the acquired spectra were used for database searches. Spectra were from a few protein 
gels with cell extracts from the two strains and a total of 8 gel slices corresponding to 6 
kDa were cut from the protein gels and analysed by trypsin digestion and nano-LC-
MS/MS. Both pClosCluster and pClosCluster + pPnisA_ cA34 in UKLc10 strains were 
used.  
The results shown in Appendix 3, clearly demonstrate the presence of preClosA in all 
analysed gel slices. All possible detectable tryptic peptides of preClosA1 and preClosA23 
have been detected with at least 95 % probability, so that the complete sequence of those 
preClosA forms has been covered. A peptide from the leader sequence of preClosA4 has 
also been detected indicating the presence of a certain amount of this form as well. 
Altogether, 368 spectra were matched to the three identical preClosA1 peptides (Table 
29). This is the first piece of evidence that the preClosA peptide with the correct amino 
acid sequence is present in the analysed samples. 
Number of PSM’s  Type of preClosA23 tryptic peptide  Location  
368 total number of tryptic peptides 
109 AKFDDFDLDVTK Leader peptide 
1 AKFDDFDLDVTKTAAQGGIEPK 
30 FDDFDLDVTK 
127 SACTPGCPTGILMTCPLK Rings A-C area (Core peptide) 
5 SKSACTPGCPTGILMTCPLK 
22 TAAQGGIEPK Leader peptide 
4 TAAQGGIEPKIEPKYKSK Leader peptide & start of Core  
66 TATCGCHITGK Rings D-E area (Core peptide) 
4 YKSKSACTPGCPTGILMTCPLK 
Table 29 - Typical tryptic peptides identified in the mascot search. PSM’s: peptide spectra matches. 
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Using the variable modification settings described above and listed in Appendix 3, a 
number of peptides with dehydrated Ser and Thr residues (Dha and Dhb) were detected 
(Table 29). Altogether, the results from the 8 samples show that every Ser and Thr residue 
(8 residues) in the core clos sequence were dehydrated, while no dehydration was detected 
in the leader sequence as expected. 
Cysteine residues were alkylated with iodoacetamide (IAA) during sample preparation, 
and this modification was also detected by the database search. Overall it was found that 
all 5 Cys residues of the clos sequence can be modified. However, by checking individual 
spectrum/peptide matches a number of spectra were observed with unmodified 
(unlabbeled) Cys residues.  
For instance, a mixture of peptides for the C-terminal part of preClosA1 (Ring D-E, 
TATCGCHITGK) was identified, each with at least 95 % probability and the possible 
ring formation for this peptide is discussed in section 6.3.2.3. Altogether, 66 spectra were 
matched to this peptide. Some of the peptides (11) were dehydrated (all 3 Thr residues or 
the 2 Thr residues essential for rings). Only those dehydrated peptides had free Cys 
residues (no IAA modification), all other peptides had at least 1 Cys residue modified, 26 
had both Cys residues modified (Table 30). 
At the same time, in the spectra for the dehydrated peptides no MS2 fragments (neither 
b- nor y-ions) were formed from the part of the sequence potentially forming the Rings 
D and E as described in section 6.3.2.3 (Figure 68).  
Number of PSM’s Modifications seen in the 
TATCGCHITGK peptide in Mascot 
in  
Number of possible rings  
66 total number of tryptic peptides 
26 Both C + CAM  No rings  
8 Only C4 + CAM  1 possible ring  
21 Only C6 + CAM  1 possible ring 
11 Both C free 2 possible rings 
11 7 3 dehydro T 
 4 2 dehydro T (T1, T3) 
1 with C(-1) only No rings  
Table 30 - Detection of alkylated cysteine residues and dehydrated amino acids in TATCGCHITGK 
peptide. PSM’s: peptide spectra matches. 
T1AT3C4GC6HIT9GK. T is threonine and the number of the residue is associated with this peptide. Plus 
CAM (+CAM = carbamidomethyl) means that cysteine (C) residue is alkylated since it is not forming a 
ring and it is free in the peptide.  
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 Cleavage of the preClosA peptide with trypsin  
Cleavage of the preClosA peptides with trypsin, known as trypsinolysis, typically 
involves the digestion of a peptide after the lysine (K) or arginine (R) residue when they 
are not followed by proline. Some lysine sites in the Clos peptides may be more prone to 
be digested than others such as the Lys sites around the ring structures. It was assumed 
that trypsin can cleave after a lysine residue which is incorporated inside a ring structure, 
however fragments will not be formed as they are held together by the ring structure 
(section 6.3.2.5). The ClosA1 peptide does not have any arginine residues whereas the 
leader peptide of ClosA4 contains Arg. ClosA1 has the advantage that trypsin can cleave 
at the predicted start site (the YK), therefore one of the tryptic peptides that is formed 
could be the active form of the Clos peptide. Based on the predicted cleavage sites for 
trypsin (blue arrow), preClosA can be fragmented into several tryptic peptides that are 
listed in Table 31 and in more detail in Appendix 3. 
 
 
MAK FDDFDLDVTK TAAQGGIEPK YK SK SACTPGCPTGILMTCPLK 
TATCGCHITGK 
FDDFDLDVTK a 
TAAQGGIEPK 
SACTPGCPTGILMTCPLK 
TATCGCHITGK 
AKFDDFDLDVTK b 
SKSACTPGCPTGILMTCPLK 
YKSKSACTPGCPTGILMTCPLK 
Table 31 - Sequence of preClosA1 with cleavages sites for trypsin (blue arrow) and tryptic peptides detected 
in the Mascot search.  
 a The results in Appendix 3 indicate that there are no missed cleavages, therefore 4 peptides were more 
frequently observed. However, the small peptides YK and KS are not observable. 
b Missed cleavages have been observed for K3, K25, K27 resulting in three observed peptides. 
According to the fragmentation pattern given by digestion with trypsin (Table 31, 
Appendix 3), it was observed that the preferential cleavage site for trypsin is at the 
K↓SAC site (within the region for Ring A which proves no Ring A) as well as around the 
rings leaving the fragmentation within the (Me)Lan rings for some peptides of the C-
terminal part of preClosA untouched [134].   
Table 31 illustrates the location of the trypsin cleavage sites in the ClosA1 core peptides: 
Lys4-Tyr5, Lys8-Dha9, Lys6-Ala7, Lys26-Abu27; for the ClosA4 core peptide, the 
cleavage sites are: Lys 21-Abu 22, Lys 29-Leu 30, Lys 31-Gly 32 (if IT is the start site). 
It is possible that unidentified trypsin sites could be discovered in the future.  
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 Detection of PTM in the C-terminal part of the preClosA peptide 
A mixture of different forms of tryptic peptide for TATCGCHITGK were seen where 
some had no rings, others had one ring or even the two expected rings. Results in Figure 
68 indicated that there is a strong indication that cysteine was non-alkylated/unmodified 
by IAA. These cysteine residues and the dehydrated amino acids must have formed two 
(Me)Lan rings. The first observation on the spectra in Figure 68 is that all the serines and 
threonine residues were dehydrated, labelled as T-18 (threonine minus 18 Da for loss of 
water). This means that that they could form ring structures with the neighbour cysteine 
residues. Next, there are no peaks assigned for TATCGC peptide (in black, forward and 
reverse) as no fragmentation and no ions could be assigned. A lack of fragmentation 
indicates that both Rings D and Ring E are likely to be present. 
 
 
 
Figure 68 - Mascot search to identify modifications in the C-terminal part of preClosA peptide.   
Analysed tryptic peptide: TATCGCHITGK from ClosA1 core peptide detected with 95 % probability. B4 
is at the noise level. 
The modifications used to identify the presence of rings and of dehydrated residues were: 
Ser->Dha (T-18), Thr->Dhb (T-18), Cys -> Cys+57. Modifications within the rings were 
not investigated as they are not expected to take place and the total mass remains the 
same. The colour coded b and y ions were detected by LC-MS fragmentation. The 
assigned b4 ion is most likely a false assignment; the intensity of this ion is at the noise 
level. 
Mascot search for the C-terminal peptide, TATCGCHITGK, identified a mixture of 
fragments with different modifications with 95 % probability. The b and y ions (1-11) 
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were assigned on the structure of preClosA1 (in red and blue) as well as a spectrum with 
assigned ions is included (Figure 68). The spectrum shows that there are no ions assigned 
for T1 to C4 (b1 to b4, the software assigned b4 but it is at the noise level) and for T3 to 
C6 (y6 to y11) which means that fragmentation was not possible; this is an indication that 
rings were present since rings are generally known to prevent the MS fragmentation. 
None of the Cys residues were labelled with IAA since Cys residues did not have a 57 Da 
corresponding to added IAA. Therefore, the absence of labelling with IAA of 
TATCGCHITGK was not possible due to the presence of rings. Also, all the Ser and Thr 
residues are dehydrated as illustrated by the loss of 18 Da (T-18).  
The b4 ion appears on the spectrum however, a closer inspection of the spectra reveals 
that the software assigned b4 ion is at the noise level. Therefore, these ions do not really 
exist whereas all the other ions in the table and on the spectrum confirm a fragmentation 
around Rings D-E in TATCGCHITGK but not within the ring region. This peptide was 
determined with 95 % probability and MS analysis (Figure 70) confirms it contains all 
the dehydrations and the two possible rings. 
 Detection of PTM in the N-terminal part of the preClosA peptide 
The clos modification machinery is expected to introduce PTM such as dehydrations and 
rings and so far only a few peptides seem to have all the PTM in the C-terminal part of 
Clos.  
From the N- and C-terminal sequences of the detected tryptic peptides in Appendix 3, it 
can be concluded that all the potential tryptic cleavage sites (which means all Lys 
residues) can experimentally be cleaved by complete digestion with trypsin. This includes 
the Lys27 residue, which is located in the predicted Ring A region of preClosA. The 
cleavage at this site together with cleavage at the next downstream site (Lys45) leads to 
the formation of the peptide SACTPGCPTGILMTCPL (Figure 69). This peptide has been 
identified by 132 spectra (out of a total of 368 spectra for ClosA1 core peptide) from the 
gel samples. In the vast majority of those peptides all three Cys residues are modified by 
IAA (e.g. 122x C3, 110x C7, 127x C15, and 107x all three C, were found). Dehydration 
of Thr residues was observed in 65 spectra.  
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Figure 69 - Mascot search to identify modifications in the N-terminal part of preClosA.    
The b and y ions were detected in MS and they were colour coded as highlighted in the table after MS 
fragmentation. Analysed tryptic peptide: SAC3TPGC7PTGILMTC15PLK from preClosA1 core peptide 
detected with 99 % probability. 
The spectra in Figure 69 shows that some cysteine residues did not form a ring in the 
original sequence as they were free. Therefore, these Cys residues were labelled by IAA, 
57 Da mass addition, (C3+57 and C15+57). Appendix 3 indicates that the cysteine 
residues were all modified by IAA (C+57), which reconfirms that there is strong evidence 
that this peptide does not contain rings. All the other tryptic peptides for this region of 
preClosA were the same. The software also assigned dehydration of the terminal Ser 
residue in 10 spectra (out of the 132), but visual inspection showed that there is no direct 
evidence for dehydration of this Ser28 residue. Inspection of the spectra also reveals that 
MS2 fragmentation occurs throughout the complete predicted ring regions for Rings A to 
C without the occurrence of the predicted modified amino acid residues for ring breakage 
as discussed below (section 6.3.2.5).  
This kind of modification has only been assigned for 6 out of the 132 spectra in the 
SACTPGCPTGILMTCPL peptide. Visual inspection revealed that 5 of those spectra are 
of very low quality, and in the remaining spectrum there is no direct evidence for the 
modified residues (no peaks directly covering the modified residues).  
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  Investigation of ring fragmentation in lantibiotics 
Two possible scenarios for ring fragmentation are illustrated in Figure 70, where the 
linkages in the rings could be broken by MS. This phenomenon had previously been 
demonstrated in experiments where different lantibiotics were fragmented based on their 
structure such as for nisin, lacticin 481, haluduracin β [179-181]. 
A.  
B.  
Figure 70 - Illustration of fragmentation in lantibiotics of a ring thio-ether linkage within the backbone of 
lantibiotic peptides.  
(A) Break 1 – sulfur goes to Cys to give Cys (-1), (B) Break 2 – Sulfur goes to Ser to give Ser ( +15), Cys 
(-1) or Thr (+15). Using these proposed modification in database search, they were not detected as being 
present in the actual peptides.      
Fragmentation gives b and y ions and their masses are used to identify the amino acid sequence of the 
fragmentation product [179]. 
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In case 1, the break will give rise to cysteine (-1 Da) and serine (-17 Da) or threonine  
(-17 Da). In case 2, cysteine (-33 Da) or alanine (-1 Da) and serine (+15 Da) or cysteine 
(-1 Da) or possibly threonine (+15 Da) could be formed. These modifications were used 
in a database search with tandem mass spectra, and no peptides that had the special 
modifications highlighted in Figure 70 were detected.  
In conclusion, it was demonstrated that specific modifications associated with the 
breakage of a (Me)Lan ring were not identified in the database search even if 
fragmentation of the ring may take place in preClosA. For the N-terminal part of 
preClosA, no tryptic peptides that have Rings A-C were detected, however some 
dehydrations did occur in this peptide. It was demonstrated that in the presence of a linear 
N-terminal peptide, the full fragmentation of this region of preClosA is possible. This is 
a strong indication that no rings are present. For the C-terminal part of preClosA, a small 
number of peptides that did have Rings D-E was detected. However, there were more 
peptides of this kind without any rings present. Even if the number of tryptic peptides 
with Rings D-E was small, the results demonstrated the presence of some ring formation.  
A survey of the literature suggests that there is one example where the Ring A of nisin 
was fragmented by MS and the b and y ions confirmed that the ring structure was 
completely cleaved and it split into two fragments [182]. The possible special 
modifications were discussed and searches were made in the database to confirm that no 
fragmentation inside the rings was possible in the work with preClosA since no tryptic 
peptides with these special modifications were found. This is not surprising since the 
same behaviour is observed with other lantibiotics in contrast to the unusual case of nisin.  
 
 
 
 
 
 
 
Chapter 6 
   
215 
 
 Scaled-up production of preClosA and structure elucidation  
 Large scale IP preparation of the preClosA peptide  
According to the results in the previous chapter, the overexpression of closA3 and closA4 
genes did not improve the production of clos heterologous expression. The pClosCluster 
in UKLc10 strain was selected for scaled up production, as well as for further antibody 
antigen purification.  
The aim was to increase the amount of the purified preClosA peptide, therefore the same 
ratio of antibody antigen as in the small IP reactions was maintained (Table 28).  
The binding capacity of the resins is 50 mg/ml and the assumption was that the beads 
would really bind approx. 32 mg of antibody, which would correspond to 64 % of the 
binding capacity of the used resin. In here, the antibody did bind efficiently to the resins 
as it was measured by direct detect machine from Millipore (data not shown). A drop in 
the concentration of the antibody, when it was measured before incubation and after 
incubation with the resins, was detected. Therefore, the crosslinking reaction was 
successful as the antibodies were crosslinked to the resins. The crosslinker antibody resin 
complex was incubated overnight with the cell extract and the bound preClosA peptide 
was then eluted from the resins as confirmed both by the western blot (Figure 71) and the 
LC-MS analysis.  
 
Figure 71 - Western blot to detect preClosA peptide.  
Samples are eluates (E) and aliquots from the scaled up purification of Clos using 0.025 M Tris HCl, pH 
7.4 buffer and crosslinker. WB9 a is a small scale reaction with no crosslinker, WB9 b is a large scale 
reaction performed with the crosslinking step. M is SeeBluePlus 2 marker in kDa. The black arrow 
highlights the peptide at 6 kDa.  
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Figure 71 is a comparison of a small scale and a large scale IP reaction using the same 
buffers but with and without crosslinker. Results in WB9,a confirm that preClosA was 
mainly eluted as a complex with the Ab in elutions 1-3 and a significant amount of Clos 
in complex with the Ab was still bound to the resins as shown by elution 5. Therefore, 
the elution of Ab-Clos complex from the beads (Wb9,a) was not entirely efficient since 
the beads still contained a high amount of non-eluted Clos. Instead, the results in Figure 
71 (WB9 b) confirms that 0.025 M Tris HCl, pH 7.4 is a suitable buffer for the successful 
extraction of specific preClosA peptides. The advantage to use the crosslinking method 
(Figure 71, WB9 b), is to exclusively extract the preClosA peptide. The ‘no crosslinking’ 
method would allow for the extraction of an Ab-Ag complex which is not be suitable to 
be used for further structure characterisation in LC-MS. This is because preClosA is a 
much smaller peptide of only 6 kDa compared to the antiClos leader antibody which is 
typically 150 kDa.  
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 Structure characterisation of the preClosA peptide  
The post-translational modifications (PTM) in preClosA, dehydrations and ring 
formations, were investigated in this section. PTM are expected to be introduced by the 
clos biosynthetic machinery (Figure 72) [15, 63, 69, 183]. 
 
Figure 72 - Illustration of amino acid dehydration which involves the loss of a water molecule (-18 Da) and 
the formation of a double bond in the new unusual amino acid: dehydroalanine (Dha) or dehydrobutyrine 
(Dhb) [184]. Relationship between Cys, Ser, Dha residues.  
In this process, serine and threonine residues are dehydrated by ClosB. Then, ClosC will 
mediate the formation of rings between cysteine and dehydrated amino acids residues. 
The ClosC cyclase couples the unusual amino acids formed in the first step, such as 
dehydroalanine and dehydrobutyrine, to cysteine residues to generate formation of 
(methyl)lanthionine ring structures. The dehydration step involves the loss of 18 Da 
(Figure 72) equivalent to a water molecule. The following cyclization reaction does not 
involve a mass change since hydrogen only moves across the structures (Figure 73) [184]. 
 
Figure 73 - Illustration of the cyclization between cysteine residues and dehydrated amino acids (A-B) [184, 
185]. 
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An essential observation about lantibiotic peptides is that the dehydrated residues 
(deydroalanine and dehydrobutyrine) have a double bond (Figure 73, A) which is a 
prerequisite for sulphur to attach to carbon (Figure 73, B) to form a new bond (Figure 73, 
C) [184]. Even though the PTM processes are drawn separately as a complete dehydration 
event before the initiation of cyclization, different studies proposed that the dehydration 
and cyclization steps are interchanging [185, 186].  
Therefore, the work in this section involved taking two types of pepties: 1. pure IP eluted 
preClosA, 2. preClosA from excised protein gel slices, to alkylate the cysteine residues 
in preClos, to trypsin digest and to characterise the peptide on MS for PTM and structure 
confirmation.  
To study PTM processes in preClosA, the tryptic peptides were generated and analysed 
by tandem MS. The tandem mass spectra allow for identification of the peptide sequence 
including the detection of modified (dehydrated) amino acid residues. The observed 
fragmentation patterns also indicated the presence of rings because these structures 
usually do not fragment in MS. Furthermore, the commonly used alkylation of the 
cysteine residues helps to identify free cysteine residues not involved in ring formation. 
Since a rare case of ring fragmentation has been reported for nisin [182], the acquired 
Clos spectra were also checked for possible ring fragmentation.  
The preClosA peptide can be synthesised as a linear peptide that is fully or partially 
dehydrated. The masses for the sequences of the tryptic peptides were determined using 
the software: http://web.expasy.org/peptide_mass/ (data not shown). The monoisotopic 
mass was calculated using this software.  
To investigate the PTM introduced by the clos biosynthetic machinery, dehydrations and 
(Me)Lan rings, the cysteine residues were labelled with an S-alkylating agent such as 
iodoacetamide, IAA. Similar work was done to elucidate the structure of the two- 
component lantibiotic, haloduracin, lacticin 481 [187], subtilin and nisin [188-190].  
Ring formation is otherwise difficult to detect in lantibiotics [69, 191, 192]. In here, the 
structure characterisation of preClosA was possible by using IAA labelling of cysteine 
residues as well as digestion of lysine residues with trypsin which are methods for 
common structure characterisation of lantibiotic peptides. 
The eluates from the small scale IP reactions that were previously confirmed by western 
blot (Figure 67) were collected and analysed on LC-MS. The sample was named ‘clos 
pulldown, big elution 2’. A similar characterisation process of the fractions collected from 
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the scaled-up IP reaction was performed, however the LC-MS analysis reported in here 
was performed on the ‘clos pulldown, big elution 2’. 
Eluate 2 from the ‘clos pull down’ from several small scale reaction (Figure 67) was 
loaded on a C4 column for LC-MS analysis. Figure 74 shows the gradient and a base peak 
chromatogram where the m/z of the most abundant charge state of Clos (8+) was 
highlighted.  
 
Figure 74 - Elution profile of preClosA (pulldown, big elution 2 sample) on C4 column on LC-MS.   
ClosA eluted in 30 % acetonitrile at 2.75 min as highlighted by the arrow; a standard gradient from 10-90 
% acetonitrile in 0.1 % formic acid was used.  
The spectra under the LC-MS peak at 698.32 (Figure 74) were combined to reveal a series 
of charge states from 4+ to 9+ (Figure 75). 
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Figure 75 - Different charge states of preClosA obtained from the C4 column. 
PreClosA is a 6 kDa peptide that can be multiply charged and it appears as a series of 
different charge states (Figure 75). The charge state series was deconvolunted to 
determine the actual mass of the protein. By simplifying the complicated appearance of 
the spectra, a series of peaks of the charge states is reduced to one single peak of the 
peptide (Figure 76). The deconvoluted mass was given by the MS software as the singly 
charged monoisotopic mass [M+H]+, the calculated mass and the observed masses were 
compared and the matches were highlighted in red (Figure 76,C). 
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Figure 76 - LC-MS spectra to detect preClosA1 peptide at different dehydrations.  
The calculated ppm error confirms that the masses of the peaks fit with the calculate masses in red0. Ppm 
is part per million. 
Figure 76 illustrated the deconvoluted spectrum (Figure 75) showing the m/z for 1+ 
charge state. The two main observed masses match the predicted masses for preClosA1 
and preClosA23 (-8H2O) as seen in the table (Figure 76) as well as one peak has an 
addional mass of 17 Da.  
Figure 77 is a deconvoluted spectrum from another eluted sample and it shows stronger 
peaks fitting in different dehydration stages of preClosA1 and preClosA23. The 
dehydrations of specific amino acid residues to give dehydroalanine and dehydrobutyrine 
was investigated by analysing the tryptic peptides obtained in the Mascot search 
(Appendix 3) as well as by detecting them in LC-MS analysis (Figure 77). In here, a 
complex mixture of dehydrated preClosA peptides, mainly for the three preClosA1, with 
different states of dehydrations for preClosA1 and preclosA23 were observed. 
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Figure 77 - Deconvoluted spectrum showing a complex mix of dehydrated preClosA1 and preClosA23 
peptides in red.  
Interestingly there was one isolated LC-MS case where the preClosA peptide was 
detected possibly with a loss of the C-terminal lysine (K) to give group 1; the work done 
on this particular form of preClos is presented below (Figure 78 to Figure 80). Figure 78 
shows the charge state spectrum from another eluted sample of preClosA, however in 
here there is a second group of charge states shifted to lower m/z as highlighted by the 
blue arrows. Interestingly, a common feature in the spectra for preClosA is the presence 
of a peak with an addition of 17 Da (Figure 76, Figure 77).  
 
Figure 78 - Different charge states of preClosA1 (group 1, no terminal Lys) from the C4 column. Two 
peaks per charge state.  
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Figure 79 - Retention times of group 1 and group 2 of preClosA. Peak for group 1 elutes later. 
Group 2 is the unmodified dehydrated preClosA1 and preClosA23. The two groups elute 
slightly differently and the deconvoluted spectrum is in Figure 79. 
The charge state 4+ was zoomed in to reveal the presence of two forms of preClosA. The 
spectra for group 1 and group 2 were deconvoluted, and as observed in other experiments, 
the group 2 contained fully dehydrated preClosA1 (m/z = 5560) and preClosA23 (m/z = 
5574) (Figure 80).  
The calculated error (ppm) had a very low value which indicates that the observed masses 
were very accurate and they were identified compared to the calculated masses (see tables 
in Figure 80).  
PreClosA23 is the strongest and most abundant peak since the clos gene cluster encodes 
for three copies of the closA1 structural genes, but the group 1 and 2 peaks for preClosA1 
are also present. In both cases, the mass difference between group 1 and 2 is -128 Da for 
group 2. This mass difference could be associated with a loss of a Lys(K) from the C-
terminus of preClosA which may have been removed during biosynthesis or post-
translational processing. Alternatively, preClos may have been degraded or the 
pClosCluster in the L. lactis strain is producing a new form of preClosA peptide.   
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Figure 80 - Deconvoluted spectra for charge state 4+ from two groups of preClosA1 and preClosA23 
peptides: group 2 (A), group 1 (B). Special case, difference between 2 peaks is 128 Da for terminal Lys 
residue. 
Group 1 shows a loss of 128 Da compared to group 2 which corresponds to the previously observed masses 
of preClosA1 and preClosA23 minus 8H2O, 8 water molecules (in red). 128 is the mass of a Lys residue, 
and it could mean that both preClosA1 and preClosA23 have lost the C-terminal Lys residue. 
Some eluates of the preClosA peptide were treated with IAA with the aim to label the 
free cysteine residues and to measure the intact mass. 
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Figure 81 - Detection of preClosA23 in a sample that was treated with IAA.  
The IAA labelled Cys residues, marked by 1 CAM per 1 Cys residue, indicated that the amino acids are 
free; free Cys residues do not form a ring with the neighbouring dehydrated amino acids. CAM adds a mass 
of 57 Da. In red is the calculated mass for preClosA that matched the observed mass for alkylated 
preClosA23. CAM is carbaimidomethyl. In the linear preclosA23, one, two, three, four or all the 5 Cys 
residues can be labelled with IAA.  
The results in Figure 81 with IAA treated preClosA validate the observations previously 
made about the labelling of cysteine residues of the preClos peptide in the gel slices 
(Mascot search, Appendix 3). In here, a solution of pure preClosA peptide was treated 
with IAA and peaks for dehydrated preClosA23 were detected. The masses for 
preClosA23 that were identified were:  
4) one peak is 5574 Da for preClosA23 with 8 dehydrations: [M+H-8x18] + = 5574  
5) one peak is 5592 Da for preClosA23 with 7 dehydrations: [M+H-7x18] + = 5592. 
The main new peak at 5785 matching to preClosA23 with 8 dehydrations and with 4 Cys 
residues labelled (IAA) but with a loss of a mass of 17. This is evidence of absence of 
rings, only one possible ring can be formed which is likely to be in the C-terminal part of 
the ClosA peptide. Another weaker peak was detected for a form of preClosA23 with all 
the 5 cysteine residues labelled by IAA at m/z 5859, which is evidence of absence of 
rings. The most abundant peak in here is for preClosA with no rings since 4 out of 5 
cysteine residues were probably labelled with IAA which means that they were part of a 
linear preClosA23 peptide. The mass difference of 17 Da occurred in many spectra and 
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seems to be a common pattern encountered in the LC-MS analysis of preClosA. There 
may be indication that one cysteine residue was forming a ring since it was not alkylated. 
Peaks for completely unmodified (not alkylated) forms of preClosA1 and preClosA23 are 
also present in the spectrum which suggests that the peptides contain all the rings. 
Complete ring formation has however not been detected when analysing the tryptic 
digests from protein gel bands (Figure 68, Figure 69).  
In conclusion, an optimal Ab-Ag ratio was determined and the crosslinking method was 
used for the purification of high yield pure preClosA peptide. The amino acid sequences 
and PTM for the novel antimicrobial peptides, preClosA1 and preClosA23 were 
confirmed and future work with the pure preClosA peptides should allow for the isolation 
of the active tryptic Clos peptides and their further structural and biological activity 
characterisation.   
Apart from analysing preClosA from solution, Mascot analysis of 8 independent and 
excised protein gel slices from cell extracts and TCA precipitated supernatant samples 
revealed that they were all comprised of exactly the same tryptic peptides. This means 
that the preClosA peptide is present both inside the cell but it is also exported in the 
supernatant. There are two types of PTMs that can be considered: 1. PTM introduced by 
the clos modification machinery, 2. modifications of cysteine residues in preClosA 
introduced by labelling with IAA alkylator. Fragmentation of preClosA by LC-MS is also 
possible. The initial modifications involved dehydrations such as Ser -> Dha (S) and Thr 
-> Dhb with a change in mass of 18.010565 Da per dehydrated residue. According to 
literature [184, 187, 193], there is no mass change for ring formation when Cys is 
converted to Ala in ring formation (Cys -> Ala). This required IAA labelling of Cys 
residues. Therefore, it was interesting to investigate fragmentation of a thiol-ether 
crosslinkage by MS. The typical modification introduced during alkylation of preClosA 
and detected by LC-MS include a +57 Da mass change introduced because of IAA 
labelling (carbamidomethyl (C)) which made it easy to distinguish between free cysteines 
and cysteine in rings. The IAA S-alkylating agent is most commonly used for the 
structure-function characterisation of lantibiotics [181, 187, 194, 195]. IAA was selected 
for further target labelling of Cys residues. The small size of IAA is an advantage over 
other alkylators. 
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Only the ClosA4 leader peptide was detected and it was interesting to observe that even 
if the antiClos leader antibody was designed to bind to the sequence of the leader 
preClosA1 peptide, the preClosA4 leader also hybridised to the Ab. 
The biological activity of the trypsin treated Clos peptide was assessed in chapter 5 using 
an overlay assay which proved to be a good method for the confirmation of antimicrobial 
activity. Interestingly, preClosA1-3 peptides have the advantage that trypsin can cleave 
at the predicted start site (the YK), therefore one of the tryptic peptides that is formed 
could be the full length leaderless form of the Clos peptide. Also, two major tryptic 
peptides were detected: one for the N-terminal part of preClos which proved to have no 
rings and another one for the C-terminal part of preClosA, where some peptides had the 
rings introduced. All the possible Ser and Thr residues were dehydrated efficiently by the 
clos modification machinery as confirmed by MS.  
Therefore, there was no evidence for the presence of Rings A to C in the MS data from 
tryptic digests of IP Clos sample (Figure 81). These results are in contradiction with the 
argument that the presence of ring structure would be necessary for the antimicrobial 
activity in Clos. Based on previous work on structure elucidation of nisin and subtilin [89, 
196-198], it is highly unlikely that in the absence of Rings A-C the full leaderless peptide 
would be active. Nisin and subtilin are lantibiotics to which preClosA peptide is predicted 
to have structural similarity. Different studies suggest that the modification machinery 
introduces the dehydrations in the precursor peptide, then the rings are formed possibly 
starting with Ring A [187, 193]. Consequently, more peptides with the Rings A-C were 
expected to be observed in the analysed samples which is not the case in the present study.  
Even if we assumed that fully modified preClosA with no leader present would be formed 
and would give the antimicrobial activity, the MS analysis indicates that two main tryptic 
fragments are mainly present: N-terminal peptide (linear peptide also comprising the 
hinge region) and C-terminal peptide (a mixture of linear, partial ring and full Rings D-
E). This would suggest that these fragments are also most likely formed during the 
screening for biological activity using the overlay assays rather than the full leaderless 
sequence of Clos (see the evidence of a mixture of peptides as listed in Appendix 3).   
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 CONCLUDING REMARKS  
In this chapter, I was able to demonstrate the following: 
1) Using the IP reactions, the ClosA1 prepeptide was successfully purified in high yield,  
2) Using Mascot search, Maldi-ToF and LC-MS analysis of two types of samples:  
2.1 excised 6 kDa gel slices and 2.2 eluted Clos in solution, confirmed the identity of 
preClosA according to the detected masses. Therefore, the structure of the preClosA 
peptide and the PTM were determined. A mixture of fully and partially dehydrated 
preClosA peptide were obtained, Rings D and E are more likely to be formed, however 
no evidence for Rings A-C was found. 
3) PreClosA was completely digested with trypsin, all the cysteine residues were labelled 
with the IAA alkylator to obtain tryptic peptides with PTM (dehydrations and ring 
formations) as listed in Appendix 3. The following peptides were more currently found: 
FDDFDLDVTK, TAAQGGIEPK, SACTPGCPTGILMTCPLK and TATCGCHITGK, 
whereas if trypsin missed a cleavage site, some examples of these peptides can also be 
found but in a very low proportion: AKFDDFDLDVTK, SKSACTPGCPTGILMTCPLK 
and YKSKSACTPGCPTGILMTCPLK. 
The observations on the MS data confirmed that the results were not consistent with the 
previously predicted structure for the N-terminal peptide, however they were consistent 
for hinge region and the C-terminal peptide. However, there was no MS data as evidence 
for the presence of a full peptide with the leader removed (IE or most likely YK as start 
site). This could be because trypsin normally removes the leader but it also further digests 
the leaderless core peptide at the cleavage sites along the peptide to form more tryptic 
fragments.  
The heterologous expression system used in here has its limitations in that it produced 
peptides with the leader still attached at different stages of secretion, however the system 
is able to export precursor peptides that are partially modified.  
In here there is no evidence of the machine exporting fully modified peptides with all 
dehydrations and all rings formed. It is known that during processing of the precursor 
peptide the leader is attached and it is necessary for the maturation of the lantibiotic 
peptide [168, 169]. However, if that were to be the case we would expect for the same to 
happen with Clos. Instead, it is likely that preClosA not fully converted into the mature 
form (with complete dehydrations and ring formation). More rings are expected to be 
formed in the early part of the preClosA in the N-terminal part and current results could 
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suggest that the system is different compared to nisin and subtilin. Successful and 
complete PTM of preClosA may require the presence of another component from the 
original bacteria that is not present in the heterologous system such as a protease.  
Despite problems with preClosA peptide detection by Maldi-ToF due to detergent 
contamination in the eluted fractions, there was good indication that preClosA is present. 
The fragmentation pattern observed in the Mascot search indicated that preClosA is 
completely digested by trypsin. Searches for ring fragmentation using special 
modifications and identification of tryptic peptides that start from inside the region of 
Ring A (K↓SAC) confirmed that Ring A is not introduced by the clos biosynthetic 
machinery. The rest of the N-terminal peptide is likely to be devoid of rings as well since 
fragmentation characteristic to a linear peptide was observed. Some peptides for the C-
terminal part of preClosA were linear, some were with one ring and a few others had both 
rings present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
CHAPTER SEVEN 
 
7. Conclusions and future perspectives 
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The work in this PhD thesis demonstrated that novel and active lantibiotics can be 
obtained from the novel clos gene cluster isolated from a gut bacterium that have 
biological activity against gut pathogens. The activation of clos promoters and the 
structure of the preClosA peptides have been addressed. In addition, clos-like nisin 
mutants were generated and characterised, however peptides with improved properties 
compared to nisin were not detected in this work. Exploring the complex GI tract for 
novel antimicrobials still holds the potential for the discovery of novel lantibiotics active 
against gut pathogens such as in the case with the Clos peptides identified in this PhD 
thesis. 
Chapter 3 - Generation and characterisation of clos-like nisin mutants 
In chapter 3, it was shown that although it was possible to use a nisA construct as a 
template to incorporate features of the ClosA1 peptide to successfully substitute 
individual or multiple amino acids in 12 nisin variants, their biological activity was not 
better or significantly improved in any of the biological tests when compared to nisin and 
tested at pH 3.0 to 7.0.  
A preliminary antimicrobial screening approach was used to assess the biological activity 
of the mutants and their induction/self-induction properties. Results indicated that only 
M21L was a self-inducer, whereas all the other mutants required continuous induction 
with nisin. All the nisin mutants were produced either in liquid or solid media. Testing 
the mutants against different indicator strains and colony MS allowed the successful 
detection of most of the peptides and the identification of mutants with similar or less 
antimicrobial activities to nisin A was possible. Purification and further characterisation 
of the specific activity of I4K and H27G at the temperature, pH and using indicator strains 
relevant to the GI tract did not demonstrate improved thermostability and/or spectrum of 
activity for the purified peptides. Future work could involve generating mutants to make 
them look more like ClosA1 or ClosA4. The observations made in this PhD project on 
the effect of particular amino acid substitutions can be used to rationally design future 
Clos mutant peptides by introducing particular amino acid substitutions in the rings and 
in the C-terminal part of nisin. However, generation of a nisin mutant with improved 
properties is limited by the lack of knowledge on the tolerance of the nisin biosynthetic 
machinery to the amino acid substitutions which is something that was explored in chapter 
3.  
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Chapter 4 - Identification and functional characterisation of promoters in the clos 
operon 
In chapter 4, bioinformatics led to the identification of four putative clos promoters; the 
expression system confirmed that PClosA and possibly PClosR2K2 are a potential target 
recognition site for NisR or potentially for the ClosR regulatory proteins. The other two 
clos promoters either showed no activation with no induction with nisin or they were not 
real clos promoters. Current results indicate that the nisRK genes may be essential for the 
production of the intermediate preClos peptide when the strain is induced with nisin.  
Measurements of the specific pepI activity using the closRK or nisRK two-component 
regulatory systems demonstrated that the LanRK regulatory system is not capable of 
switching on the other putative clos promoters when expressed in the UKLc10 
heterologous expression system. It was speculated that perhaps the ClosRK systems do 
play a role in the regulation of preClosA biosynthesis, however this is only possible when 
the preClosA peptide is already present in the medium. Inducer peptides regulating 
lantibiotic biosynthesis are generally encoded by genes from the same lantibiotic gene 
clusters [162]. Perhaps after the accumulated Clos inducer peptide reaches a threshold 
concentration during growth in a cell density-dependent manner, a positive feedback 
mechanism creates a burst of the signal hence the fast response. Future work may 
demonstrate that all clos promoters are functional when they are present on the clos gene 
cluster, and tests should include the correct transcriptional repressors and transcription 
activators from the Blautia obeum A2-162 strain.  
Heterologous expression of active Clos peptides described in chapter 5 also involved 
creating and testing of fusions of the closA structural genes to the nisin A leader peptide; 
a putative cleavage site for the NisP was also created and expression in L. lactis indicated 
that the nisin biosynthetic machinery was incapable of producing, modifying or releasing 
active Clos peptides.  
However, based on the knowledge of the activation and expression of the pepI gene in 
nisin inducible and nisRK controlled UKLc10 host strain, expression of the entire gene 
cluster with nisin induction allowed for the successful identification by MS and preClosA 
detection, using the antibody designed for the preClosA leader peptide. The presence of 
the specific preClosA peptides was confirmed in both TCA precipitated supernatant and 
in the cell extracts from nisin induced clos cluster containing strains.  
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It was hypothesised that the preClosA biosynthetic machinery is able to produce, modify 
and export the preClosA peptide and that external proteases would be capable to remove 
the leader peptide and generate active Clos peptide or Clos fragments.  
Chapter 5 - Heterologous expression of Clos peptides 
Heterologous expression was shown to be a beneficial system for the production of 
lantibiotic peptides from gene clusters isolated from different organisms [182]. Following 
the successful biosynthesis and post-translational modification of preClosA when it is 
expressed in the presence of the nisin regulatory genes, trypsin treatment of the preClosA 
peptide generated fragments with high biological activity compared to nisin. These 
trypsin-cleaved ClosA peptides are expressed from more than one structural closA gene. 
Antimicrobial activity was demonstrated against Gram-positive gut pathogens such as C. 
difficile, a major cause of hospital acquired infections and C. perfringens as well as 
against L. lactis MG1614. Therefore, Clos has the potential to be developed as a novel 
clinical antimicrobial peptide active against infections with MDR bacteria. Interestingly, 
the leaderless nisin was also active both in the absence and in the presence of trypsin. 
This suggests that the tryptic nisin fragments obtained by treatment with 1 to 15 ng/µl of 
trypsin were active despite not comprising the entire original nisin structure which is 
consistent with previous reports in literature [199, 200]. Possibly the same takes place 
with the Clos peptide. Also, it was demonstrated that an increasing amount of trypsin 
allowed for the accumulation of a higher number of completely digested tryptic peptides, 
therefore the size of the halo increased proportionally in the overlay assay.  
In chapter 5, it was demonstrated that good preClosA production takes place between 2 
and 6 h of nisin induction whereas the biosynthesis is switched off after 6 to 12 h. It is 
known that leaderless lantibiotic peptides, despite being active, can be degraded by 
internal proteases. This may imply that at lower trypsin concentrations there are different 
forms of tryptic peptides are produced due to the incomplete cleavage of preClosA at low 
trypsin concentration. Since antimicrobial activity against other tested indicator bacterial 
strains was not seen due to their different sensitivity to digested Clos peptide, in the future 
a higher amount of preClosA may allow for the accumulation of the correct active tryptic 
peptides. Future work on the screening for active Clos peptide should involve testing the 
purified trypsin digested preClosA and comparing it with current results obtained on plate 
assays where preClosA was produced by the L. lactis UKLc10 producing strain.  
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Since the GI tract is such a complex ecosystem, the effectiveness of nisin induction and 
trypsin-dependent active Clos production and the regulation of these processes in vivo is 
likely to depend on relations with numerous GI tract environmental factors. Also, these 
processes could be inhibited by digestive proteases, however the significance of these 
enzymes is yet to be determined in future in vivo studies.  
Similar work was performed on another GI tract derived lantibiotic peptide, 
Ruminococcin A produced by the Ruminococcus gnavus strain from the human intestinal 
microbiota [162]. It would be interesting to study the impact of the gut environmental 
factors on the clos promoter activity in the gut-derived Blautia obeum A2-162, as it was 
previously investigated for another gut-derived bacteriocin produced by Lactobacillus 
salivarius [201]. Similarly, the GI survival of the Clos lantibiotic-producing strain, L. 
lactis UKLc10 could be investigated in in vitro and in vivo studies. The aim would be to 
further use the producing strain as a delivery system for biologically active Clos peptides 
to the gut in order to treat infections with Clostridiales gut pathogens. Similar work has 
already been done to study the fate and efficacy of the lacticin 3147 lantibiotic peptide 
[202].  
Chapter 6 - Structure confirmation of the preClosA peptide 
In chapter 6, the heterologously produced and nisin induced preClosA peptide was 
successfully purified in very high yield by using an optimised immunoprecipitation (IP) 
reaction with the antiClos leader antibody. Mascot database search, Maldi-ToF and LC-
MS analysis of two types of samples including the 6 kDa protein gel slices and eluted 
preClosA in solution, confirmed the identity of the investigated peptides as preClosA. 
This was achieved by sequence identification of tryptic peptides and by comparing 
accurate experimental masses to the calculated masses and sequences. The Mascot 
database search also allowed for the detection of the post-translational modifications 
including the presence of possible ring structures. Results demonstrated that the clos 
biosynthetic machinery is either not efficient in introducing the PTM (e.g.: all the 
predicted ring structures) or the predicted structures of preClosA are incorrect.  
Evidence of a mixture of fully and partially dehydrated preClosA peptides was found. A 
few spectra for some tryptic peptides indicated that one or both Rings D and E can be 
formed. However, no evidence for Rings A-C was found. This would suggest that the clos 
modification machinery can introduce the dehydrations, however the thio-ether linkages 
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are not efficiently introduced perhaps due to the lack of the correct Clos signal/inducing 
molecule. 
In vitro work with immune-purified preClosA peptides could involve trypsin digestion 
and RP-HPLC separation of the individual tryptic peptides. C18 RP-HPLC was used in 
chapter 3 to purify clos-like nisin mutants, therefore the methods are in place for the 
isolation of the tryptic Clos peptides. Next, the purified peptides would need to be tested 
for their antimicrobial spectrum and activity, host range and their stability against a range 
of Gram-positive species. As a result, tryptic peptides with improved characteristics 
compared to nisin may be detected. The interaction and mode of action of tryptic peptides 
with the bacterial cell membrane can be assessed in comparison to nisin by solid state 
NMR [203, 204]. This future work will involve looking at the ability of the Clos 
lantibiotics to bind to membrane constituents and/or components involved in cell wall 
biosynthesis. The potential of the Clos leader peptide to form pores can be studied with 
the aim of investigating their mechanism of action against sensitive indicator strains 
including clinically important pathogens. Once the Clos tryptic peptides are isolated, it 
would be interesting to investigate if they can act as an inducer in the heterologous 
expression system or in the original Blautia obeum A2-162. The stability of the active 
Clos peptides in vitro can also be tested.  
Future work with purified tryptic peptides could also involve assessing their antimicrobial 
activity in in vitro models. Lantibiotics with activity against colonic bacteria could be 
tested in pathogen challenged models using batch cultures as well as the full colon models 
that are designed to reproduce the microbiological and the physiological conditions of the 
human large intestine. These model systems mimic the GI tract conditions [205]. The 
effect of the lantibiotic on the composition and diversity of the commensal gut microbiota 
could be assessed for microbial profiling using 16S rDNA sequencing via the 454 
platform. The data obtained would provide phylogenic information on any changes in the 
complex gut microbiota. 
Furthermore, future studies could involve determining the possible induction conditions 
of the original Blautia obeum A2-162 strain where a number of Clos or tryptic peptides 
containing samples could be used to act as potent signal molecules. For instance, inactive 
Clos precursor peptides from supernatants or cell extracts from nisin induced 
pClosCluster in L. lactis UKLc10 strain could be incubated with various trypsin 
concentrations in the Blautia obeum A2-162 strain. Alternatively, active tryptic peptides 
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isolated from RP-HPLC or even IP pure preClosA in solution treated with various trypsin 
concentrations can act as inducing peptides.  
More detailed analysis of the supernatant and cell extracts samples from the induced 
strains may confirm the presence of both ClosA3 and ClosA4 peptides. Future work could 
involve to understand if both ClosA3 and ClosA4 are necessary for the induction and 
antimicrobial activity since it was assumed that they are both part of a two-component 
system.  
From the MS analysis of the IP enriched preClosA, it is apparent that preClosA23 is 
predominant and some preClosA1 is also present. PreClosA4 could not be detected which 
is most likely due to the difference in the sequence of the leader peptide which could not 
bind to the antiClos leader antibody originally designed for the ClosA1 leader peptide. 
The induction experiments would allow us to investigate if there is any Clos peptide 
production from the original strain as well as to test and establish the optimal conditions 
for antimicrobial biosynthesis under GI tract conditions. Tests could then include 
antimicrobial activity bioassays, RT-PCR, western blotting and mass spectrometry 
analysis.  
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Original Sequencesa 
Hybrid name Shorter name   
NisinA 
Leader+ 
Nisin        
NisL+N MSTKDFNLDLVSVSKKDSGASPR↓ITSISLCTPGC 
KTGALMGCNMKTATCHCSIHVSK 
ClosLeader+ 
ClosA              
ClosL+ClosA1 
(GG_IE) 
MGKFDDFDLDVTKTAAQGG↓IEPK↓YKSK 
SACTPGCPTGILMTCPLKTATCGCHITGK 
 ClosL+ClosA2 MAKFDDFDLDVTKTAAQGG↓IEPK↓YKSK 
SACTPGCPTGILMTCPLKTATCGCHITGK 
 ClosL+ClosA3 MAKFDDFDLDVTKTAAQGG↓IEPK↓YKSK 
SACTPGCPTGILMTCPLKTATCGCHITGK 
 ClosL+ClosA4 MAKFDDFDLDIIEKKVRRDI↓IPAS↓ITSQHS 
FCTPNCLTGFLCPPKTQLTCTCKLKGQ 
Mutagenesis – to cleave with ArgC  (to introduce R)* 
ClosL + 
ClosA 
ClosL+ClosA 
(GR_IE) 
MGKFDDFDLDVTKTAAQGR↓IEPKYKSKSAC 
TPGCPTGILMTCPLKTATCGCHITGK 
 ClosL+ClosA 
(GG_IEPR) 
MGKFDDFDLDVTKTAAQGGIEPR↓YKSKSAC 
TPGCPTGILMTCPLKTATCGCHITGK 
ClosL + 
ClosA 
ClosL+ClosA4 
(DR_IP) 
MAKFDDFDLDIIEKKVRRDR↓IPASITSQHSFC 
TPNCLTGFLCPPKTQLTCTCKLKGQ 
ClosL + 
ClosA 
ClosL+ClosA4 
(DI_IPAR) 
MAKFDDFDLDIIEKKVRRDIIPAR↓ITSQHSFC 
TPNCLTGFLCPPKTQLTCTCKLKGQ 
 
Table 32 - Cleavage of prenisin and preClosA with trypsin and with the engineered ArgC peptidase sites.  
* Putative cleavage site in the preClosA peptides are indicated in green for trypsin and in red, boldface type 
for ArgC.  
The peptides in the supernatant or in the cell extracts from the total protein can be identified by Maldi-ToF. 
The proposed hybrids that can be used to engineer the ArgC site are: nisinA Leader + nisin core peptide (as 
positive control), Clos leader (ClosL) + Clos core peptide. The conserved sequence of F(N/D)LD(L/V) in 
nisin and in the Clos leader peptide was highlighted in yellow [169]. 
 
Table 32 illustrates a strategy of introducing cleavage sites for ArgC protease in the 
sequences of ClosA1 and ClosA4 core peptides in order to facilitate the release of the full 
Clos peptide without the predicted leader attached. The ArgC sites would allow for the 
specific release of Clos peptides with either IE or YK start site since ArgC cleaves only 
after the Arg residue.  
The IP reaction can be developed into a standard screening technique to identify and 
purify lantibiotics for which the leader peptide sequence is known. The IP reaction could 
allow for the purification of preClosA peptide in very high amounts. If the new Clos 
peptides are confirmed to be produced by the gut bacteria, antibodies could be used in 
western blotting for Clos leader detection, followed by the specific extractions and further 
MS characterisation to further confirm the identity of the Clos peptides.  
From a clinical point of view, it would be interesting to explore if the Blautia obeum A2-
162 has probiotic traits similar to other gut bacteria [29] and it could be used to develop 
a delivery system for the Clos peptide with a view to treat GI tract infections. One 
example would be the use of faecal microbiota transplantation [10, 206].  
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From a commercial, industrial and pharmaceutical perspective, Clos could be explored 
for its potential to inhibit food-poisoning pathogens such as L. monocytogenes or 
sporulation from different bacteria by using it as a food preservative. Investigations of the 
heat-stability and shelf life of pure preClos as well as the development of a scaled-up 
production system would also be interesting to explore. 
In conclusion, the UKLc10 heterologous system with the nisRK genes on the 
chromosome allowed for the expression of the preClosA peptides in high yield, and the 
trypsin digested Clos displayed very high antimicrobial activity comparable to nisin when 
tested against L. lactis MG1614, C. perfringens and C. difficile. PreClosA was 
successfully purified by immunoprecipitation. This is the first demonstration of a 
bacteriocin from the Blautia obeum A2-162 gut species that could be digested by trypsin 
to give very significant antimicrobial activity against clinically important gut pathogens. 
This is also the first study on the post-translational modifications of the preClosA peptide 
as introduced by the clos biosynthetic machinery confirming the occurrence of 
dehydrations and some ring formations. The current study also showed that all the four 
forms of preClosA peptides were present, and that ClosA2 is the most abundant one. 
Future studies on the characterisation of the Clos structure using isolated tryptic peptides 
from the RP-HPLC column will improve the current knowledge on the role of the post-
translational modification for the activity of the tryptic peptides. 
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Appendix 1 - Calculated and observed masses of clos-like nisin mutants 
that were detected in Maldi-ToF analysis  
In red, observed and calculated are 100 % match; in black and bold, there is 1-unit 
difference between the observed and calculated mass of the peptide. 
Nisin positive control  
 
Ring A mutant peptides 
 
 
 
 
 
 Nisin A
Deh. M+H M+O M+Na M+K
8 3352.64 3368.64 3374.62 3391.60 3352.64
7 3370.64 3386.64 3392.62 3409.60 3369.64
6 3388.64 3404.64 3410.62 3427.60 3373.17
5 3406.64 3422.64 3428.62 3445.60 3375.60
2 3460.64 3476.64 3482.62 3499.60 3386.63
1 3478.64 3494.64 3500.62 3517.60 3389.16
3390.61
3394.38
3499.71
Calculated monoisotopic mass (m/z) Observed 
(m/z)
I4K
Deh. M+H M+O M+Na M+K
8 3367.65 3383.65 3389.63 3406.61 3367.63
7 3385.65 3401.65 3407.63 3424.61 3383.66
6 3403.65 3419.65 3425.63 3442.61 3386.67
3402.67
Calculated monoisotopic mass (m/z) Observed 
(m/z)
L6A
Deh. M+H M+O M+Na M+K
8 3310.59 3326.59 3332.57 3349.55 3327.34
7 3328.59 3344.59 3350.57 3367.55 3343.41
6 3346.59 3362.59 3368.57 3385.55 3383.54
5 3364.59 3380.59 3386.57 3403.55 3398.56
4 3382.59 3398.59 3404.57 3421.55
Calculated monoisotopic mass (m/z) Observed 
(m/z)
I4K_L6A
Deh. M+H M+O M+Na M+K
4 3397.60 3413.60 3419.58 3436.56 3413.47
3 3415.60 3431.60 3437.58 3454.56
6 5693.80 5709.80 5715.78 5732.77 5694.59
5 5711.80 5727.80 5733.78 5750.77 5750.59
Calculated monoisotopic mass (m/z) Observed 
(m/z)
active 
peptide 
propeptide 
(uncleaved)
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Ring C mutant peptides 
 
 
Hinge mutant peptides  
 
 
 
A15I
Deh. M+H M+O M+Na M+K
8 3394.68 3410.68 3416.66 3433.65 3394.78
7 3412.68 3428.68 3434.66 3451.65 3412.35
6 3430.68 3446.68 3452.66 3469.65 3429.76
5 3448.68 3464.68 3470.66 3487.65 3467.77
4 3466.68 3482.68 3488.66 3505.65 3544.67
1 3520.68 3536.68 3542.66 3559.65 3450.35
Calculated monoisotopic mass (m/z) Observed 
(m/z)
G18T
Deh. M+H M+O M+Na M+K
8 3396.66 3412.66 3418.64 3435.63 3434.34
7 3414.66 3430.66 3436.64 3453.63 3473.10
6 3432.66 3448.66 3454.64 3471.63 3486.71
5 3450.66 3466.66 3472.64 3489.63 3560.27
3 3486.66 3502.66 3508.64 3525.63
1 3522.66 3538.66 3544.64 3561.63
0 3540.66 3556.66 3562.64 3579.63
Calculated monoisotopic mass (m/z)
Observed 
(m/z)
N20P
Deh. M+H M+O M+Na M+K
8 3335.65 3351.65 3357.63 3374.61 3334.18
7 3353.65 3369.65 3375.63 3392.61 3353.36
6 3371.65 3387.65 3393.63 3410.61 3370.06
4 3407.65 3423.65 3429.63 3446.61 3386.19
3 3425.65 3441.65 3447.63 3464.61 3408.35
2 3443.65 3459.65 3465.63 3482.61 3425.47
3442.01
3460.02
Calculated monoisotopic mass (m/z) Observed 
(m/z)
M21L
Deh. M+H M+O M+Na M+K
8 3334.68 3350.68 3356.66 3373.64 3335.62
7 3352.68 3368.68 3374.66 3391.64 3350.64
6 3370.68 3386.68 3392.66 3409.64 3354.63
5 3388.68 3404.68 3410.66 3427.64 3369.68
4 3406.68 3422.68 3428.66 3445.64 3392.64
3407.62
Calculated monoisotopic mass (m/z) Observed 
(m/z)
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C-terminal mutant peptides 
 
 
 
 
 
 
 
 
 
 
 
 
N20P_M21L
Deh. M+H M+O M+Na M+K
8 3317.69 3333.69 3339.67 3356.65 3318.76
7 3335.69 3351.69 3357.67 3374.65 3333.80
3335.69
Calculated monoisotopic mass (m/z) Observed 
(m/z)
H27G
Deh. M+H M+O M+Na M+K
8 3272.60 3288.60 3294.58 3311.56 3271.33
7 3290.60 3306.60 3312.58 3329.56 3288.68
6 3308.60 3324.60 3330.58 3347.56 3304.68
5 3326.60 3342.60 3348.58 3365.56 3307.65
3342.67
Calculated monoisotopic mass (m/z) Observed 
(m/z)
H27G_S29H_H31T_V32
G_S33K
Deh. M+H M+O M+Na M+K
8 3285.63 3301.63 3307.61 3324.59 3301.42
7 3303.63 3319.63 3325.61 3342.59 3317.70
5 3339.63 3355.63 3361.61 3378.59 3356.83
4 3357.63 3373.63 3379.61 3396.59
Calculated monoisotopic mass (m/z) Observed 
(m/z)
H31T_V32G_S33K
Deh. M+H M+O M+Na M+K
8 3315.6417 3331.64 3337.62 3354.61 3312.56
7 3333.64 3349.64 3355.62 3372.61 3347.79
6 3351.64 3367.64 3373.62 3390.61 3369.83
5 3369.64 3385.64 3391.62 3408.61 3385.74
Calculated monoisotopic mass (m/z) Observed 
(m/z)
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Appendix 2 - Activity and stability of I4K, H27G and nisin against L. lactis 
MG1614 under GI tract conditions (37◦C, pH 3.0, 5.5, 6.0, 6.5, 7.0) 
measured for 7 days 
The specific activity of nisin, H27G and I4K given by 9 µg/ml of pure peptides was 
plotted for time points A. T0, B. T48, C. T68 hours.   
The bioactivity of the nisin variants and nisin follows the same pattern. At any given time 
point and pH, the activity of I4K is 99 % less and the activity of H27G is between 60-80 
% less compared to nisin. 
A.  
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B.  
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C.  
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Appendix 3 - Mascot files for preClosA fragments labelled and digested 
with trypsin.  
3.1. Mascot search for tryptic peptides from the preClosA1-4 leader 
peptides  
List of peptide spectrum matches (PTM) for the leader peptide of the preClosA1-4 
peptides extracted from a results file (Scaffold proteomics software) after a Mascot search 
with data from nano-LC-MS/MS of tryptic digested gel samples. 
Table. A: Tryptic Peptide AKFDDFDLDVTK (1 missed cleavage) from ClosA2-3 
leader peptide 
Total spectra observed: 109; No PTMs observed 
Two PSMs of charge states 1 to 3 each are shown (Data extracted from Scaffold software) 
  
Probability 
Observed 
m/z Charge 
Actual 
mass 
Calculated 
M+1H 
Error 
(ppm) 
Intensity 
(TIC) 
0.997 471.9012 3 1412.6817 1413.6899 -0.652 18664300 
0.997 471.9012 3 1412.6817 1413.6899 -0.652 13379400 
0.997 707.3490 2 1412.6834 1413.6899 0.518 6238690 
0.997 707.3490 2 1412.6834 1413.6899 0.518 5244830 
0.997 1413.6915 1 1412.6843 1413.6899 1.123 332312 
0.997 1413.6897 1 1412.6825 1413.6899 -0.144 268013 
 
Table. B: Tryptic Peptide FDDFDLDVTK from ClosA1-3 leader peptide 
Total spectra observed: 30; No PTMs observed 
Three PSMs of charge state 2 each are shown, no other charge states observed 
  
Probability 
Observed 
m/z Charge 
Actual 
mass 
Calculated 
M+1H 
Error 
(ppm) 
Intensity 
(TIC) 
0.997 607.7821 2 1213.5497 1214.5578 -0.706 1976410 
0.997 607.7821 2 1213.5497 1214.5578 -0.706 1791220 
0.997 607.7824 2 1213.5503 1214.5578 -0.188 358520 
 
Table. C: Tryptic Peptide TAAQGGIEPK from ClosA1-3 leader peptide 
Total spectra observed: 22; No PTMs observed 
Three PSMs of charge state 2 each are shown, no other charge states observed 
  
Probability 
Observed 
m/z Charge 
Actual 
mass 
Calculated 
M+1H 
Error 
(ppm) 
Intensity 
(TIC) 
0.997 486.2617 2 970.5089 971.5158 0.292 642814 
0.997 486.2617 2 970.5089 971.5158 0.292 563809 
0.997 486.2613 2 970.5081 971.5158 -0.461 168335 
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Table. D: Tryptic Peptide TAAQGGIEPKYK (1 missed cleavage) from ClosA1-3 
leader peptide 
Total spectra observed: 4; No PTMs observed 
Three PSMs of charge state 2 each are shown, no other charge states observed 
  
Probability 
Observed 
m/z Charge 
Actual 
mass 
Calculated 
M+1H 
Error 
(ppm) 
Intensity 
(TIC) 
0.997 631.8414 2 1261.6682 1262.6741 1.082 26473 
0.997 631.8414 2 1261.6682 1262.6741 1.082 23005 
0.997 631.8412 2 1261.6678 1262.6741 0.757 10428 
 
Table. E: Tryptic Peptide GKFDDFDLDVTK from ClosA1 leader peptide 
Total spectra observed: 53; No PTMs observed 
Two PSMs of charge states 1 to 3 each are shown (Data extracted from Scaffold software) 
  
Probability 
Observed 
m/z Charge 
Actual 
mass 
Calculated 
M+1H 
Error 
(ppm) 
Intensity 
(TIC) 
1.00 467.2299 3 1398.6678 1399.6739 0.492 1792850 
1.00 467.2291 3 1398.6656 1399.6739 -1.062 1695910 
1.00 700.3411 2 1398.6676 1399.6739 0.377 523015 
1.00 700.3411 2 1398.6676 1399.6739 0.377 478187 
1.00 1399.6755 1 1398.6682 1399.6739 0.799 78757 
1.00 1399.6755 1 1398.6682 1399.6739 0.799 26022 
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3.2. Mascot search for tryptic peptides from the ClosA1-3 core peptides  
List of peptide spectrum matches (PTM) for ClosA1-3 core tryptic peptides extracted 
from results file (Scaffold proteomics software) after a Mascot search with data from 
nano-LC-MS/MS of tryptic digested gel samples. Lower case residues mean that they 
were modified: dehydrated and/or with the Cys residues labelled by IAA. The 
modifications are located by the number associated with the residue.  
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Table 33 - List of all PSMs for tryptic peptide TATCGCHITGK covering the DE ring area of ClosA1-3 peptides. 
Number of PSMs: 66, all modified, no missed cleavage,  
Note that PSMs in bold have 2-3 dehydrations and are not (italic) or not fully modified by CAM (on Cysteines) 
Visual inspection of the corresponding spectra showed missing fragmentation in ring area in some spectra (see chapter 6, Figure 68). 
Abbreviations for all those tables: P=probability, CAM=Carbamidomethyl, Ox=Oxidation, dehydr=Dehydration, PSMs=Peptide Spectra Matches. 
Peptide sequence P Variable modifications identified by spectrum 
TATcGcHITGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02) 
TATcGcHITGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02) 
TATcGcHITGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02) 
TATcGcHITGK 0.984 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02) 
TATcGcHITGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02) 
TATcGcHITGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02) 
TATcGcHITGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02) 
TATcGcHITGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02) 
TATcGcHITGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02) 
TATcGcHITGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02) 
TATcGcHItGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.992 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
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TATcGcHItGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.997 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.979 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHItGK 0.982 c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TATcGcHITGK 0.987 c4: Dehydro (-1.01), c6: Dehydro (-1.01) 
tATCGcHItGK 0.952 t1: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
tAtCGCHITGK 0.955 t1: Dehydrated (-18.01), t3: Dehydrated (-18.01) 
tAtCGCHITGK 0.997 t1: Dehydrated (-18.01), t3: Dehydrated (-18.01) 
tAtCGCHITGK 0.997 t1: Dehydrated (-18.01), t3: Dehydrated (-18.01) 
tAtCGCHITGK 0.987 t1: Dehydrated (-18.01), t3: Dehydrated (-18.01) 
tAtCGCHItGK 0.961 t1: Dehydrated (-18.01), t3: Dehydrated (-18.01), t9: Dehydrated (-18.01) 
tAtCGCHItGK 0.997 t1: Dehydrated (-18.01), t3: Dehydrated (-18.01), t9: Dehydrated (-18.01) 
tAtCGCHItGK 0.997 t1: Dehydrated (-18.01), t3: Dehydrated (-18.01), t9: Dehydrated (-18.01) 
tAtCGCHItGK 0.997 t1: Dehydrated (-18.01), t3: Dehydrated (-18.01), t9: Dehydrated (-18.01) 
tAtCGCHItGK 0.997 t1: Dehydrated (-18.01), t3: Dehydrated (-18.01), t9: Dehydrated (-18.01) 
tAtCGCHItGK 0.997 t1: Dehydrated (-18.01), t3: Dehydrated (-18.01), t9: Dehydrated (-18.01) 
tAtCGCHItGK 0.997 t1: Dehydrated (-18.01), t3: Dehydrated (-18.01), t9: Dehydrated (-18.01) 
TAtcGCHITGK 0.955 t3: Dehydrated (-18.01), c4: Carbamidomethyl (+57.02) 
TAtcGCHITGK 0.997 t3: Dehydrated (-18.01), c4: Carbamidomethyl (+57.02) 
TAtcGCHITGK 0.997 t3: Dehydrated (-18.01), c4: Carbamidomethyl (+57.02) 
TAtcGCHITGK 0.953 t3: Dehydrated (-18.01), c4: Carbamidomethyl (+57.02) 
TAtcGCHITGK 0.965 t3: Dehydrated (-18.01), c4: Carbamidomethyl (+57.02) 
TAtcGcHItGK 0.997 t3: Dehydrated (-18.01), c4: Carbamidomethyl (+57.02), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtcGCHItGK 0.972 t3: Dehydrated (-18.01), c4: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtcGCHItGK 0.971 t3: Dehydrated (-18.01), c4: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtcGCHItGK 0.997 t3: Dehydrated (-18.01), c4: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
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TAtCGcHITGK 0.997 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02) 
TAtCGcHITGK 0.997 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02) 
TAtCGcHITGK 0.997 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02) 
TAtCGcHITGK 0.975 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02) 
TAtCGcHITGK 0.975 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02) 
TAtCGcHITGK 0.954 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02) 
TAtCGcHITGK 0.959 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02) 
TAtCGcHITGK 0.947 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02) 
TAtCGcHITGK 0.997 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02) 
TAtCGcHITGK 0.997 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02) 
TAtCGcHItGK 0.997 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtCGcHItGK 0.997 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtCGcHItGK 0.974 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtCGcHItGK 0.975 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtCGcHItGK 0.979 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtCGcHItGK 0.97 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtCGcHItGK 0.997 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtCGcHItGK 0.997 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtCGcHItGK 0.997 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
TAtCGcHItGK 0.977 t3: Dehydrated (-18.01), c6: Carbamidomethyl (+57.02), t9: Dehydrated (-18.01) 
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Table 34 - List of all PSMs for tryptic peptide SACTPGCPTGILMTCPLK covering the ABC ring area of ClosA1-3 peptides. 
Number of PSMs: 127, all modified, no missed cleavage, note that all matches have at least 1 CAM modification. 
Abbreviations for all those tables: P=probability, CAM=Carbamidomethyl, Ox=Oxidation, dehydr=Dehydration. 
Visual inspection of the corresponding spectra showed missing fragmentation in ring area in some spectra (see chapter 6, Figure 69). 
Peptide sequence P Variable modifications identified by spectrum 
SAcTPGcPTGILmTcPLK 0.966 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SActPGCPTGILMtcPLK 0.972 c3: CAM (+57.02), t4: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
sAcTPGCPTGILMtcPLK 0.974 s1: dehyr (-18.01), c3: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILmtcPLK 0.98 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILMtcPLK 0.984 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.989 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILMtcPLK 0.99 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.995 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPtGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SActPGCPTGILMtcPLK 0.997 c3: CAM (+57.02), t4: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SActPGcPTGILMtcPLK 0.997 c3: CAM (+57.02), t4: dehyr (-18.01), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
   
 
264 
 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPtGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SActPGCPTGILmTcPLK 0.997 c3: CAM (+57.02), t4: dehyr (-18.01), m13: Ox (+15.99), c15: CAM (+57.02) 
SACTPGcPtGILMTcPLK 0.997 c7: CAM (+57.02), t9: dehyr (-18.01), c15: CAM (+57.02) 
sAcTPGCPtGILMtcPLK 0.997 s1: dehyr (-18.01), c3: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
sAcTPGCPtGILMtcPLK 0.997 s1: dehyr (-18.01), c3: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SActPGCPTGILMTcPLK 0.997 c3: CAM (+57.02), t4: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SActPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), t4: dehyr (-18.01), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
sACTPGcPTGILMtcPLK 0.997 s1: dehyr (-18.01), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SActPGCPTGILMTcPLK 0.997 c3: CAM (+57.02), t4: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SActPGCPTGILMtcPLK 0.997 c3: CAM (+57.02), t4: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPtGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
sAcTPGCPtGILMtcPLK 0.997 s1: dehyr (-18.01), c3: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGCPtGILmtcPLK 0.963 c3: CAM (+57.02), t9: dehyr (-18.01), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
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SActPGCPTGILMTcPLK 0.963 c3: CAM (+57.02), t4: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.972 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SActPGCPTGILMtcPLK 0.973 c3: CAM (+57.02), t4: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.974 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILMtcPLK 0.979 c3: CAM (+57.02), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.993 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPtGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPtGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
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SAcTPGcPtGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SActPGCPTGILmTcPLK 0.997 c3: CAM (+57.02), t4: dehyr (-18.01), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPtGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
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SAcTPGcPtGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SActPGCPTGILMtcPLK 0.997 c3: CAM (+57.02), t4: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
sACTPGcPTGILmTcPLK 0.997 s1: dehyr (-18.01), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SACTPGcPtGILMtcPLK 0.997 c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILMtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SActPGCPTGILMtcPLK 0.951 c3: CAM (+57.02), t4: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
sAcTPGcPtGILMtcPLK 0.951 s1: S(+15) (+14.97), c3: C(-33) (-32.98), c7: CAM (+57.02), t9: dehyr (-18.01), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmtcPLK 0.959 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
sAcTPGCPTGILMtcPLK 0.974 s1: dehyr (-18.01), c3: CAM (+57.02), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILmtcPLK 0.975 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILmTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), m13: Ox (+15.99), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
SAcTPGcPtGILmtcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), m13: Ox (+15.99), t14: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPtGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), t9: dehyr (-18.01), c15: CAM (+57.02) 
SAcTPGcPTGILMTcPLK 0.997 c3: CAM (+57.02), c7: CAM (+57.02), c15: CAM (+57.02) 
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Table 35 - List of all PSMs for tryptic peptide SKSACTPGCPTGILMTCPLK covering the ABC ring area of ClosA1-3 peptides. 
Number of PSMs: 5, all modified, 1 missed cleavage. 
The last PSM in this list shows modifications which would be related to ring fragmentation, but visual inspection of the spectrum revealed that the 
spectrum is of poor quality. 
Peptide sequence P Variable modifications identified by spectrum 
sKSACTPGcPTGILMtcPLK 0.997 s1: dehydr (-18.01), c9: CAM (+57.02), t16: dehydr (-18.01), c17: CAM (+57.02) 
SKsAcTPGcPTGILMtcPLK 0.997 s3: S(-17) (-17.00), c5: CAM (+57.02), c9: Dehydro (-1.01), t16: dehydr (-18.01), c17: CAM (+57.02) 
SKSACTPGcPTGILMTcPLK 0.997 c9: CAM (+57.02), c17: CAM (+57.02) 
SKSACTPGcPTGILMTcPLK 0.997 c9: CAM (+57.02), c17: CAM (+57.02) 
sKsAcTPGcPtGILMtcPLK 0.997 
s1: S(-17) (-17.00), s3: S(-17) (-17.00), c5: Dehydro (-1.01), c9: C(-33) (-32.98), t11: dehydr (-18.01), t16: dehydr (-18.01), c17: 
C(-33) (-32.98) 
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Table 36 - List of all PSMs for tryptic peptide YKSKSACTPGCPTGILMTCPLK covering the ABC ring area of ClosA1-3 peptides. 
Number of PSMs: 4, all modified, 2 missed cleavages. 
The last PSM in this list shows modifications which would be related to ring fragmentation, but visual inspection of the spectrum revealed that the 
spectrum is of poor quality. 
Peptide sequence P Variable modifications identified by spectrum 
YKSKsAcTPGcPtGILmTcPLK 0.997 s5: S(+15) (+14.97), c7: C(-33) (-32.98), c11: CAM (+57.02), t13: dehydr (-18.01), m17: Ox (+15.99), c19: CAM (+57.02) 
YKSKsAcTPGcPTGILmtcPLK 0.997 s5: S(+15) (+14.97), c7: C(-33) (-32.98), c11: CAM (+57.02), m17: Ox (+15.99), t18: dehydr (-18.01), c19: CAM (+57.02) 
YKsKSACTPGcPTGILmtcPLK 0.997 s3: dehydr (-18.01), c11: CAM (+57.02), m17: Ox (+15.99), t18: dehydr (-18.01), c19: CAM (+57.02) 
YKsKsAcTPGcPtGILmTcPLK 0.997 
s3: S(+15) (+14.97), s5: S(+15) (+14.97), c7: Dehydro (-1.01), c11: Dehydro (-1.01), t13: dehydr (-18.01), m17: Ox (+15.99), 
c19: Dehydro (-1.01) 
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